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In the studies to establish structure-reactivity relationships in the hydrolytic 
reaction of phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidyl 
L-serine (PS) catalyzed by the phospholipase C from Bacillus cereus (PC-PLCBc), a 
number of water-soluble, non-hydrolyzable substrate based inhibitors of PLCBc were 
prepared. These include ω-hydroxy phosphorodithioates and phosphonates of choline, 
ethanolamine and L-serine. Kinetic assays reveal that all the ω-hydroxy 
phosphorodithioates are good inhibitors with good aqueous solubilities. However, 
ethanolamine and L-serine derivatives of phosphonates fail to inhibit PLCBc at their 
maximum solubilities. The three-dimensional structures of phosphonate-PS with E4G, 
E4Q and wild type PC-PLCBc revealed that these mutants bind the PS analogue in a very 
different manner than wild-type does a PC analogue. The structural difference shed new 
views on our understanding of the mechanistic and kinetic aspects of PLCBc catalyzed 
hydrolytic reactions.  
 vii
In the application of our glycosyl furan/benzyne cycloaddition methodology 
towards natural product synthesis, a two-stage benzyne/furan cycloaddition strategy was 
used to assemble the anthrone core of Group I C-aryl glycoside 5-hydroxyaloin A. Proof 
of concept was established in the generation of benzyne from a chloronaphthol precursor 
4.142 and subsequent cycloaddition with furan afford the cycloadduct 4.143. However, 
the cycloadducts of 4.142 and alkoxy/silyloxy furans were unstable, and attempts to 
convert them into 5-hydroxyaloin A were unsuccessful. During the course of the 
investigation, cycloadditions using glycal-substituted furans were investigated and a one-
step novel approach to the C-aryl glycal was established starting from 2-deoxy sugar 
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Chapter 1: Phospholipase C and Phospholipid Analogues 
The primary goal of this project is to establish structure-reactivity relationships in 
the hydrolytic reaction of phosphatidylcholine (PC), phosphatidylethanolamine (PE) and 
phosphatidyl L-serine (PS) catalyzed by the phospholipase C from B. cereus (PLCBc). 
This chapter serves as an introduction to PLCBc and phospholipid synthesis, starting with 
the biology of phospholipids and phospholipases in general, followed by a description of 
the structural and mechanistic aspects of PLCBc. This chapter concludes with the 
chemical synthesis of phospholipids and their analogs since substrate mimics are 
important tools that were used in our group to elucidate the basis of the kinetic and 
thermodynamic differences.  
 
1.1 PHOSPHOLIPIDS AND SIGNAL TRANSDUCTION  
Biological membranes are lipid bilayers that form the barrier between the cell 
interior and its external milieu. They are also involved in cell compartmentalization to 
delimit cells and to divide the cytoplasm into its organelles and compartments. 
Mammalian cells contain a great variety of complex lipids. Phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) and sphingomyelin are quantitatively the most abundant 
lipids in biological membranes (Figure 1.1). For decades, it has been thought these 
phospholipids serve only structural roles responsible for maintaining the integrity of 
cellular membrane. The discovery that the breakdown products of cellular phospholipids 
actively participate in biological processes and as such can interfere with cell physiology 




































Figure 1.1: Common membrane phospholipids 
Since then, the role of the membrane integral PLC class of enzymes in the cell 
signal transduction pathway has been studied extensively. In particular, extensive efforts 
have been devoted to the inositol specific phospholipase C (PI-PLC) because of its key 
role in initialing cellular response.1-3 Activation of a hormone-sensitive PI-PLC at the 
plasma membrane results in rapid catabolism of the polyphosphoinositides to form the 
two secondary messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). 
The initially formed water-soluble inositol 1,4,5-trisphosphate (IP3) acts upon Ca
2+ 
storage, resulting in a transient intracellular calcium concentration spike. However, IP3 is 
rapidly metabolized by the action of a specific phosphatase in vivo through the removal 
of 5-phosphate, and the Ca2+ concentration in most tissue cells therefore returns rapidly to 
basal or even below basal levels.4, 5 The other hydrolytic product, diacylglycerol (DAG) 
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remains in the plasma membrane and activates protein kinase C (PKC) (Figure 1.2). 
DAG dramatically increases the affinity of protein kinase C for Ca2+ and thereby renders 
it active in the presence of micromolar concentration of Ca2+.6, 7 
 
 
Figure 1.2: A schematic and simplified representation of receptor-mediated activation 
of multiple phospholipases in signal transduction. Note that all of the SAPs 
depicted are not necessarily occur in one particular cell. only G protein-
mediated receptor-phospholipase coupling is depicted. Abbreviations: DAG, 
diacylglycerol; Cho, choline; Ins, D-myo-inositol; LPA, lysophosphatidic 
acid; LPC, lysophosphatidylcholine; PA, phosphatidic acid; PAF: platelet 
activating factor; PKC, protein kinase C; PIP2, phosphatidylinositol-4,5-
diphosphate.8 
Isotope labeling studies indicate that DAG is metabolized very rapidly by a group 
of enzymes both when it is produced endogenously and when it is added exogenously. It 
is either converted back to inositol phospholipids by way of phosphatidic acid (PI 
turnover) or to its further degradation product, cis unsaturated fatty acids, such as 
arachidonic acids. Consequently, the burst of membrane DAG concentration and 
cytosolic calcium concentration due to hydrolysis of phosphoinositides is rather short 
lived.  
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Recent experiments have established that sustained PKC activation is essential for 
long-term cellular response such as gene expression, cell proliferation and differentiation. 
Asaoka and Aihara demonstrated that a single dose of a membrane-permeable 
diacylglycerol (DAG), 1,2-dioctanoylglycerol (1,2-DiC8), was insufficient to allow HL-
60 cells to differentiate to macrophages due to its rapid metabolism. However, either a 
single dose of the slowly-metabolized phorbol 12-myristate 13-acetate (PMA)9 or an 
increase in the duration of exposure of HL-60 cells to 1,2-DiC8 by multiple additions 
greatly enhanced their differentiation to macrophages.10 Similar phenomena were also 
observed in the activation of resting T lymphocytes.11  
The sustained activation of PKC for a certain period of time is required for long-
term cellular responses; however, the biochemical mechanism prolonging this enzyme 
activation under physiological conditions are not fully known. The formation of DAG by 
the mechanism of inositol phospholipid hydrolysis is transient and appears to be 
insufficient. The sustained elevation of cellular diacylglycerol concentration required for 
continuing activation of PKC accompanying with basal Ca2+ concentration in the relative 
later phase in cell response must therefore come from other hydrolytic pathways. 
Analysis of fatty acid compositions in cell membranes has indicated that the second 
phase of DAG formation probably results from hydrolysis of the more abundant 




1.2 PHOSPHATIDYL CHOLINE-PREFERRING PHOSPHOLIPASE C FROM BACILLUS 
CEREUS 
1.2.1 Overview of Phospholipases  
Signal-activated enzymatic hydrolysis of phosphatidylcholine involves three 
distinct enzymes: phospholipase A2 (PLA2), phospholipase C (PLC), and phospholipase 























































Figure 1.3: Phospholipase and their corresponding hydrolytic sites 
Phospholipase A2 catalyzes the release of fatty acid from the sn-2 position of 
phospholipids with concurrent formation of a lysophospholipid. The hydrolyzed product, 
cis unsaturated fatty acids including oleic, linoleic, linolenic, arachidonic acids activate 
PKC to various degrees. The PLA2s that hydrolyze PC and PE occurs in both 
extracellular and intracellular forms. The former are found in secretory granules, snake 
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and bee venoms and pancreatic secretion. They are of low molecular weight and are 
believed not to be involved in cell signal transduction. The latter are found in plasma and 
intracellular membranes and also cytosol. Numerous extracellular phospholipase A2 
isoenzymes and their mutants from various sources, such as snake venom,12-16 
mammalian17-19 and human20-22 have been purified and crystal structures in native form 
and complexed with inhibitors have been obtained. Cytosolic PLA2s from several sources 
have also been purified23-26 and cloned,27-31 and structurally established.32, 33 
Phosphatidylcholine-specific phospholipase D (PLD) catalyzes the generation of 
choline and a second messenger phosphatidic acid, which acts directly as a signaling 
molecule.34, 35 But the major metabolic fate of phosphatidic acid is phosphatase-
mediated dephosphorylation to form diacylglycerol,36 which represents an alternative 
pathway for DAG formation. PLD activity was first identified in plants, and it was the 
first PC-hydrolysing enzyme purified and successfully cloned.37 The cloning of the first 
plant PLD and identification of yeast SPO14 as the yeast PLD based on gene sequence 
homology38 opened the door for the subsequent cloning of mammalian PLDs.39-41 The 
crystal structure of several members of the PLD superfamily and its homologs from 
cowpea,42 Streptomyces sp. Strain PMF43-47 and human48, 49 have been published.  
Phosphatidylcholine preferring phospholipase C (PC-PLC) catalyzes the 
formation of sn-1,2-diacylglycerol and choline phosphate. Although the closely related 
inositol counterpart PI-PLC has been well studied with a number of high-resolution 
crystal structures from bacterial50 and mammalian sources51-53 being made available, the 
phospholipase C reactive with phosphatidylcholine remains elusive and has not been 
purified extensively. No PC-PLC isoforms have been cloned from mammalian sources, 
nor has the mechanism by which the enzyme is involved in the cell response to mitogens 
and induction of DNA synthesis been fully elucidated. The occurrence of this enzyme in 
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tissue, however, is expected because an enzymatic activity exists that produces choline 
phosphate from phosphatidylcholine.  
 Despite the potential significance of PC-PLCs in eukaryotic signal transduction, 
cell-free studies on such enzymes are scarce. Only on a few occasions has PC-PLC been 
moderately purified. Wolf partially purified a 29-kDa neutral PC-PLC by anion 
exchange, hydroxylapatite, chromatofocusing, and gel filtration chromatography from the 
cytosolic fraction of canine myocardium.54 Srivastava isolated an enzyme, composed of 
two subunits of 69 and 55 kDa, from the 70% ammonium sulfate extract of bull seminal 
plasma and the enzyme was purified to homogeneity through multiple 
chromatographies.55 By use of an antibody raised in New Zealand white rabbit against 
the PC-PLC from Bacillus cereus, a one-step, 3000-fold enrichment of 
phosphatidylcholine preferring phospholipase was achieved from human monocytic 
U937 cells.56 Based on the observed antigenic similarity of mammalian and bacterial PC-
PLCs, it was suggested that they might be structurally and evolutionarily related.56 This 
enzyme was calcium dependent, most active at neutral pH and inhibited by EGTA. SDS 
Gel electrophoresis revealed it had a molecular weight of 40 kDa, nearly twice as heavy 
as Bacillus cereus phospholipase C to be discussed later.  
 
1.2.2 Bacteria PC-Preferring Phospholipase C  
Thus far, none of the mammalian PC-PLCs have been characterized with respect 
to primary protein structure. Most studies were in the past devoted to the isolation, 
cloning and characterization of prokaryotic PC-PLC enzymes.57 However, PC-PLCs 
have been detected in a wide variety of bacteria.57 All of the bacterial PC-PLCs reported 
to date are single polypeptide proteins, which are found in the culture media. The 
enzymes have been purified by a variety of techniques: for examples, an affinity 
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chromatography on agarose-linked egg yolk lipoprotein has been used to purify the 
Bacillus cereus phosphatidylcholine-preferring phospholipase C (PC-PLC)58 and the C. 
perfringens enzyme.59-61 Pseudomonas aeruginosa phospholipase C was purified by 
binding to ammonium groups on DEAE-Sephacel followed by eluting with 
tetradecyltrimethylammonium bromide.62 
 Several of the bacterial phospholipases, such as those sourced from Clostridium 
perfringens,63-65 Bacillus cereus66 and Staphylococcus aureuse,67 have been 
characterized by their amino-acid sequence, and the respective DNAs have been cloned. 
The primary structures have revealed typical signal sequences.68, 69 Among them, the C. 
perfringens alpha-toxin and B. cereus PC-PLC are the most intensively studied and 
therefore the best characterized.  
C. perfringens alpha-toxin PC-PLC is involved in the symptom of gas gangrene 
and is a potent toxin with hemolytic, lethal, dermonecrotic, vascular permeabilization and 
platelet-aggregating properties. In contrast, the enzyme from B. cereus is nontoxic, non-
hemolytic,70 and does not cause platelet aggregation71 or hydrolyze sphingomyelin. 
PLC from B. cereus are widely available from commercial supplies and its 
purification protocol has been well established. As a result of extensive investigations in 
the past 25 years, this enzyme has acquired the status of a prototype bacterial PC-PLC. 
The extracellular B. cereus PC-PLC is posttranslationally activated by the removal of 14 
N-terminal amino acids.66 This enzyme is believed not to be involved in cell signal 
transduction, and in vivo, the only known function is phosphate retrieval in times when 
phosphate becomes limited. Antibodies to PLCBc have shown to cross react with at least 
some of the mammalian activity as mentioned previously.56 Several experiments also 
demonstrated that PLCBc can mimic mammalian PC-PLC in vitro. Levine observed 
increased arachidonic acid metabolites in rat liver cells (the C-9 cell line), porcine aorta 
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endothelial cells, bovine aorta smooth muscle cells, bovine aorta endothelial cells, mouse 
fibroblasts and rat keratinocytes cell culture after treatment with PLCBc.72 Johansen73 
reported that constitutive expression of the gene encoding PC-PLC from B. cereus led to 
chronic elevation of the cellular DAG level and oncogenic transformation of NIH 3T3 
cells. The expression of the bacterial PC-PLC gene was both necessary and sufficient for 
induction and maintenance of the transformed phenotype. Moscat observed that the 
exogenous addition of PC-PLC from B. cereus was able to cause mimicking of both a 
significant portion of the mitogenic response to platelet-derived growth factor (PDGF) in 
Swiss 3T3 fibroblasts and the constitutive activation of protein kinase C (PKC) in ras- or 
src-transformed NIH 3T3 cells.74, 75 
The phosphatidylcholine-preferring PLCBc is a 28.5-kDa monomeric 
metalloenzyme containing 245 amino acids and three zinc atoms in its active site. The 
enzyme processes PC preferentially, relative to PE and PS (ratio of kcat = 10:5:2, kcat/Km 
= 9:6:1).76 Crystallographic77 and chemical modification78 studies of B. cereus PC-PLC 
have provided an insight into the molecular architecture of this enzyme and, by 
extrapolation, the possible tertiary structures of homologous regions in other zinc-binding 
phospholipase C. The enzyme is quite resistant to denaturation by urea, sodium 
dodecylsulfate or heat (70 °C for 10 min), probably due to the structural stabilization of 
the zinc ions.79 
The three-dimensional crystal structure of B. cereus PC-PLC at 1.5Å resolution 
revealed that the enzyme is composed of ten helices, forming a roughly ellipsoidal 
structure with approximate dimensions of 40 Å x 30 Å x 20 Å (Figure 1.4).77, 80 The 
molecular surface is smooth except for a cleft, which is approximately 8 Å deep and 5 Å 
wide. Neutral, basic, and acidic amino acid residues are evenly distributed on the 
molecular surface of PLCBc except for two regions located close to the active site cleft. In 
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the first region, amino acid residues form a non-polar hydrophobic surface, while 
residues in the other region are primarily acidic and in close proximity to the metal ions. 
The crystal structure confirmed the presence of three zinc ions, all within the cleft, 
refuting the traditional view of two from atomic absorption analysis. These metal ions 
appear to play important roles in stabilizing the enzyme since they are coordinated to 
widely separated segments of the peptide chain. The three zinc ions, one of which is 
loosely bound, coordinate with amino acid residues from different helices and thus 
conformationally restrain the tertiary structure. All three zinc icons in the native structure 
are pentacoordinated: Zn1 is coordinated by two histidines (His69 and His118), two 
aspartic acids (Asp55 and Asp122) and an active-site water. Zn2 is ligated with two 
histidines (His128 and His142) and glutamic acid-146 with the remaining two covalent 
vacancies filled with active site waters, and Zn3 is loosely bound with histidine 14, 
aspartic acid 122 and the carboxyl and N-terminal amino groups from tryptophan 1 and a 
water molecule. All three zinc ions appeared to have three oxygen and two nitrogen 
ligands in what could be described as trigonal bipyramidal coordination. Asp 122 forms a 
carboxylate bridge between Zn1 and Zn3 (Zn-Zn distance 3.3Å), and an active-site water 




Figure 1.4: An illustrate drawing of PL-PLC from B. cereus.  
 
Figure 1.5: The active site of PL-PLC from Bacillus cereus showing the coordination 
between amino acid resides and three zinc ions.77 
 12
A number of X-ray crystal structures of PLCBc complexed with several different 
ligands have also been solved.80-82 The active site of B. cereus PC-PLC was tentatively 
identified by examining the cocrystal of the enzyme with an inorganic phosphate.77 This 
assignment was later confirmed by a structure of PLCBc complexed with a 
phosphatidylcholine-derived phosphonate inhibitor.80 This crystal structure revealed that 
the phosphonate binds to the active site in a similar fashion to inorganic phosphate. The 
two non-bridging oxygen atoms of the phosphonate bind to all three zinc ions, displacing 
two of the coordinating water molecules in the active site of native PLCBc, one of which 
bridging Zn1 and Zn3 and the other coordinating to Zn2 in the native structure of the 
PLCBc. The major difference is that the other Zn2 ligand water appeared to be gone as 
well, thus leaving Zn2 tetracoordinated, rather than pentacoordinated as it was in the 
native structure (Figure 1.6). This tri-metal-center binding pattern resembles that of E. 




Figure 1.6: Interaction at the active site of PLCBc complexed with a non-hydrolyzable 
substrate analog.80, 87 
 
E. coli alkaline phosphatase (AP) has two zinc and one magnesium ions at the 
active site (Figure 1.7). Extensive investigations into the catalytic mechanism of AP 
resulted in well-accepted kinetic scheme for the enzymatic 
hydrolysis/transphosphorylation of phosphate monoesters, establishing this particular 
bacterial enzyme as a model for other phosphatases that use metal ions in phosphate ester 
hydrolysis and transphosphorylation reactions.88, 89 It was accepted that the nucleophilic 
Ser 102 is transiently phosphorylated giving a covalent phosphorylated-enzyme 
intermediate, which is then hydrolyzed to release the inorganic phosphate. Isotope 
labeling with a chiral (16O, 17O, 18O) phosphoryl diester conformed that the hydrolytic 
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reaction proceeded with overall retention of configuration at the phosphorous atom,90 
consistent with the double displacement mechanism via in-line attack and the formation 
of a covalent phosphorylated enzyme intermediate. The detailed mechanism invokes a 
rather classic two metal ion catalysis with a zinc ion activating the nucleophilic hydroxyl 
and the other stabilizing the leaving alkoxide. Both zinc ions chelate to the non-bridging 
oxygen on the phosphorus atom. The magnesium ion appeared to be required to 
structurally stabilize the enzyme in its catalytically most active form and is not essential 
for reactivity. The enzyme with three zinc ions is still active, and elimination of the 
functional link between Mg and Zn2 in the D51N mutant enzyme resulted in the vacancy 
of the Mg site with a mere 20-40 fold loss of enzymatic activity being observed.89  
 
 
Figure 1.7: Active site of the E. coli alkaline phosphatase. Some residues and water 
molecules are omitted for clarity. In the mammalian sequences all the 
residues involved in the metal binding are conserved except for Thr155, 
which is replaced by serine in some cases. Others in this region are also 
conserved as well except for a few.83 
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P1 nuclease from Penicillium citrinum is also a phosphodiesterase, cleaving the 
bond between 3’-hydroxyl and 5’-phosphoryl group of the adjacent nucleoside in the 
nucleic acid, and at the same time, acting as a phosphomonoesterase to remove the 3’-
terminal phosphate group.91 In its active form, P1 nuclease contains three zinc ions per 
molecule.92 Superimposition of the three dimensional structures Penicillium citrinum P1 
nuclease and B. cereus phospholipase C revealed a striking similarity despite the fact that 
the two enzymes share only 18% of the sequence identity in the superimposed segment. 
Eight of the nine α-helices in PLCBc appear to correspond to α-helical segments in P1 
nuclease. The zinc-coordination pattern is essentially the same in both enzymes, 
including the presence of three water ligands. The only difference in zinc-coordination is 
that an aspartic acid at position 153 in P1 nuclease coordinated to Zn2, which comes out 
to be a glutamic acid in PLCBc. The stunning similarity in three-dimensional structure 
and almost identical disposition and coordination of the three zinc ions has led to the 
probably false assumption that P1 and PLCBc may be evolutionary related and share 
similar hydrolytic mechanism.86, 93 The crystal structure of P1 with a non-hydrolyzable 
R-diastereomer of monothiophosphorylated oligonucleotides, solved at 2.8Å, revealed 
significant differences in substrate binding. The relatively inaccessible dinuclear Zn ions 
(Zn1 and Zn3) don not make direct contact with the ligand, and the more exposed Zn2 is 
the only zinc ion that bound to the phosphate group. Arginine 48, where no analogous 
amino acid residue found in PLCBc, is in close proximity to the phosphate, probably 
stabilizing the negative charge in the pentacovalent transition state with its positively 
charged guanidinium group.  
Several possible hydrolytic mechanisms have been envisaged,86, 94, 95 and all of 
these involve nucleophilic attack by a zinc activated water molecule and stabilization of 
the pentacovalent transition state by Arg48 without the involvement of a covalent 
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phosphorylated enzyme intermediate. However each mechanism assigns different roles to 
the three zinc ions and the firmly bound water molecules seen in the P1 crystal structure. 
The overall stereochemistry at phosphorous center hence is inverted, compatible with 
experimental discovery using isotope labeled thiophosphorylated substrate. The reaction 
mechanism was investigated using single-stranded dithiophosphorylated oligonucleotides 
as substrate analogs in Sucks’ group. Based on the 1.8 Å structure, he suggested that the 
water molecule bridging Zn1 and Zn3 acted as the nucleophile for an in-line attack on the 
phosphodiester P-O bond. Asp 45, which also serves as a ligand of Zn1, helps to orient 
the hydroxide for attack.96 The resulting pentacoordinate intermediate with the additional 
negative charge was stabilized by Arg48 guanidinium with the incoming hydroxide ion 
and the leaving O3 occupying apical positions. The more exposed Zn2, as a Lewis acid, 
plays a dual role in activating the phosphate and stabilizing the leaving O3-alkoxide 




Figure 1.8: On the left: Zn coordination in P1 nuclease. Carbon, nitrogen and oxygen 
atoms are represented by open spheres with radius depending on atom type. 
Zn ions (Zn1, Zn2 and Zn3) and water ligands (O1, O2 and O3) are depicted 
by two concentric sphere. Dashed line indicate Zn-ligand interaction.86 On 
the right: Proposed catalytic mechanism of P1 nuclease based on a crystal 
structure with a substrate analog. The hydroxide ion (shaded sphere) 
bridging Zn1 and Zn3 and Zn2 is stabilizing the leaving O38-oxyanion.96 
 
One of the noticeable features in the PLCBc-inhibitor complex is that the choline 
head group adopts an unusual orientation in which it is folded back over the 
diacylglycerol part of the inhibitor and is almost parallel with the two acyl side chains. 
Three amino acid residues Glu4, Tyr56, and Phe66 comprise the site to which the 
positively charged choline head group binds (Figure 1.9).80 The carboxyl group on the 
side chain of Glu4 is 3.9Å away, perhaps stabilizing the choline positive charge via 
electrostatic interaction. The center of the aromatic rings of Tyr56 and Phe66 are 4.7Å 
and 4.2Å from the positively charged methyl group, respectively. They are positioned so 
that one π-face of the respective aromatic rings, which have partial negative character due 
to the quadrupole moment, is coordinated with choline trimethylammonium cation to 
stabilize the opposite charged, probably through cation-π interaction.97-100 Those 
interactions around the positively charged trimethylammonium ion are important for the 
substrate binding and catalysis as a phosphatidylcholine analogue with the 
trimethylammonium moiety replaced by an isosteric tert-butyl group was found to 
undergo hydrolysis 1000 times less efficiently by PLCBc.101  
The other two natural substrates of PLCBc, phosphatidylethanolamine (PE) and 
phosphatidylcholine (PS), probably also bind to the active site in a similar fashion. It 
seems reasonable to assume that Glu4, Tyr56, and Phe66 contribute differently in 
stabilizing/destabilizing the charged head groups of the phospholipids, whether it is the 
 18
positively charged trimethylammonium/ammonium ion or the negatively charged 
carboxylate. These amino acid residues could therefore play roles in dictating the 
substrate specificity of PLCBc.  
 
 
Figure 1.9: View of Glu4, Tyr56, and Phe66 interacting with a substrate analogue 
inhibitor; the distances between the methyl groups of the ammonium group 
of the choline moiety and the center of the aromatic rings of Tyr56 and 
Phe66 and the carboxyl group of Glu4 are shown.  
 
Less is known about the interaction between the amino acid residue of PLCBc and 
the two acyl side chains. No clear-cut interactions could be identified except a hydrogen 
bonding between sn2-carbonyl and asparagine 134. Both side chains of the diacylglycerol 
moiety are somewhat disordered with the sn-1 acyl chain bring more loosely bound. The 
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thermal motions increase along the aliphatic tail. The lacking of any obvious interactions 
come with a surprise since phosphorylated serine, ethanolamine and choline themselves 
do not bind to PLCBc and phospholipids with longer side chains are generally more 
reactive substrates.  
Base on evidence from X-ray crystallography and kinetic analysis, and in analogy 
to other phosphodiesterases,102 it was proposed that PLCBc hydrolyzes a phosphodiester 
by activating an active site water molecule for in-line attack on the phosphodiester. 
Collapse of the resultant pentacoordinated intermediate then provides a diacylglycerol 
and a phosphorylated head group with inversion of configuration at phosphorus atom.  
A series of studies were conducted to understand the mechanistic aspects of the 
PLCBc catalyzed hydrolysis of phospholipids in the Martin group.103 The absence of the 
solvent viscosity effects suggested that an internal, chemical step was the rate-
determining step for hydrolytic reaction of water-soluble phospholipids, refuting the 
proposal that release of DAG is rate determining.103, 104 Solvent isotope effect and 
proton inventory studies indicated a single proton transfer; either the deprotonation of the 
nucleophilic water or the protonation of the leaving cholinephosphate, is involved in the 
rate-limiting step.103 Mutagenesis studies provided evidence to support Asp55 rather than 
Glu4 to be the general base that activated the water for nucleophilic attack on the 
phosphodiester, and mutations at this position generate enzymes having similar structures 
to that of the wild type but whose catalytic activities are reduced by 104-106 fold.105, 106  
 
1.3 CHEMICAL SYNTHESIS OF PHOSPHOLIPIDS AND THEIR ANALOGS  
The phospholipids to be discussed in this and upcoming chapters are generally 
phosphomonoester and phosphodiesters. The key issues in the chemical synthesis of 
phospholipids are the generation and preservation of the stereocenter at sn-2 position, 
 20
introduction of the fatty acid side chains in a site-specific manner and the incorporation 
of phosphatidyl diester functionality.107-110 
 
1.3.1 A Brief Overview of Phosphorylation  
The key issue in the syntheses of phospholipid is the generation of a well-defined 
stereocenter at the glycerol 2-position followed by introduction of the fatty acid 
substituents in a regiospecific manner that preserves the stereochemical integrity of the 
central carbon.111 As a result, most stereospecific synthetic approaches that have been 
developed require multiple protecting group manipulations, which is particularly true for 
those methods aimed at preparing phospholipids with different acyl groups.  
The sn-2 stereocenters are generally derived from chiral pools. Most of the 
approaches developed to date still follow the synthetic scheme devised by Baer in his 
landmark synthesis of 1,2-distearoyl-sn-glycero-3-phosphorylholine in 1950,112 which 
involved derivatization and protecting group manipulations of an orthogonally protected 
glycerol derivative.87, 107, 112-116 The glycerol derivatives were often obtained from 1,2-
isopropylidene-sn-glycerol (1.1), a currently commercially available material that is also 
readily available from D-mannitol.117 They can also be prepared through 









1.1 1.2 1.3  
Figure 1.10: Commonly used chiral starting materials for phospholipids synthesis 
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Methods employing derivatives of enantiomerically pure S-glycidol (1.2), which 
became available from stereospecific epoxidation of allylic alcohols, for preparing 
optically active glycerophospholipids and analogue have recently been published.118-120 
In Burgos’ approach, the titanium-assisted nucleophilic opening of S-glycidol (1.2), 
which was prepared via Sharpless asymmetric epoxidation of allylic alcohol, with stearic 
acid gave (S)-(+)-1-stearoyl-sn-glycerol (1.5).118 Selective silylation of the primary 
alcohol in 1.5 with tert-butyldimethylsily chloride followed by esterification of the 
resultant secondary alcohol with stearoyl chloride and removal of the silyl protecting 
group afforded distearoyl-sn-glycerol 1.7.118 Exposure of 1.7 to 2-bromoethoxy-
phosphonic dichloride followed by displacement of the bromide with trimethylamine 
according to literature precedence would provide (R)-1,2-distearoyl-sn-glycero-3- 









1. TBSCl, imidazole, 97%





















Guivisdalsky prepared ether-linked phospholipids (alkyl phospholipids) from R-
glycidyl tosylate (1.9) and R-glycidyl tert-butyldiphenylsilyl ether, which have the same 
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absolute stereochemistry at C2 as S-glycidol (1.2).120 Regio- and stereospecific 
nucleophilic opening of R-glycidyl tosylate with 1-hexadecanol in the presence of 
BF3⋅Et2O as catalyst and subsequent O-methylation under mild conditions afforded 
dialkylglycerol 1.11 without concomitant formation of epoxide. Treatment of 1.11 with 
potassium superoxide in the presence of 18-crown-6 led to the direct displacement of 
tosylate to form alcohol 1.12. The phosphocholine moiety was introduced by reaction of 
1.12 with 2-chloro-2-oxo-l,3,2-dioxaphospholane (1.13), followed by heating the cyclic 
dioxaphospholane intermediate 1.14 with trimethylamine, affording phosphorylcholine 
1.15 in good yield (Scheme 1.2).121 Alkyl phospholipids with different head groups 
could also accessed by opening the dioxaphospholane with a variety of nucleophiles in 
the presence of trimethylsilyl triflate.122 The method starting from S-glycidol or its 
derivatives has found widespread application to the synthesis of ether lipids, yet it turned 











































1.14 1.15  
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A second issue in the phospholipid synthesis is the introduction of the 
phosphodiester functionality. Thanks to the development of new methods originally 
designed for the phosphorylation of nucleic acids, peptides, carbohydrates and steroids, 
numerous reagents and approaches are now available to address the issue of 
phosphorylation of protected glycerol derivatives. Most of the approaches involved either 
activation of the phosphorylating reagent, the alcohol or both. Some commonly used 
phosphorylating reagents are dichlorophosphate 1.16 (Scheme 1.1), chlorophosphate 1.17 
(acid chloride) (Scheme 1.3), pyrophosphate 1.18 (acid anhydride), phospho-1,2,4-
triazolide 1.19, phosphobenzotriazole 1.20 and phsophoimidazole (Figure 1.11). 
Phosphoric acid can also be used in conjunction with trichloroacetonitrile, arylsulfonyl 
chloride (2,4,6-triispropylbenzene sulphonyl chloride) or carbodiimide (Scheme 1.4). 
Alcohol can be activated as its corresponding epoxide or alkyl halide, and 
phosphorylation is achieved by nucleophilic substitution with a metal phosphonate. The 
silver phosphonate is commonly used to activate the phosphate concurrently (Scheme 
1.3). Because of the close resemblance to ester syntheses, the details of phosphorylation 
using phosphate chemistry will not be discussed. Instead, a brief discussion of the 





































X = Cl, imidazole, CEP
1.19 1.20 1.21  
















































1.25 1.26 1.27  
 
Tri-coordinate phosphorus compounds containing suitable leaving groups are 
indispensable phosphorylation reagents for the syntheses of phospholipids and their 
analogues. Nucleophilic displacements on the electrophilic phosphorus and subsequent 
oxidation of the resultant P(III) compound is one of the most important routes to 
biophosphates. P (III) compounds can also behave as nucleophiles due to the presence of 
a free electron pair, reacting with a wide range of electrophiles to give P(IV) compounds, 
which have been converted into P(V) compounds. This second advantageous property 
allows conversion of P (III) compounds into biophosphates and their important analogues 
such as phosphorothioates and phosphonates.123 
Chlorophosphite and dichlorophosphite are among the first being used in the 
synthesis of phospholipids. Martin has developed a procedure of coupling simple 
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alcohols with two common polar head groups (L-serine and ethanolamine).124 For 
example, phosphatidylserine 1.31 was prepared in six steps (45% overall yield) from diol 
1.32 via a sequence that featured the phosphite coupling of diacylglycerol 1.29 with 



















COOBn 1. PhOPCl2. i-PrNEt. THF
2. 1.29
1. H2O2, CH2Cl2




















Phosphatidylscholine could prepared similarly though the corresponding 
bromoethanol analog such as 1.36a.124 Phosphite coupling of the diacylglycerol 1.33a 
and bromoethanol using methyl dichlorophosphite delivered an intermediate phosphite 
triester 1.34a that was oxidized with hydrogen peroxide to furnish the phosphate triester 
1.36a (Scheme 1.6). Deprotection of the O-methyl group in 1.36a by trimethylamine with 
concomitant nucleophilic displacement of the bromide gave the phosphatidylcholine 
analogue 1.38a. The phosphorothioate analogue 1.39 could be readily prepared from the 
triester 1.37. Triester 1.37 was in turn prepared via the coupling of the diacylglycerol 
1.33 with 2-bromoethanol using 2-(trimethylsilyl)ethyl dichlorophosphite followed by 
sulfurization of the intermediate phosphite triester 1.35. Reaction of 1.37 with 
trimethylamine and subsequent deprotection using dilute aqueous hydrofluoric acid gave 
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choline phosphorothioate 1.39. Martin also demonstrated that thiophospholipid, such as 
1.38b, could be synthesized likewise.87 The diacylglyceryl thiol 1.33b was coupled with 
bromoethanol using methyl dichlorophosphite, and the thiophosphite triester 1.34b thus 
obtained was oxidized to give the thiophosphate triester 1.36b. Reacting of 1.36b with 














1.33a: Y = OH















1.34a: Y = O, R = OMe
1.34a: Y = S, R = OMe
1.35: Y = O, R = O(CH2)2TMS
1.36a: Y = O, W = O, R = OMe (71% over three steps)
1.36b: Y = S, W = O, R = OMe (38% over three steps)













1.38a: Y = O, W = O (83%)
1.38b: Y = S, W = O (82%)
1.39: Y = O, W = S (64%)  
 
Phosphoroamidites are nowadays the most commonly used phosphorylating 
reagents for the synthesis of various biomolecules. However, they do not react readily 
with alcohols unless a proper activator, such as tetrazole, is employed.123, 125 
Konradsson recently developed a route to enantiopure phospholipids utilizing a 
phosphoroamidite coupling. Thus lysophosphatidic acid 1.44 and phosphatidic acid 1.45 
were obtained in good overall yields in only three and four steps from S-glycidol (1.2).126 
The oxidative phosphorylation of (S)-glycidol (1.2) with dialkyl phosphoramidite 1.40 
furnished phosphorylglycidol 1.41 in 74% yield (Scheme 1.7). Regioselective opening of 
the epoxide with cesium palmitate afforded the monoester 1.42, which underwent further 
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esterification with oleic acid to produce the mixed 1,2-diacyl phosphatidic acid di-tert-
butyl ester 1.43 in 87% yield. Deprotection of 1.42 and 1.43 with TFA in CH2Cl2 
produced the lysophosphatidic acid 1.44 and the mixed 1,2-diacyl phosphatidic acid 1.45 
in quantitative yields. Coupling of phosphatidic acid 1.45 with choline- and ethanolamine 
derivatives would lead to phosphatidylcholine and phosphatidylethanolamine. This 
approach allows both natural and unnatural enantiomers of phospholipids, and analogues 
thereof, to be obtained in high optical purity from commercially available (S)- or (R)-
glycidol. If an alcohol is used to open the epoxide, then sn-1 ethereal analogs of 




































































Hebert and Just used an inverse phosphite triester approach in their synthesis of 
phospholipids (Scheme 1.8).127 Chlorophosphinite 1.46 was condensed with 
bromoethanol to give dialkylphosphoramidite 1.47, which was reacted with 
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diacylglycerol 1.48 followed by oxidation of the intermediate phosphite in situ with 
iodine affording phosphotriester 1.49. Treating phosphotriester 1.49 with trimethylamine 
allowed introduction of the trimethylammonium group and simultaneous removal of the 













1. tetrazole, CH3CN, 1.48
70% over two steps





































Mlotkowska described the one-pot synthesis of rac-S-(2-acetoxy-3-
hexadecyloxypropyl)-thiophospholine using an Arbuzov type reaction.128 The disulfide 
1.51 derived from a thioglycerol was chlorinated with sulfuryl chloride to give the 
corresponding sulfenyl chloride 1.52. Phosphorylation of 1.52 with triethylsilyloxy-1,3,2-
dioxaphospholane afforded thiophospholane 1.53. The crude thiophosphate 1.53 was then 
converted into the desired thiophosphocholine by treatment with trimethylamine (Scheme 






































1.3.2 Prior Work From Our Group 
1.3.2.1 Substrate-Based Non-Hydrolyzable Analogs 
In the course of the program directed toward elucidating the mechanism of 
hydrolysis of the phosphodiester bond of phospholipids by enzymes of the phospholipase 
C class, a number of phospholipids analogues (X = NH, NBn, S, CH2, and CF2) of the 
general type 1.38 were prepared and examined to establish a pattern of structure-activity 
relationships and to identify those compounds that might be inhibitors of PLCBc (Figure 
1.12). The design of these inhibitors followed the simple principle that altering functional 
group involved in the transformation, namely the scissile P-O bond of the phosphodiester 
linkage, to give compounds that were no longer hydrolytically labile. The rest of the 
structure was then modified to improve the lipophilic interaction, hydrogen bonding and 









1.55a, 1.38a: R = choline
1.55b: R = ethanolamine







1.38a: X = Y = Z = O
1.38b: X = S, Y = Z = O
1.38c: X = CH2, Y = Z = O
1.38d: X = CF2, Y = Z = O
1.38e: X = O, Y = S, Z = O, Sp
1.38f: X = O, Y = O, Z = S, Rp
1.38g: X = O, Y = S, Z = S
1.38h: X = O, Y = S, Z = S, C5 analog of 1.56g
1.38i: X = NBn, Y = Z = O
NMe3
 
Figure 1.12: Substrate-based phospholipase analogs 
The phosphonate 1.38c was prepared by the Arbuzov reaction of the known 
bromide 1.56 with triethyl phosphite. Cleavage of the acetonide moiety followed by 
diacylation of the intermediate diol and subsequent hydrolysis of the phosphonate diester 
provided an intermediate phosphonic acid 1.58c, which was coupled with choline 
chloride in the presence of trichloroacetonitrile/pyridine to furnish the 
phosphatidylcholine analog 1.38c. Application of a similar sequence of reactions starting 



























1.57c: Z = H, 86%
1.57d: Z = F
1.58c: Z = H, 64%
1.58d: Z = F, 68%
1.38c: Z = H, 35%









Dithiophosphate analog 1.38g was prepared from 1,2-isopropylidene-sn-glycerol 
(1.1). Phosphorylation of 1.33a with 2-chloro-1,3,2-dithiaphospholane (1.59) followed by 
treating the intermediate phosphite with sulfur provided the 2-alkoxy-2-thio-1,3,2-
thiaphospholane 1.60, which upon exposure to choline tosylate in the presence of DBU 


































The phosphoramide analog 1.38i was also prepared from 1,2-isopropylidene-sn-
glycerol (1.1). Thus, the enantiomerically pure 1.1 was first converted into the N-benzyl 
glycerol 1.61 via its tosylate. Phosphite coupling of 1.61 with 2-bromoethanol using 
methyl dichlorophosphite followed by oxidation of the intermediate phosphite with 
hydrogen peroxide afforded 1.62 in 78% yield. Subsequent removal of the isopropylidene 
group and acylation of the intermediate diol with n-hexanoic acid in the presence of 
DCC/DMAP followed by treatment with trimethylamine delivered the 

































21% over two steps
 
 
Table 1.1: Results of Kinetic and Solubility Studies on Phospholipid Analogues 
Analogue Ki (mM) KM (mM) Inhibition 
1.38a  0.39±0.02  
1.38e: Y = S  0.015±0.001  
1.38i: X =NBn 0.015  competitive 
1.38b: X =S 0.007  competitive 
1.38c: X =CH2 1.15  competitive 
1.38d: X =CF2 2.68  competitive 
1.38f: Z = S 0.013  competitive 
1.38g: Y = Z = S 0.010  competitive 
 
The phosphatidylcholine analogues 1.38a-g were found to inhibit PLCBc, and 
were determined to be competitive inhibitors by examination of the corresponding 
Lineweaver-Burk plots at different inhibitor concentrations.87 The thiophospholipid 
analogues 1.38b, 1.38f and 1.38g, where sulfur replaced one or more phosphate oxygens, 
were highly effective inhibitors of PLCBc, with all three being approximately equipotent. 
Interestingly, thiophosphate 1.38e, which has the S configuration at phosphorus, is a 
substrate that must bind to the active site with the sulfur atom serving as a ligand for the 
two structural and cocatalytic zinc ions Znl and Zn3. On the other hand, 1.38f, which has 
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the R configuration at phosphorus, is an inhibitor that must bind so that the sulfur atom is 
coordinated to the zinc ion (Zn2) that seems to be involved in catalysis (Table 1.1). Thus, 
binding of a sulfur ligand to the catalytic zinc ion critically affects the ability of the 
enzyme to hydrolyze the phosphodiester linkage. 
 
1.3.2.2 Cyclic Zinc-binding N, N’-Dihydroxyurea Inhibitors  
As described in the prior sections, most of the inhibitors of PLCBc synthesized in 
the Martin group are substrate analogs in which the bridging and/or the non-bridging 
oxygens have been replaced.87, 124 However, a large number of non-substrate based 
inhibitors of PLCBc have been known. Monovalent anions, such as HCO3-, Br-, Cl-, NO3-
, CNO- and I-, and Tris were found to be weak inhibitors of PLCBc.131 The most notable 
non-substrate analogue is the xanthate derivative D609 1.68 (Ki = 15 µM), a potent 
competitive inhibitor.132, 133 
The PC-PLCBc active site contains three zinc ions. The two structural and 
cocatalytic zinc ions Znl and Zn3 define a dinuclear center bridged by the carboxyl group 
of Asp122 and a water molecule, with an internuclear distance of 3.5 Å. Thus bidentate 
ligands that would bind to this bimetallic site could potentially be inhibitors.134, 135 
Hydroxamic acids are well-known stable zinc chelators, and are analogs of the less stable 
2,7-dihydroxytropolone (1.63), which we have found to be a potent inhibitor of PLCBc at 
pH 7.3. It was proposed that the polyhydroxy tropolone inhibits the enzymes by chelating 
to both metal ions at the active site (Figure 1.13)134, 136 Hence, a series of hydroxamic 
































1.65a: n = 0
1.65b: n = 1










1.68 1.69  
Figure 1.14: Non-substrate-based PLCBc inhibitors 
Dr. Follows prepared compounds 1.65a-c and 1.66 in a straightforward fashion 
that relied on the dialkylating of an O-protected hydroxylurea 1.70 with 1,ω-
dibromoalkane such as 1.71 or succinyl chloride 1.72 (Scheme 1.13). The unsaturated 












O KH, THF, 0°C then
1.71, KH, -40 °C→ rt (31%)
or






1.73: X = H2










1.65c: X = H2











Table 1.2: Results of Kinetic Studies on Cyclic N, N´-Dihydroxyureas 
Compounds pKa1, pKa1 Ki (µM) at pH 7.3 Ki (µM) at pH 9.5 
1.63 5.6, 7.0 16 23 
1.64 5.6, 7.1 no inhibition no inhibition 
1.65a  no inhibition 303 
1.65b  no inhibition 146 
1.65c 9.4, 11.2 no inhibition 71 
1.66  no inhibition no inhibition 
1.67 5.0, 8.7 388 53 
 
As can be seen, a number of N, N´-dihydroxyureas were inactive at pH 7.3 but 
active at pH 9.5. It appeared that at least one of the N-hydroxyl groups must be ionized in 
order for the N, N´-dihydroxyurea to serve effectively as a ligand for the zinc ions. 
Consequently, the pKas of the two hydroxyl groups play major roles in the potency of N, 
N´-dihydroxyureas as inhibitors.  
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1.4 CONCLUSION  
Significant progress has been made in the understanding of the kinetic and 
mechanistic aspects of the PLCBc-catalyzed hydrolysis of phospholipids in the past 
decades. The crystal structure was published; the active site was identified; and a 
mechanism was proposed based on the kinetic and structural data. On the other hand, 
little is known about the structure-reactivity relationships in the hydrolytic reaction of 
phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidyl L-serine 
(PS), all of which are known natural substrates of PLCBc. In the upcoming chapter, we 
will discuss the design of the water-soluble substrate-base analogue, using the X-ray data 
described in this chapter; we will prepare such inhibitors, using the chemistry discussed 
here, to gain understanding about the structure-reactivity relationship.  
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Chapter 2: The Synthesis of C-Aryl Glycoside 
2.1 C-ARYL GLYCOSIDE  
The C-aryl glycoside antibiotics are a relatively small class of natural products, 
but they have attracted considerable attention over the past 25 years among synthetic 
organic chemists and biochemists because of their potent biological activity.137-140 
Furthermore, the incorporation of C-glycoside chiral building blocks in the syntheses of 
biologically important compounds, such as palytoxin (Figure 2.1)141-143 and 
halichondrin B,144 has stimulated the development of new glycosidation methodologies. 
Modern glycobiology has consistently shown that most biological recognition 
phenomenon involves the glycosidic part of the cell wall glycoproteins and glycolipids.  
 
2.1  
Figure 2.1: Palytoxin Structure 
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The replacement of the anomeric oxygen of the O-glycoside with carbon in C-
glycoside renders it resistant to both acid hydrolysis and enzymatic hydrolysis by α- and 
β-glycosidases. Therefore, C-glycosides are potential inhibitors of carbohydrate 
processing enzymes and are stable analogs of glycans involved in important intra- and 
inter-cellular processes. 
Some representative members of this class of natural products are shown in 
Figure 2.2. The gilvocarcins (2.2a-c)145, 146 and related compounds ravidomycin (2.3) 
and chrysomycin are metabolites of certain Streptomyces species sharing a common 
tetracyclic aromatic nucleus to which rare sugars are attached as C-glycosides at C4. 
Several of these antibiotics exhibit significant antitumor activity.147 In particular, 
gilvocarcin V (2.2b) has attracted considerable attention due to its remarkable antitumor 
activity and exceptionally low toxicity. Its activity can be enhanced with low-energy 
visible light irradiation.148 Galtamycinone (2.4),149-151 an unusual member of 
angucycline family with a linear tetracycle rather than the angular tetracycle structure 
possessed by most other members, exhibits both antitumor and antibiotic activities. The 
Streptomyces-derived kidamycin antibiotics, including kidamycin (2.5), pluramycin and 
hedamycin, displayed anti-tumor activity.152 The mechanism of action is believed to 
















































gilvocarcin M (2.2a):   R = methyl
gilvocarcin V  (2.2b):   R = vinyl
gilvocarcin E  (2.2c):   R = ethyl
 
Figure 2.2: Representing examples of C-aryl glycoside antibiotics 
Parker categorized C-aryl glycosides into four major subgroups based on the 
orientation of the carbohydrate substituent(s) relative to the phenolic hydroxyl group(s) 
on the aromatic core.154 Group I C-aryl glycoside has a glycoside linkage para to the 
phenolic hydroxyl; In group II, the linkage is ortho to the phenolic hydroxyl. The Group 
III has two sugars attached to the aromatic ring, one ortho and the other para to the 
phenolic hydroxyl. In group IV, the carbohydrate moiety is ortho to one of the two 


















Figure 2.3: Major groups of C-aryl glycosides 
The two fundamental issues in C-aryl glycoside synthesis involve control of the 
absolute stereochemistry at the anomeric center and control of the point of carbohydrate 
attachment to the aromatic core. Stereoselective syntheses of C-aryl glycosides and C-
glycosides have been reviewed a number of times in literature, by Postema140, 155, 
Knpap156, Levy157, Beau137, Nicotra138 and Du139. Therefore, the discussion in the 
following sections only serves to provide an overview of the synthetic methods currently 
available, and the emphasis is upon recently developed approaches. 
 
2.2 THE FORMATION OF C-GLYCOSIDE BONDS  
The commonly used routes to C-aryl glycosides can be roughly classified into the 
following four major approaches: 
1. Substitution reactions, where the glycosyl donor can be either nucleophilic or 
electrophilic. 
2. Transition metal catalyzed two-partner couplings, especially with palladium catalyst.  
3. Pericyclic reactions, most notably hetero-Diels-Alder cycloadditions for the de novo 
synthesis of the carbohydrate moiety of C-aryl glycosides. 
4. Intramolecular cyclizations, such as ring closing metathesis, cyclotrimerization and 
electrophilic ring closure. 
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2.2.1 Substitution With Electrophilic C-Glycosyl Donors  
Nucleophilic substitution at the anomeric carbon is by far the most widely used 
method for glycosidyl bond formation. This approach takes advantage of the inherent 
electrophilicity of the anomeric carbon. For convenience, reactions involving 
electrophilic glycosyl donors such as lactol, O-glycoside, S-glycoside, anomeric ester, 
halide, imidate, lactones, glycal, 1,2-anhydride and enitol, are included in this category.  
 
2.2.1.1 Anomeric Halides, Esters and Ethers  
Glycosyl halides are frequently used as electrophilic donors. Anomeric chlorides, 
bromides and fluorides have all received considerable attention. Lewis acids are used 
extensively to enhance the electrophilicity of the anomeric carbon through the formation 
of oxocarbenium ions, which are trapped with electron-rich arenes to form C-aryl 
glycosides. With pyranose sugars, electrophilic attacks are often from the α-face leading 
to α-C-glycosides. This is due to the anomeric effect of the ring oxygen directing the 
incoming nucleophile to the α-face. In the more flexible furanose, the steric bias of the 
two faces usually dictates the product ratio often resulting in forming a mixture. 
Oxocarbenium intermediates can also be generated from anomeric acetates, 
trifluoroacetates, O-glycosides, S-glycosides or lactols. The anomeric leaving group 
ability dictates the strength of the Lewis acid needed for the reaction 
Toshima158 demonstrated that treatment of pyranose (2.6b or 2.6d) or O-methyl 
pyranoside (2.6a or 2.6c) with TMSOTf/AgClO4 in the presence of 2-naphthol gave 
excellent yields of the corresponding β-C-aryl glycosides 2.7 (Scheme 2.1). The 
α/β ratios were usually excellent with the lowest being 15:1. Unprotected sugars and 














2.7a: R1 = Me, R2 = Bz (99%, >99:1 β/α)
2.7b: R1 = H, R2 = Bz (99%,70:1 β/α)
2.7c: R1 = Me, R2 = H (91%, >99:1β/α)












2.6a: R1 = Me, R2 = Bz
2.6b: R1 = H, R2 = Bz  
2.6c: R1 = Me, R2 = H






Further optimization revealed TMSOTf alone was an efficient activator in most 
cases.160 The reaction process most likely involved an O→C-glycoside rearrangement as 
the use of 10% mol promoter gave a considerable amount of O-glycosylated product. The 
high β selectivity resulted from product equilibration, which favors the more 
thermodynamically stable β anomer. Toshima and coworkers a few years later completed 
the total synthesis of urdamycinone B (2.13) via C-glycosidation of naphthol 2.10 with 





































Alternatively, the oxocarbenium could be trapped internally to form a bicycle as 
demonstrated in Martin’s162-164 and Araki’s165 work (Scheme 2.3). Veyrieres and 
coworkers166 prepared D-glucopyranosylbenzoic acid 2.19, which cannot be accessed 
through intermolecular reaction due to the presence of an electron-withdrawing 
carboxylate, from glycosyl chloride 2.16 via an intramolecular Friedel-Crafts reaction 


















































2.2.1.2 Suzuki's Approach to C-Aryl Glycosides 
Some of the more elegant aspects of the O→C-glycoside rearrangement were 
developed by Suzuki and demonstrated in his syntheses of a number of C-aryl glycoside 
natural products. His group167 discovered that Cp2HfCl2/AgClO4 was a highly effective 
catalyst for the glycosidation of phenols with glycosyl fluorides at low temperature.  
Later development of the O→C-glycoside rearrangement allowed the use of the 
more readily available and shelf stable anomeric acetates as glycosyl donors.168 Suzuki 
also found that the use of Cp2HfCl2/AgClO4 in 1:2 rather than 1:1 ratio provided much 
higher reactivity for the activation of the glycosyl fluoride. The activating catalyst 
proposed by the author was Cp2Hf(ClO4)2 or Cp2Hf(ClO4)Cl, depending upon the ratio 
of Cp2HfCl2 and AgClO4.169 A variety of 2-deoxy-C-aryl glycosides including amino 




















The mechanism proposed by Suzuki involves activation of a glycosyl fluoride by 
the fluorophilic hafnium complex to generate the reactive oxocarbenium intermediate, 
which is rapidly trapped by the phenolic hydroxyl group to provide the O-aryl glycoside. 
Upon warming up, the O-glycoside rearranges in situ in the presence of a suitable Lewis 
acid into C-glycoside. Mechanistic studies suggested that the O→C-glycoside 
rearrangement occurred via a loose ion pair involving an oxocarbenium,167 which 
underwent an irreversible Friedel-Crafts alkylation regioselectively at the carbon ortho to 
the phenolic hydroxyl. This "ortho selectivity" of the aryl C-glycoside bond formation 
was generally high, if not excusive.167 Another important point was the anomeric 
stereocontrol of C-aryl glycoside. The α/β selectivity was determined not only kinetically 
but also by a possible contribution of an ortho-quinone methide intermediate, which 
resulted in epimerization at the anomeric carbon (Scheme 2.6). The ring 
opening/reclosure process, if it occurred, would prefer the thermodynamically more 
stable β-anomer since the anomeric effect was no longer decisive at the stage of the final 
product.170 Suzuki concluded that the α-anomer was typically the kinetic product and 
less sterically congested β-anomer was the thermodynamic product in the O→C-
glycoside rearrangement of pyranoside.167 It is therefore possible to obtain either anomer 


































In the synthesis of vineomycinone B2, Suzuki observed that the BF3⋅Et2O 
mediated O→C-glycoside rearrangement gave C-naphthyl glycoside 2.25 as mixture 
(3.4:1) of anomers in 70% yield favoring the α anomer. The remaining mass was 
unrearranged O-glycoside, whereas the hafnocene promoter led to almost exclusive β-























BF3.Et2O              70%                      α/β= 3.4:1




An impressive reversal of selectivity was observed in the key step of Suzuki’s 
total synthesis of gilvocarcin M (2.2a).146 Glycosyl acetate 2.26 was treated with 
SnCl4/AgClO4 in the presence of the resorcinol derivative 2.27 affording high β-
selectivity of the C-aryl furanoside 2.28 even at low temperature. In sharp contrast, the 
hafnocene combination Cp2HfCl2/AgClO4 gave the desired α-anomer 2.28a in 86% and 
8:1 α/β selectivity. No anomerization was observed upon warming to room temperature. 
This represented a striking difference since prior studies had established that hafnocene 
combination Cp2HfCl2/AgClO4 often resulted in thermodynamic control. Later 
optimization found that the combination of a silyl chloride and AgClO4 afforded higher 
α stereoselectivity, and norbonane derived chlorosilane 2.29 gave the highest selectivity. 
None of the product distributions, however, corresponded to the 1:1 ratio the author 
obtained when he equilibrated α- and β-anomer 2.28a and 2.28b separately in the 
presence of protic acid under forcing conditions (Scheme 2.8). The author rationalized 
the difference based on the relative stability of α- and β-anomer coordinated to the Lewis 






























SnCl4/AgClO4     -20°C         70%                      α/β = 1:58
Cp2HfCl2/AgClO4     -20°C         98%                      α/β = 8.2:1









Suzuki also developed a convergent approach to C-aryl glycosides that relied on 
regioselective cycloadditions of glycosyl-substituted α-alkoxybenzynes and alkoxy- or 
silyloxyfurans.171, 172 The requisite glycosyl benzynes were obtained through 
functionalization of C-aryl glycosides from the O→C-glycoside rearrangement. The 
[2+4]-cycloadditions of α-alkoxyarynes and 2-methoxy- or 2-siloxy-furans proceeded 
regioselectively in the head-to-head manner. No head-to-tail adducts were detected 
(Scheme 2.9). This regiochemical mode of cycloaddition can be attributed to the polar 



















2.30a: R = Me
2.30b: R = MOM
2.30c: R = Bn
2.31 2.32 2.33a: R = Me (75%)
2.33b: R = MOM (74%)








A number of natural products have been prepared using O→C-glycoside 
rearrangement and α-alkoxybenzyne/alkoxyfuran cycloaddition.145, 151, 173-177 In his 
synthesis of Group II C-aryl glycoside antibiotic galtamycinone (2.4),151, 178, Suzuki 
treated anomeric acetate 2.35 with Cp2HfCl2/AgClO4 in the presence resorcinol 2.36 to 
obtain C-glycoside 2.37. The two hydroxyl functional groups on the aromatic ring were 
then elaborated to afford the benzyne precursor 2.38. Regioselective cycloaddition of 
alkoxybenzyne from 2.38 and siloxyfuran 2.39 followed by oxidation afforded C-
glycosyl juglone 2.40 in high yield. The chloroquinone 2.40 was then cyclized with the 
enolate of anhydride 2.41 in highly regioselective manner to give, after spontaneous 
decarboxylation, naphthacenequinone 2.42 in 90% yield. The protecting groups were 
removed globally on exposure to BBr3 at –78 °C to afford galtamycinone (2.4) 





























1. NaH, (MEO)2SO2, 96%
2. TBAF, THF. 100%













































The total synthesis of antibiotic C104 (2.48) represents a more daring application 
of these tactics.175, 179 Siloxyfuran 2.44, prepared in situ from butenolide 2.43, was 
cyclized with the benzyne generated from 2.30b. The cycloadduct was oxidatively 
worked up to afford quinone 2.45 (head-to-head cyclization) and its head-to-tail 
regioisomer in 14:1 ratio. Reduction and bismethylation of quinone 2.45 followed by 
removal of the MOM protecting group afforded phenol 2.46. Phenol 2.46 was converted 
to β-C-glycoside 2.47 upon reaction with D-olivosyl acetate 2.35 in the presence of the 

























































2.47 C104 (2.48)  
 
Suzuki also applied the strategy to the syntheses of Group I C-aryl glycoside 
antibiotics, such as ravidomycin (2.3).173, 180 The presence of C-glycosidic bond at the 
position para to a phenolic hydroxyl ravidomycin was a serious obstacle to the adoption 
of the tactics previously described. Hence, Suzuki translated this “ortho selectivity” in 
O→C-glycoside rearrangement into the “para selectivity” by applying the reaction to 
monoprotected resorcinol 2.27. Hafnocene promoted glycosidation of 2.27 with glycosyl 
fluoride 2.49, whose large tert-butyldiphenylsilyl protective group favored the axial 
disposition to avoid unfavorable gauche interaction when disposed equatorially, gave β-
C-glycoside 2.50 with the additional oxygen functionality at the para position.181 Phenol 
2.50 was then converted to its triflate 2.51 with trifluoromethanesulfonic anhydride. 
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Treatment of 2.51 with n-BuLi generated the reactive benzyne, which was trapped by 2-
methoxyfuran to provide the corresponding cycloadduct. Spontaneously opening of the 
cycloadduct during aqueous work-up and subsequent protection of the naphthol hydroxyl 
as its MOM ether afforded C-naphthyl glycoside 2.52 in 77% yield over 3 steps (Scheme 



























1. n-BuLi, 2-methoxyfuran, -78°C
2. MOMCl, NaH/DMF













2.2.1.3 C-1 Lactones  
Carbohydrate-derived lactones are excellent electrophiles. Organometallic 
reagents, in particular organolithium and Grignard reagents, are used frequently for the 
synthesis of hemiacetals/lactols of the general type 2.54 via nucleophilic addition to 
lactones 2.53. Stereoselective hydride reduction of 2.54 under Brønsted182 or Lewis 
acidic conditions183, 184 furnishes β-C-aryl glycosides 2.56, typically in good yields and 
excellent stereoselectivities. This represents one of the more reliable methods for 
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synthesizing gluco- and galacto-β-C-aryl glycosides. Ellsworth recently examined a 
number of commercially available organosilanes for their abilities as reducing reagents, 
and he found that the critical factor promoting β selectivity was the steric bulk 
surrounding the silyl hydride center.185 The highest β selectivity was obtained with 
triisopropylsilane. Alternatively, dehydration of the hemiacetal intermediate derived from 
2-deoxy sugar, such as 2.53a, with Martin’s sulfurane (Ph2S[OC(CF3)2Ph]2) affords C-






























2.53a: R = H
2.53b: R = OBn
2.56a: R = H, 75% over two steps
2.56b: R = OBn, 71% over two steps
or BF3.Et2O, Et3SiH
Martin's sulfurane





Sulikowski obtained the key intermediate 2.58 via addition of aryllithium to a 
sugar lactone followed by reduction of resultant lactol with acidic sodium 
cyanoborohydride in his total syntheses of the angucycline antibiotics urdamycinone B 
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(2.62a) and 104-2 (2.62b).182, 186 Another key step was the Diels-Alder cycloaddition 




























2.62a: X = H, urdamycinone B
2.62b:  X = OH, 104-2



























1,2-Anhydrosugars have also served as electrophilic glycosyl donors. These 
epoxides187 are mostly generated via stereoselective epoxidation of the corresponding 
glycals with dimethyldioxiran (DMDO) under very mild conditions.188 No purification is 
required except for evaporation of the solvents prior to the addition of carbon 
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nucleophiles. Various organometallic reagents have been used to open the glycal epoxide. 
Among them, Grignard reagents,189-191 organocuprate,192, 193 and organostannanes194 
generally prefer to give β-C-glycosides, where the C2 hydroxyl and the newly formed 
anomeric carbon-carbon bond are trans to each other.  
Only until recently were methods preferentially providing the α-glycoside starting 
to emerge. Rainier utilized triarylaluminum- and triarylboron-reagents to open 1,2-
anhydrosugars to yield 1,2-cis-α-C-aryl glycoside with high stereoselectivity.195 The 
overall stereochemistry at the anomeric center was retained after the reaction. The author 
proposed the syn opening was due to complexation of aluminum or boron to the oxirane 
oxygen followed by “intramolecular” ligand delivery to an oxocarbenium intermediate. 
Thus, it is now possible to obtain either α- or β-C-glycoside from a single glycosidic 
donor by choosing the proper organometal reagent.  
More recently, Xue observed high α-selectivity in the reaction of 1, 2-
anhydrosugar with an organozinc reagent.190 Treatment of tri-O-benzyl-D-glucal epoxide 
2.64 with organozinc trifluoroacetate generated from the corresponding dialkyl- or 
diarylzinc and trifluoroacetic acid, or preformed organozinc chloride afforded the α-C-
aryl glycoside 2.65a with almost complete stereocontrol. However, Rainier reported 
earlier that when zinc chloride and 1-lithiofuran, rather than preformed furylzinc 
chloride, was used in the reaction at colder temperature (-60°C), β-glycoside 2.65b was 
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2.2.1.5 Glycal and the Ferrier Rearrangement  
The vinylougous version of the electrophilic substitution, where the leaving group 
is located at allylic C3 position rather than the anomeric carbon, is typically referred to as 
the Ferrier rearrangement.196 Though the original version of Ferrier rearrangement 
limited itself to oxygen nucleophiles and hence the synthesis of O-glycoside. Carbon 
nucleophiles, such as electron rich aromatics, can nonetheless be used. The reaction 
usually proceeds through a vinyl oxocarbenium intermediate, and subsequent Friedel-
Crafts arylation affords C-aryl glycoside. There have not been as many successful 
examples in this area of research. The α/β stereoselectivity is not often prominent due to 
the more flexible intermediate and nucleophilic attack at the C3 allylic position poses an 
additional obstacle especially when softer carbon nucleophiles are used.197 
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Casiraghi developed a highly regio- and diastereoselective approach to 1-C-aryl-
2,3-ene-a-D-glycosides,198, 199 such as 2.68 and 2.71, via direct arylation of acetylated 
pyranoid glycals at C-l using bromomagnesium phenolates in dichloromethane (Scheme 
2.16). It was necessary, however, to use large excess (typically four equivalents) of the 
bromomagnesium phenolate combined with ultrasonic irradiation to achieve successful 
arylation in the heterogeneous mixture. The reaction was regiospecific with respect to 
both the arylation and the substitution site, with the glucal anomeric carbon being 
arylated and the phenol ortho-carbon being substituted. In addition, the reaction was 
stereoselective with α-anomer being produced predominantly or exclusively, as a result 
of kinetic discrimination of the two diastereotopic faces of the transition state, wherein 
the aromatic ortho-carbon preferentially entered the anomeric carbon from the axial 
direction at C-l and anti to the 3- and 5-substituents according to a SN2’ anti-selective 
process.199 The reaction was sensitive to the disposition of the C4-acetoxy group 
adjacent to the leaving group, therefore the method was not applicable to the syntheses of 































Du Bois200 and coworkers recently disclosed a procedure involving nucleophilic 
addition of organozinc to 1,2-dihydropyranyl-3-acetate to produce Ferrier type product in 
good yield with high α selectivity (Scheme 2.17). The broad compatibility of the 













2.72 2.73  
 
More recently, Minehan reported the uncatalyzed addition of triarylindium to 
glycal acetates.201 Couplings were performed between a variety of arylindiums 
possessing both electron-donating and -withdrawing substituents and glucal-, rhamnal- 
and galactal-acetates and the yields were good in most cases. However, the 
stereoselectivity (α/β ratio) was only moderate (5:1) for glucal- and rhamnal-acetate. 
Crootti reported that treatment of 1,2-unsaturated-3,4-anhydroglucals 
(pseudoglucal) 2.75 and 2.78, generated in situ from D-glucal derived hydroxy mesylates 
2.74 and 2.77, with aryllithium reagents afforded 2,3-unsaturated-C-glycosides 2.76 and 
2.79, respectively, with excellent 1,4-regioselectivity (Scheme 2.18).202, 203 The 1,4-
displacement was highly stereospecific with α- and β-epoxide leading to the exclusive 
formation of α- and β-C-glycoside, respectively. It was necessary to generate the reactive 
vinyl oxiranes in situ in a separate step since direct treatment with PhLi only yielded a 
complex mixture. Other organometals, such as Grignard reagent, organocuprate and 
organozinc, displayed more complex behavior in their reactions with epoxides 2.75 and 
2.78. The author explained the complete yet opposite stereoselectivity of α and β-
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oxiranes based on a model where chelation of the lithium ion with the oxirane oxygen 
prompted delivery of aryl nucleophile from the same face as oxirane oxygen, resulting in 

































2.2.1.6 Enitols and Michael Type Conjugate Addition 
Enones, also known as 1,5-anhydroenitols, have been used successfully in the 
synthesis of C-aryl glycosides, with or without a transition metal catalyst. Bellosta and 
Czernecki204 illustrated that Michael type addition of a higher order cyanoarylcuprate to 
1,5-anhydro-1-enitol 2.80b in the presence of acetic anhydride afforded the 
corresponding α-C-aryl glycoside 2.81b in 87% yield with complete stereocontrol. The 
author also observed a small amount of C4-epimerization when 2.80a was subjected to 
the same chemical transformation (Scheme 2.19). The high facial selectivity was 
rationalized based on a chair-like transition state where the nucleophile approached from 


















2.81a: R1 = H, R2 = OAc, 83%








2.80a: R1 = H, R2 = OAc
2.80b: R1 = OAc, R2 = H  
 
A few years later, Czernecki reinvestigated the same reaction205 using Pd(OAc)2 
as catalyst and benzene as glycosyl acceptor. The author observed complete lack of C4-
epimerization and exclusive formation of α-C-aryl glycoside. However, the reaction was 
complicated by simultaneous formation of arylated enone attributed to isomerization of 
intermediate organopalladium species and subsequent syn β-hydride elimination. 
More recently, Maddaford206 synthesized C-aryl glycoside using the Rh(I)-
catalyzed 1,4-addition of an arylboronic acid to 1,5-anhydroenitol. Heating a 
dioxane/water solution of enones 2.80a-c and phenylboronic acid in the presence of 
cationic rhodium catalyst Rh(cod)2BF4 delivered α-C-phenylglycosides 2.83a-c 
exclusively in good yields. The reactions proceeded smoothly with boronic acids bearing 
either electron-donating or electron-withdrawing substituents. No epimerization at C4 
was observed and acid/base labile protecting group could be used (Scheme 2.20). The 
mechanism involved initial transmetalation of the aryl group from boron to rhodium and 
the organometallic species then added stereoselectively to the α-face of the enone double 
bond with subsequent hydrolysis of the Rh-O bond. The reaction products could be 
readily converted into 3-deoxy sugars by stereoselective reduction or to 3-aminosugars 
















2.83d: R = OMe, 81%, only α
2.83e: R = Cl, 50%, only α
ArB(OH)2
R
2.80a: R1 = H, R2 = OAc
2.80b: R1 = OAc, R2 = H














2.83a: R1 = H, R2 = OAc, 70%, only α
2.83b: R1 = OAc, R2 = H, 76%, only α




Lately, Cossy207 reported an interesting regio- and stereoselective synthesis of α-
C-aryl glycoside 2.85 and β-C-alkylglycoside 2.86 from the same C2-formyl glycal 2.84 





























2.2.2 Substitution With Nucleophilic C-Glycosyl Donors  
Some researchers have reversed the intrinsic polar nature of the anomeric carbon 
from electrophilic to nucleophilic to generate a nucleophilic glycosyl donor and trapped it 
with appropriate carbon electrophiles to produce C-aryl glycosides (the “umpolung” 
strategy). This can typically be done in two ways: 1) Direct and indirect metallation of 
the anomeric carbon, including lithiation, reductive metallation or transmetallation. 2) 
Installation of a strongly electron-withdrawing group, such as nitro, carbonyl 
functionality, sulphone or sulfoxide, at anomeric carbon to lower the pKa of the anomeric 
proton. The latter method has found more applications in the synthesis of C-alkyl 
glycosides, and it is less applicable to the syntheses of C-aryl glycosides. 
 
2.2.2.1 C-1 Alkyl Lithium and Alkylstannane 
Sinay208 has developed an approach for reversing the polar nature of the 
anomeric center to gain access to both the α and β-anomers of C-glycoside from a 
common precursor. Treatment of the unstable 3,4,6-tri-O-benzyl-2-deoxy-D-arabino-
hexopyrosyl chloride 2.87 with tributylstannyllithium in THF at 0 °C provided the 
β−glycosylstannane 2.88b in 85% yield with 60:1 β/α selectivity via a likely direct SN2 
displacement. Reductive lithiation of the same glycosyl chloride 2.87 with two 
equivalents of lithium naphthalenide in THF at -78°C, followed by the quenching with 
tributyltin chloride provided the α−glycosylstannane 2.88a in 70% yield. The 
stereoselectivity results from reduction of the transient axial anomeric radical stabilized 
by anomeric effect under kinetic control to α-glycosyllithium, an anomeric anionic 
species that is stereochemically stable at -78°C but has a tendency to equilibrate to the 
more stable β-anomer upon warming up.209 These glycosylstannanes bear the advantage 
of being configurationally stable at room temperature; and they are generally stable to 
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silica chromatography and can be carried many steps into natural product syntheses 
(Scheme 2.22). 
Cleavage of the tin-carbon bonds in 2.88a and 2.88b with BuLi at low 
temperature occurred rapidly with retention of configuration to give the α-
glycosyllithium 2.89a and β-glycosyllithium 2.89b respectively. Sinay successfully 
trapped the anomeric organolithiums using external carbon electrophiles with complete 







































2.89b 2.89a  
 
This approach, while providing a rapid access to both α and β-anomers of C-
glycoside from a common precursor, is limited to 2-deoxy sugars. Elimination to form 
glycal presents a serious problem when a 2-oxygenated functionality is present. Kessler 
and coworkers avoided β-elimination by leaving the C2-hydroxy unprotected.211, 212 The 
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presence of C2-lithium alkoxide effectively prevents the elimination thus blocking the 
formation of undesired glycal. Hence, dianions 2.93a and 2.93b were generated from 
vicinal halohydrin 2.96 and β-glycosylstannane 2.92 to provide access to α- or β-C-
glycoside, respectively. The author was also able to effect similar transformations on 2-













69% over two steps































2.95 2.96 2.93a  
 
2.2.2.2 Lithioglycal-Parker's Approach to C-Aryl Glycoside  
Parker developed a “reversed polarity strategy” for the synthesis of C-aryl 
glycoside synthesis that relied on the addition of a lithio glycal to a quinol ketal or 
quinone followed by subsequent reductive or non-reductive aromatization.213 For 
example, treatment of ketal 2.99, obtained from the addition of lithiated glycal 2.98 to 
quinone ketal 2.97, with DIBAL-H gave a mixture (2:l) of methyl ether 2.100 and 
aromatized product 2.101. Exposing the mixture to POCl3 in pyridine afforded 2.101 in 
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95% yield. Subsequent stereoselective hydroboration/oxidation with borane afforded the 
desired C-aryl glycoside 2.102 (Scheme 2.24). Alternatively, hydrogenation of C-aryl 
glycal 2.101 provided 2-deoxy C-aryl glycoside.214 The position of attachment of the 
carbohydrate to the aromatic core is determined by the quinol ketal starting material. 
Benzoquinone could also be used214 when sodium dithionite was employed in the 
reductive aromatization step. Alternatively, when the intermediate glycal quinine ketal 
2.99 was treated with ZnCl2 in Et2O, the rearranged C-aryl glycoside 2.103 was obtained 
(Scheme 2.25). Hence, both Group 1 and Group IV C-aryl glycosides can be accessed 





























































Parker proposed that both reductive aromatization and rearrangement (non-
reductive aromatization) arose from a common oxocarbenium intermediate 2.104. 
Trapping with a hydride afforded 2.100 and subsequent loss of water afforded aromatic 
2.101. Alternatively, dienone-phenol rearrangement followed by loss of a proton would 


























































Parker also developed an approach to Group III bis-C-aryl glycoside by sequential 
addition of lithiated glycals to quinone followed by non-reductive aromatization (Scheme 
2.27). Hence addition of lithiated glycal 2.98 to either quinol 2.106b or its bromo 
counterpart 2.106a216 afforded 1,4-diols 2.107b or 2.107a in moderate yields. 1,2-Glycal 
shift took place upon treatment with ZnCl2 providing the two kidamycin model 
compounds, 2.108b and 2.108a in excellent yields. Complete regiocontrol in the 




































2.106a: X = Br, 78%
2.106b: X = H, 91%
2.107a: X= Br (65%)
2.107b: X= H (56%)
2.108a:X = Br (82%)












Bisglycal C-aryl glycosides such as 2.112b derived from naphthoquinone and 1,4-
anthraquinone however cannot be prepared via the above-mentioned method directly. 
Those compounds were extremely sensitive to acid and selective hydrolysis of the glycal 
substituent ortho to the phenolic hydroxyl group occurred merely upon chromatography 
on silica or neutral alumina. This event necessitated the protection of one of the two 
hydroxyls as its silyl ether before the rearrangement to prevent the formation of acidic 
naphthol 2.112b. An additional advantage of introducing a silyl protective group was that 











































2.111 2.112a: R = TBS (92%)




This regiospecific rearrangement is consistent with the mechanism proposed by 
Parker and discussed earlier.215 Selectively chelation of the zinc chloride to the sterically 
more available hydroxyl group rather than the silyloxy group activates the hydroxyl and 
triggers the formation of the cyclohexadienyl cation. Migration of the glycal substituent 
geminal to the silyloxy group followed by loss of a proton, rather than the silyl moiety, 
resulted in the formation of aromatized product 2.112a (Scheme 2.28). Therefore, it is 
possible to choose which one of two different glycal substituents becomes the migrating 
group by specifying the order of glycal introduction in the 
addition/silylation/addition/migration sequence. This methodology provides an alternate 
approach to bis-C-aryl glycosides, such as pluramycin and kidamycin antibiotics. To 
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date, no total syntheses of any naturally occurring bis-C-aryl glycosides have been 
reported.217 
 
2.2.3 Transition Metal Mediated Coupling 
Although electrophilic and nucleophilic substitutions at the anomeric carbon have 
provided access to a variety of C-aryl glycosides, they have their own limitations. The 
use of strong Lewis acid in electrophilic sugar substitution and the strong basicity of 
anomeric organolithium in nucleophilic sugar substitution preclude the presence of 
functionalities that are acid or base sensitive. On the other hand, transition metal 
mediated cross coupling typically entails milder conditions and therefore has an 
advantage of broad functional group tolerance. Substantial progress has been made in the 
past decade in processes that rely on the cross coupling of appropriately functionalized 
aromatic compounds with carbohydrate derivatives. Couplings have been performed with 
aryl organometallic species and iodoglycals or alternatively with aryl halides and 
metallated glycals. 
 
2.2.3.1 Heck Type Coupling  
Daves was the one of first to apply a Heck-type coupling to prepare C-aryl 
glycosides. He observed that stirring a solution of 4-methoxynaphthyl-mercuric acetate 
2.114, which was prepared by electrophilic aromatic substitution using mercury 
acetate,218 and glycal 2.113 with palladium acetate at room temperature afforded the C-
aryl glycoside 2.115 in 96% yield.219 The method was later extended to include 
arylstannanes such as 2.116 (Scheme 2.29).219, 220 The regioselectivity was excellent 
with the tin or mercury directing the site of glycosidation. The double bond thus formed 
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was well positioned for further manipulation. The main drawbacks of this approach to C-
aryl glycosides were the mandatory use of stoichiometric palladium acetate and the 
formation of multiple products in some cases due to other competing decomposition 
































2.113 2.116 2.117  
 
It was soon discovered that when an aryl iodide was used in place of the 
arylmercuric acetate, only a catalytic amount of palladium acetate was required.221 The 
formation of the aryl palladium complex occurred in this case via oxidative addition of 
the aryl iodide to the palladium (0) catalyst. In a model study directed towards the 
synthesis of gilvocarcin by Daves and coworkers,221 aryl iodide 2.119 was reacted with 
furanoglycal 2.118 to furnish C-aryl glycoside 2.120. Desilylation with TBAF followed 

























89% over three steps
NaOAc, Bu3N







Maddaford however observed exclusive formation of the Ferrier-type product 
2.123 resulting from anti elimination of palladium acetate in the coupling of tri-O-acetyl 
glycal 2.122 with phenylboronic acid (Scheme 2.31).222 The anti palladium acetate 
elimination pathway regenerated the active palladium catalyst at the end of the reaction, 
therefore only a catalytic amount of palladium was needed. The author suggested that the 

























More recently, Schmidt223 reported a palladium (0)-catalyzed Heck arylation of 
substituted dihydropyran with aryldiazonium tetrafluoroborate. High C1, C5-trans 
selectivity was observed.  
 
2.2.3.2 Stille/Negishi/Suzuki Type Coupling  
It was later discovered that introduction of functional groups in both glycosyl 
donor and acceptor provided the mildest and the most efficient protocol for palladium-
mediated arylation of glycals. The palladium promoter can be used substoichiometrically, 
and the C-aryl glycoside is formed through reductive elimination instead of β-hydride 
elimination. Since the glycal double bond doesn’t participate in the coupling, no double 
bond isomer is observed, 
Friesen,224 Beau225 and Tius226, 227 disclosed independently at roughly the same 
time that a Stille-type cross coupling of C-1 tributylstannyl glycal 2.125 with aryl 
bromides 2.126 in the presence of a palladium catalyst to give C-aryl glycosides 2.127. 
Varying amounts of dimer 2.128 were isolated accounting for up to 30% of the staring 
material (Scheme 2.32). Aryl bromides with electron-withdrawing substituents generally 
provided higher yield of the coupled products than those with electron-donating 
substituents. The glycal double bond in the final product 2.127a-c could be functionalized 
through regio- and stereo-selective hydroboration-oxidation to provide the 2-oxy sugar 
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2.126a: R = H
2.126b: R = 2-OBn
2.126c: R = 4-NO2
2.127a: R = H (52%)
2.127b: R = 2-OBn (44%)
2.127c: R = 4-NO2 (78%)
2.128a: R = H
2.128b: R = 2-OBn (4%)






2.127a: R = H
2.127b: R = 2-OBn





2.129a: R = H (44%)
2.129b: R = 2-OBn (82%)









2.130a: R = H (69%)
2.130b: R = 2-OBn (65%)




pH 7 phosphate buffer
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In Beau’s syntheses of the core structures of papulacandins and chaetiacandin,229 
1-stannylglycal 2.131 was allowed to react with aryl bromide 2.132 to provide the 
bicycloketal 2.133 as a single diastereomer at the spiro center. The formation of the 
tetracycle was explained by an acid catalyzed ketalization of the initial product 2.134. 
Coupling under buffered conditions provided the expected C-aryl glycal 2.134 in 78% 
yield. Stereoselective epoxidation of 2.134 with meta-chloroperbenzoic acid at low 
temperature produced two anomeric isomers, β-C-aryl glycoside 2.135b (70%) and α-C-
aryl glycoside 2.135a (15%). Both isomers were converted to the core structure of 









































































Friesen later reversed the polarities of the glycosyl donor and acceptor.230 He 
discovered that the reaction of iodoglycal 2.136 with phenylzinc chloride 2.137a or 
phenylboronic acid 2.137b in the presence of (PPh3)2PdCl2 catalyst proceeded cleanly 
and gave high yields of coupling products 2.138a and 2.138b, respectively (Scheme 
2.35). This modification delivered C-aryl glycosides in significantly higher yields, and 
the formation of glycal dimers was not observed even with electron-rich aromatic 
















2.138a: R = H, M = ZnCl,  90% 
2.138b: R = H, M = B(OH)2,  81% 
2.138c: R = H, M = SnBu3,  20%
2.137a: R = H, M = ZnCl
2.137b: R = H, M = B(OH)2




Tius explored both the Stille and the Negishi coupling in his total synthesis of 
vineomycinone B2 methyl ester.226, 227 The couplings of glycal 2.139 and anthracene 
2.140 in the presence of both Ni and Pd catalyst were examined. Reaction between 
metalloanthracene 2.140 (Y = MgBr, ZnCl, SnBu3) and iodo sugar 2.139 (X = I) gave 
2.141 in yields no higher than 32%. A significantly improved yield of 79% was obtained 
with glycosylzinc chloride 2.139 (X = ZnCl) as nucleophilic glycosyl donor and aryl 
iodide 2.140 (Y = I) as glycosyl acceptor. The optimal yield can only be obtained when 
the active Pd(0) catalyst was generated in situ through reduction of Pd(PPh3)2C12 with 
diisobutylaluminum hydride. Stereoselective reduction of C-anthracyl glycal 2.141 in 
acidic NaBH3CN produced the advanced synthetic intermediate 2.142 as a single 

















































Recently, Vogel231 demonstrated that the arylmethanesulfonyl chloride 2.145 and 
glycal stannane 2.144 underwent Stille cross coupling with concomitant desulfitation to 
afford 2.146 in the presence of Pd2(dba)3, trifurylphosphine (TFP), and CuBr·SMe2 
(Scheme 2.37). The formation of glycal homocoupling dimer 2.147, however, was not 
































Minehan232 developed an approach to C-aryl glycoside involving coupling 
between aryl iodides and glycal indiums. Reactions with electron-deficient and electron-
rich aryl iodides proceeded equally well affording the coupled product in moderate yields 
(Scheme 2.38). Aryl bromides typically gave inferior results. The exact nature of the 
organoindium species was not clear, and the author suggested either a mono- or di-glucal 












1. 1.5 equiv. t-BuLi
2. 0.5  equiv. InCl3
3.
2.149a: R = 4-COCH3 (55%)
2.149b: R = 2-CH  (60%)






2.2.3.3 Palladium π-Allyl Chemistry: Carbon-Ferrier Reaction  
Dunkerton233 pioneered the use of π-allylpalladium complex in the synthesis of 
C-glycosides. Treatment of 2.150 with phenylzinc chloride in the presence of 5 mol% of 
Pd(PPh3)4 gave the C-glycoside 2.151 in 94% yield (Scheme 2.39). This type of reaction 
was regio- and stereoselective with inversion of the stereochemistry at anomeric center. 
This stereochemical outcome was consistent with inversion during the formation of the π-
allyl-palladium complex followed by retention of configuration in the transmetallation 
and reductive elimination steps. Substrates with C4-oxygenated groups gave at best 
moderate yields (16-30%) and the allylic transposed acetates didn’t undergo alkylation 
under reaction conditions. 
Scheme 2.39 
O OAc





2.150 2.151  
 
Sinou and coworkers234, 235 disclosed that treatment of 1-(4’-tert-
butyl)phenyloxy-2-enopyranoside 2.152 with arylmagnesium bromide in the presence of 
catalytic PdCl2(dppf) afforded the corresponding unsaturated C-aryl glycoside 2.153a in 
excellent yield with retention of anomeric stereochemistry. When the same reaction was 
performed with NiCl2(dppe) as the catalyst at -40 °C, the C-aryl glycoside 2.153b with 
inverted stereochemistry at the anomeric carbon was obtained instead (Scheme 2.40). 
Other arylmetallic reagents, such as tetraphenylborate, phenylzinc chloride and 
























single steroisomer  
 
The author rationalized the reversed selectivity based on the assumption that 
oxidative addition of the Pd(0) or Ni(0) species to the unsaturated carbohydrate occurred 
with inversion of configuration at the anomeric center to give π-allyl intermediate. In the 
case of the allyl-Ni intermediate, transmetallation with the organomagnesium was 
followed by syn reductive elimination to form the unsaturated C-aryl glycoside with 
overall inversion of configuration. In the case of the allyl-Pd intermediate, exo attack of 
the organomagnesium reagent on the π-allyl intermediate delivered the substituted 
product with an overall retention of configuration resulting from double inversion.236 
 
2.2.4 Pericyclic Reactions  
2.2.4.1 Diels-Alder Cycloaddition: De Novo Synthesis of Carbohydrate 
The hetero Diels-Alder (HDA) reaction to assemble the dihydropyran skeleton 
has found application in C-aryl glycoside chemistry and represents probably the most 
powerful and widely used tool for de novo construction of carbohydrates on pre-existing 
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aromatic systems. The method is particularly useful for assembling non-natural sugars, 
which otherwise are difficult to prepare. 
One of the early examples is found in Danishefsky’s synthesis of the core 
structure of the papulacandins.237 The ytterbium catalyzed, hetero Diels-Alder reaction 
of Danishefsky’s diene 2.155 and aromatic aldehyde dieneophile 2.154 provided the 
substituted carbohydrate 2.156 (Scheme 2.41), which possessed proper functionality 























Schmidt238 reported the application of inverse electron demand hetero-Diels-
Alder reactions for the synthesis of C-aryl glycosides. For example, the functionally 
substituted α,β-unsaturated carbonyl compounds 2.158a and 2.158b cyclized with 
substituted styrene 2.159 to yield C-aryl glycosides. The reaction, proceeded smoothly 
under high pressure (5.2 kbar, 60°C), in a regio- and endo-specifically fashion to deliver 
compounds 2.160a and 2.160b in 57 % and 81% yields, respectively. Subsequent 
desulfurization and hydroboration/oxidation delivered 2-deoxy-C-aryl glycosides. 
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Asymmetric induction of these reactions was illustrated using a O-methylmandeloyl 
group as a chiral auxiliary in the synthesis of 2.160b, thus providing convenient entries 
into both D- and L-sugars. Schmidt also obtained 2-oxy-C-aryl glycoside 2.164 in 41% 
overall yield after four steps using β-acetoxy styrene 2.162 as the dienophile (Scheme 
2.42). The use of an acetoxy group was crucial to the success of the cycloaddition, and 



























































Yamamoto239 developed the first reliable asymmetric hetero-Diels-Alder 
approach to C-aryl glycosides. The chiral BINOL-AlMe complex 2.165 was found to be 
highly efficient for HDA reaction of various aldehydes and Danishefsky type dienes. The 
presence of a bulky triarylsilyl moiety was crucial for obtaining high enantioface 
differentiation of the prochiral aldehydes. Other chiral Lewis acids have also been 
successful used in the HAD reaction, among them are Yamamoto’s chiral 
(acyloxy)borane (CAB) catalyst 2.166,240, 241 Jacobsen’s tridentate Schiff base 
chromium(III) complexes 2.167,242 Hashimoto's chiral dirhodium(ii) carboxylate and 
carboxamidate catalysts,243 Ding’s BINOLate-zinc complex 2.168,244 Jorgensen’s chiral 



























2.167 2.168  
Figure 2.4: Chiral Lewis acid used in HDA reactions 
 
2.2.4.2 [2+3] Dipolar Cycloaddition  
[2+3] cycloadditions have been used to append functional groups on an already 
existing carbohydrate or to construct the aromatic appendage. Kozikowski246 used a 
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nitrile oxide dipolar cycloaddition to build the aromatic attachment (Scheme 2.45). The 
C-1 nitromethyl substituted carbohydrate derivative 2.169 was exposed to phenyl 
isocyanate and triethylamine to generate nitrile oxide 2.170 in situ, which was reacted 
with a allylated arene to provide isoxazoline 2.171. Hydrogenation using Raney nickel 
cleaved N-O bond providing an intermediate β-hydroxyketone that was readily cyclized 





















1. H2, Raney Ni;
















In contrast, Hauser247 constructed the carbohydrate backbone from a cycloadduct 
obtained from a dipolar cycloaddition. The nitrile oxide, which was generated from 
reaction of the anthraquinone oxime 2.173 with NCS, underwent cycloaddition with 
racemic 2.174 to afford the isoxazole 2.175. Hydrogenolysis of 2.175 followed by acid 
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treatment to effect cyclization/dehydration of the intermediate diketone afforded 
pyranone 2.176. α-Acetoxylation of 2.176 with manganic acetate gave a mixture (3:1) of 
C2-epimers 2.177. The major isomer was reduced under Tius’ conditions227 to deliver 2-






















2.176: X = H
2.177: X = OAc (64%)
1. H2,  Pd/C; K2CO3, Me2SO4, 92%













2.2.5 Intramolecular Ring Closure  
Intramolecular cyclization consists of a broad category of reactions where either 
the C-aryl substituent or the sugar backbone can be built on existing structures. These 
cyclizations range from simple electrophilic addition and nucleophilic substitution to 
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metal-catalyzed alkyne trimerization and ring closing metathesis. Biomimetic synthesis 
involving cascade aldol condensation will also be covered in this section. 
 
2.2.5.1 Olefination/Cyclization Sequence 
Schmidt248 converted aldehydo-D-arabinose 2.179 into 2-deoxy-C-aryl 
glucopyranosides by iodonium-induced cyclization of 2.182 and 2.183. Both geometric 
isomers cyclized if an electron-donating methoxy group present on the para-position of 
the aromatic ring, although the trans-double bond isomer cyclized at a significantly 
greater rate. The cyclization gave exclusively β-anomers, regardless of the double bond 
geometry in the starting material (Scheme 2.45). When an electron-withdrawing nitro 
group present, no cyclization was observed with either double bond isomer. The 
stereochemical outcome was rationalized by proposing a reversible electrophilic attack of 
N-iodo succinamide on the olefin double bond forming a three-membered iodonium ion 
followed by C5-hydroxyl attack at the C1 carbon. Therefore the presence of electron-
withdrawing group was deleterious to the cyclization. Reversible NIS attack at the double 
bond does not result in ring closure in the cis isomers due to the unfavorable 1,3-
interaction in the chair-like transition state. However, in the more electron-rich 2.183b, 
this problem was overcome by generating a more stable para-methoxybenzyl cation 

























1. Dowex 50W, MeOH, 0°C












































2.180a: Ar = phenyl (cis/trans: 2:1, 94% total)
2.180b: Ar = 4 -methoxyphenyl (cis/trans: 3:2, 75% total)
2.180c: Ar = 3,5-dimethoxyphenyl (cis/trans: 3:2, 65% total)
2.182a: Ar = phenyl
2.182b: Ar = 4 -methoxyphenyl
2.182c: Ar = 3,5-dimethoxyphenyl
2.183b: Ar = 4 -methoxyphenyl
Ar
2.179
2.184b, 80%2.184a: Ar = phenyl (90%)
2.184b: Ar = 4 -methoxyphenyl (78%)







2.2.5.2 Ketalization and Etherification  
Terashima, in the synthesis of nogalamycin congener,249-251 used a ketalization 
to form the tetrahydropyran ring. The aryl substitution was installed though a 
nucleophilic addition of an aryllithium to D-arabinose derived ketone 2.185. Removal of 
the silyl protective group in 2.187 followed by regioselective oxidation of the resultant 
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1,5-diol triggered a spontaneous cyclization to form a mixture of epimeric acetals, which 
was immediately alkylated with chloromethyl methyl ether to deliver 2.188 (Scheme 
2.46). Hydrogenolysis followed by Lewis acid catalyzed transacetalization then delivered 












































1. TBAF, THF, 94%
2. SO3Py, DMSO, Et3N, THF, 88%























Cyclodehydration of 1,4-diols under either Bronsted acidic or Lewis acidic 
conditions were used to synthesis C-aryl glycofuranosides. The requisite 1,4 diol was 
generally obtained by nucleophilic addition of an organometallic reagent to a sugar 
furanose. Sharma and co-workers discovered that C-phenyl glycoside 2.191 and 2.192 
could be obtained in good yields by simply stirring a solution of 1,4-diol 2.190 or 2.192 
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with a catalytic amount of Yb(OTf)3, respectively (Scheme 2.47).252 The 
stereoselectivity was substrate dependent and not always predictable; both high α and β 


























Nucleophilic substitution was also used to access C-aryl glycoside. For example, 
displacement of the C5-sulfonate in 2.194 furnished dihydropyran 2.195 as an 
inseparable diastereomeric mixture,253 which was subjected asymmetric dihydroxylation 
and subsequent acetylation to afford a single β-aryl glycoside 2.197 (Scheme 2.48). The 
author suggested that anomerization probably occurred during acetylation. Krishna also 
used a Mitsunobu etherification to activate 1,4-diol in order to graft a tetrahydropyran 



































2.196 2.197  
 
2.2.5.3 Ring Closing Metathesis 
Schmidt, in the late nineties, explored the possibility of ring closing metathesis 
(RCM) for the synthesis of C-aryl glycoside.255-263 He prepared a variety of 2-aryl 
dihydropyrans via RCM. In one of his recent publications, Schmidt obtained C-aryl 
glycoside 2.201 as a single diastereomer in enantiomerically pure form.263 Treatment of 
optically pure α-hydroxy ketone 2.198 with allyl bromide and silver oxide afforded R-
allyloxy ketone 2.199 without any noticeable racemization. Reaction of 2.199 with 
vinylmagnesium chloride produced the requisite diene 2.200 with high 
diastereoselectivity. Ring closing metathesis of the allylic homoallylic ethers in the 
presence of 3 mol % of the first generation Grubbs’ catalyst gave the dihydropyran 2.201 
in excellent yields. Slight modification of reaction sequence allowed the ready conversion 
of R-hydroxy ketone 2.198 to α,β-unsaturated lactones 2.202. Ring-closing metathesis of 
diene 2.202 delivered dihydropyranone 2.203 in excellent yield with second-generation 
Grubbs’ catalyst (Scheme 2.49). The dihydropyrans could be readily converted to 
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Postema also developed an approach to C-aryl glycal using ring closing 
metathesis.264 For example, Wittig olefination of pentose 2.206 afforded alcohol 2.207, 
which was acylated with the appropriate carboxylic acid. Subsequent olefination afforded 
the metathesis precursor 2.208. Exposing diene 2.208 to Schrock’s catalyst afforded C-
aryl glycal 2.55a in moderate yield (Scheme 2.50). The method provides a 
complementary approach to C2-aryl substituted dihydropyrans. However this approach 
 93
lacks practicability due to its length and high catalyst loading (25 to 50 mol%) in order to 























1. DCC, DMAP,BzOH, 98%





















2.2.5.4 The Metal-Catalyzed Cyclization  
One route to C-aryl glycosides involves the construction of the aryl group on a 
pre-existing carbohydrate framework. Using this strategy, McDonald265 was able to 
access the core structures of papulacandins and vineomycinone using rhodium catalyzed 
alkyne cyclotrimerization. The nucleophilic addition of 2-
(trimethylsilyl)ethynylmagnesium bromide to the lactone 2.209 followed by dehydration 
of the intermediate hemiacetal yielded the alkynylglycal 2.210. Fluoride induced 
deprotection of the silyl ether followed by reprotection of the alcohols as their acetates 
furnished enyne 2.211. Cyclotrimerization with diyne 2.212 in the presence of 20 mol% 
Wilkinson's catalyst in ethanol delivered glycosidyl anthraquinone 2.213 in moderate 
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yield (Scheme 2.51). A lower yield of 35% was obtained when the carbohydrate 





































McDonald also prepared spiroglycoside 2.216 using a similar strategy.265 
Addition of 2-(trimethylsilyl)ethynyllithium to gluconolactone 2.53b followed by 
acetylation gave a mixture of anomeric acetates 2.214. Lewis acid-catalyzed 
glycosidation afforded diyne 2.215, and subsequent cyclotrimerization of each anomer in 
a saturated ethanolic solution of acetylene provided the corresponding unfunctionalized 
spirocyclic C-aryl glycosides 2.216 in excellent yield, which resembled the skeleton of 
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2. aq NaOH, BnNEt3Cl





















2.2.5.5 Biomimetic Synthesis  
The major classes of C-aryl glycosides are believed to arise biosynthetically from 
polyketide precursors. A biomimetic synthesis of (-)-urdamycinone B utilizing 
cyclization of a previously formed C-glycosyl polyketide as key step was accomplished 
by Yamaguchi and coworkers in 1992.266, 267 The 2-deoxy sugar 2.217, which was 
readily prepared from L-rhamnal, was condensed with 3-oxoglutarate under Knoevenagel 
conditions followed by reduction with ethanolic NaBH4 to afford 2.218. Claisen 
condensation of 2.218 with the dianion of acetoacetate afforded 2.219, which was 
cyclized in situ by treatment with Ca(OAc)2 to produce the C-naphthyl glycosidic 2.220 
as a single stereoisomer. No Group I C-aryl glycoside 2.222 was detected. The author 
explained the lack of conformer 2.219b, the immediate precursor for 2.222 based on 
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unfavorable 1,3-allylic strain between the vinylic hydrogen and carbohydrate substituent. 
C-Naphthyl glycoside 2.220 was then converted into (-)-urdamycinone B, the enantiomer 




































    C6H6, reflux, 47%+
CO2Et
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2.219b 2.222  
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2.3 PRIOR WORK IN MARTIN GROUP  
The previous sections have mainly focused on the synthesis of C-aryl glycoside 
on a case-by-case basis, consequently the importance of the control of the absolute 
stereochemistry at the anomeric center often appears to outweigh that of the control of 
regiochemistry, namely the placement of the carbohydrate moiety on the aromatic ring. 
However, in a systematic and unified approach to major classes of the C-aryl glycosides, 
the ability to deploy the carbohydrate moiety at a fixed position of an oxygenated 
aromatic core in a predictable manner and to preserve or invert the stereochemistry at the 
attachment in the subsequent transformations is not only important, it is required for such 
a method to be useful. In this area of chemistry, Suzuki and Parker have done tremendous 
amount of work. The major part of their work has already been covered in the previous 
sections. In this section, we will briefly review the work in the Martin group in 
developing a unified approach to major classes of C-aryl glycoside natural products based 
on glycosyl-furan/benzyne cycloadditions.268, 269  
 
2.3.1 United Strategy For the Synthesis of C-Aryl Glycoside  
The strategy to access the four major structural types of C-aryl glycosides relies 
on the regiospecific opening of glycosyl furan/benzyne cycloadducts of the general type 
2.225 as outlined in Scheme 2.54. The first route (Path A) features the cycloaddition of a 
glycosyl furan 2.224 (R1 and/or R2 = Sug) with a substituted benzyne 2.223 followed by 
acid-catalyzed opening of the resultant adduct 2.225 to give Group I–IV of C-aryl 
glycosides. The second pathway (Path B) involves the SN2′-like opening of cycloadduct 
2.225 (R1 = H, Sug; R2 = H) with sugar nucleophiles followed by oxidative 






















Group I: R1 = Sug: R2 = H
Group II: R1 = H: R2 = Sug
Group III: R1 = Sug: R2 = Sug





The first approach is illustrated by deprotonation of 2.227 to give an anion that 
was allowed to warm to room temperature in the presence of 2-glycosyl furan 2.226. 
During the course of warming, benzyne generation and cycloaddition ensued to give 
2.228. Acid-catalyzed rearrangement of 2.228 delivered the Group I C-aryl glycoside 

































In a relates sequence, cyclization of 3-glycosyl furan 2.230 and 1,4-
dimethoxybenzyne followed by acid-catalyzed rearrangement gave the Group II C-aryl 
glycoside model 2.232a in 80% yield as a single diastereomer accompanied with small 
amount (8%) of the isomeric m-substituted product 2.232b. Oxidation of 2.232a with 
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PhI(OAc)2 and subsequent reduction of the resultant quinone with Na2S2O4 gave the 






















































In a similar manner, reaction of 1,4-dimethoxybenzyne with the 1,3-diglycosyl 
furan 2.234 delivered 2.235, which was converted to Group III model 2.236 as a single 



















































Alternatively, Group I and III C-aryl glycosides can also be accessed from SN2’ 
type ring opening with a sugar nucleophile followed by oxidative aromatization. The 
palladium-catalyzed reaction of the sugar-substituted cycloadduct 2.237 with 2.136 gave 
the naphthol 2.238, which could be oxidized using freshly recrystallized 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ)269 or IBX270 to afford Group I model 2.239 (Scheme 
2.58). When the cycloadduct 2.240 was subjected to palladium catalyzed SN2’ type 
opening, Group III model 2.241 was obtained directly without a separate oxidation step 

































































At this stage, the viability of our general entries to the four major groups of C-aryl 
glycoside had been clearly established. All four major C-aryl glycosides could be 
accessed through cycloaddition of benzyne with a properly substituted glycosyl furan 
following by acid-catalyzed rearrangement of the resultant cycloadducts. Alternatively, 
Group I and III C-aryl glycosides can also be accessed from SN2’ type ring opening with 




2.3.2 The Control of the Regiochemistry Using A Disposable Tether  
In the process of establishing the underlying feasibility of the approach, 
symmetrical benzynes were universally employed as reaction partners, so there was never 
a regiochemical issue. The issue of global regioselectivity however cannot be ignored 
shall we apply the method to the syntheses of C-aryl glycoside natural products. It should 
be noted that all of the naturally occurring C-aryl glycoside antibiotics are 
unsymmetrically substituted, and hence it is essential to control the regiochemistry in the 
key benzyne-furan cycloaddition. 
Literature precedence and research in the Martin group had shown that benzyne-
furan cycloadditions was insensitive to steric factors;271, 272 a disposable silicon tether 
was therefore used instead. Protocols using silicon tethers with one or two carbon atoms 
were developed and applied successfully in controlling the regiochemistry of benzyne-
furan cycloadditions by former group members Dr. Kaelin and Dr. Sparks and the 
technique is illustrated in Scheme 2.66.268. Thus, α-lithiation of the epimeric 1,3-
diglycosyl furans 2.242 followed by silylation provided a furylsilane intermediate, that 
underwent nucleophilic substitution with phenol 2.243 to produce 2.244. Selective 
deprotonation of 2.244 followed by intramolecular benzyne/furan cycloaddition and 
exhaustive cleavage of the carbon-silicon bonds and acid-catalyzed ring opening 

















































1. LDA, THF; Me2Si(Cl)CH2Br, 82%































In a similar manner, α-lithiation of the 1-glycosyl furans 2.226 followed by 
silylation with chlorodimethylvinylsilane provided a furylvinylsilane intermediate 2.247, 
which underwent hydroboration/oxidation followed by Mitsunobu etherification with 
phenol 2.243 to produce 2.249 with a two-carbon tether. Selective deprotonation of 2.249 
followed by intramolecular benzyne/furan cycloaddition delivered the cycloadduct 2.250 
Cleavage of the silyl tether followed by O-alkylation of the resultant alcohol and acid-
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catalyzed ring opening gave 2.251 as a single diastereomer in which each of phenolic 





















































1. TBAF, DMF, 70°C, 80%
2, NaH, BnBr, 95%











After establishing the regiocontrol by use of a disposable silyl tether in the 
cycloaddition, efforts in the Martin group shifted towards applying the methodology to 
the syntheses of naturally occurring C-aryl glycosides. In the upcoming section, a brief 
examination of the synthetic efforts in the Martin group toward vineomycinone B2 
methyl ester will be presented. 
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2.3.3 Synthetic Efforts Toward Vineomycinone B2 Methyl Ester  
The vineomycins were isolated from the culture broth of Streptomyces matensis 
vineus and found to be active against Gram-positive bacteria and sarcoma-180 solid 
tumors in mice.273, 274 The key structural features of vineomycinone B2 methyl ester are 
the presence of the β-D-olivose and the 3-(R)-hydroxyisovaleryl on opposing ends of an 
anthrarufin core. A number of total syntheses of vineomycinone B2 methyl ester have 
been published since its isolation.227, 275-277 
The synthesis of vineomycinone B2 (2.143) undertaken by Dr. Sparks relied on a 
double intramolecular benzyne-furan cycloaddition to form a bisoxabenzonorborna-diene 
ring system 2.252 in a regio-controlled fashion. Vineomycinone is envisioned to arise 
from 2.252 via tether removal, regioselective ring opening and functional group 






























































The west potion of the molecule was prepared from the known sugar lactone 
2.257. Addition of 3-lithiofuran to lactone 2.257 followed by stereoselective reduction of 
the intermediate hemiacetal with NaCNBH3 afforded glycosyl furan 2.258. α-Lithiation 
of 2.258 followed by trapping the lithiofuran with chlorodimethylvinylsilane provided 
vinyl silane 2.259, which was converted to β-D-olivosyl furan 2.254 by 









O 1. 3-lithiofuran, THF
2. EtOH, HCl






1. LDA, THF, -78 °C



















The east potion of vineomycinone B2 was prepared from 3-methyl-3-butenol 
2.260 (Scheme 2.64). Protection of 2.260 as its PMB ether followed by Sharpless 
asymmetric dihydroxylation afforded diol 2.261 in excellent yield and high enantiomeric 
excess. Diol 2.261 was converted to an epoxide, which was opened with 3-lithiofuran in 
the presence of BF3•OEt2 to provide 2.262. Benzyl protection of the tertiary alcohol of 
2.262 followed by bromination furnished 2-bromofuran 2.263, which was subjected to 
metal-halogen exchange, and the resulting anion was trapped with 
chlorodimethylvinylsilane to afford an intermediate vinylsilane. Hydroboration/oxidation 









1. PMB-OH, DIAD, PPH3, 98%
2. AD-mix α, 95%, 96% ee OPMB
HO
HO Me
1. TsCl, NEt3, DMAP, CH2Cl2
2. n-BuLi, THF; 
3-lithiofuran, BF3⋅Et2O
72% over two steps
OPMB
HO MeO 1. KH; BnBr, 100%




1. n-BuLi, THF, -78°C;
Me2Si(Cl)CH=CH2, 87%







2.263 2.256  
 
Mitsunobu etherification of mono-protected tetrabromodihydroquinone 2.264 
with alcohol 2.256 provided aryl ether 2.265 in 75% yield. Removal of the silyl 
protecting group with HF•pyridine followed by a second Mitsunobu etherification 
delivered 2.253 in excellent yield. Dropwise addition of a dilute solution of n-BuLi to a 
cooled solution of tetrabromide 2.253 in Et2O effected the crucial double benzyne-furan 
cycloaddition affording bisoxabenzonorbornadiene 2.252 as a mixture of 4 diastereomers 
in 68% yield (Scheme 2.65).278 The final stage of the synthesis entails ring opening and 
oxidation of the bisbenzonorbornene core followed by functional group manipulation of 































1. HF⋅Pyr, THF, 75%































A brief discussion of the synthetic methods currently available was presented in 
this chapter. It should be clear at this point the key issues in forming the C-aryl glycosyl 
bond are the control of the regiochemistry and the control of stereochemistry at the 
anomeric center. The presence of carbohydrate moiety introduces extra chiral centers, 
multiple Lewis basic sites and steric bulk, thereby complicating this issue of selectivity 
both sterically and electronically. Furthermore, the ready epimerization of the anomeric 
carbon in a large number of C-aryl glycosides have provided challenges and opportunities 
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to their syntheses. A number of methods have been developed to address those issues, 
and majority of them take advantage of the inherent electrophilicity of the anomeric 
carbon. Methods that provide either anomer reliably and predictably have been reported 
from a few research groups and a number of naturally occurring C-aryl glycosides have 
been synthesized. Parker, Suzuki and Martin have individually developed systematic 
approaches to major classes of C-aryl glycosides. The upcoming chapter will discuss our 
efforts in the application of the tactics to the synthesis of C-aryl glycoside natural product 





Chapter 3: Synthesis and Kinetic Evaluation of Substrate-based 
Phospholipid Analogues 
The major focus of the phospholipase C project within the Martin group has been 
on studying the mechanistic aspects of the PLCBc-catalyzed hydrolysis of phospholipids. 
Prior studies were carried out with the preferred substrate-phosphatidylcholine almost 
exclusively.103, 105, 279, 280 The enzyme, however, also hydrolyzes the other two natural 
substrates-phosphatidylethanolamine and phosphatidylserine with only slightly less 
efficiency. The ratio of kcat/KM for enzymatic hydrolysis of the synthetic phospholipids 
1,2-dihexanoyl-sn-glycero-3-phosphocholine (1.55a, C6PC), 1,2-dihexanoyl-sn-glycero-
3-phospho-ethanolamine (1.55b, C6PE), and 1,2-dihexanoyl-sn-glycero-3-phospho-L-
serine (1.55c, C6PS) is 9:6:1.76 Since the three PLCBc natural substrates differ only at the 
polar head groups, the structural differences between the head groups are in one way or 
another responsible for the differences in specificity. Each substrate bears a positively 
charged ammonium moiety at physiological pH as part of the head group, while PS also 
carries a negatively charged carboxylate. With respect to size, the head groups of PC and 
PS are relatively similar to each other, while the primary ammonium group in PE is 
significantly smaller. Probably more significantly, PC lacks the capability to act as either 
a hydrogen bond donor or acceptor. Because it is not clear how PLCBc recognizes the 
difference in the head groups among the three very similar phospholipid substrates, 
efforts were initiated towards developing a better understanding of the structural basis for 
































Figure 3.1: Hydrolyzable phospholipids 
Initial work in our group by Dr. Antikainen281 revealed that replacing one or 
more of the three choline-binding-pocket amino acids residues Glu4, Tyr56, and Phe66 
led to the modulation of substrate specificity of PLCBc.282 A set of mutants was thus 
identified that can be used as a starting point to study structure-function relationships. In 
order to gain a better understanding of the structural factors that are involved in substrate 
recognization by PLCBc, it is necessary to examine the three dimensional structure of the 
wild type enzyme and selected mutants thereof and their complexes with appropriate non-
hydrolyzable substrate analogues using X-ray crystallography. It would also be important 
to obtain the thermodynamic profile of the binding of the enzyme and mutants with non-
hydrolyzable substrates using isothermal titration calorimetry (ITC), to semi-quantify the 
contributions of individual amino acid residues. Structural and thermodynamic studies of 
such mutant enzymes and their complexes with substrate analogues can lead to a better 
understanding of the structural basis responsible for the substrate selectivity of PLCBc 
towards PC, PE, and PS and may provide valuable insights into the interactions between 
amino acid side chains in the head group binding pocket of PLCBc and its substrates. 
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In order to determine the thermodynamic parameters (∆G, ∆S, and ∆H) in a 
binding event accurately by ITC, a specific combination of ligand affinity and 
concentration are required. For example, a compound having a Ki of 1 mM must be 
soluble at a concentration of about 2 M.283 The requirements for X-ray crystallography 
are less clear, and structures of wild type PLCBc and its Asp55Asn mutant complexed 
with a phosphonate inhibitor having a Ki of 1.15 mM and a solubility of 0.5 M in 45% 
aqueous (NH4)2SO4 have been obtained. Therefore, it seems that a phospholipid 
analogue having solubility of at least 1 mM and Ki below 0.1 mM would be suitable 
candidate for both techniques.  
 
3.1 Design of Water-Soluble Phospholipids  
Prior studies had revealed that replacing one or more of the phosphate oxygen 
atoms with sulfur led to some of the most potent inhibitors of PLCBc. For example, the 
dithiophosphatidylcholine derivative 1.38g exhibited a Ki of 30 µM284 or 10 µM87. 
However, the solubility of 1.38g in water is only 0.2 mM,285 which is too low to be of 
practical use in ITC and crystallographic studies. Inhibitors that are more water-soluble 
were required for further studies. The dithiophosphonate 1.38g was chosen as the starting 
point due to the short synthetic route to prepare this type of compounds compared to 
other thioanaologs, such as 1.38b and 1.38f.  
Preparing dithiophosphatidylcholine analogues of 1.38g having greater water 
solubility would be only a matter of either increasing the overall hydrophilicity by 
installing of polar functionalities or decreasing the overall lipophilicity of the molecule 
by truncation of non-polar functionalities. The three-dimensional crystal structure of PC-
PLC from B. cereus80 and its D55N mutant106 complexed with nonhydrolyzable 
substrate analogues revealed extensive interactions between the amino acid residues and 
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the phosphate and choline head group moieties of the substrate analog. Modification of 
this potion of the molecule would thus be expected to deprive the substrate analog of the 
ability to bind to PLCBc. The crystal structure also revealed the lack of any obvious 
interactions between two acyl side chains and the enzyme except for the presence of a 
distinct hydrogen bonding between the sn2-carbonyl and asparagine 134. Both fatty acid 
tails were somewhat disordered with thermal motion increasing along the aliphatic side 
chain. The termini of the lipophilic side chains appeared to be completely solvent 
accessible. Thus it seemed reasonable that modifications to the termini of the sn-1 and sn-
2 acyl side chain would have a minimal impact on the binding affinity of the substrate 
analog. On the other hand, kinetic experiments have shown that shortening the lipophilic 
side chains is detrimental to KM of phospholipid substrate. Therefore, analogues with 
shorter side chains would likely be less potent inhibitors.  
There are two possible approaches to maintain longer side chain(s) while 
increasing water solubility. The first of these involves partial or complete removal of the 
lipophilic sn-1 side chain, which was not involved in any identified significant 
interactions in the crystal structure.80 In fact, phospholipid derivatives bearing a single 
acyl chain have been shown to be substrates for PLCBc.286 Therefore, it is reasonable to 
believe a non-hydrolyzable substrate analog with only sn-2 side chain, such as 3.4 could 
be a potential inhibitor that is more soluble than its diacyl counterpart. The second tactic 
would involve installing highly hydrophilic substituent(s), such as hydroxyl, amino and 
carboxyl groups, at the end of one or both of the acyl side chains to increase water 
solubility. Because termini of the side chains are exposed to solvent in the lipid-enzyme 
complex, the presence of terminal polar groups was not expected to adversely affect 
binding. Hence, dithiophosphatidylcholines possessing hydroxyl groups at the terminus 
of each acyl side chain were identified as targets. It was expected that screening of 
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analogs with different side-chain lengths would be needed to produce the best inhibitor 
due to the correlation between the potency of the inhibitor (Ki), the solubility and the 
length of the lipophilic side chains. 
Inasmuch as one of the long-range goals of this project was to correlate enzyme 
structure with specificity, the related series of phosphatidylcholine 3.3, the 
phosphatidylethanolamine 3.4, and the phosphatidyl-L-serine 3.5, were chosen as the 
































































Figure 3.2: Non-hydrolyzable phospholipid analogs 
 
3.2 Synthesis of Water-Soluble Phospholipids 
The phosphorodithioate inhibitors 3.3-3.5 that were chosen as the targets were 
synthesized using a chlorophosphite coupling developed in our lab (Scheme 3.1).130 This 
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protocol employs the reactive 2-chloro-1,3,2-dithiaphospholane followed by sulfuration 
and is extremely efficient for syntheses of various phospholipid analogs. 
 
3.2.1 Ethylene-Glycol Derived Cholinephosphorodithioate 
Chris Franklin synthesized the ethylene glycol-derived phospholipid analogues 
3.2a and 3.2b according to the sequence of reactions depicted in Scheme 3.1.287 The acid 
chlorides were treated with an excess of ethylene glycol to give monoesters 3.6a and 
3.6b, respectively. The alcohols 3.6a and 3.6b were then converted into 3.2a and 3.2b, 
respectively, via their corresponding thiophosphorodithiolanes 3.7a and 3.7b using the 
































3.6a: n = 5 (64%)
3.6b: n = 7 (71%)
3.7a: n = 5 (91%)
3.7b: n = 7 (65%)
3.2a: n = 5 (82%)





The ethylene glycol-derived phosphocholines 3.2a and 3.2b were both good 
inhibitors, exhibiting similar Ki’s and solubilities (Table 3.1). Hence, the presence of an 
sn-1 fatty acid subunit is neither mandatory for substrates of PLCBc,286 nor it is an 
essential structural requirement for inhibitors. 
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Table 3.1: Results of Kinetic and Solubility Studies on Ethylene Glycol Derived 
Phospholipid Analogues 
Phospholipid Solubility (mM) Ki (mM) Enzyme 
3.2a 3 0.51 PLCWt 
3.2b 1 0.42 PLCWt 
 
3.2.2 ω-Hydroxy Cholinephosphorodithioate 
The synthesis of the ω-hydroxy phosphorodithioates 3.3-3.5 required the design 
of a protocol for introducing a hydroxyl group on the terminus of the acyl side chain, 
Chris Franklin adopted a strategy in which a terminal alkene was used as the latent 
hydroxyl functional group. (R)-3-(4-Methoxybenzyloxy)propane-1,2-diol (3.8), prepared 
according to literature procedure,112, 117 was diacylated with ω-unsaturated fatty acid, 
prepared from the corresponding bromide, to afford 3.9b-c (Scheme 3.2). Oxidative 
deprotection of the 4-methoxybenzyl (PMB) ether with dichlorodicyano-benzoquinone 
(DDQ) proceeded smoothly to furnish the alcohols 3.10b-c, which were immediately 
used in the next steps to avoid 1,2-acyl migration.288 The 4-methoxylbenzyl was chosen 
as the protective group instead of benzyl because it can be removed in the presence of 
double bonds.114 Oxidative phosphorylation of 3.10b-c using 2-chloro-1,3,2-
dithiaphospholane 1.59 and sulfur followed by treatment of the intermediates 3.11b-c 
with choline tosylate in the presence of DBU provided the unsaturated 
phosphatidylcholine derivatives 3.12b-c in good overall yields. Ozonolysis of the 
terminal double bonds and subsequent reduction of the intermediate aldehyde using 
sodium cyanoborohydride provided the ω-hydroxy phosphorodithiocholines 3.3b-c in 
















3.9b: n = 6 (100%)















3.11b: n = 6 (63%)








3.10b: n = 6 (80%)





















3.12b: n = 6 (74%)
3.12c: n = 9 (81%)
3.3b: n = 6 (16%)









3.2.3 Ethanolamine- and Serine Phosphorodithioates  
It was initially expected that the corresponding ethanolamine and L-serine 
derivatives could be prepared similarly by using a terminal alkene as the latent hydroxyl 
functional group. Toward this goal, the protected ethanolamine analog 3.13a was 

































The synthetic route to 3.3b-c enabled us to install different head groups at the end 
of the synthesis, thereby allowing the preparation of phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) and phosphatidyl L-serine (PS) from a common 
intermediate 3.11b-c. However the priority of project was to screen for the best 
inhibitors, which would have low Ki and high aqueous solubility. Because the length of 
the fatty acid side chain is the likely determinative factor. The strategy in which the fatty 
acid side chains were installed in the first step of the syntheses is ill fitted for the purpose 
of synthesizing a number of analogs with different lengths of side chains. Therefore, a 
different approach was developed so that different fatty acids could be installed at a later 
stage of the synthesis.  
The known 2,3-O-isopropylidene-glycerol (1.1)117 was subjected to phosphite 
coupling conditions to deliver dithiaphospholane 3.14 in good yield. Upon exposure of 
3.14 to N-Boc-ethanolamine in the presence of DBU, the phosphatidylethanolamine 
derivative 3.15 was obtained quantitatively. Removal of the acetonide with acetic acid in 
t-BuOH afforded the 1,2-diol 3.16, which was subsequently diacylated with the 
appropriate acid chloride in neat pyridine to give the unsaturated 
phosphatidylethanolamine derivative 3.17 in good yield. This approach had an additional 






















































As described previously, ozonolysis of 3.12b-c followed by reduction provided 
ω-hydroxyl choline phosphorodithioates 3.3b-c, albeit in very poor yields. The 
procedure, however, resulted in concurrent partial or complete replacement of sulfur with 
oxygen in the dithiophosphate moiety when ethanolmine derivatives 3.17 and its DBU 
salt 3.13a were used (Scheme 3.5). The oxidation of sulfur was clearly a competing 
process. The 31P NMR spectrum revealed three peaks with chemical shifts at 126, 63, 5 
ppm in an approximate 2.5:2:4 ratio in a carefully controlled ozonolysis using Sudan III 
dye as end-point indicator.289 Assuming the peak at 126 ppm corresponded to the desired 
product, the isolated yield was at best no more than 10%. In addition, the reaction 
mixture is difficult to purify, and the fractions after column chromatograph were often 


















NHBocX 3.4a3.13a or 3.17
3.18  
 
In order to develop a more efficient approach to compounds related to 3.3-3.5, a 
strategy in which a protected hydroxyl group was present from the onset of the synthetic 
sequence was examined so a late-stage oxidation could be avoided. The newer approach 
was expected to be similar in length due to the added protection/deprotection steps. Thus, 
protected hydroxy acids were used as starting materials. Caprolactone was subjected to 
acid-catalyzed methanolysis, and the free alcohol of the resulting hydroxy ester 3.19a 
was protected as its TBDMS ether.290 The methyl ester was then saponified with aqueous 
NaOH to afford the desired O-protected ω-hydroxyl carboxylic acid 3.21a (Scheme 3.6). 
Alternatively, the terminal differentiated ω-carbonyl carboxylic acid 3.22 was prepared 
via the nonsymmetrical ozonolysis protocol developed by Schreiber.291 Further 




































1. TBSCl, DBU, CH3CN
2. NaOH, MeOH/THF/H2O








Diacylation of the 1,2-diol 3.8 with protected ω-hydroxyl acid 3.21a using 
DCC/DMAP coupling followed by removal of the PMB protecting group with DDQ gave 
3.24a, which was converted into the thiophosphorodithiolane 3.25a in the usual manner 
by dithiophosphite coupling and sulfurization. Reaction of 3.25a with choline tosylate or 
N-Boc ethanolamine in the presence of DBU followed by unmasking of the terminal 
hydroxyl group using dilute hydrofluoric acid292 provided the requisite 
dithiophosphatidylcholine 3.3a (Scheme 3.9) and the partially protected ethanolamine 
analogues 3.28a (Scheme 3.8), respectively. N-Deprotection of 3.28a was effected with 
SnCl4293 to deliver dithiophosphatidylethanolamine 3.4a (Scheme 3.14), while global 



































































3.28a: n = 4, R = H, R' = Boc (85% over two steps)







3.29a: n = 4, R = COOt-Bu, R' = Boc (85% over two steps)
3.25a: n = 4 (87%)
3.25b: n = 6 (80%)
3.25d: n = 8 (19%)
3.23a: n = 4 (80%)
3.23b: n = 6 (76%)
3.23d: n = 8 (82%)
3.24a: n = 4 (81%)
3.24b: n = 6 (96%)
3.24d: n = 8 (90%)
3.8
3.26a: n = 4, R = COOt-Bu



















































3.25a: n = 4
3.25b: n = 6
3.25d: n = 8
3.30a: n = 4 (85%)
3.30b: n = 6 (77%)
3.30d: n = 8 (76%)
3.3a: n = 4 (95%)
3.3b: n = 6 (82%)




The success in preparing L-serine analog 3.36 lay in the selection of the proper 
protective group for the carboxyl group. We had originally envisioned that the acid group 
of serine might be best protected as its tert-butyl ester because both the tert-butyl ester 
and the Boc group could be removed in a single operation. However, cleavage of the tert-
butyl ester from 3.29a required more forcing conditions than was necessary to remove the 
N-Boc group, and the deprotection of 3.29a was never clean.  
The deprotection of 3.26a and 3.29a was complicated by two issues. 1) Both 
terminal hydroxyl groups were esterified in the presence of excess organic acid (TFA or 
formic acid), as confirmed by FAB-MS and 1H. The trifluroacetate could be hydrolyzed 
by simply stirring in methanol (Scheme 3.10). 2) The released t-butyl cation was partially 
trapped by the dithiophosphate ester, even in the presence of large excesses of cation 
scavengers such as Et3SiH,294 anisole, ethanedithiol and/or thioanisole. In the very best 
case, the contaminant 3.31b was reduced to ca. 5% (based on 1H NMR) from typical 
20% when the solvent was thioanisole and TFA (1:1) and 20 equivalents of ethanedithiol 
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were added. The desired product 3.5a could be purified using reverse-phase HPLC or 













































3.31a: R = H
3.31b: R = -COCF3
3.5a  
 
At this point, we wondered whether the protection of the carboxyl group was truly 
necessary. Namely, could the phosphorylation proceed in the presence of an unprotected 
carboxylic acid? In a preliminary experiment to address this question, dithiaphospholane 
3.25a was found not to react with N-Boc-Ser(Ot-Bu)-OH (3.32) in the presence of DBU 
(1 equivalent) and both dithiaphospholane 3.25a and the serine 3.32 were recovered 
cleanly after the reaction, suggesting that the free carboxyl group alone was not reactive 
in the phosphorylation. However, a later attempt with derivatized serine 3.33 failed to 
deliver the desired product 3.34a. Clearly, the presence of carboxylic acid did interfere 












































The search for an easily removable protective group in place of tert-butyl ester 
finally ended up with trimethylsilylethyl ester295 as the protective group of choice. The 


















Sequential treatment of 3.38a-b, which were obtained from 3.25a-b after 
chlorophosphite coupling and reaction with 3.37, with tetrabutylammonium fluoride 
(TBAF) and SnCl4 cleanly removed carboxyl and amino protective group to deliver the 
desired L-serine phosphorodithioate 3.5a and its C8 analog 3.5b (Scheme 3.13). Though 
it was possible to remove the terminal silyl ether and trimethylsilylethyl ester from 3.38a-
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b concurrently with TBAF, the yield was lower than the two-step procedure and 





































3.38a: n = 4 (84%)
























3.39a: n = 4 (91%)
3.39b: n = 6 (91%)
3.34a: n = 4 (88%)
3.34b: n = 6 (97%)
3.5a: n = 4 (75%)







3.25a: n = 4 




3.2.4 Other Phosphorodithioate  
Meanwhile, it was thought a polar functionality isosteric to an alkyl group could 
mimic the fatty acid tails to improve water solubility without impairing the inhibition 
potency. Thus the synthesis of 3.46 was undertaken. Protected ω-methoxymethoxy 
ethanolamine phosphorodithioate 3.45b was prepared from 3.8 in the usual manner 
(Scheme 3.14). Removal of the trimethylsilylethyl carbamate protective group (Teoc) of 
3.45b was achieved with TBAF in CH3CN affording dithiophosphatidylethanolamine 
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3.46. The tert-butyl carbamate analog 3.45a could not be converted into 3.46 because 




1. MOMCl, iPr2NEt, CH2Cl2, 95%
HO OMOMO









3.42: R = PMB
3.43: R = H
DDQ


































3.45a: R = Boc (87%)





















3.2.5 Phosphonate  
Nina Antikainen obtained complexes of D55N mutant of PLCBc with C6-
cholinephosphonate 1.38c and C5-choline phosphorodithioate 1.38h. The two analogs are 
nearly equipotent as inhibitors with inhibition constant (Ki) being 1.15 M for 1.38c76 and 
1.21 M for 1.38h287. Similar level of active site occupancy (~80%) in the crystal 
structure of D55N was observed even though phosphorodithioate 1.38h was about 10 
times more soluble than choline phosphonate 1.38c (5 mM versus 0.5 mM) under the 
 129
soaking conditions.106 It was suggested that the phosphorodithioate might not be the best 
candidate for X-ray crystallization studies and phosphonate might be better suited for this 
purpose. Therefore the syntheses of phosphonate serine 3.48 and ethanolamine analogs 
3.53 were undertaken. 
The synthesis of L-serine phosphonate 3.48 closely followed that of 1.38c 
published by Martin and Wong.87 Thus, phosphonic acid 1.58c and N-Boc-ser-Ot-Bu 
were coupled in the presence of CCl3CN or 2,4,6-trisopropylbenzenesulfonylchloride 
followed by global deprotection of the carbamate and tert-butyl ester with TFA in 
CH2Cl2 to afford the desired phosphonate 3.48 in 67% yield over two steps (Scheme 
3.15).  
The phosphonate ethanolamine 3.53c was prepared similarly, from phosphonic 
acid 3.29c and N-Boc-ethanolamine followed by deprotection of the intermediate 
carbamate 3.52c with TFA in CH2Cl2. It was later found that 3.53c was too insoluble, so 
analogs 3.52a and 3.52b with shorter-carbon chains (C4 and C5) were prepared using 

































3.47: R' = t-Bu, R = Boc
3.48: R' = R= H
TFA/CH2Cl2










1. acetone, TsOH, 95%
2. CBr4, PPh3, 87%
3. P(OEt)3, ∆, 80%



































































3.51a: n = 1 (56%)
3.51b: n = 2 (40%)
3.51c: n = 3 (83%)
3.52a: n = 1 (36% over two steps)
3.52b: n = 2 (19% over two steps)
3.52c: n = 3 (53% over two steps)
CCl3CN
3.53a: n = 1 (77%)
3.53b: n = 2 (74%)




3.3 KINETIC EVALUATION OF WATER-SOLUBLE PHOSPHOLIPIDS  
With several substrate-based analogues in hand, the immediate task was to 
evaluate them as inhibitors of PLCBc through a kinetic assay. Since the PLCBc analogues 
were structurally similar to the natural substrate phosphatidylcholine, it was expected that 
they would interact with PLCBc in the same manner as the natural substrate. In fact, all of 
the non-hydrolyzable substrate-based analogues thus far prepared in the Martin group, 
including phosphorodithioate 1.38g and phosphonate 1.38c, were all shown to be 
competitive inhibitors by the analysis of Lineweaver-Burk (double-reciprocal) plots.87 X-
ray diffraction data of complexes of PLCBc and mutant D55N with C6-
cholinephosphonate 1.38c and C5-choline phosphorodithioate 1.38h revealed that these 
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analogs bound in the active site where the natural substrate would have otherwise 
bound,80, 106 further suggesting that any inhibition observed due to those substrate-based 
analogues would be competitive. Therefore, it is reasonable to assume that the substrate-
based analogues prepared in the prior sections of this chapter would be competitive 
inhibitors as well.  
The kinetic assays were run under steady state conditions using a chromogenic 
assay previously developed for determining the kinetic parameters of PLCBc in this 
group. The assay quantitates the amount of the inorganic phosphate produced from the 
alkaline phosphatase catalyzed hydrolysis of phosphorylcholine, which is a hydrolyzed 




























Soluiton A: Ammonium Molybdate
Solution B: Ascorbic acid; Trichloroacetic acid
Solution C: Sodium metaarsenite; Sodium citrate;
                   Acetic acidMolybdenum "Blue" Complex











Figure 3.3. The chromogenic assay for determining the kinetic parameters of PLCBc  
The initial velocities at different substrate concentrations were obtained from the 
intensity of the absorption of the phosphate-molybdenum complex in the assay, and the 
inhibition constants for all the analogues were extrapolated. Since the initial velocity was 
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measured under steady-state conditions, and the data was processed according to a 
simplified Michaelis-Mentor equation for competitive inhibition, it is beneficial to 
present a brief overview of related steady state kinetics concepts, mathematic equations 
and data processing methods in the upcoming sections. 
  
3.3.1 Steady-state Kinetics and Competitive Inhibition 
Kinetic assays were performed under steady-state conditions to simplify the 
mathematic equations necessary to process the data to obtain the kinetic parameters. In 
the steady state model, the enzyme-substrate complex ES can either dissociate into 
unbound enzyme and free substrate or undergo chemical reactions releasing product and 
reform free enzyme (Figure 3.4). The enzymatic reaction starts with a pre-steady-state 
(transient-state) build-up of enzyme-substrate complex concentration (typically a few 
milliseconds). Since the rates of both dissociation pathways are first-order in the 
concentration of ES, the rate of decomposition of ES complex catches up rapidly. If the 
substrate concentration is in large excess of the enzyme concentration, the enzyme-
catalyzed reaction reaches a situation of steady state after a few turnovers where the 
concentration of intermediate ES stays constant usually until an appreciable amount of 
substrate is consumed (Figure 3.4). The establishment of steady state is typically 
completed almost instantaneously after the catalytic reaction is initiated.  
 











Figure 3.5: Concentration of major components in an enzymatic reaction. 
Though the steady state can last for a period of time in a kinetic assay, only the 
initial velocities are typically measured. The concentration of the product at the time of 
measurement is thus practically negligible, which avoids the complications due to 
product inhibition. Another assumption is that the uncatalyzed chemical reaction is much 
slower than enzymatic catalyzed reaction so that its contribution to the overall product 
formation can be ignored. Briggs and Haldane in 1925296 applied the steady-state 
approximation (Eq. 3.1) and mass balance (Eq. 3.2) to the kinetic scheme shown in 
Figure 3.4, provided a theoretical rationalization of the previously empirical Michaelis-
Menten equation (Eq. 3.3).297 
 
Steady state assumption [ ] [ ][ ] [ ] [ ] 0211 =−−= − ESkESkSEkdt
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Abbreviations 
0E : enzyme concentration when t = 0, ie: total enzyme concentration 
E: free enzyme concentration 
S: free substrate concentration 
I: free inhibitor concentration 
0I : total inhibitor concentration. 
ES: enzyme-substrate complex concentration 
EI: enzyme-inhibitor complex concentration 
v: observed velocity of the enzymatic reaction 
k: rate constant 
Vmax: maximum velocity for the enzymatic reaction, ∞→sv  
KM: equilibrium constant related to Michaelis-Menten kinetics 
app
MK : apparent Michaelis constant 
Ki: inhibition constant 
Ks: Dissociation constant for enzyme-substrate complex 
 
Experimental data are traditionally analyzed by linear regression or more recently 
by computer assisted non-linear regression. The classical linear fitting approaches, 
Lineweaver-Burk298 is simply an algebra conversion of the general Michaelis-Menten 
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equation to yield straight lines with with the slope being
maxV








Michaelis-Menten curve (perfect data)
substrate [S]












Lineweaver-Burk plot (perfect data) 
1/[S]












Figure 3.6: Michaelis-Menten curve and linearized data processing plot 
The kinetics of the enzymatic reaction changes when compounds capable of 
interacting with the enzyme are present. The rest of this section will briefly discuss 
competitive inhibition since all the phospholipid analogs thus far prepared in the Martin 
group are competitive inhibitors.  
By definition, a competitive inhibitor binds reversibly to the enzyme active site in 
place of the substrate, so the binding of the inhibitor excludes the binding of the 
substrate. This type of competitive inhibitor almost always bears some close structural 
and chemical similarity to the natural substrate of the enzyme. Alternatively, the inhibitor 
may bear no resemblance to the substrate and simply blocks the entry to the active site so 
that the substrate cannot enter. Another type of competitive inhibitor is one that binds to a 
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different site of the enzyme causing a conformation change in the enzyme rendering the 
active site unable to bind the natural substrate. Similarly, prior binding of the substrate to 
the active site causes a change in the inhibitor site preventing the inhibitor from binding. 
In either case, the binding to inhibitor and substrate are mutually exclusive, so it is 
impossible for both to bind to the enzyme at the same time. Mathematic deduction using 
the steady state assumption (Eq. 3.9), mass balance of the enzyme-containing species 
(Eq. 3.10) and inhibition constant equation (Eq. 3.11) would then give the competitive 
inhibition equation (Eq. 3.12). 
 
 







Figure 3.7:  Simplified scheme for a one substrate-one product enzymatic reaction with a 
competitive inhibitor 
 
Steady state assumption [ ] [ ][ ] [ ] [ ] 0211 =−−= − ESkESkSEkdt
ESd  (3.9) 
Mass balance EIESEE ++=0  (3.10) 
Inhibition constant [ ][ ][ ]EI
EIKi =  (3.11) 
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K  (3.14) 
 
It is easily recognizable from the Michaelis-Menten plot that the inhibitor 
substantially reduces enzyme velocity at low substrate concentrations, but it does not 
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 Graph D 
Figure 3.8: Michaelis-Menten and Lineweaver-Burk plot for competitive inhibitors 
Graph C: Michaelis-Menten curve using perfect data. upper: control assay; 
lower: inhibition assay; Graph D: Lineweaver-Burk plot. upper: control 
assay; lower: inhibition assay 
3.3.2 Modification To the Kinetic Analysis  
The computer-assisted non-linear regression using the Michaelis-Menten equation 
was used in our group to obtain both KM and Kcat. However, it has become a problem to 
establish accurate kinetic parameters when PLCBc mutants or inhibitors were used in the 
current project.299 The intrinsic problems were the larger MK or 
app
MK  and the tendency 
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of the phospholipid substrate to form aggregates at higher concentration. Most of the 
mutants we obtained were inferior to the wild type phospholipase C with regard to 
catalytic efficiencies, so they had higher KMs for substrates. The Michaelis-Menten 
curves remained nearly linear at concentrations close to the critical micelle concentration 
(CMC) of the substrate C6PC 1.38a. Hence the Vmax thus obtained from non-linear 
regression bore a large error. The same problem existed with the inhibition assay as 
app
MK  is larger than Ks. Increasing the substrate concentration further was not an option 
since the kinetics of the hydrolysis changes at substrate concentrations above CMC, and 
significant acceleration of hydrolysis was reported.300 Theoretically, we could use 
phospholipids with higher CMC’s in the kinetic assays; unfortunately, those are generally 
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Consequently, the data were collected and processed as described below. The 
assay was performed at lower substrate concentrations, and consequently higher 
concentrations of enzyme were sometimes used to obtain a normal response. Under these 




Ek 0 . 





k  alone was sufficient to derive inhibition constant Ki (Eq. 3.14), the kinetic 
parameter of interest. An illustrative example is shown in Figure 3.9. The inhibition 
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constant was obtained from the ratio of the slopes of Michaelis-Menten plots at low 
substrate concentrations.  
Initial velocity curve of the control assay 
time (min)
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[S] = 0.75 mM 
[S] = 0.6 mM 
[S] = 0.45 mM 
[S] = 0.3 mM 
[S] = 0.15 mM 
Graph E 
Initial velocity curve of the inhibition assay (3.5a)
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[S] = 9.0 mM 
[S] = 7.5 mM 
[S] = 6 mM 
[S] = 4.5 mM 
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[S] = 1.5 mM 
Graph F 
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Figure 3.9: Initial Velocity Curve and Michaelis-Menten Plot at Low Substrate 
Concentration. Graph E: Initial velocity curve of the control assay 
(experimental data); Graph F: Initial velocity curve of the inhibition assay in 
the presence of 3.5a (2.55 mM) (experimental data); Graph G: Michaelis-
Menten plot at low substrate concentration. 
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3.3.3 Kinetic Evaluation of Water-Soluble Phospholipids  
The potencies of the phospholipid analogues 3.34-3.36, 3.48 and 3.53 as 
inhibitors of PLCBc were determined,284 and most of the synthetic analogues were found 
to be inhibitors. The Ki and solubility of each analogue are shown in Table 3.2. 
Table 3.2: Results of Kinetic and Solubility Studies on Phospholipid Analogues 
Phospholipid Solubility Ki  Enzyme 
C5-phosphonatePE 3.53b 7.7 mM No inhibition# PLCWt 
C6-phosphonatePE 3.53c 280 mM No inhibition# PLCWt 
C6-phosphonatePS 3.48 6.8 mM No inhibition# PLCWt 
C6-hydroxydithioPE 3.4a 3.0 mM 0.17 mM PLCWt 
C6-hydroxydithioPC 3.3a 37 mM 1.0 mM PLCWt 
C8-hydroxydithioPC 3.3b 4.5 mM 2.6 mM* PLCWt 
C10-hydroxydithioPC 3.3d 0.50 mM 0.04 mM PLCWt 
C6-hydroxydithioPS 3.5a very soluble 1.2 mM PLCWt 
C8-hydroxydithioPS 3.5b 6.3mM 1.4 mM* PLCWt 
Ki values are average of two or more assays except as noted otherwise, *Values are from 
a single kinetic assay; #No inhibition observed at maximum solubility;  
 
Examination of the results in Table 3.2 revealed some useful trends between 
inhibitor structure and potency. As expected, the short-chain 3.53b was sufficiently 
soluble in water; however, no inhibition was observed at its maximum solubility. In fact, 
none of the phosphonate analogs inhibited PLCBc at their maximum solubilities. The 
dithiophosphatidylethanolamine 3.4a and dithiophosphatidyl-L-serine 3.5a, which were 
congeners of dithiophosphatidylcholine 3.3a, were good inhibitors. The C6 
dithiophosphatidylcholine 3.3a and -L-serine 3.5a and their C8 analogs 3.3b and 3.5b 
were about equipotent, while further increasing the length of the acyl side chains 
produced a more potent and less soluble C10 analog 3.3d. Current data also suggested 
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that choline-, ethanolamine- and L-serine- derived phospholipids analogs have similar Kis 
with PS being the most soluble and PE the least soluble, which is expected considering 
the relatively low selectivity of PLCBc towards its natural substrates. 
 
3.4 CRYSTALLIZATION STUDIES301  
Experiments involving random mutagenesis of PC-PLCBc demonstrated that 
randomly changing the three amino acids residues E4, Y56, and F66 afforded variants 
with altered substrate specificities.282 Recently, Antikainen and colleagues discovered 
that mutating Y56 to threonine changed the selectivity of wild type from PC to PE, while 
mutants E4G and E4Q were found to be specific for PS (Figure 3.10).281 These mutants 
exhibited an impressive catalytic activity for their preferred phospholipids, about 2-4 
times higher than the wild type. The fact that these dramatic changes in substrate 
specificity arose from a single amino acid mutation makes them interesting candidates for 
structural studies.  
Obtaining crystal structures of the Y56T, E4G, and E4Q mutants complexed with 
analogs similar to their preferred substrates, PE and PS, respectively, will provide insight 
into the structural basis for the selectivity of these mutants. The structure of the unbound 
forms of E4G, E4Q and Y56T mutants were obtained and solved by Benfield301 and 
found to be nearly superimposable to that of wild type. Many attempts were made to 
acquire crystal of complexes of these mutants of PLCBc with phospholipid analogs. High 
ligand occupancy was never achieved using phosphorodithioates, ω-hydroxy-
phosphorodithioates 3.3-3.5 and phosphonate-PE 3.53. Aaron Benfield successfully 


































Figure 3.10: Catalytic Activity (Kcat/Km) of Wild-Type PC-PLCBc and Mutants E4G, 
E4Q, and Y56T Towards PC, PE & PC.281 
These three-dimensional structures are almost identical in that the backbone 
atoms align with an rmsd of 0.09 Å for E4G and E4Q complexed with phosphonate-PS 
3.48. However, these mutants bind the PS analogue in a very different manner than wild-
type PC-PLCBc does a PC analogue. Both structures reveal that a large conformational 
change involving the first 15 N-terminal residues occurred upon binding of the substrate 
analogue 3.48. One of the zinc ions appears to have been lost. The phosphonate and fatty 
acid tails are located in the vicinity where Zn3 and Trp1 were found in the wt-PLCBc-PC 
structure.80 The non-bridging oxygen atoms of the phosphodiester appear to contact Zn1, 
D55, His118, and Asp122 through electrostatic forces and hydrogen bonds. Additionally, 
the carboxyl group of the serine head group interacts with Zn2, Glu146, and His128. The 
zinc-binding pattern is very different from the wt-PLCBc-PC structure, where all three 
zincs are in close contact with the non-bridging oxygen atoms of the phosphodiester. 
There also appears to be a π-cation interaction between the amine nitrogen of the serine 
head group and Phe66 (Figure 3.11 and 3.12).301  
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Figure 3.11: Side by side comparison of PLCwt-PS and PLCwe-PC complexes. On the 
































































Figure 3.12: Interactions Between PLC mutant E4Q and 3.48. Top: Interactions Between 
L-serine Phosphonate 3.48 and PLC (R1= Serine); Bottom: Interactions 











































































Figure 3.13: Cartoon representation of selected active site interactions in the structure of 
wt PLCBc bound to cholinephosphonate analog. Distances between atoms 
are shown in Ångstroms. 
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The observation that the PS analogue 3.48 binds these mutants and wild type in a 
very different manner as compared to the PC analogue 1.38c suggests the enzyme could 
hydrolyze phosphatidylserine in a different fashion from phosphatidylcholine. Both 
mutants (E4G and E4Q) and wild type bind the PS analogue with only two zinc atoms. 
Only one of the two zinc atoms makes contact to one non-bridging oxygen atom of the 
phosphodiester, while the other involves in static interaction with the serine carboxyl 
group. Wild-type PC-PLCBc utilizes all three zinc atoms to bind both non-bridging 
oxygen atoms of the phosphodiester of PC. It is suggested these three zinc atoms could 
play roles in activating the nucleophile water together with Asp 55, stabilizing the 
pentacovalent intermediate and stabilizing the leaving alkoxide as the general acid. 
However, in the crystal structure of PS analogue 3.48 with PS selective mutants E4G and 
E4Q and wild type, only one zinc ion within their active sites can potentially be involved 
in the catalysis. While a mechanism involving a single zinc ion could be proposed,86, 103 
extensive kinetic experiments beyond the scope of this project would be required to 
validate the proposal. Alternatively, these structures presented above could merely 
represent how these proteins bind the PS analogue 3.48 under certain conditions. It is 
possible that the PS binds in a very different manner in vivo. Without further 
experimental proof, an unambiguous conclusion cannot be drawn at this point. 
 
3.5 CONCLUSION 
A number of water-soluble non-hydrolyzable substrate analogs were prepared, 
including ω-hydroxy phosphorodithioates and phosphonates of choline, ethanolamine and 
L-serine. The phosphorodithioates function by chelation to one or more of the zinc ions at 
the active site of the enzyme. Kinetic assays reveal that ω-hydroxy phosphorodithioates 
in general are good inhibitors with decent aqueous solubility. Ethanolamine and L-serine 
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derivatives of phosphonates, however, failed to inhibit PLCBc at their maximum 
solubility. The three-dimensional structures of phosphonate-PS 3.48 with E4G, E4Q and 
wild type were solved by Benfield and revealed that these mutants bind the PS analogue 
in a very different manner than wild-type PC-PLCBc does a PC analogue. The structural 
difference again raised a number of questions about our understanding of phospholipase, 
presenting us with more challenges and opportunities in the future work. 
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Chapter 4: Studies Towards the Synthesis of 5-Hydroxyaloin A 
4.1 THE CHEMISTRY AND BIOLOGY OF ALOE NATURAL PRODUCTS 
Aloe is a group of tropical/subtropical plants that is characterized by lance shaped 
leaves with jagged edges and sharp points. It consists of over 400 different species, most 
native to the dry regions of Africa with most species found in southern and eastern Africa 
and the island of Madagascar. Most sources have placed Aloe in the Lily family 
(Liliaceae), which includes garlic, onion, and asparagus. Aloes vary in size ranging from 
little one-inch miniatures to species that can reach height of 60–90 cm long and 5–10 cm 
across the base.302  
 
 
Figure 4.1: The economically most important aloe species: Aloe vera (Aloe 
barbadensis) (Pictures are used with consents from the photographers) 
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The term aloe is derived from the Arabic word “alloeh”, which means a shining 
bitter substance in reference to the exudate.303 Aloes have been used therapeutically for 
the treatment of constipation, burns, cuts, rashes and skin disorders since biblical times 
and probably long before.304 The leaves of Aloe yield two medicinal products – a thick, 
mucilaginous, colorless gel from the leaf and a bitter exudate from the outer layer of the 
leave. The gel is a typical ingredient in a range of healthcare, nutraceutical and cosmetic 
products, such as shampoos and skin care creams because of its moisturizing and 
soothing properties. Aloe gel has been reported to enhance immunity, improve liver 
function, prevent asthma and act as an anti-inflammatory, anti-ulcer, anti-diabetes, anti-
hypertension, anti-cancer and antibiotic agent.304 The bitter exudates known as "bitter 
aloes" or "aloe drug" are used mainly as laxatives and as bittering agents in certain 
beverages.303  
For centuries, the leaves of the Aloe plant were used for its therapeutic properties 
without any insight of the chemical and biological basis for the wide spectrum of 
biological activities. Only in the last several decades did scientists begin a quest to 
understand the significant chemical ingredients that are responsible for the varied 
biological activities.  
The leaf pulp (inner gel) contains more than 98% water, and its alcohol-insoluble 
portion has a high content of polysaccharides, monosaccharides, uronic acid and a few 
enzymes. Most researchers attribute the beneficial medicinal properties of the inner gel to 
the polysaccharide component. Significant variations in the composition of pulp 
polysaccharide species were reported in early studies, and a variety of polysaccharides 
have been detected or isolated from the pulp, including mannan, galactan, arabinan, 
arabinorhamnogalactan, pectic substance and glucuronic acid-containing polysaccharide. 
The reason for the variance in composition was probably related to seasonal change 
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and/or different geographic locations of the samples. The gel most likely has more than 
one active constituent, which may be addressing different biological properties.  
The exudates are largely phenolic in nature. More than 130 secondary metabolites 
have been isolated from the leaves and roots of Aloe, including many alkaloids, 
anthraquinones, pre-anthraquinones, anthrones, chromones, flavonoids, coumarins and 
pyrones. The UV spectrum can be used to get a rapid idea of the different classes of 
compounds present in the methanol extract of leaf exudate and establish the chemical 
profiles in Aloe, if the analysis is performed using a modern reversed phase HPLC 
equipped with photodiode array detector.303  
Anthrones are the most important secondary metabolites of all the classes of 
compounds present in Aloe. The gastrointestinal effects of the leaf exudates, particularly 
the laxative properties, are associated with the anthraquinone contents of the plant. The 
representative members of this class are aloin A (4.1a) and B (4.1b), which are 
collectively known as barbaloin. Aloin A/B are two β-C-anthracyl glucosides that are 
epimeric at C-10 where the glucose moiety is attached to the anthrone core. The absolute 
configuration of aloin B is established to be (10R, 1'S), and the epimeric orientation (i.e. 
10S, 1'S) has been assigned to aloin A. These compounds are believed to be the primary 
factor for the bitter and purgative properties of the commercial aloe drug.  
Grün and Franz have studied the biosynthesis of aloin, and they demonstrated that 
aloin B (4.1b) was formed by attachment of glucose to the aloe-emodin anthrone 4.2, 
which in turn appeared to arise biosynthetically from a polyketide precursor. They further 
established that aloin B (4.1b) is the true natural product, which upon standing gradually 






4.1a: R1 = Glu, R2 = H






4.3a: R1 = Glu, R2 = OH












5-hydroxyaloin A nataloin A/B
 
Figure 4.2: Representative anthrones in Aloe 
On the other hand, 5-hydroxyaloin A (4.4), which is isolated from leaf exudates of 
many Aloe plants, including Aloe microstigma, Aloe broomii, and Aloe marlothiionly, is 
known only in the more stable A-configuration (10R, 1'S), thus being the only known 
anthrone-C-glycoside that has not been found as diastereomeric pair in plants. 
 
4.2 5-HYDROXYALOIN A 
The aloin C-aryl glycosides possess 2-oxygenated sugars para to the central 
anthryl hydroxy functional group, and therefore they are technically classified as 
members of the Group I C-aryl glycoside family. However, Aloin C-aryl glycosides 
differ significantly from typical members of major classes of C-aryl glycosides, including 
Group I C-aryl glycosides in two aspects. 
1. The point of the carbohydrate attachment to the aromatic core is different. In 
aloin C-aryl glycosides; the attachment is at the center of the anthrone ring, while all 
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other known naturally occurring C-aryl glycosides possess the carbohydrate moiety on 
the outermost ring of the aromatic system. 
2. The nature of the carbohydrate moiety is different. The aloin C-aryl glycoside 
contains a 2-oxygenated carbohydrate, either a glucose or a derivative thereof; while 
most other known natural occurring C-aryl glycosides contain 2-deoxy sugars with only a 
few exceptions. Those exceptions all belong to the Group I C-aryl glycosides, such as 






















gilvocarcin M (2.2a):   R = methyl
gilvocarcin V  (2.2b):   R = vinyl
gilvocarcin E  (2.2c):   R = ethyl  
Figure 4.3: Group I C-aryl glycosides possessing 2-oxygenated carbohydrate moiety. 
 
4.1.2 The First Generation Approach  
We were interested in the synthesis of a representative aloin C-aryl glycoside 
using the tactics developed in our group to establish the feasibility of our unified 
approach to prepare the major classes of naturally occurring C-aryl glycosides. In our 
prior investigations, the more commonly occurring 2-deoxy sugars such as 4.6 were 
universally employed. Cycloaddition with benzyne followed by acid-catalyzed 
rearrangement then delivered glycosyl-substituted naphthol 4.8. Hence the reactivity of a 
glycosyl furan with a 2-oxygenated carbohydrate moiety such as 4.9 had never been 
explored. Both the cycloaddition of 4.9 and the acid-catalyzed ring opening of 4.10 could 
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We were particularly interested in the synthesis of Group I C-aryl glycosides, 
because of the advantage of our glycosyl furan/benzyne cycloaddition methodology in 
generating the 1,4-subitituion pattern of the glycosyl-substituted phenol. As discussed in 
the prior chapter, Suzuki developed a convergent approach that relied on regioselective 
cycloadditions of glycosyl-substituted α-alkoxybenzynes with alkoxyfurans.171, 172 
However, since the requisite glycosyl-substituted α-alkoxybenzynes were obtained from 
the ortho selective O→C-glycoside rearrangement, Group I C-aryl glycosides cannot be 
accessed directly. Hence Suzuki applied the O→C-glycoside rearrangement to a 
monoprotected resorcinol such as 4.13 to afford the 6-glycosyl resorcinol 4.14, in which 
one phenolic hydroxyl was ortho to the carbohydrate moiety and the other para (Scheme 
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4.2). Subsequent benzyne generation eliminated the unwanted ortho phenolic hydroxyl. 
This tactic allowed Suzuki to circumvent the obstacle inherent in the ortho selective 
O→C-glycoside rearrangement, and his group later completed the total syntheses of three 
representative Group I C-aryl glycosides, gilvocarcin M (2.2a),146 gilvocarcin V 
(2.2b)146 and ravidomycin (2.3).173, 180 Our benzyne cycloaddition/ring opening 
methodology, however, allows direct access to the Group I C-aryl glycosides. Therefore 
we were expecting to demonstrate the effectiveness of our methodology in the synthesis 

























1. NaH, (MEO)2SO2, 96%
2. TBAF, THF. 100%

















The distinctive architecture of the aloin C-aryl glycoside with a 2-oxygenated 
carbohydrate attached at the center of a polyphenolic aromatic core provides an excellent 
opportunity to demonstrate the strength and utility of our newly developed methodology. 
The representative 5-hydroxyaloin A (4.4) was chosen as the synthetic target. It was 
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envisioned it could be synthesized through annulating new aromatic rings onto an 
existing ring in two directions, Our approach, which is illustrated in Scheme 4.3, 
highlights two consecutive furan-benzyne [4+2] cycloadditions. These are a glycosyl-
furan/benzyne cycloaddition and a regioselective glycosyl-substituted α-
alkoxybenzyne/alkoxyfuran cycloaddition. Successful completion of this route relies on 
the ability to generate a benzyne intermediate from a naphthalene precursor 4.21. Since 
the glycosyl-furan/benzyne cycloaddition has consistently given poor global 
regioselectivity, regiocontrol via a disposable silyl tether in the first cycloaddition is 
required to produce the correct regioisomer 4.22. The symmetric disposition of 
substitution of A ring however renders the control of regiochemistry in the second 
cycloaddition unnecessary. Thus, the three essential components are the siloxyfuran 4.19, 




























































































The required phenol 4.29 was synthesized from the known methyl ester 4.26 
(Scheme 4.4). Reduction of the ester 4.26 with DIBAL-H or aqueous sodium borohydride 
afforded the hydroxymethyl phenol 4.27. Both hydroxyl groups of 4.27 were protected as 
their di-tert-butyldimethylsilyl ethers. Selective deprotection of bis-TBDMS ether 4.28 
with tetrabutylammonium fluoride (TBAF) at low temperature afforded the requisite 
phenol 4.29. Treatment of m-hydroxymethylphenol 4.27 with TBSCl/DMAP/ Et3N305 in 
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an attempt to achieve selective protection of the primary hydroxyl group in the presence 
of a phenolic hydroxyl resulted in protection of the phenolic hydroxyl group, instead of 

















4.28 4.29  
 
The synthesis of glycosyl furan 4.33 started from known 2,3,4,6-tetra-O-benzyl-
D-glucopyranolactone (4.31)306 and 3-chlorofuran (4.30)307, 308 (Scheme 4.5). 
Regioselective α-lithiation of 3-chlorofuran (4.30) with LDA and subsequent addition of 
the resultant 2-lithio-3-chlorofuran to glucopyranolactone 4.31 afforded the hemiacetal 
4.32. Without purification, hemiacetal 4.32 was treated with trimethylsilyltriflate 
(TMSOTf) in the presence of triethylsilane, during which time oxocarbenium generation 
and regioselective hydride reduction ensued to give the β-furyl glucopyranose 4.33 
predominantly184 (Scheme 4.5). The β configuration of the anomeric carbon was 
evidenced by the large coupling constant (J = 10.5 Hz) of the anomeric proton. If desired, 
the small amount α-anomer may be conveniently removed through recrystallization of 
the mixture from hexanes/chloroform. The acidic NaCNBH3, which was used to reduce 































Sterics to Control Regiochemistry 
Prior to adopting the tethering strategy for effecting regiocontrol in glycosyl 
furan/benzyne cycloaddition, model studies were conducted to probe whether 
regiochemistry could be controlled based on steric factors. This tactic would have 
avoided multiple-step tethering and tether cleavage. We envisioned that a bulky 
protecting group, such as triphenylmethyl (trityl), might hinder the approach of 2-
glycosylfuran 4.33, and hence raise the activation energy associated with Path B. Hence 
the formation of the desired regioisomer 4.36a, in which the carbohydrate moiety was 
further away from the bulky protecting group, would be favored (Scheme 4.6). We were 
however cautious about this strategy due to precedence in the literature of poor selectivity 
in intermolecular benzyne cycloadditions and our past failure in controlling 








































To test the viability of using steric effects to control regiochemistry in the 
cycloadditions, m-chlorophenol trityl ether 4.41 was prepared from the known phenol 
4.26 (Scheme 4.8), and the related m-chloroanisole 4.39a was made as the control 
compound (Scheme 4.7). We found that 4.39a readily underwent metallation ortho to the 
methoxy group and chloride upon exposure to s-BuLi at low temperature. Subsequent 
warming up in the presence of furan or 2-glycosylfuran 4.33 led to the desired 
cycloadducts. In sharp contrast, the trityl ether 4.41 failed to undergo ortho-metallation 
using n-BuLi, s-BuLi or LDA and consequently there was no cycloaddition with glycosyl 
furan 4.33. The very steric bulk imposed on the phenolic oxygen in order to achieve the 
regiocontrol in the cycloaddition step worked against us in the metallation step, depriving 
the phenolic oxygen of the capability of serving as an ortho-directing group. Although 
4.41 could be altered to allow ortho-lithiation and subsequent benzyne generation, either 
by installing a secondary functional group such as a halide or by reducing the steric bulk 
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around the phenolic oxygen. The precedented failure in the literature promoted us to steer 




















1. LAH, ether, 81%
2. TBSCl, DBU, CH2Cl2
94% CH2OTBSCl
OTr
4.26 4.40 4.41  
 
Tether to Control Regiochemistry-Williamson Etherification 
In view of our inability to exploit steric effects to control regiochemistry in the 
[4+2] cycloaddition, we turned to a tether strategy. Thus a silyl tether was installed onto 
4.33 using a method developed in the Martin group.268 α-Lithiation of 3-chloro-2-
glycosylfuran 4.33 with LDA followed by trapping the resultant lithiofuran with 
bromomethyldimthylsilyl chloride afforded the furylsilane 4.42. Bromomethylsilane 4.42 
and its corresponding iodide 4.43 were then subjected to Williamson etherification in an 
effort to attach the arene moiety and obtain the cycloaddition precursors 4.44 or 4.45. 
Unfortunately, attempts to implement this strategy gave either no reaction or trace 
amounts of desired product 4.44 or 4.45 that was accompanied with significant quantities 
of 4.46, which no longer possessed the silyl tether handle (Scheme 4.9). The formation of 
4.46 was apparent with an upfield shift of furan proton by 0.7 ppm and the formation of a 
singlet at 2.2 ppm in the 1H NMR spectrum. It was also found that the 
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bromomethylsilane 4.42 was not stable to the standard Williamson etherification 
conditions that were used in our group to similar ethereal compounds.268 Simply stirring 
4.42 with Cs2CO3 and TBAI in acetone in the absence of phenol 4.29 cleanly afforded 





























4.44: R = TBS
4.45: R = TIPS













The main decomposition pathway responsible for the formation of 4.46 was 
presumably initiated by the nucleophilic attack on silicon rather than carbon. Subsequent 
aryl migration and desilylation, either through protodesilylation or a second nucleophilic 
attack followed by elimination, resulted in the formation of 4.46 (Scheme 4.10). This 
type of rearrangement has been reported several times in literature, but mostly with 




4.42: X = Br




































Shechter and Kreeger investigated the reaction of chloromethyl dimethyl-
phenylsilane (4.49) with sodium methoxide at 65 ºC in methanol (Scheme 4.11).313 The 
major product of the reaction was 4.50, which was formed by displacement of chloride 
with methoxide. Small amounts of 4.51 and toluene, both of which were resulted from 
initial attack of methoxide on silicon were also isolated (Scheme 4.11). Addition of 18-
crown-6 in trace amounts caused a shift from predominant methoxide attack on carbon to 
that on silicon and as a result a dramatic shift in the product distribution. Substituting 
potassium methoxide or cesium methoxide for sodium methoxide or switching solvent 
from methanol to dioxane had similar impact on the reaction pathway. The use of lithium, 
magnesium, or calcium methoxide in this reaction gave only recovered starting material. 
Shechter therefore concluded that the more separated and thus more nucleophilic 
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In a separate study probing the effects of the steric bulk and nucleophilicity on the 
reaction of alkoxides (t-BuO-, i-PrO- and MeO-) with chloromethylvinylsilane in 
tetrahydrofuran, Shechter observed that as the bulk of the alkoxide increased, attack on 
silicon diminished. He proposed that attack on silicon to generate a pentavalent 
intermediate was a process that was more sensitive to steric hindrance. Therefore, the 
more bulky alkoxide ion preferentially attacked the less steriC-demanding carbon.314  
With these precedents in mind, attempts were made to optimize the etherification 
reaction by using a bulky protic solvent (t-butyl alcohol and t-amyl alcohol), and a pre-
formed lithium or sodium salt of the phenol 4.29 in hopes that the nucleophilic attack on 
the less hindered carbon would prevail. However, all of these efforts, including the use of 






Tether to Control Regiochemistry-Mitsunobu Etherification 
An alternate means to activate the alcohol as a leaving group in order to link 3-
chloro-2-glucosyl furan 4.33 and phenol 4.29 via a Mitsunobu reaction was developed. 
Toward this end, the model α-silanol 4.58 was chosen to probe the feasibility of this 
strategy. The α-silanol 4.58 was prepared by reduction of the corresponding acetate with 
lithium aluminum hydride (LAH), which in turn was prepared by direct displacement of 
the bromide of 4.57 with acetate. Gratifyingly, the Mitsunobu etherification between α-
silanol 4.58 and phenols 4.29 and 4.26 proceeded smoothly to afford the desired products 
4.59 and 4.60 in good yields (Scheme 4.12).  
This success notwithstanding, etherification of α-silanol 4.62 proved to be 
problematic. The reaction did afford the desired product; however, the yield was rather 
poor, ranging from 20-30% (Scheme 4.13). Attempts to optimize the reaction by 
changing solvents, reaction temperature and order of addition resulted in only little 
improvement. It was initially thought that the phenolic hydroxyl was not acidic enough, 
so the more reactive combination-tributyl phosphine and ADDP (azodicarbonyl 
dipeperidine) was employed.315 The yield, however, was not improved and in one case 
the yield actually dropped unexpectedly to 9%. Use of the more acidic phenol 4.26 was 
equally unsuccessful. NMR again revealed the formation of the desilylated product 4.46, 






1. KOAc, NaI, DMF, 86%





























































































Table 4.1: Attempts in the Mitsunobu Etherification of 4.62 
Entry Phenol Other reagents solvent Temp. yield 
1 4.29 PPh3, DIAD toluene rt 20% 
2 4.29 PPh3, DIAD THF rt slow reaction 
3 4.29 PPh3, DIAD CH2Cl2 rt 24% 
4 4.29 PPh3, DIAD benzene rt 20-31% 
5 4.29 PPh3, DIAD benzene 0 °C 18% 
6 4.29 PPh3, DIAD benzene –15 °C 11% 
7 4.29 PPh3, DIAD benzene –78 °C 0% 
8 4.29 PBu3, ADDP benzene rt 9% 
9 4.26 PPh3, DIAD toluene rt 24% 
10 4.26 PBu3, ADDP benzene rt 22% 
11 4.26 PBu3, ADDP THF rt 10% (slow reaction) 
12 4.26 PBu3, ADDP CH2Cl2 rt 29% 
 
It was thought that a better leaving group would facilitate the second-order SN2 
substitution on the carbon, and subsequent displacement with phenoxide would then 
afford the desired cycloaddition precursor.316 Hence α-silanol 4.62 was transformed into 
its triflate and allowed to react with phenol 4.29. However, only trace amounts of the 
desired product 4.63 were observed from this one-pot reaction (Scheme 4.14). It was not 




























To get around the problem of the competing α-halosilane rearrangement initiated 
by nucleophilic attack on silicon, a strategy using a silyl tether containing an additional 
carbon atom that was developed by group member Dr. Sparks was adopted.278 The 
model β-silanol 4.66 was prepared via oxidation/hydroboration of the corresponding 
vinylsilane 4.65, which was obtained by the reaction of 2-ethyl-5-lithiofuran with 
dimethylvinylchlorosilane. When β-silanol 4.66 and phenol 4.29 were subjected to 
Mitsunobu etherification conditions, the desired product 4.67 was obtained in an 




















In a similar manner, α-lithiation of the 3-chloro-2-glycosylfuran 4.33 followed by 
silylation, hydroboration and oxidation delivered β-silanol 4.69. β-Silanol 4.69 was then 
converted to 4.70 by reaction with 4.29 under Mitsunobu conditions (Scheme 4.16). 
Unfortunately the yield was poor (20~30%) despite of many efforts at optimizing the 
reaction conditions. At this point, we concluded that the activation of the alcoholic 
















































There are other ways to form C-O bonds.317, 318 For instance, Buchwald recently 
disclosed a procedure for preparing alkyl aryl ethers via a palladium-catalyzed alkylation 
of an alcohol with an aryl chloride or bromide (Scheme 4.14).319 By employing the 
appropriate monodentate biphenyl phosphine ligand 4.75a or 4.75b, β-hydride 
elimination was largely suppressed, and reductive elimination provided the required C-O 
linkage. m-Substituted aryl halides with inductively electron withdrawing substituents 
such as OMe, CO2Me, CF3, Ac or NO2 gave high yields of the alkyl aryl ethers, and 
functionalities such as ketones, esters, nitriles were well tolerated in the alkylation 
(Scheme 4.17). Hence a direct transformation to the requisite alkyl aryl ether 4.63, 4.64, 
4.70 and 4.76 was envisioned as depicted in Scheme 4.18, which, if successful, would 
afford the cycloaddition precursor in fewer synthetic steps. However, initial attempts with 
model compounds α-silanol 4.58 and β-silanol 4.66 revealed no formation of the desired 







Pd(OAc)2, Cs2CO3, n-BuOH, 4.75b
P(t-Bu)2
R
4.75a: R = H

































4.63: n = 1, R = CH2OTBS
4.64: n = 1, R = COOMe
4.70: n = 2, R = CH2OTBS





With limited amounts of 4.70 in hand, the key benzyne/furan cycloaddition was 
explored. It had been found that the model compound 4.67 readily underwent metallation 
ortho to -OMe with excess s-BuLi at low temperature. Subsequent warming of the 
solution afforded the desired cycloadduct 4.77 in an unoptimized yield of 30% (Scheme 
4.19). In contrast, metallation on the model 4.59 was accompanied with significant loss 
of silyl tether probably due to nucleophilic attack of organolithium on the silicon, and no 
cycloadduct 4.78 was observed (Scheme 4.20). The ortho-lithiation of 4.70 was 
complicated by the loss of the chloride from the furan ring, as evidenced by the upfield 
shift of the furan proton from 6.7 ppm to 6.4 ppm and a change from a singlet to a 
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doublet if MeOH instead of MeOH-d4 was used to quench the reaction. It appeared that 
lithium-chloride exchange, usually a slow process, took place under the lithiation 
conditions, probably assisted by one of the many Lewis basic oxygenated functionalities. 
The unexpected loss of the furan chloride and silyl tether in the ortho-lithiation step dealt 
a final blow to this synthetic route. Because of our inability to effect metallation cleanly 
and because of the low yields plaguing the etherification reactions, this approach was 

















































The Intermolecular Cyclization 
In the process of establishing the feasibility of our unified approach to major 
classes of naturally occurring C-aryl glycosides using the glycosyl furan/benzyne 
cycloaddition, glycosyl-substituted furans possessing no other substituents were 
universally employed as reaction partners. The frontier orbitals of the dienes are nearly 
symmetric due to the lack of polarizing groups, and so the global regiocontrol in the 
cycloadditions had been very poor with ratios of approximately 1:1 commonly 
encountered. In one of the more selective instances, Dr. Kaelin observed that the 
cycloaddition of the benzyne derived from 4.80 and 2-glycosyl furan 4.6 gave the 
expected cycloadducts 4.81 and 4.82 as a mixture of regio- and diastereoisomers (Scheme 
4.22). The ratio of 4.81 to 4.82 was determined to be 0.8:1 by integration of the 
bridgehead protons in the 1H NMR and the structure of 4.82 was assigned by comparison 





























82%   0.8:1
4.6
4.80
4.81 4.82  
 
On the other hand, excellent regiocontrol in benzyne/alkoxyfuran cycloadditions 
were well precedented in literature. For example, Suzuki observed that the head-to-head 
products 4.86a,b was dominant in glycosyl-substituted benzyne/2-alkoxyfuran 
cycloadditions (Scheme 4.23).172 Sargent observed reversed selectivity in a benzyne/3-
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alkoxyfuran cycloaddition, where the head-to-tail product 4.91 was the predominant 
species (Scheme 4.24).320, 321 Sargent and Suzuki rationalized the observed 
regioselectivity based on the polar effect of the alkoxy groups on the dienenophile 













4.83a: R = Me
4.83b: R = MOM
4.84 4.85 4.86a: R = Me (75%)

























The regioselectivity could be rationalized based on a two-step mechanistic model 
in which each new bond was formed in a kinetically different step and a discrete 
zwitterionic intermediate was involved. The zwitterionic intermediate, such as 4.92 and 
4.93, was stabilized by the inductively electron-withdrawing methoxy group on the 
benzyne and resonance electron-donating methoxy group on the furan. This led to the 
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Hence the intermolecular cyclization involving the 3-clorofuran 4.33 was 
attempted. We reasoned that the inductively electron-withdrawing 3-chloro substituent 
could potentially polarize the π-system of 3-chlorofuran to induce a regiochemical 
preference favoring the desired head-to-tail product in the cycloaddition with α-


























The cycloadditions between 3-chloro-2-glycosylfuran 4.33 and benzynes 
generated from the chloroanisoles 4.39a and 4.39b were thus examined. Only one 
bridgehead proton was observed in the 1H-NMR of the cycloadduct from either reaction 
(Scheme 4.26). This observation suggested that it was most likely that only one 
regioisomer was formed, as a large difference in chemical shift of the bridgehead protons 
between the two regioisomers would be expected. A NOSY experiment confirmed the 



















4.33 4.39a: R = OTBS
4.39b: R = OTIPS
4.95a: R = OTBS











4.96a: R = OTBS







A major concern, however, was that yields were constantly low being no better 
than 30%, despite efforts to optimize the reaction conditions (Scheme 4.26). A few 
representative examples of these attempts are presented in Table 4.2. As can be seen, 
significant amounts of 3-chloro-2-glycosylfuran 4.33 were recovered, even in the 
presence of large excesses of chloroanisole 4.39a or 4.39b. It was later discovered that 
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the pathway accounting for the consumption of benzyne was not formation of a 
cyclobutane via benzyne dimerization, but rather the nucleophilic addition of the 
organolithium 4.97 to the benzyne 4.98 resulting in the formation of a single regioisomer 
4.99 (Scheme 4.27), whose structure was identified by 1H-NMR in which no ortho-
coupling, but only meta-coupling, was observed.  
 
Table 4.2: Attempts in the Cycloaddition 
entry reagents products 
1 solvent Base 4.39b 4.99 4.95b Glucofuran 4.33 
2 s-BuLi, THF* 3.0 3.0  26%  
3 s-BuLi, THF 3.0 3.0  26% 55% 
4 s-BuLi, ether 3.0 3.0  12% 80% 
5 s-BuLi, THF 5.0 5.0 47% 23% 37% 
6 s-BuLi, THF 7.5 7.5 52% 20% 37% 
7 s-BuLi, THF 10 10 75% 30% 29% 
















The last and final blow to this approach was the resistance of cycloadducts 4.95a 
and 4.95b to undergo acid catalyzed ring opening to give 4.96a and 4.96b, respectively, 
and we were not able to cleave the oxa-bridge while keeping the rest of the structure 
intact. When TFA and BF3⋅Et2O were used, unchanged starting material was recovered. 
When more forcing conditions such as TMSOTf was employed, decomposition to a 
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phenol that no longer possesses the carbohydrate moiety became the main reaction 
pathway. The surprising stability of the cycloadduct toward acids and together with the 
low yields in the cycloaddition effectively signed the death warrant for this approach. 
    
A Re-examination of the Benzyne/Furan Cycloaddition 
The efforts to control the regiochemistry using a 3-chlorofuran were discontinued, 
but a question crucial to the success of the project needed to be addressed: What was 
wrong with the cycloaddition? Dr. Kaelin demonstrated that the cycloaddition between 2-
glycosylfuran 4.6 with a 2-deoxy sugar moiety and the symmetric benzyne 4.102 
generated from 2-chloro-1,4-dimethoxybenzene (4.103) proceeded smoothly to afford the 
cycloadduct 4.7 in 86% yield (Scheme 4.1). However, we constantly obtained the 
cycloadduct 4.95 in yields of 20~30% in the cycloaddition of 3-chloro-2-glycosylfuran 
4.33 with a non-symmetric benzyne 4.101 (Scheme 4.26). So, what makes our system 
behave so differently than Dr. Kaelin’s? Is it a problem with the glucosyl furan or a 
problem with the benzyne? A number of studies were initiated to answer those questions. 
Benzyne 4.101, which was generated from chloroanisole 4.39b, cyclized with 
furan smoothly (Scheme 4.28), to afford cycloadduct 4.100, albeit in a lower yield than 
the reaction with the benzyne from 2-chloro-1,4-dimethoxybenzene (4.103) and furan 
(>80%).272 The observation that 4.101 participated in benzyne/furan cycloadditions 
appeared to indicate that the problem in the cycloaddition was not with benzyne 4.101. 
Hence the problem seemed to be with the 3-chloro-2-glycosyl furan 4.33. The major 
differences between the two glucosyl-substituted furans 4.33 and 4.6 are the presence of 
































MM2 energy minimization using Chem3D suggested that the lowest energy 
conformer of 4.33 is the one in which the glycosyl substituent is nearly orthogonal to the 
planar furan ring. Thus the 3-chloro substituent of the furan could have a deleterious 
effect preventing the rotation of carbohydrate moiety thus blocking the access of the 
benzyne from either diastereotopic face of the furan. To test this hypothesis, glucosyl 
furan 4.104 lacking the 3-chloro substituent was prepared using standard procedures as 




















Alternatively, the 2-glycosyl furan 4.104 was prepared from the anomeric acetate 
4.106, which was allowed to react with furan in the presence of a Lewis acid to afford 
4.104 (Scheme 4.30). In both cases, the β-configuration at the anomeric center of the 

























Glycosyl furan 4.104 was then allowed to react with the benzyne 4.101, which 
was generated form 4.39b. However, dimer 4.99 was again the major product, and only 
traces of the desired cycloadduct 4.107 were observed with the remaining mass being the 
unreacted glycosyl furan 4.104 (Scheme 4.31). This finding refuted the hypothesis that 
the presence of the chloro substituent was solely responsible for the low yields in the 
benzyne/furan cycloadditions of the 3-chloro-2-glycosylfuran 4.33 and the benzyne 
4.101. In general, those cycloadducts were characterized by a distinctive doublet with a 
smaller coupling constant or a broader single at ~6 ppm in the 1H-NMR corresponding to 






























The presence of the oxygenated substituent at the 2-position of the carbohydrate 
moiety could increase the steric bulk around the reactive center or it could have a 
negative effect on the conformation of the reactive species, thereby being detrimental to 
the cycloaddition. To check the validity of this hypothesis, 2-deoxyglucosyl furan 4.6 
(Scheme 4.32) and glucosyl furan 4.113 (Scheme 4.33) were prepared via Friedel-Craft 
arylations. The methyl protected compound 4.6 was chosen in preference to the 
corresponding benzyl protected derivatives to facilitate interpretation of proton NMR. 
Both Friedel-Craft arylations afforded predominantly the thermodynamically more stable 
β-anomers under the equilibrating conditions, as evidenced by the large coupling 
constants (J1,2 = 11.7 and 9.7 Hz in 4.6 and 4.113, respectively) and the occurrence of the 



































KOH, 18-C-6, THF, MeI, 58%

























Cycloaddition of the benzyne generated from 4.39b with either 2-deoxyglucosyl 
furan 4.6 or the control compound glucosyl furan 4.113 afforded no more than trace 
amounts of the cycloadducts (Scheme 4.34), which was apparent by examining the 1H-
NMR of the crude reaction mixture. This represented a remarkable difference in 
reactivity, where benzyne generated from 4.103 reacted efficiently with 4.6 (Scheme 4.1). 
The observation indicated that the 2-oxygenated substituent on the carbohydrate moiety 
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of cycloadduct







During the course of these studies, it has become clear that not all benzynes are 
created equal. The high reactivity of benzyne is a doubly edged sword, bestowing the 
benzyne with the ability to cyclize with the relatively uncreative diene-furan and on the 
other hand rendering it vulnerable to other side reactions. The observation that benzyne 
4.101 does not add efficiently to any of the glycosyl furans thus far tried suggested that it 
should never be taken for granted that a benzyne, once generated, would cyclize with a 
substituted furan. Hence an examination of the benzyne 4.101 itself was warranted. 
Although the benzyne 4.101 failed to undergo significant cyclization with the 
three glycosyl furans 4.6, 4.104 and 4.113 to afford the cycloadducts (Scheme 4.34), the 
same cyclizations using benzyne 4.102 proceeded smoothly with all three glycosyl furans 
to afford the desired cycloadducts in good to excellent yields (Scheme 4.35). This 
observation also reconfirmed the prior conclusion that neither the 3-chloro on the furan 
nor the 2-oxygenated functionality on the carbohydrate moiety was the primary factor 









































4.114: R1 = Bn, R2 = Cl, R3 = OBn
4.115: R1 = Me, R2 = H, R3 = OMe















In a competitive trapping experiment, an equimolar mixture of two chloroanisoles 
4.39b and 4.103 was treated with two equivalents of s-BuLi at –95 °C in THF. Previously 
under this condition, benzyne 4.101 and 4.102 had been generated individually and 
trapped with furan successfully. In the presence of only one equivalent of furan, a single 
cycloadduct 4.116 rather than a mixture of two cycloadducts 4.116 and 4.100 was 
observed upon warming (Scheme 4.36). This observation suggested that the benzyne 
4.102 might be formed from its corresponding aryllithium at a lower temperature than 
that required to form benzyne 4.101. The benzyne 4.102 would then fully consume the 
furan. Alternatively, the benzyne 4.101 could be a poor dienophile thus failing in the 


























The simpler chloroanisoles 4.117 also failed to cyclize with glycosyl furans 4.33 
and 4.113 (Scheme 4.37), indicating that the silyloxymethyl group away from the 
benzyne reactive center was likely not to blame for the low reactivity of the benzyne 
4.101 in the benzyne/furan cycloaddition. No control cycloaddition experiment between 
the benzyne derived from chloroanisoles 4.117 and furan was performed; However, 
complete deuterium incorporation occurred when 4.117 was treated with s-BuLi at –95 
ºC followed by quenching with CD3OD at the same temperature. In analog of 4.39b, 
generation of the benzyne from the corresponding organolithium of 4.117 was the likely 
































4.118: R1 = Me, R2 = H








Evidently, the second methoxy group on the benzyne had a tremendous effect on 
its reactivity. The inductively electron-withdrawing methoxy group could lower the 
LUMO of the benzyne and thus facilitate a normal electron-demand cycloaddition. The 
presence of the p-methoxy group could help stabilizing the zwitterionic intermediate 
inductively. As a result, the lack of the 4-methoxy functional group in the benzyne 4.101 
altered the reaction course, promoting the nucleophilic addition of the organolithium to 
the benzyne over the cycloaddition with a glycosyl furan and leading to dimer 4.99. 
When furan itself was used in the cycloaddition, a satisfactory yield could be 
obtained with benzyne 4.101 as long as furan was present in large excess (Scheme 4.28). 
It is not clear whether the same can be said when the structurally more complicated 
glycosyl substituted furan was employed in excess.  
 
4.2.2 The Second Generation Approach 
In view of our discovery regarding the reactivity of benzynes of general type 
4.101 and our inability to effect the intramolecular benzyne/furan cycloaddition of 4.70, 
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the synthetic approach was revised to preclude the involvement of such a benzyne. The 
second-generation approach called for initial construction of the AB ring and subsequent 
appendage of C ring via a benzyne/siloxyfuran cycloaddition (Scheme 4.38). This route 
again featured the same theme of two benzyne/furan cycloadditions. The feasibility of the 
first of two cycloadditions has already been demonstrated in the earlier section (Scheme 
4.35), and the correct regioselectivity in the second cycloaddition between an 
alkoxyfuran 4.121 and the naphthalene derived benzyne 4.122 was expected based on 
Suzuki’s earlier work in the syntheses of ravidomycin173, 180 and gilvocarcins.146 The 
major disadvantage was the extra phenolic functional group brought in during the second 
cyclization, which would have to be removed in the subsequent manipulations. The late-










































The Use of 3-Chloro Glycosyl Furan 
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We envisioned that cleavage of the oxa-bridge in cycloadduct 4.114, which was 
obtained from cycloaddition of chloroanisole 4.103 and 3-chloro-2-glycosylfuran 4.33, 
followed by protection of the naphtholic hydroxyl as its methoxymethyl ether would 
yield a proper candidate for generation of the second benzyne and set the stage for the 
final benzyne/furan cyclization. However, the cycloadduct 4.114 persistently defied the 
acid-catalyzed rearrangement. Under conditions previously used to open said 
cycloadducts, starting material remained intact even after prolonged periods. At elevated 
temperatures or in the presence of strong Lewis acids such as TMSOTf, the cycloadduct 
underwent extensive decomposition with loss of carbohydrate moiety, and instead a 






































































The extraordinary resistance of the cycloadduct 4.114 toward acids could be 
ascribed to the inductively electron-withdrawing effects of the 3-chloro substituent on the 
furan and the 2’-benzyloxy group on the carbohydrate moiety. The cooperative effect 
greatly raised the energy of the intermediate carbocation and consequently severely 
slowed down the oxabicyclic ring cleavage pathway. The formation of naphthol 4.128 
likely proceeded via protonation of 4.130 to give 4.131, which suffered a reversed 
Friedel-Craft alkylation (Scheme 4.40). Such as mechanism would necessitate the 
formation of the desired product 4.130 as the intermediate, which was, however, not 





























































4.131a 4.131b  
 
Installation of an electron-donating functionality that would stabilize the 
developing positive charge in the transition state on either the furan or the carbohydrate 
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moiety might help. Alternatively one or both of the two electron-withdrawing groups 
could be removed to increase the stability of intermediate carbocation. 
 
The Use of Glycosyl Furan 
Removal of the chloro-substituent from the glycosyl-substituted furan 4.33 would 
decrease the destabilization of the intermediate carbocation in the acid catalyzed 
rearrangement. The implementation of such a tactic necessitates installing a chloride on 
the naphthalene ring at a later stage. Hence, cycloaddition of 2-glycosyl furan 4.104 and 
chloroanisole 4.103 followed by treatment of the resultant cycloadduct 4.132 with 
BF3·Et2O attenuated by 2,6-lutidine afforded the desired naphthol 4.133 in 61% yield 
over two steps (Scheme 4.41). Use of TMSOTf led to significant decomposition of 
materials and formation of at least five phenols as shown in the 1H-NMR while BF3·Et2O 










































We envisioned a chloride could be installed at either position 2 or 3 of 
naphthalene B ring of 4.133 to furnish a chloronaphthalene capable of generating the 
requisite benzyne upon exposure to alkyllithium since both the naphtholic alkoxy and the 
pyran ring oxygen could serve as the directing group for the lithiation at 2- and 3- 
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position of the corresponding chloronaphthol 4.136 and 4.135 (Scheme 4.42). Hence, 


















































Direct chlorination of the naphthol 4.133 using Sheldon’s ortho-chlorination 
protocol with different secondary amines all afforded a variety of unidentified by-
products.323 The desired 4.141 was obtained in moderate yield when NCS was used as 
the chlorination agent in AcOH; however, it was difficult to purify 4.141 due to the 
presence of impurities with similar polarity in the reaction mixture (Scheme 4.43).  
On the other hand, bromination of naphthol 4.133 using Br2 in CCl4 or 
trimethylbenzyl-ammonium tribromide in CH2Cl2/MeOH gave 4.138 in acceptable yield. 
Hence, the bromonaphthol 4.138 was protected as its methoxymethyl ether 4.139 or 
methyl ether 4.140. Compound 4.140 was then converted to its chloro counterpart 4.142 
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via lithium-bromide exchange followed by quenching the aryllithium with electrophilic 























































4.139: R = MOM, 95%
4.140: R = Me, 96%
BuLi; NCS, THF. 57%
or BuLi; C2Cl6, THF, 79%
 
  
The direct lithiation of the 3-position of bromonaphthol methyl ether 4.140 was 
first attempted with non-nucleophilic bases.324 Thus, treatment of 4.140 with LDA at –78 
°C followed by quenching with CD3OD did not result in any deuterium incorporation. 
When lithium 2,2,6,6-tetramethylpiperidide (LTMP) was used, a complicated mixture 
was obtained. However, treatment of chloronaphthalene 4.142 with s-BuLi or t-BuLi 
followed by quenching with CD3OD led to significant D-incorporation ortho to the pyran 
ring with no benzylic deprotonation as total integration of benzylic protons remained 
unchanged. A model benzyl/furan cyclization was attempted in the presence of excess 
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furan, and we obtained 55% yield of the cycloadduct 4.143. Exposure of the cycloadduct 
4.143 to TFA afforded two compounds, whose structures were assigned to be 4.144a 
(33%) and 4.144b (17%) based on 1H-NMR and MS (Scheme 4.44). Both spectra 
revealed the loss of an ethereal methyl group. The absence of the anomeric proton from 
its typical region (6.1 ppm) in 1H-NMR indicated that both compounds existed in their 
ketone forms. The poor regioselectivity in the opening of the oxabicycle 4.143 was not 
very surprising in light of Dr. Sparks’ observation in the studies towards vineomycinone 
B2 methyl ester.278 This lack of selectivity, however, ddidn’t present a problem in the 
natural product synthesis as alkoxyfuran would have to be used in the cycloaddition and 











s-BuLi, THF; furan, 55%





































The cycloaddition represented the first successful example where a benzyne was 
generated from a chloronaphthol precursor 4.142 to form an oxabicylic alkene system. 
 191
With proof of concept demonstrated, variation of substitution on the furan partner could 
afford a cycloadduct that would lead to 5-hydroxyaloin A. 
A 3-chloronaphthol such as 4.125 could have been available if the benzyne/furan 
cycloaddition with 3-chloro-2-glycosylfuran 4.33 and subsequent acid-catalyzed ring 
opening had been successful (Scheme 4.39). Alternatively, 3-chloronaphthol such as 
4.125 could be accessed by metallating the 3-position of a protected naphthol of form 
4.134, which would be directed by the pyran ring oxygen, followed by electrophilic 
chlorination. Toward this goal, the naphthol 4.133 was treated with TBSOTf and 2,6-
lutidine to give 4.145 in moderate yield (Scheme 4.45). Use of TBSCl/imidazole in DMF 
afforded a mixture (1:1) of the desired product 4.145 and an unidentified side product 
together with significant amount of unreacted starting material, even after prolonged 
stirring. The lack of reactivity reflected the generally low reactivity of a hydrogen bonded 
aromatic hydroxyl functional group and probably also the relative steric hindrance around 
the reacting center in naphthol 4.133. The presence of an intramolecular hydrogen bond 
was well documented and has been known to be the cause of the downfield shift of the 
naphtholic hydroxyl group in 8-methoxy-1-naphthol systems. However, treatment of 
4.145 with butyllithium or LDA followed by quenching the mixture with CD3OD reveled 
no deuterium incorporation and 4.145 remained intact in all the cases, hence the effort to 





















































The observation that the pyran ring oxygen was not potent enough to promote the 
ortho-lithiation of 4.145 raised a question as to whether the same oxygenated 
functionality could act as the directing group in the ortho-lithiation of 4.142. Iwao 
reported that the direct lithiation of chlorobenzene with s-BuLi at –105 °C in THF, 
suggesting chloride alone might be enough to induce ortho-deprotonation.325 
Cycloadduct 4.143 lacks the proper functionalities to be elaborated easily into the 
5-hydroxyaloin A (4.4). To access the natural product efficiently, it was desirable to have 
the requisite functionality already present on the cycloadduct, this requirement 
necessitated the use of a siloxylfuran such as 4.149 as the dienic partner. It would then be 
necessary to remove the anthracenol hydroxyl from 4.152 (Scheme 4.46). The 
corresponding cycloaddition of 4.142 and siloxyfuran 4.148a or 4.149 appeared to have 
produced the desired cycloadducts 4.150 and 4.151 as indicated by the 1H NMR of the 
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crude material and LRMS. However, a number of unidentified impurities were inevitably 
produced in the cycloaddition. Because the cycloadduct was not particularly stable, it was 
never successfully purified to homogeneity. On the other hand, even if the cycloadduct 
4.151 could be purified and converted to anthracenol 4.152 cleanly, the deoxygenation at 




























4.150: R1 = OTBS, R2 = H
4.151: R1 = OTIPS, R2 = CH2OTIPS
4.142
4.148a: R1 = OTBS, R2 = H

























4.152: R1 = OTIPS, R2 = CH2OTIPS 4.153: R1 = OTIPS, R2 = CH2OTIPS  
 
To address this problem, a slightly different strategy was developed involving the 
SN2’ ring opening of the cycloadduct 4.150 with a hydroxymethyl anion equivalent 
followed by dehydration to eliminate the extra hydroxyl and aromatize the system 
(Scheme 4.47). Such dehydrations were known to be facile transformations and often 






































4.150 4.154 4.155  
 
The Deoxygenation via Dehydration 
A model system was designed to explore the feasibility of this strategy. The 
oxabicyclic alkenes 4.156a,b were prepared from the benzyne/siloxyfuran cyclization of 
4.102 and silyloxyfurans 4.148a,b (Scheme 4.48). Because these compounds were 
unstable, they were purified by partitioning between acetonitrile and hexanes. Rapid 
decomposition of 4.156a,b to naphthols 4.157a,b was observed on contact with 
chromatographic medias such as silica, Et3N attenuated silica, basic alumina and neutral 
alumina. The purified cycloadducts 4.156a,b as pale yellow solids slowly darkened to 
orange even when stored in freezer and under argon. This extremely facile ring opening 











4.156a: R = TBS
4.156b: R = TIPS
4.148a: R = TBS
4.148b: R = TIPS 4.157a: R = TBS





Initial attempts indicated that the oxabicycle 4.156a could be opened with n-BuLi 
to give 4.158 (Scheme 4.49). However, various amounts of naphthol 4.157a were 
inevitably formed in all the cases, presumably because of the Lewis acidity of the lithium 
cation. Addition of Lewis acid such as BF3·Et2O greatly promoted the formation of 
naphthol 4.157a. Dehydration of the product mixture above obtained with MsCl in the 
presence of Et3N afforded the desired naphthalene 4.159 smoothly. Attempted 
dehydration of 4.158 with TFA, however, afforded a different product, which was 


























Reaction of 4.156a,b with the less nucleophilic MeLi, however, was unsuccessful. 
Methyllithium alone failed to open the cycloadducts 4.156a,b with or without activation 
of a weak Lewis acid; naphthols 4.157a,b were the only products observed in the 
reactions. Even under strongly nucleophlic conditions, as in the presence of HMPA, 12-
C-4, DMPU or TMEDA, opening of the oxa-bridge to form naphthols dominated the 
reactions, and no trace of the desired product was observed in 1H-NMR. Attempted 
coupling of 4.156b with organocuprates, generated from corresponding Gringard 
reagents, gave only the naphthol 4.157b together with recovered starting material. The 
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SN2’ displacement with methoxymethoxymethylithium, which was generated from 
methoxymethoxymethyltributylstannane326 and BuLi, was attempted, but no desired 
product was observed. This approach was hence abandoned since the desired SN2’ ring 
opening of the cycloadducts 4.156a,b didn’t compete favorably with the facile ring-
opening process. 
Wege discovered that 1,4-epoxy-1,4-dihydroarenes can be converted in high 
yields into the corresponding arenes with nonacarbonyldiiron in refluxing benzene. 
Indeed, heating a mixture of 4.156b and Fe2(CO)9 afforded the desired product 4.161b in 
good yield (Scheme 4.50), although small amount of the corresponding naphthol 4.157b 





















To apply this methodology to our synthesis, a hydroxymethyl substituted siloxyl 
furan was required in the benzyne/furan cycloaddition. The model oxabicycle 4.162 was 
thus prepared, but it was fairly unstable. When the crude 4.162 was subjected to Wege’s 











4.162 4.163  
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Having failed to effect the nucleophilic opening and direct reductive 
aromatization of the oxabicycle, we were forced to go through the route involving 
deoxygenation of the anthracenol 4.152. However, the corresponding cycloadduct 4.151 
was very unstable. Attempted opening of 4.150 and 4.151 all produced mixtures of 
compounds that offered little if anything conclusive. The anthracenol 4.152 may have 
been formed as a phenolic peak was observed in the 1H-NMR. Attempts were also made 
to protect the anthracenol hydroxyl group of 4.152 as it acetate or alkyl ether 4.164 in situ 
in hope that a stable compound could be isolated (Scheme 4.52). However, mixtures of 
unidentified compounds were always obtained, and it was not clear whether the 
anthracenol 4.152 was actually formed in the first step of the reaction. Due to the 














































If the deoxygenation was successful, the rest of the synthesis only entails 
deprotection of all the protecting groups. Spontaneous enol-ketone tautomerization would 
then afford 5-hydroxyaloin A.327 
To emphasize, proof of concept was established in our two-stage benzyne/furan 
cycloaddition strategy to assemble the anthrone core of the 5-hydroxyaloin A. A benzyne 
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can be generated from a chloronaphthol precursor 4.142 and subsequent cycloaddition 





















4.142 4.143  
 
4.2.3 Revisiting of the Tether Strategy 
It was an obvious disadvantage that the unsymmetrical C ring had to be 
constructed at the final stage of the synthesis with the proper functional groups attached. 
Strategically, it was better to form the C ring at the onset of the synthesis. Hence the 
tether approach was revisited and revised, and we decided this time to use a dihalopehnol 
as the benzyne precursor to address two primary issues in the prior synthesis: These are 
the low yield in the etherification and the loss of the furyl chloride during lithiation. The 
lower pKa of the dihalophenol could facilitate the etherification and help improving the 
chemical yield. The facile lithium-bromide exchange can thwart undesired lithium–
chloride exchange previously observed during the lithation of 4.70. The major issue at 
stake was the reactivity of the tether benzyne, which had been known to be a poor 
dienophile when not tethered. Tethering the benzyne and furan partner together would 
significantly increase the effective concentration of the glycosyl furan and thereby 
potentially compensate the low reactivity of the benzyne.  
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The synthesis of dihalo phenols 4.174 and 4.175 started with the known aniline 
4.165 (Scheme 4.54).328, 329 The free amino group of 4.165 was transformed into a 
bromide or an iodide through its diazonium salt under Sandmeyer conditions, and the 
aromatic methyl ether was selectively deprotected in the presence of the methyl ester. 
However, it is operationally more convenient to effect global deprotection and then 
reform the methyl ester. The methyl ester 4.168 and 4.169 were then converted to 





















4.170: X = Br (104% crude)
4.171: X = I (109% crude)
4.172: X = Br (81% over two steps)
4.173: X = I (87% over two steps)
4.174: X = Br (90%)
4.175: X = I (90%)
CH2OH CH2OTBS
CH2OTBS
4.165 4.166: X = Br (79%)4.167: X = I (73%)
4.168: X = Br (91%)









The etherification of α-bromosilane 4.42 with phenols 4.168 or 4.174 was again 
troubled with the infamous α-halosilane rearrangement. The desired product was barely 
formed, and instead by-products 4.33, 4.46, 4.178 and 4.179 were isolated in various 
ratios dependent on the reaction conditions (Scheme 4.55). The presence of the anisole 
4.178 in the reaction mixture appeared to suggest that the desired product 4.176 or 4.177 
may have formed during the course of the reaction. Subsequent desilylation of 4.176 or 
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R = COOMe or CH2OTBS
4.168 or 4.1744.42 4.176: R = COOMe
4.177: R = CH2OTBS
4.33 4.46 4.178 4.179
+






Etherification of the phenols 4.168 and 4.169 with bromomethylsilane 4.181 
lacking the furyl chloride substituent, however, proceeded smoothly to afford the desired 
products 4.182 and 4.183 respectively in excellent yields when the reactions were run in 
DMF in the presence of sodium carbonate as base (Scheme 4.56). The reaction was 
highly sensitive to the nature of the metal counter ion of the carbonate base and the 
solvent, as the potassium and cesium carbonate caused extensive α-halosilane 
rearrangement and the rate of the etherification was significantly slower in acetonitrile 
and acetone. The bromosilane 4.181 was prepared via the bromofuran 4.180, which was 
converted to the corresponding organolithium upon treatment with n-BuLi. The direct 
lithiation of 4.104 followed by silylation with either bromomethylchlorodimethylsilane or 
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chlorodimethylvinylsilane gave only poor yields of the desired silanes, and significant 
amounts of the starting material remained even after prolonged period of lithiation 
(Scheme 4.57). This presented another sharp difference in reactivity between the 2-













70 °C, 7 h
4.182: R = Br (94%)










































































In a similar manner, the vinyl silane 4.184 was prepared from 2-bromofuran 
4.180. Metal-halide exchange followed by quenching the resultant furyllithium with silyl 
chloride provided vinyl silane 4.184 in excellent yield. Compounds 4.184 was then 
converted into the β-silanol 4.185 by hydroboration with 9-BBN and oxidation with basic 
peroxide. Mitsunobu etherification of the β-silanol 4.185 and the phenol 4.168 afforded 
the desired product 4.186 in acceptable yield (Scheme 4.58). Significant improvement in 
yield was observed when the benzyl hydroxyl protective group was switched from a TIPS 











































benzene, 70 °C, 2 h
































The success in the etherification set the stage for the key cyclization. The lithium-
bromide exchange, which was used to generate the requisite aryllitihum, is a facile 
process.330, 331 It has been reported that the rate of lithium-halogen exchange can exceed 
the rate of proton transfer in some instances,331 and the exchange is typically more rapid 
than addition reactions that might compete (Scheme 4.60).330 Hence the intramolecular 
cycloaddition of 4.182 and 4.186 was attempted at room temperature in hope that the 
lithium-halide exchange and subsequent elimination of the chloride and cyclization could 
effectively compete against the attack on the methyl ester by the organolithium. 
However, when a THF or ether solution of 4.182 or 4.186 was treated with n-BuLi at –
78, 0°C or rt, only intractable mixture consisting of many unidentified compounds was 






































4.182: n =1 





The methyl esters 4.182, 4.183 and 4.186 were thus reduced to the benzylic 
alcohols, which were then protected as their silyl ethers 4.194, 4.195 and 4.196, 
respectively (Scheme 4.62 and Scheme 4.63). Alternatively, the requisite ethers, such as 
4.197 can be prepared directly via Williamson etherification of the bromide 4.181 and an 
























4.194: X = Br, R = TBS (87%)
4.195: X = I, R = TIPS (76%)
4.182: R = Br


















































   70 °C








As expected, complete lithium-halide exchange took place rapidly upon treatment 
with n-BuLi at –95 ºC. Quenching the resultant organolithium with methanol at low 
temperature afforded the chloroanisole 4.198 (Scheme 4.65). If the aryllithium was 
allowed to warm up, spontaneous repulsion of the chloride should take place to deliver 
the requisite benzyne. However, when the THF or ether solution of 4194, 4.195, 4.188 or 
4.196 was treated with n-BuLi at –78, 0°C or rt, only very small amounts of the desired 
cycloadducts were formed in all the cases as observed from the 1H NMR of the crude 
material and TLC. 1H NMR of the crude material also revealed that significant premature 



































4.199: R = TBS 











4.194: X = Br, R = TBS
























4.201: R = MOM
4.202: R = TIPS
4.188: R = MOM




It became clear that our attempts to compensate the low reactivity of the benzyne 
4.101 and improve the chemical yield of the cyclization by increasing the effective 
concentration of the glycosyl furan by ways of an intramolecular cyclization just could 
not deliver the desired cycloadducts in acceptable yields. Therefore, future efforts should 
be directed at studying the substituent effect of the benzyne in the cyclization. The 
success of the route shown in Scheme 4.68 will be dependent on our ability to nail down 
an appropriate benzyne substituent (G: a latent hydroxylmethyl group). The rest of the 
proposed synthesis is relatively straightforward as major transformations have been 


















































































n = 1 or 2
 
 
4.3 THE SYNTHESIS AND DERIVATIZATION OF C-ARYL GLYCAL  
During the course of the investigation, it came to our attention that benzyne/furan 
cycloadducts possessing oxygenated sugars such as 4.132 were more resistant to the acid-
catalyzed ring opening than those with 2-deoxy sugars such as 4.7. Harsher conditions 
were typically required to cleave the oxabicyclic ring of 4.132, and the product naphthol 
4.133 underwent slow decomposition under reaction conditions. This necessitated 
material recycling to obtain a better yield in some cases. It was also discovered that when 
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a second electron-withdrawing group was present on the cycloadducts, such as 4.114, the 
cycloadducts were highly resistant to acid-catalyzed ring opening and harsher condition 
only led to the decomposition of materials. It was thought that the acid catalyzed ring 
opening could be facilitated if an electron-donating functionality was present on the 
carbohydrate moiety, which would stabilize the developing positive charge in the 
transition state. Hence, the possibility of bringing in a glycal functional group was 
conceived, such a functional group could be readily converted in to 2-deoxy sugar and 2-
oxygentaed sugars when needed.  
 
4.3.1 Benzyne-Furan Cycloaddition of Furyl Glycal 
One potential problem involves the regioselectivity of bond formation in the 
dienic unit in the cycloaddition. Namely, two modes of cycloadditions are plausible as 
depicted in Scheme 4.56, and the conjugated system involving the exocyclic double bond 
in 2-vinyl furan was reported to be generally more reactive than the furan ring itself in the 
cycloadditions.332 The reactivity pattern, however, was affected by both electronic and 
steric factors. For example, Kotsuki observed that a electron withdrawing acetyloxy 
group at R2 decreased the reactivity of the diene system involving the exocyclic double 





















It was envisioned that by introducing steric hindrance around the exo-double bond 
in the furyl glycal, cycloaddition via path A might be favored. Thus, furyl glucal 4.211 
was prepared through Negishi coupling and subjected to the cycloaddition condition.334 
We were delighted to find that the cycloaddition proceeded smoothly, and the exo-double 
bond remained intact throughout the reaction (Scheme 4.70). This is the first example of 
an intermolecular benzyne-furan cycloaddition in which a furyl glycal was employed as 
the dienic unit to form the oxabicyclic ring system. The oxa-bridge of the cycloadduct 
4.212 could be opened under much milder condition than was needed for the 
cycloadducts possessing 2-deoxy sugars. Indeed, lower temperature and mild Lewis 
acidic conditions were needed to avoid significant decomposition of materials and 





AcO 1. K2CO3, MeOH









































This strategy effectively allows the access to all major classes of C-aryl 
glycosides, hence constituting a natural extension of our glycosyl furan/benzyne 
cycloaddition methodology. It also represented an alternative approach to glycal-
substituted naphthols. Previously, Dr. Lopez has demonstrated that Group II and IV C-
aryl glycals could be accessed through a Pd(0) catalyzed SN2’ ring opening of 
benzyne/furan cycloadducts (Scheme 4.71).269 However, since the sugar substitution 
inevitably ends up ortho to the phenolic hydroxyl being generated, Group I C-aryl 
glycosides, where no sugar is ortho to phenolic hydroxyl, cannot be accessed directly 

















Zn, ZnCl2, THF, 50oC







The glycal enol ether double bond could be subsequently derivatized to afford C-
aryl glycosides with different carbohydrate moieties. For example, hydrogenation with 
platinum catalyst would afford a 2-deoxysugar, while hydroboration followed by 
oxidation or amination would afford 2-oxygenated sugars or 2-aminosugars, respectively. 
Hence the free naphtholic hydroxyl was protected as its MOM ether to avoid 
complication in the basic peroxide oxidation step, and the 4.216 thus obtained was 
subjected to hydroboration. However, the hydroboration was sluggish, and large amounts 
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of staring material remained unreacted in the presence of large excess of BH3⋅THF at 
elevated temperature for extended period of time (Scheme 4.72). Subsequent oxidation 
with basic peroxide afforded nothing identifiable in the 1H NMR spectrum. It appeared 
that the very steric bulk that blessed us in the benzyne/furan cycloaddition was now 




























Thus, global deprotection of the trisopropylsilyl protecting group of 4.216 with 
TBAF afforded 4.218, which was then reprotected as its tribenzyl ether 4.219. 
Hydroboration of 4.219 with BH3⋅DMS or BH3⋅THF at room temperature followed by 
oxidation with basic peroxide afforded the desired product 4.220 as a single diastereomer 
in satisfactory yield (Scheme 4.73). The β-configuration was evident by the large 









































4.219 4.220  
 
Encouraged by this discovery, we subsequently explored the cycloaddition of the 
benzyne 4.102, which was generated form 2-chloro-1,4-dimethoxybenzene (4.103), with 
the tribenzylglucal 4.222, which was again prepared by deprotection and reprotection of 
its TIPS counterpart 4.211. To our pleasure, the cycloaddition proceeded smoothly to 
afford the desired cycloadduct 4.223 as a mixture (1:1) of stereoisomers in excellent yield 




































Thus far, we had cleared two major obstacles in our route to C-naphthyl 
glycosides. We have demonstrated that the cycloaddition of the selected benzyne 4.102 
with benzyl protected furyl glycal can occur in a regioselective manner to afford the 
expected cycloadducts. The subsequent hydroboration/oxidation proceeded in regio- and 
stereo-specific manner to provide the desired product. At this stage, the two remaining 
problems to a successful method were to streamline the synthesis of the staring dienic 
partner 4.222 and to open the oxabicycle 4.223 in a regiocontrolled fashion.  
 
4.3.2 Synthesis of Furyl Glycals 
The tribenzylglucal 4.222 was previously prepared from the TIPS counterpart 
4.211 after protecting group swap. Consequently, its synthesis was rather clumsy even 
though it had provided an easy access to the requisite material at that time. However to 
establish the value of the method, an overhaul of the synthesis was mandated. It was 
however not possible to apply the synthetic strategy used to prepare 4.211 shown in 
Scheme 4.70, which was prepared from the corresponding iodoglucal 4.210. The 
preparation of iodoglucal required large excess of t-BuLi to generate the vinyl 
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glycosyllithium intermediate,230, 335 and the benzylic protons will be competitively 
lithiated in the process. Attempted direct lithiation of benzyl-protected glycals has been 
reported to be unsuccessful in earlier work.336-338 
Researchers have prepared functionalized glycals to perform cross couplings with 
aryl organometallic species to access C-aryl glycols by a number of methods. For 
instance, Nicolaou prepared cyclic ketene acetal phosphates from the corresponding 
sugar lactones and successfully used them in Stille couplings with vinylstannanes.339, 340 
Sasaki reported a Suzuki cross-coupling between an eight-membered ketene acetal 
phosphate and a seven-membered alkylborane in his synthesis of HIJK ring model of 
ciguatoxin.341 Coudert reported the Suzuki cross-coupling of aryl boronic acids with 
vinyl phosphates derived from lactams.342  
Gabrielle Kolakowski, a graduate student in the Group, examined the reaction 
between ketene acetal enol phosphate 4.225339 and metallofurans under a number of 
coupling reaction conditions (Scheme 4.75). Unfortunately, attempted Suzuki, Negishi 
and Stille couplings of phosphate 4.225 with metallofurans produced the desired C-aryl 



































Aryl glycals have also been prepared from its corresponding lactones on several 
occasions. Sulikowsk182 reported earlier that hemiketal 4.229 could undergo dehydration 
with Martin’s sulfurane to produce phenylglucal 4.230 in good yield (Scheme 4.76). 
McDonald demonstrated that POCl3 could effect the dehydration of the hemiacetal 
generated from addition of 2-(trimethylsily1)ethynylmagnesium bromide to a tert-
butyldiphenylsilyl protected 2-deoxy-D-gluconolactone, albeit in low yield.265 Because 
Sulikowsk’s optimized conditions required five equivalents of the expensive and unstable 
Martin's sulfurane, this approach was hardly practical. The dehydrations were performed 
at room temperature in a separate step, so the hemiketal intermediate 4.229 must stay in 
closed form throughout the dehydration to assure reasonable yields. However, the 
hemiketal 4.232, obtained from addition of 2-lithiofuran to 2-deoxygluconolactone 4.224, 
existed predominantly as the open form 4.231a at room temperature in CDCl3, and a 
number of other hemiacetals prepared in the group in the past existed as mixtures of open 
and closed forms. Understandably, attempts to obtain the 2-furylglucal 4.222 from 























87% over two steps
 
 
It was envisioned that the acyclic form of the lactol 4.231a might cyclize and 
undergo dehydration under acidic conditions to afford glucal 4.222 (Scheme 4.77). 
However, when Gabrielle Kolakowski subjected the 5-hydroxy ketone 4.231a to a variety 
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of Brønsted and Lewis acids, only complex product mixtures were obtained. Hence, 
attempts were made to effect the dehydration of 4.231a in a stepwise manner 
incorporating a separate cyclization step to form the cyclic acetal 4.233. Exposure of 
ethyl cyclic acetal 4.233 to Brønsted and Lewis acid in the presence of a non-nucleophilic 
base did not provide Kolakowski any of the desired 4.222.343 In the case of cyclic ethyl 
ketal 4.233, the generation of the oxocarbenium may require a stronger acid than what 
could be tolerated by the product 4.222. Therefore a leaving group better than alkoxy 













4.224 4.231a: R = H





















4.233: R = Et
4.234: R = Ac  
  
Seeing that attempt to generate the glucal 4.222 from 4.231a was unsuccessful, 
we decided to trap the lithium alkoxide of the lactol before it opened. Thus, treatment of 
the alkoxide, which was generated by the action of 2-lithiofuran on the lactone 4.224, 
with acetic anhydride under Rychnovsky’s conditions (DMAP/pyridine/Ac2O)344 did not 
yield the acetylated lactol 4.234. Rather the glucal 4.222 was obtained in 19% yield along 
with large amount of acetylated 5-hydroxylketone 4.231b.344, 345 It was reasonable to 
assume that the glucal was formed from the acylated lactol 4.234, and so the collapse of 
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lithium alkoxide of the lactol was competing with the acetylation of the tertiary alcohol 
under the reaction conditions. The occurrence of the unfavorable competition was not 
unexpected since we were attempting to trap a hindered tertiary alkoxide. Use of an 
electrophile better than acetic anhydride would be expected to accelerate the rate of the 
acylation so that it could be faster than the rate of the ring-opening of the lithium 
alkoxide of the lactol. Hence trifluoroacetic anhydride (TFAA) was employed as the 
trapping reagent. Switching to TFAA (4 equivalent) nearly doubled the yield of the 
desired arylglucal 4.222; however, a major impurity, which was identified as the acylated 
glucal 4.235, was also formed. The acylated glucal 4.235 was formed through 
electrophilic acylation of the enol ether (Scheme 4.78). Similar transformations have 



















To avoid the problem of over-acylation, the stoichiometry of TFAA was reduced 
to 2.5 equivalents, and the furylglucal 4.222 was obtained in an improved yield of 75%. 
Methanesulfonyl chloride and triflic anhydride were also used as electrophiles to trap the 
lithium alkoxide of the lactol 4.232, but they were found not to be as effective as TFAA.  
Hence, we have discovered that lithium alkoxide 4.237 that was generated by 
addition of 2-lithiofuran to the 2-deoxygluconolactone 4.224 could be trapped in situ with 
trifluoroacetic acid anhydride (TFAA) at low temperature before it opened to form 5-
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hydroxyketone 4.231a (Scheme 4.79). Elimination of the trifluoroacetate of 4.238 
afforded the furylglucal 4.222 in good yield. In the presence of large excess TFAA, the 
glucal 4.222 could be further acylated at 2-position leading to 1-furyl-2-
trifluoroacetoxyglucal 4.235 as a common byproduct. Should 4.235 be the desired 





























































Table 4.3: Partial Optimization in Converting Sugar Lactone to Furylglucal  
 Acylation/Sulfonation Reagent Equivalent Observation and yield 
1 4.224, AcCl  4 19% of 4.222 and acylated  
ring-opened product 
2 4.224, TFAA, ZnCl2 (1.2 mol) 4 12% of 4.222 and 25% of 4.235 
3 4.224, TFAA 4 35% of 4.222 and 22% of 4.235 
4 4.224, MsCl 4 32% of 4.222 
5 4.224, TFAA 1.5 57% of 4.222 
6 4.224, TFAA 2.5 75% of 4.222 
7 4.224, TFAA (reverse addition) 2.5 49% of 4.222 
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8 4.224, TFAA 3.0 66% of 4.222 and trace of 4.235 
9 4.236, Tf2O 2.5 13% of 4.252 
10 4.236, TFAA 2.5 64% of 4.252 
* All reactions were run in THF at -78°C, pyridine (3 mol), DMAP (1 mol), and a 
solution of furyllithium was added to a solution of lactone at –78 °C. 
 
Further exploration revealed that a variety of aryllithium reagents could be added 
to the known sugar lactones 4.224, 4.198, 4.243 and 4.246 to obtain generally good to 
excellent yields of the corresponding aryl glycals (Table 4.4). The lactones were prepared 
from the corresponding commercially available peracetoxy glycals according to 
established procedures,272, 347 involving saponification of the acetoxy groups and 
reprotection as the benzyl ethers followed by hydration of the glycal with PPh3·HBr 





BnO1. K2CO3, MeOH  1. PPh3·HBr, CH2Cl2/H2O









4.241: X = H, Y = OBn (85%)
4.242: X = OBn, Y = H (55%)
AcO
X X X
4.208: X = H, Y = OAc
4.240: X = OAc, Y = H
2. TPAP, NMO
4.224: X = H, Y = OBn (72%)
4.243: X = OBn, Y = H (96%)  
Scheme 4.81 
















64% over two steps
4.244 4.246  
 
As shown in Table 4.4, the general trend in this transformation was that rhamnals 
were formed in the best yields in all the case. The formation of galactals proved to be 
problematic, and significant quantities of unidentified impurities were always isolated 
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(Entry 7). The acetylation of the alkoxide of the lactol derived from galactal might have 
been slow. The galactal derivatives also appeared to be less stable than other aryl glycals, 
which might be a contributing factor in the lower yield. When alkyllithium and 
alkylmagnesium reagents were used (Entry 9 and entry 10), only the endo-glycal was 
obtained; no E-exo or Z-exo glycals were detected.348, 349 However, the chemical yields 














Table 4.4: Partial Optimization of Converting Sugar Lactone to Furylglycal  








































































































































The transformation above represents an alternate approach to prepare the C-aryl 
glycals starting with the corresponding 2-deoxysugar lactones. Furyl glycals prepared 
thus way can be directly used in our glycosylfuran/benzyne cycloaddition methodology. 
 
4.3.3 The Acid Catalyzed Rearrangement of Oxabicycles With Glycal Substituent 
The cycloadducts possessing glycal substituents have shown to undergo facile 
ring opening and simultaneous rapid decomposition when exposed to Brønsted and Lewis 
acids. The cycloadduct 4.223 and the corresponding naphthol 4.255 are significantly 
more sensitive towards acids than their triisopropylsilyl protected counterpart 4.212 and 
4.213, probably due to more exposed enol ether double bond. Condition previously used 
to open cycloadduct 4.212 (BE3⋅Et2O, 2,6-lutidine, -5 °C) only led to a mixture of 
multiple phenols. 
Kristen Procko, another graduate student in the group, examined the use of a 
number of Lewis acids on the opening of oxabicycle 4.223 and she discovered that 
although zinc chloride did not effect ring opening at –78 ºC, warming up the mixture to 0 
ºC led cleanly to the desired naphthol 4.255 (Scheme 4.82). If the reaction was conducted 
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at 0 ºC, multiple compounds were formed. It was thus necessary that all the components 






























The success in the opening of the oxabicycle 4.223 hence cleared the final hurdle 
in the sequence, establishing the feasibility of our approach to C-naphthyl glycosides 


































2. BnBr, NaH, DMF


















Though the above discussed method could be applied in the synthesis of 5-
hydroxyaloin A, at this moment, clear advantage of bringing in the glucal as a latent 
oxygenated carbohydrate is lacking. The furyl glucal 4.211 has behaved quite similarly to 
glycosyl-substituted furans, and cycloaddition with benzyne 4.101 failed to deliver the 
desired cycloadducts and the furyl glucal 4.211 was recovered (Scheme 4.84). Bringing 
in an extra enol ether function functionality into the synthesis of 5-hydroxyaloin A 



























4.4 CONCLUSION  
In the application of our glycosyl furan/benzyne cycloaddition methodology 
towards natural product synthesis, a two-stage benzyne/furan cycloaddition strategy was 
used to assemble the anthrone core of Group I C-aryl glycoside 5-hydroxyaloin A. Proof 
of concept was established in the generation of benzyne from a chloronaphthol precursor 
4.142 and subsequent cycloaddition with furan afford the cycloadduct 4.143 (Scheme 
4.53). However, the cycloadducts of 4.142 and alkoxy/silyloxy furans were unstable, and 
attempts to convert them into 5-hydroxyaloin A were unsuccessful. During the course of 
the investigation, the scope and limitation of the benzyne/furan cycloaddition was 
examined, and it was found that the second methoxy group on the benzyne had a 
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tremendous effect on its reactivity as the dienophile; Lack of this methoxy resulted in the 
low reactivity of benzyne 4.101 in the cycloaddition. Unfortunately, attempts to optimize 
the cyclization by increasing the effective concentration of glycosyl furan by ways of an 
intramolecular cyclization failed to deliver the cycloadducts in acceptable yields. 
During the course of the investigation, an approach to the C-naphthyl glycosides 
featuring a benzyne/furan cycloadditiont using a glycal-substituted furan was developed. 
The derivatization of the glycal double bond allows us to access C-aryl glycoside 
containing 2-deoxy and 2-oxygenated sugars from a common intermediate, including 
members from Group I C-aryl glycoside, A novel approach to C-aryl glycals was 
established during the course. This transformation allows us to access C-aryl glycals from 
the corresponding deoxy sugar lactones after a single step. 
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Chapter 5: Experimental Procedures 
5.1  MATERIALS 
The phospholipid substrate 1,2-dihexanoyl-sn-glycero-3-phosphocholine (C6PC) 
was purchased from Avanti Polar Lipids (Alabaster, AL). Alkaline phosphatase (P-5521), 
3,3-dimethylglutaric acid (DMG), bovine serum albumin (A-3059), and PLCBc (P-7147) 
were purchased from Sigma (St. Louis, MO). Ammonium molybdate tetrahydrate, L-
ascorbic acid, and sodium metaarsenite were obtained from Aldrich Chemical Co. 
(Milwaukee, WI). Trichloroacetic acid and sodium citrate were obtained from EM 
Science (Gibbstown, NJ). The kinetic assays were performed in 96-well plates obtained 
from Fisher Scientific. The microplate reader used was a SpectraMax 340 from 
Molecular Devices. 
 
5.2 METHODS FOR INORGANIC PHOSPHATE QUANTITATION ASSAY 
The specificity constants Kcat/KM of PLCBc were determined using a sensitive, 
enzyme-coupled assay that is based on the quantitation of Pi.284 In short, the 
cholinephosphate produced by the PLC-catalyzed hydrolysis of C6PC was treated with 
alkaline phosphatase to liberate Pi, which formed a complex with ammonium molybdate. 
The complex was then reduced to a blue molybdenum state with ascorbic acid to yield a 
blue solution with a maximum absorbance at 700 nm. The initial velocity versus substrate 
concentration data were obtained in at least duplicate in the presence and absence of 
inhibitor at substrate concentrations well below their CMCs in the assay buffer. The 
specificity constants, Kcat/KM, were obtained from the slopes of the initial velocity 
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versus substrate concentration curves at low substrate concentrations, and the Ki for each 
inhibitor was determined from these data using equation 3.14 
 
5.3  EXPERIMENTAL 
5.3.1  General 
Unless otherwise noted, solvents and regents were used without purification. 
Methylene chloride (CH2Cl2) was distilled from calcium hydride prior to use. 
Tetrahydrofuran (THF) was dried by passage through two column of activated neutral 
alumina. N, N-dimethylformamide (DMF) was dried by passage through two columns of 
activated molecular sieves. Acetonitrile (MeCN), diethyl ether (Et2O) and methanol 
(MeOH) were passed over molecular sieves prior to use. All solvents were deemed to 
contain less than 50 ppm H2O by Karl Fischer coulomeric moisture analysis. Reactions 
involving air or moisture sensitive reagents or intermediates were performed under an 
inert atmosphere of argon in glassware that had been oven or flame dried. Reagents were 
purchased from Aldrich and used without furthur purification unless indicated otherwise. 
Chemical abbreviations used are as follows: borane-tetrahydrofuran complex (BH3·THF), 
Boron trifluoride etherate (BF3·Et2O), tert-butyldimethylsilyl chloride (TBDMSCl), 
chloromethyl methyl ether (MOMCl), 2,6-dichloro-3,5-dicyanoquinone (DDQ), 
diisopropylamine (iPr2NH), dicyclohexylcarbamide (DCC), ethyl acetate (EtOAc), 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), N, N-dimethylaminopyridine (DMAP), 
hexachloroethane (C2Cl6), tetrabutylammonium fluoride (TBAF), trifluroacetic 
anhydride (TFAA), trifluoroacetic acid (TFA). 
Thin-layer chromatography (TLC) was performed on EM 250 micro silica gel 
plates. The plates were visualized by staining with AMCAN (ammonium 
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molybdate/cerium ammonium nitrate), or potassium permagnate. Flash chromatography 
was performed with ICN Silica gel 60 according to established protocol.351 
The 1H, 13C NMR's were obtained on a Varian 500 series, Varian MERCURY 
400, or a Bruker AM-250 spectrometer, operating at 500 (400, 250) and 125 (100, 62) 
MHz respectively. Unless indicated otherwise, all spectra were run as solution in CDCl3. 
For 1H NMR, chemical shifts are reported in parts per million (ppm) downfield from 
tetramethylsilane (TMS) and are, in all cases, referenced to the residual protio-solvent 
present: δ 7.24 for CHCl3, δ 7.15 for benzene-d6, δ 3.30 for the methyl peak of CD3OD, 
2.04 for acetone-d6. In 13C NMR, chemical shifts were reported in ppm relative to the 
center line of the multiplet for deuterium solvent peaks: δ 77.0 (t) for CDCl3, δ 128.0 (t) 
for benzene-d6, δ 49.0 (septet) for the methyl peak of CD3OD, δ 29.8 (septet) for 
acetone-d6. 13C spectra were routinely run with broadband 1H decoupling. Coupling 
constants for all spectra are reported in Hertz (Hz). 
Infrared spectra were measured on a Perkin Elmer 1600 FTIR spectrometer either 
neat or as solutions in the indicated solvent on sodium chloride plates and are recorded in 
units of cm-1. Low-resolution chemical ionization (CI) mass spectra were performed on 





















ethanolamine (3.13a). To a solution of 3.11a (170 mg, 0.39 mmol) and N-Boc-
ethanolamine (60 µL, 0.39 mmol) in dry CH3CN (5 mL), was added DBU (58 µL, 0.39 
mmol) dropwise at rt. The solution was stirred at rt overnight. The solution was filtered, 
and the filtrate was concentrated under reduced pressure. The residue was purified by 
chromatography eluting with acetone/CHCl3/H2O (67:32:1) to yield 220 mg (82%) of 












To a solution of 1.1 (820 mg, 6.2 mmol) and diisopropylethylamine (880 mg, 6.8 mmol) 
in CH3CN (52 mL) at –38 °C (dry ice/1,2-dichloroethane) was added 2-chloro-1,3,2-
dithiophospholane dropwise (980 mg, 6.2 mmol) . The solution was stirred at –38 °C for 
2 h. The cold bath was removed and the mixture was stirred for another 60 min. A 
solution of sulfur (620 mg, 19.4 mmol) in CS2 (16 mL) was added in one portion at rt. 
The solution was stirred vigorously for 7 h. The mixture was then concentrated under 
reduced pressure and the residue was dissolved in acetone. The insoluble solid was 
removed by filtration and washed with acetone. The combined filtrate and wash were 
concentrated under reduced pressure. The residue was purified by chromatography 
eluting with CHCl3 to yield 1.534 g (86%) of 3.14 as a pale yellow oil: 1H NMR (250 
MHz) δ 4.29 (p, J = 5.6 Hz, 1 H), 4.07-3.99 (comp, 3 H), 3.77 (dd, J = 8.6, 5.5 Hz, 1 H), 
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3.67-3.54 (comp, 4 H), 1.36 (s, 3 H), 1.29 (s, 3 H); 13C NMR (62 MHz) δ 109.8, 73.7 (d, 
J = 9.9 Hz), 67.6 (d, J = 9.3 Hz), 66.08, 41.4 (d, J = 5.3 Hz), 26.6, 25.2; 31P NMR (121 






















N-tert-Butoxylcarbonyl-sn-glyceryl-3-phosphodithioethanolamine (3.16). To a 
solution of 3.14 (260 mg, 0.90 mmol) and N-Boc-ethanolamine (165 mg, 1.02 mmol) in 
dry CH3CN (10 mL), was added DBU (155 µL, 1.02 mmol) dropwise at rt. The solution 
was stirred for 40 min and the solvent removed under reduced pressure. The residue was 
purified by column chromatography over silica gel, eluting with acetone/CHCl3 (2:1) to 
yield 487 mg (99%) of 3.15 as yellow oil. 
The 3.15 (114 mg, 0.21 mmol) thus obtained was dissolved in t-BuOH/AcOH (2 
mL, 1:3), and the solution was stirred overnight at rt. The solvent was removed under 
reduced pressure, and the residue was purified by flash chromatography eluting with 
acetone/CHCl3 (2:1) to yield 45 mg (61%) of 3.16 as a glass: 1H NMR (300 MHz, 
acetone-d6) δ 6.18 (s, 1 H), 4.72-4.50 (br, s, 1 H), 4.50-4.15 (br, s, 1 H), 4.10-3.87 (comp, 
5 H), 3.70-3.61 (comp, 2 H), 3.31(dd, J = 9.0, 5.4 Hz, 2 H), 1.39 (s, 9 H); 13C NMR (75 
MHz, acetone-d6) δ 156.6, 78.5, 71.1 (d, J = 7.1 Hz), 66.4 (d, J = 7.1 Hz), 64.6 (d, J = 6.0 
Hz), 63.0, 41.2 (d, J = 7.1 Hz), 28.1; 31P NMR (121 MHz, acetone-d6) δ 118.2; IR 
(CHCl3) 3562, 3308, 2973, 1693, 1646, 1520, 1453 cm-1; mass spectrum (CI) m/z 
348.0703 [C10H23NO6PS2 (M+1) requires 348.0704], 282, 258, 199, 185 (base). 
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NMR assignments. 1H NMR (300 MHz, acetone-d6) δ 6.18 (s, 1 H, S-H), 4.72-
4.50 (br, s, 1 H, C2-OH), 4.50-4.15 (br, s, 1 H, C1-OH), 4.10-3.87 (comp, 5 H, C1-H & 
C2-H & C3-H), 3.70-3.61 (comp, 2 H, C4-H), 3.31 (dd, J = 9.0, 5.4 Hz, 2 H, C5-H), 1.39 
(s, 9 H, C8-H); 13C NMR (75 MHz, acetone-d6) δ 156.6 (C6), 78.5 (C1), 71.1 (d, J = 7.1 
Hz, C2), 66.4 (d, J = 7.1 Hz, C3), 64.6 (d, J = 6.0 Hz, C4), 63.0 (C7), 41.2 (d, J = 7.1 Hz, 
































ethanolamine (3.17). To a solution of diol 3.16 (17 mg, 0.049 mmol) in dry pyridine (0.3 
mL), was added 5-hexenoyl chloride (13 mg, 0.098 mmol) dropwise at 0 °C. The mixture 
was stirred at rt for 2 h. The solution was diluted with CH2Cl2 (5 mL) and washed with 
saturated NaHCO3 (5 mL), 1 N HCl (5 mL), H2O (5 mL), dried (Na2SO4), and filtered. 
The solvent was removed under reduced pressure, and the residue was purified by 
chromatography eluting with acetone/CHCl3 (2:1) to yield 22 mg (82%) of 3.17 as a pale 
yellow liquid: 1H NMR (300 MHz) δ 5.86-5.70 (m, 2 H), 5.42-5.20 (comp, 2 H), 5.08-
4.96 (comp, 4 H), 4.41 (dd, J = 12.0, 3 Hz, 1 H), 4.24 (dd, J = 12.0, 6.6 Hz, 1 H), 4.16- 
3.98 (comp, 4 H), 3.50-3.00 (comp, 3 H), 2.37 (q, J = 7.7 Hz, 4 H), 2.12-2.02 (comp, 4 
H), 1.80-1.68 (comp, 4 H), 1.45 (s, 9 H); 13C NMR (75 MHz) δ 173.5, 156.9, 137.0, 
115.1, 115.0, 79.7, 70.2 (d, J = 8.5 Hz), 65.8, 63.5, 62.3, 40.5, 33.1 (d, J = 15.2 Hz), 32.5 
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(d, J = 2.1 Hz), 28.0, 23.5, 23.4; 31P NMR (121 MHz) δ 115.8; mass spectrum (CI) m/z 
540.1825 [C22H39NO8PS2 (M+1) requires 540.1854], 496, 422, 267 (base), 171. 
NMR assignments. 1H NMR (300 MHz) δ 5.86-5.70 (m, 2 H, C13-H & C13’-H), 
5.42-5.20 (comp, 2 H, C2-H & N-H), 5.08-4.96 (comp, 4 H, C14-H & C14’-H), 4.41 (dd, 
J = 12.0, 3 Hz, 1 H, C1-H), 4.24 (dd, J = 12.0, 6.6 Hz, 1 H, C1-H), 4.16-3.98 (comp, 4 H, 
C4-H & C3-H), 3.50-3.00 (comp, 3 H, C5-H & S-H), 2.37 (q, J = 7.7 Hz, 4 H, C12-H & 
C12’-H), 2.12-2.02 (comp, 4 H, C10-H & C10’-H), 1.80-1.68 (comp, 4 H, C11-H & 
C11’-H), 1.45 (s, 9 H, C8-H); 13C NMR (75 MHz) δ 173.5 (C9 & C9’), 156.9 (C6), 
137.0 (C13 & C’13), 115.1 (C14), 115.0 (C’14), 79.7 (C2), 70.2 (d, J = 8.5 Hz, C1), 65.8 
(C3), 63.5 (C4), 62.3 (C7), 40.5 (C5), 33.2 (C12), 33.0 (C12’), 32.5(C10), 32.4 (C10’), 







6-tert-Butyldimethylsilyloxyhexanoic acid (3.21a). A solution of ε-caprolactone 
(4.0 g, 35 mmol) and conc. HCl (7 drops) in MeOH (100 mL) was heated at reflux for 12 
h. The solvent was removed under reduced pressure. The residue was partitioned between 
EtOAc (60 mL) and NaHCO3 (50 mL), and the organic phase was washed with brine (50 
mL), dried (Na2SO4), and filtered. The solvent was removed under reduced pressure, and 
the residue was purified by distillation (77~81°C/0.06 mmHg) to yield 4.56 g (89%) of 
3.19a as clear liquid: 1H NMR (250 MHz), δ 3.54 (s, 3 H), 3.50 (t, J = 6.5 Hz, 2 H), 2.42 
(s, 1 H), 2.20 (t, J = 7.4 Hz, 2 H), 1.59-1.40 (comp, 4 H), 1.33-1.20 (comp, 2 H); 13C 
NMR (75 MHz) δ 174.1, 62.2, 51.3, 33.8, 32.0, 25.1, 24.4. 
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To a solution of TBDMSCl (2.69 g, 17.5 mmol) in CH2Cl2 (34 mL) at 0 °C, was 
added DBU (2.88 g, 18.9 mmol) and then 3.19a (2.34 mg, 15.8 mmol). The mixture was 
stirred at rt for 2 h. The solution was washed with H2O (20 mL), 0.1 N HCl (20 mL), 
NaHCO3 (20 mL), dried (Na2SO4), and filtered. The solvent was removed under reduced 
pressure, and the residue was purified by distillation (83~86 °C/0.3 mmHg) to yield 3.72 
g (90%) of 3.20a as a clear liquid: 1H NMR (250 MHz), δ 3.58 (s, 3 H), 3.52 (t, J = 6.4 
Hz, 2 H), 2.20 (t, J= 7.5 Hz, 2 H), 1.61-1.38 (comp, 4 H), 1.33-1.21 (comp, 2 H), 0.83 (s, 
9 H), -0.02 (s, 6 H); 13C NMR (75 MHz) δ 174.1, 62.9, 51.4, 34.0, 32.4, 25.9, 25.4, 24.7, 
18.3, -5.4. 
A solution of 3.20a (3.62 mg, 13.9 mmol), 5 N NaOH (2.9 mL, 14.5 mmol) in 
THF/MeOH/H2O (10 mL, 2:2:1) was stirred at rt for 7 h. The solution was acidified with 
1 N HCl (25 mL) and extracted with EtOAc (3 x 25 mL), dried (Na2SO4) and filtered. 
Solvent was removed under reduced pressure to yield 3.40 g (100%) of 3.21a as a clear 
liquid: 1H NMR (300 MHz), δ 10.80-10.20 (br s, 1 H), 3.62 (t, J = 6.4 Hz, 2 H), 2.37 (t, J 
= 7.4 Hz, 2 H), 1.72-1.50 (comp, 4 H), 1.48-1.36 (comp, 2 H), 0.90 (s, 9 H), 0.06 (s, 6 









































glycerol (3.23a). To a mixture of acid 3.21a (1.00 g, 4.07 mmol), diol 3.8 (392 mg, 1.85 
mmol) and DMAP (50 mg, 0.41 mmol) in CH2Cl2 (9 mL) at 0 °C, was added DCC (1.00 
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g, 4.88 mmol) in CH2Cl2 (5 mL). The mixture was stirred at rt for 16 h. The insoluble 
solid was removed by filtration and washed with CH2Cl2. The combined filtrate and 
washing were concentrated under reduced pressure. The residue was redissolved in ether 
and filtered. The filtrate was concentrated under reduced pressure, and the residue was 
purified by chromatography eluting with EtOAc/hexanes (1:8) to yield 0.99 g (80%) of 
3.23a as a clear liquid: 1H NMR (250 MHz) δ 7.16 (d, J = 8.6 Hz, 2 H), 6.80 (d, J = 8.6 
Hz, 2 H), 5.19-5.13 (m, 1 H), 4.42 (d, J = 11.7 Hz, 1 H), 4.36 (d, J = 11.7 Hz, 1 H), 4.26 
(dd, J = 11.9, 3.8 Hz, 1 H), 4.10 (dd, J = 11.9, 6.4 Hz, 1 H), 3.73 (s, 3 H), 3.55-3.44 
(comp, 6 H), 2.29-2.19 (comp, 4 H), 1.68-1.40 (comp, 8 H), 1.35-1.20 (comp, 4 H), 0.82 
(s, 18 H), -0.03 (s, 12 H); 13C NMR (62 MHz) δ 173.2, 172.9, 159.3, 129.8, 129.3, 113.8, 
72.9, 70.0, 67.8, 62.9, 62.7, 55.2, 34.3, 34.0, 32.4, 25.9, 25.4, 24.7, 24.6, 18.3, -5.3; IR 
(neat) 2934, 1740, 1613, 1513 cm-1; mass spectrum (CI) m/z 669.4190 [C35H65O8Si2 
(M+1) requires 669.4218], 669, 653, 611 (base), 591, 531. 
NMR assignments. 1H NMR (250 MHz) δ 7.16 (d, J = 8.6 Hz, 2 H, C15-H), 6.80 
(d, J = 8.6 Hz, 2 H, C16-H), 5.19-5.13 (m, 1 H, C2-H), 4.42 (d, J = 11.7 Hz, C13-H), 
4.39 (d, J = 11.7 Hz, C13-H), 4.26 (dd, J = 11.9, 3.8 Hz, 1 H, C1-H), 4.10 (dd, J = 11.9, 
6.4 Hz, 1 H, C1-H), 3.73 (s, 3 H, C18-H), 3.55-3.44 (comp, 6 H, C3-H & C9-H & C9’-
H), 2.29-2.19 (comp, 4 H, C5-H & C5’-H), 1.68-1.40 (comp, 8 H, C8-H & C8’-H & C6-
H & C6’-H), 1.35-1.20 (comp, 4 H, C7-H & C7’-H), 0.82 (s, 18 H, C11-H & C11’-H), -
0.03 (s, 12 H, C10-H, C10’-H); 13C NMR (62 MHz) δ 173.2 (C4’), 172.9 (C4), 159.3 
(C17), 129.8 (C14), 129.3 (C15), 113.8 (C16), 72.9 (C2), 70.0 (C13), 67.8 (C18), 62.9 
(C9 & C9’), 62.7 (C1), 55.2 (C3), 34.3 (C5’), 34.0 (C5), 32.4 (C8 & C8’), 25.9 (C11 & 


































1,2-Di-(6’-tert-butyldimethylsilyloxyhexanoyl)-sn-glycerol (3.24a). To a 
suspension of DDQ (0.440 g, 1.94 mmol) and CH2Cl2/ H2O (7.2 mL, 10:1), was added 
PMB ether 3.23a (0.99 g 1.48 mmol) in CH2Cl2(6.5 mL). The solution was stirred at rt 
for 2 h. The insoluble solid was removed by filtration and washed with CH2Cl2 (50 mL). 
The combined filtrate and washes were washed with NaHCO3 (40 mL), NaCl (40 mL), 
dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was 
purified by chromatography eluting with EtOAc/hexanes (1:5 to 1:4) to yield 660 mg 
(81%) of 3.24a as a clear liquid: 1H NMR (300 MHz) δ 5.08-5.03 (m, 1 H), 4.29 (dd, J = 
11.8, 4.6 Hz, 1 H), 4.20 (dd, J = 11.8, 5.6 Hz, 1 H), 3.70-3.69 (comp, 2 H), 3.60-3.55 
(comp, 4 H), 2.36-2.28 (comp, 4 H), 2.20-1.96 (br s, 1 H), 1.68-1.45 (comp, 8 H), 1.39-
1.30 (comp, 4 H), 0.86 (s, 18 H), 0,02 (s, 12 H); 13C NMR (75 MHz) δ 173.9, 173.5, 
72.3, 63.2, 62.2, 61.7, 34.5, 32.7, 32.6, 26.2, 25.6(2), 25.6(0), 25.0, 24.9, 18.6. –5.1; IR 
(CH2Cl2) 3468 (br), 2930, 2858, 1742, 1099, 836, 775 cm-1; mass spectrum (CI) m/z 
529.3646 [C27H57O7Si2 (M+1) requires 529.3643] (base), 491, 417, 303, 247, 229. 
NMR assignments. 1H NMR (300 MHz) δ 5.08-5.03 (m, 1 H, C2-H), 4.29 (dd, J 
= 11.8, 4.6 Hz, 1 H, C1-H), 4.20 (dd, J = 11.8, 5.6 Hz, 1 H, C1-H), 3.70-3.69 (comp, 2 H. 
C3-H), 3.60-3.55 (comp, 4 H, C9-H & C9’-H), 2.36-2.28 (comp, 4 H, C5-H & C5’-H), 
2.20-1.96 (br s, 1 H, OH), 1.68-1.45 (comp, 8 H, C8-H & C8’-H & C6-H & C6’-H), 
1.39-1.30 (comp, 4 H, C7-H & C7’-H), 0.86 (s, 18 H, C11-H & C11’-H), 0.02 (s, 12 H, 
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C10-H & C10’-H); 13C NMR (75 MHz) δ 173.9 (C4’), 173.5 (C4), 72.3 (C2), 63.2 (C9 
& C9’), 62.2 (C1), 61.7 (C3), 34.5 (C5’), 32.7 (C5), 32.6 (C8 & C8’), 26.2 (C11 & C11’), 







































dithiophospholane (3.25a). 2-Chloro-1,3,2-dithiophospholane (190 mg, 1.2 mmol) was 
added dropwise to a solution of 3.24a (660 mg, 1.20 mmol) and diisopropylethyl-amine 
(171 mg, 1.32 mmol) in CH3CN (12 mL) at –38 °C (dry ice/1,2-dichloroethane). The 
solution was stirred at –38 °C for 2 h. The cold bath was removed and the mixture was 
stirred for 1 h. A solution of sulfur (136 mg, 4.25 mmol) in CS2 (4.5 mL) was added in 
one portion and the solution was stirred vigorously overnight. The mixture was 
concentrated under reduced pressure and the residue was dissolved in acetone. The 
insoluble solid was removed by filtration and washed with acetone. The combined filtrate 
and washing were concentrated under reduced pressure. The residue was purified by 
chromatography eluting with EtOAc/hexanes (from 1:6 to 1:3) to yield 733 mg (87%) of 
3.25a as a clear liquid: 1H NMR (250 MHz) δ 5.23-5.18 (m, 1 H), 4.27 (dd, J = 11.6, 4.5 
Hz, 1 H), 4.26-4.14 (m, 2 H), 4.13 (dd, J = 11.6, 5.5 Hz, 1 H), 3.68-3.52 (comp, 8 H), 
2.33-2.25 (comp, 4 H), 1.66-1.42 (comp, 8 H), 1.37-1.25 (comp, 4 H), 0,83 (s, 18 H), -
0.01 (s, 12 H); 13C NMR (75 MHz) δ 173.0, 172.6, 69.1 (d, J = 12.6 Hz), 65.3 (d, J = 
12.6 Hz), 62.8, 61.6, 41.4 (d, J = 4.6 Hz), 41.3, 34.0, 33.9, 32.3, 25.8, 25.2, 24.5, 18.2, -
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5.4; 31P NMR (121 MHz) δ 124.5; IR (neat) 2931, 1740, 1461 cm-1; mass spectrum (CI) 
m/z 703.2785 [C29H60O7Si2PS3 (M+1) requires 703.2777] (base), 687, 645, 531, 457, 
256.  
NMR assignments. 1H NMR (250 MHz) δ 5.23-5.18 (m, 1 H, C2-H), 4.27 (dd, J 
= 11.6, 4.5 Hz, 1 H, C1-H), 4.26-4.14 (m, 2 H, C3-H), 4.13 (dd, J = 11.6, 5.5 Hz, 1 H, 
C1-H), 3.68-3.52 (comp, 8 H, C9-H & C9’-H & C13-H), 2.33-2.25 (comp, 4 H, C5-H & 
C5’-H), 1.66-1.42 (comp, 8 H, C6-H & C6’-H & C8-H & C8’-H), 1.37-1.25 (comp, 4 H, 
C7-H & C7’-H), 0,83 (s, 18 H, C11-H & C11’-H), -0.01 (s, 12 H, C10-H & C10’-H); 13C 
NMR (75 MHz) δ 173.0 (C4’), 172.6 (C4), 69.1 (d, J = 12.6 Hz, C2), 65.3 (d, J = 12.6 
Hz, C1), 62.8 (C9 & C9’), 61.6 (C3), 41.4 (d, J = 4.6 Hz, C13), 34.0 (C5’), 33.9 (C5), 
32.3 (C8 & C8’), 25.8 (C11 & C11’), 25.2 (C6 & C6’), 24.5 (C7 & C7’), 18.2 (C12 & 





































ethanolamine phosphorodithioate (3.28a). DBU (47 mg, 0.31 mmol) was added 
dropwise to a solution of 3.25a (216 mg, 0.31 mmol) and N-Boc-ethanolamine (51 mg, 
0.31 mmol) in dry CH3CN (5 mL). The solution was stirred at rt for 45 min and the 
solvent was removed under reduced pressure. The residue was purified by column 
chromatography over silica gel, eluting with acetone/CHCl3 (1:1), to yield 232 mg of 
3.27a as a clear liquid.  
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The diester 3.27a (116 mg, 0.11 mmol) thus obtained was dissolved in CH3CN 
(2.5 mL) in a plastic bottle, and 2.8 M hydrofluoric acid (0.42 mL) was added. The 
mixture was stirred at rt for 45 min, and brine (5 mL) was added. The mixture was 
extracted with CHCl3 (2 x 5 mL). The combined organic phase was dried (Na2SO4), 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with acetone/CHCl3 (3:2) to yield 75 mg (85% after two steps) 
of 3.28a as a clear oil: 1H NMR (300 MHz, acetone-d6) δ 6.27-6.16 (br s, 1 H), 5.29-5.22 
(m, 1 H), 4.41 (dd, J = 11.8, 3.6 Hz, 1 H), 4.22 (dd, J = 11.8, 6.4 Hz, 1 H), 4.11-4.06 (m, 
2 H), 4.02-3.95 (m, 2 H), 3.70-3.60 (comp, 2 H), 3.60-3.50 (comp, 4 H), 3.38-3.26 
(comp, 2 H), 2.40-2.32 (comp, 4 H), 1.70-1.48 (comp, 8 H), 1.48-1.38 (comp, 13 H); 13C 
NMR (75 MHz, acetone-d6) δ 173.5, 173.3, 157.0, 78.8, 71.3 (d, J = 9.3 Hz), 64.9, 63.7 
(d, J = 6.0 Hz), 63.4, 62.2, 41.7, 34.7, 34.5, 33.2, 28.6, 26.0, 25.4. 25.4; 31P NMR (121 
MHz, acetone-d6) δ 118.2; IR (CH2Cl2) 3400 (br), 2964, 2936, 1737, 1694, 1171, 1036, 
686 cm-1; mass spectrum (CI-1) m/z 574.1915 [C22H41NO10PS2 (M-1) requires 
574.1910] (base), 473, 433, 291.  
NMR assignments. 1H NMR (300 MHz, acetone-d6) δ 6.27-6.16 (br s, 1 H, NH), 
5.29-5.22 (m, 1 H, C2-H), 4.41 (dd, J = 11.8, 3.6 Hz, 1 H, C1-H), 4.22 (dd, J = 11.8, 6.4 
Hz, 1 H, C1-H), 4.11-4.06 (m, 2 H, C3-H), 4.02-3.95 (m, 2 H, C10-H), 3.70-3.60 (comp, 
2 H, C11-H), 3.60-3.50 (comp, 4 H, C9-H & C9’-H), 3.38-3.26 (comp, 2 H, OH), 2.40-
2.32 (comp, 4 H, C5-H & C5’-H), 1.70-1.48 (comp, 8 H, C6-H & C6’-H & C8-H & C8’-
H), 1.48-1.38 (comp, 13 H, C7-H & C7’-H & C14-H); 13C NMR (75 MHz, acetone-d6) δ 
173.5 (C4’), 173.3 (C4), 157.0 (C12), 78.8 (C13), 71.3 (d, J = 9.3 Hz, C2), 64.9 (C10), 
63.7 (d, J = 6.0 Hz, C1), 63.4 (C3), 62.2 (C9 & C9’), 41.7 (C11), 34.7 (C5’), 34.5 (C5), 

































phosphorodithioate (3.4a). To a solution of 3.28a (18 mg, 0.031 mmol) in CH3CN (2.5 
mL) at 0 °C, was added dropwise 1 N SnCl4 in heptane (155 µL, 0.34 mmol). The 
solution was stirred at rt for 45 min, and the solvent was removed under reduced 
pressure. The residue was purified by flash chromatography, eluting first with 
acetone/CHCl3 (3:2), and then with CHCl3/MeOH/H2O (5:1:0.1), to yield 13 mg (88%) 
of 3.4a as a glass: 1H NMR (300 MHz, CD3OD) δ 5.28-5.20 (m, 1 H), 4.40 (dd, J = 11.8, 
3.6 Hz, 1 H), 4.23-4.05 (comp, 5 H), 3.55 (t, J = 6.6 Hz, 2 H), 3.54 (t, J = 6.5 Hz, 2 H), 
3.23-3.18 (m, 2 H), 2.40-2.31 (comp, 4 H), 1.70-1.48 (comp, 8 H), 1.48-1.34 (comp, 4 
H); 13C NMR (75 MHz, CD3OD) δ 174.9, 174.6, 71.7, 65.0, 63.7, 63.1, 62.7, 41.3, 35.2, 
24.9, 33.2, 16.4(0), 26.3(7), 25.8; 31P NMR (121 MHz, CD3OD) δ 122.0; IR (MeOH) 
3369 (br), 2934, 1732, 1009, 689 cm-1; mass spectrum (FAB) m/z 476.1553 
[C17H35NO8PS2 (M+1) requires 476.1542], 277, 242 (base), 185.  
NMR assignments. 1H NMR (300 MHz, CD3OD) δ 5.28-5.20 (m, 1 H, C2-H), 
4.40 (dd, J = 11.8, 3.6 Hz, 1 H, C1-H), 4.23-4.05 (comp, 5 H, C1-H & C3-H & C10-H), 
3.55 (t, J = 6.6 Hz, 2 H, C9’-H), 3.54 (t, J = 6.5 Hz, 2 H, C9-H), 3.23-3.18 (m, 2 H, C11-
H), 2.40-2.31 (comp, 4 H, C5-H & C5’-H), 1.70-1.48 (comp, 8 H, C6-H & C6’-H & C8-
H & C8’-H), 1.48-1.34 (comp, 4 H, C7-H & C7’-H); 13C NMR (75 MHz, CD3OD) δ 
174.9 (C4’), 174.6 (C4), 71.7 (C2), 65.0 (C10), 63.7 (C1), 63.1 (C3), 62.7 (C9 & C9’), 
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serine t-butyl ester) phosphorodithioate (3.26a). By applying the same method to make 
3.27a, PS 3.26a was prepared from 3.25a and N-Boc-Ser-O-tBu (85%) as a clear liquid: 
1H NMR (300 MHz, acetone-d6) δ 6.43-6.32 (br s, 1 H), 5.30-5.20 (m, 1 H), 4.42 (dd, J = 
12.0, 3.3 Hz, 1 H), 4.25-4.20 (comp, 4 H), 4.15-4.05 (comp, 2 H), 3.60-3.52 (comp, 4 H), 
2.40-2.32 (comp, 4 H), 1.71-1.38 (comp, 12 H), 1.49 (s, 9 H), 1.44 (s, 9 H); 31P NMR 
(121 MHz, acetone-d6) δ 119.3; mass spectrum (CI) m/z 676.2595 [C27H51NO12PS2 
(M+1) requires 676.2590], (base); (CI-) m/z 674 (base), 473, 296. 
NMR assignments. 1H NMR (300 MHz, acetone-d6) δ 6.43-6.32 (br s, 1 H, NH), 
5.30-5.20 (m, 1 H, C2-H), 4.42 (dd, J = 12.0, 3.3 Hz, 1 H, C1-H), 4.25-4.20 (comp, 4 H, 
C1-H & C3-H & C11-H), 4.15-4.05 (comp, 2 H, C10-H), 3.60-3.52 (comp, 4 H, C9-H & 
C9’-H), 2.40-2.32 (comp, 4 H, C5-H & C5’-H), 1.71-1.38 (comp, 12 H, C6-H & C6’-H 









































phosphorodithioate (3.30a). By applying the same method to make 3.27a, PC 3.30a was 
prepared from 3.25a and choline tosylate (85%) as a clear liquid: 1H NMR (300 MHz) δ 
5.30-5.16 (m, 1 H), 4.66-4.44 (br s, 2 H), 4.34 (dd, J = 12.0, 3.1 Hz, 1 H), 4.14-4.06 
(comp, 3 H), 3.96-3.86 (br s, 2 H), 3.55 (t, J = 6.4 Hz, 4 H), 3.39 (s, 9 H), 2.32-2.23 
(comp, 4 H), 1.68-1.39 (comp, 8 H), 1.39-1.22 (comp, 4 H), 0.84 (s, 18 H), -0.02 (s, 12 
H); 13C NMR (75 MHz) δ 173.8, 173.3, 70.4 (d, J = 9.3 Hz), 66.4, 63.8, 63.2, 59.7, 55.4, 
34.6, 34.4, 32.7, 26.2, 25.65, 25.62, 25.0, 24.9, 18.6, -5.0; 31P NMR (121 MHz) δ 117.7; 
mass spectrum (CI) m/z 746.3745[C32H69NO8Si2PS2 (M+1) requires 746.3741] (base), 
687, 531, 391, 257.  
NMR assignments. 1H NMR (300 MHz) δ 5.30-5.16 (m, 1 H, C2-H), 4.66-4.44 
(br s, 2 H, C14-H), 4.34 (dd, J = 12.0, 3.1 Hz, 1 H, C1-H), 4.14-4.06 (comp, 3 H, C1-H & 
C3-H), 3.96-3.86 (br s, 2 H, C13-H), 3.55 (t, J = 6.4 Hz, 4 H, C9-H & C9’-H), 3.39 (s, 9 
H, C15-H), 2.32-2.23 (comp, 4 H, C5-H & C5’-H), 1.68-1.39 (comp, 8 H, C6-H & C6’-H 
& C8-H & C8’-H), 1.39-1.22 (comp, 4 H, C7-H & C7’-H), 0.84 (s, 18 H, C11-H & C11’-
H), -0.02 (s, 12 H, C10-H & C10’-H); 13C NMR (75 MHz) δ 173.8 (C4’), 173.3 (C4), 
70.4 (d, J = 9.3 Hz, C2), 66.4 (C13), 63.8 (C1), 63.2 (C9 & C9’), 59.7 (C14), 55.4 (C15), 
34.6 (C5’), 34.4 (C5), 32.7 (C8 & C8’), 26.2 (C11 & C11’), 25.65 (C6’), 25.62 (C6), 25.0 
































O-1,2-Di-(6’-hydroxyhexanoyl)-sn-3-glyceryl, O-(choline) phosphorodithioate 
(3.3a). By applying the same method to make 3.28a, PC 3.3a was prepared from 3.30a 
(95%) as a glass: 1H NMR (300 MHz, CD3OD) δ 5.32-5.24 (m, 1 H), 4.48-4.38 (comp, 3 
H), 4.26-4.08 (comp, 3 H), 3.75-3.70 (comp, 2 H), 3.573 (t, J = 6.5 Hz, 2 H), 3.569 (t, J = 
6.5 Hz, 2 H), 3.29 (s, 9 H), 2.43-2.34 (comp, 4 H), 1.72-1.50 (comp, 8 H), 1.50-1.36 
(comp, 4 H); 13C NMR (75 MHz, CD3OD) δ 174.9, 174.6, 71.8 (d, J = 9.2 Hz), 67.2, 
64.8 (d, J = 5.9 Hz), 63.7, 62.7, 60.6 (d, J = 5.0 Hz), 54.9, 35.1, 34.9, 33.3, 26.4, 25.8; 
31P NMR (121 MHz, CD3OD) δ 117.8; mass spectrum (CI) m/z 518.2032 
[C20H41NO8PS2 (M+1) requires 518.2011], 362, 303 (base), 189.  
NMR assignments. 1H NMR (300 MHz, CD3OD) δ 5.32-5.24 (m, 1 H, C2-H), 
4.48-4.38 (comp, 3 H, C1-H & C11-H), 4.26-4.08 (comp, 3 H, C1-H & C3-H), 3.75-3.70 
(comp, 2 H, C10-H), 3.573 (t, J = 6.5 Hz, 2 H. C9’-H), 3.569 (t, J = 6.5 Hz, 2 H, C9-H), 
3.29 (s, 9 H, C12-H), 2.43-2.34 (comp, 4 H, C5-H & C5’-H), 1.72-1.50 (comp, 8 H, C6-
H & C6’-H & C8-H & C8’-H), 1.50-1.36 (comp, 4 H, C7-H & C7’-H); 13C NMR (62 
MHz, CD3OD) δ 174.9 (C4’), 174.6 (C4), 71.8 (d, J = 9.2 Hz, C2), 67.2 (C10), 64.8 (d, J 
= 5.9 Hz, C1), 63.7 (C3), 62.7 (C9 & C9’), 60.6 (d, J = 5.0 Hz, C11), 54.9 (C12), 35.1 











































serine trimethylsilylethyl ester) phosphorodithioate (3.39a). DBU (108 mg, 0.71 
mmol) was added dropwise to a solution of 3.25a (500 mg, 0.71 mmol) and trimethylsilyl 
ethyl N-Boc serine ester (3.37) (217 mg, 0.71 mmol) in dry CH3CN (13 mL) at rt. The 
solution was stirred at rt for 45 min at rt, and the solvent was removed under reduced 
pressure. The residue was purified by column chromatography eluting with 
acetone/CHCl3 (1:2) to yield 655 mg of 3.38a as a clear liquid.  
The diester 3.38a (655 mg, 0.596 mmol) thus obtained was dissolved in CH3CN 
(20 mL) in a plastic bottle, and 2.8 M HF (3.4 mL) was added. The mixture was stirred at 
rt for 1 h, and brine (30 mL) was added. The mixture was extracted with CHCl3 (4 x 30 
mL). The combined organic phases were dried (Na2SO4), filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography eluting with 
acetone/CHCl3 (3:2) to yield 390 mg (76% after two steps) of 3.39a as a clear oil: 1H 
NMR (300 MHz, acetone-d6) δ 6.44 (d, J = 7.4 Hz, 1 H), 5.24-5.17 (m, 1 H), 4.38 (dd, J 
= 12.0, 3.6 Hz, 1 H), 4.23-4.12 (comp, 6 H), 4.12-4.00 (m, 2 H), 3.60-3.48 (comp, 6 H), 
2.40-2.28 (comp, 4 H), 1.70-1.30 (comp, 21 H), 1.10-1.08 (m, 2 H), 0.05 (s, 9 H);13C 
NMR (75 MHz, acetone-d6) δ 173.5, 173.3, 171.2, 156.4, 79.2, 71.2 (d, J = 9.3 Hz), 65.2 
(d, J = 6.6 Hz), 63.9, 63.7, 63.4, 62.2, 55.5 (d, J = 7.7 Hz), 34.7, 34.5, 33.3, 28.5, 26.1, 
26.0, 25.5, 25.4, 17.9, -1.5; 31P NMR (121 MHz, acetone-d6) δ 119.4; IR (CH2Cl2) 3410 
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(br), 2932, 1731, 1250, 694 cm-1; mass spectrum (CI) m/z 718. 2520 [C28H53NO12PSiS2 
(M-1) requires 718.2516], 686, 390, 277 (base). 
NMR assignments. 1H NMR (300 MHz, acetone-d6) δ 6.44 (d, J = 7.4 Hz, 1 H, 
N-H), 5.24-5.17 (m, 1 H, C2-H), 4.38 (dd, J = 12.0, 3.6 Hz, 1 H, C1-H), 4.23-4.12 
(comp, 6 H, C1-H & C3-H & C10-H & C11-H), 4.12-4.00 (m, 2 H, C16-H), 3.60-3.48 
(comp, 6 H, C9-H & C9’-H & OH), 2.40-2.28 (comp, 4 H, C5-H & C5’-H), 1.70-1.30 
(comp, 21 H, C6-H & C6’-H & C7-H & C7’-H & C8-H & C8’-H & C14-H), 1.10-1.08 
(m, 2 H, C17-H), 0.05 (s, 9 H, C18-H);13C NMR (75 MHz, acetone-d6) δ 173.5 (C4’), 
173.3 (C4), 171.2 (C15), 156.4 (C12), 79.2 (C13), 71.2 (d, J = 9.3 Hz, C2), 65.2 (d, J = 
6.6 Hz, C1), 63.9 (C10), 63.7 (C16), 63.4 (C3), 62.2 (C9 & C9’), 55.5 (d, J = 7.7 Hz, 
C11), 34.7 (C5’), 34.5 (C5), 33.3 (C8’& C8’), 28.5 (C14), 26.1 (C6’), 26.0 (C6), 25.5 


































phosphorodithioate (3.5a). A solution of 3.39a (45 mg, 0.063 mmol) in THF (3 mL) 
containing 1 N TBAF in THF (187 µL, 0.187 mmol) was stirred for 90 min. The solvent 
was removed under reduced pressure, and the residue was purified by flash 
chromatography eluting with acetone/CHCl3 (3:1) to yield 34 mg (88%) of 3.34a as a 
clear oil, contaminated with small amount of TBAF: 31P NMR (121 MHz, CD3OD) δ 
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119.3; mass spectrum (CI-) m/z 618.1793 [C23H41NO12PS2 (M-1) requires 618.1808], 
524, 409 (base), 204. 
A solution of 1 N SnCl4 in heptane (310 µL, 0.31 mmol) was added to a solution 
of 3.34a (34 mg, 0.055 mmol) thus obtained in CH3CN (5 mL) at 0°C. The mixture was 
stirred at rt for 1 h and the solvent was removed under reduced pressure. The residue was 
purified by flash chromatography, eluting first with acetone/CHCl3 (3:1), then with 
CHCl3/MeOH/H2O (2:2:0.1), to yield 21.6 mg (75%) of 3.5a as a glass: 1H NMR (300 
MHz, CD3OD) δ 5.27-5.20 (m, 1 H), 4.52-3.97 (comp, 7 H), 3.55 (t, J = 6.4 Hz, 2 H), 
3.54 (t, J = 6.4 Hz, 2 H), 2.40-2.32 (comp, 4 H), 1.70-1.48 (comp, 8 H), 1.47-1.31 (comp, 
4 H); 13C NMR (75 MHz, CD3OD) δ 175.0, 174.7, 169.4, 71.8 (d, J = 9.3 Hz), 64.9 (d, J 
= 6.0 Hz), 64.1 (d, J = 6.0 Hz), 63.7, 62.74, 62.73, 54.4 (d, J = 8.8 Hz,), 35.1, 34.9, 33.3, 
26.42, 26.39, 25.8; 31P NMR (121 MHz, CD3OD) δ 117.9; mass spectrum (FAB-) m/z 
519.1357 [C18H37NO7P (M-) requires 519.1362], 431, 245, 205, 183 (base). 
NMR assignments. 1H NMR (300 MHz, CD3OD) δ 5.27-5.20 (m, 1 H, C2-H), 
4.52-3.97 (comp, 7 H, C1-H & C3-H & C10-H & C11-H), 3.55 (t, J = 6.4 Hz, 2 H, C9’-
H), 3.54 (t, J = 6.4 Hz, 2 H, C9-H), 2.40-2.32 (comp, 4 H, C5-H & C5’-H), 1.70-1.48 
(comp, 8 H, C6-H & C6’-H & C8-H & C8’-H), 1.47-1.31 (comp, 4 H, C7-H & C7’-H); 
13C NMR (75 MHz, CD3OD) δ 175.0 (C4’), 174.7 (C4), 169.4 (C12), 71.8 (d, J = 9.3 
Hz, C2), 64.9 (d, J = 6.0 Hz, C1), 64.1 (d, J = 6.0 Hz, C10), 63.7 (C3), 62.74 (C9’), 62.73 
(C9), 54.4 (d, J = 8.8 Hz, C11), 35.1 (C5’), 34.9 (C5), 33.3 (C8 & C8’), 26.42 (C6), 














































(3.23b). DCC (1.34 g, 6.52 mmol) in CH2Cl2 (10 mL) was added to a mixture of acid 
3.21b (1.49 g, 5.43 mmol), diol 3.8 (500 mg, 2.36 mmol) and DMAP (66 mg, 0.54 
mmol) in CH2Cl2 (8 mL) at 0 °C. The mixture was stirred at rt overnight. The insoluble 
solid was removed by filtration and washed with ether (50 mL). The combined filtrate 
and washing were concentrated under reduced pressure. The residue was redissolved in 
ether (40 mL) and filtered. The filtrate was concentrated under reduced pressure, and the 
residue was purified by chromatography eluting with EtOAc/hexanes (1:10) to yield 1.30 
g (76%) of 3.23b as a clear liquid: 1H NMR (250 MHz) δ 7.21 (d, J = 8.6 Hz, 2 H), 6.84 
(d, J = 8.6 Hz, 2 H), 5.22-5.15 (m, 1 H), 4.47 (d, J = 11.7 Hz, 1 H), 4.41 (d, J = 11.7 Hz, 
1 H), 4.30 (dd, J = 11.9, 3.8 Hz, 1 H), 4.14 (dd, J = 11.9, 6.4 Hz, 1 H), 3.77 (s, 3 H), 
3.59-3.51 (comp, 6 H), 2.32-2.21 (comp, 4 H), 1.68-1.38 (comp, 8 H), 1.35-1.20 (comp, 
12 H), 0.86 (s, 18 H), 0.02 (s, 12 H); 13C NMR (62 MHz) δ 173.2, 172.9, 159.2, 129.6, 
129.1, 113.7, 72.8, 69.9, 67.7, 63.0, 62.5, 55.1, 34.1, 33.9, 32.6, 28.9, 25.8, 25.5, 24.7, 
24.6, 18.2, -5.3; mass spectrum (CI) m/z 725.4832 [C39H73O8Si2 (M+1) requires 
725.4844] (base), 709, 667, 471, 451. 
NMR assignments. 1H NMR (250 MHz) δ 1H NMR (250 MHz) δ 7.21 (d, J = 
8.6 Hz, 2 H, C17-H), 6.84 (d, J = 8.6 Hz, 2 H, C18-H), 5.22-5.15 (m, 1 H, C2-H), 4.47 
(d, J = 11.7 Hz, 1 H, C15-H), 4.41 (d, J = 11.7 Hz, 1 H, C15-H), 4.30 (dd, J = 11.9, 3.8 
Hz, 1 H, C1-H), 4.14 (dd, J = 11.9, 6.4 Hz, 1 H, C1-H), 3.77 (s, 3 H C20-H), 3.59-3.51 
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(comp, 6 H, C3-H & C11-H & C11’-H), 2.32-2.21 (comp, 4 H, C5-H & C5’-H), 1.68-
1.38 (comp, 8 H, C10-H & C10’-H & C6-H & C6’-H), 1.35-1.20 (comp, 12 H, C7-H & 
C7’-H & C8-H & C8’-H & C9-H& C9-H), 0.86 (s, 18 H, C13-H & C13’-H), 0.02 (s, 12 
H, C12-H & C12’-H); 13C NMR (62 MHz) δ 173.2 (C4’), 172.9 (C4), 159.2 (C19), 129.6 
(C16), 129.1 (C17), 113.7(C18), 72.8 (C2), 69.9 (C15), 67.7 (C20), 63.0 (C11& C11’), 
62.5 (C1), 55.1 (C3), 34.1 (C5’), 33.9 (C5), 32.6 (C10 & C10’), 28.9 (C9 & C9’ & C6 & 
C6’), 25.8 (C13 & C13’), 25.5 (C8 & C8’), 24.7(C7’), 24.6(C7), 18.2 (C14 & C14’), -5.3 




































1,2-Di-(6’-tert-butyldimethylsilyloxyoctanoyl)-sn-glycerol (3.24b). PMB ether 
3.23b (1.30 g, 1.80 mmol) in CH2Cl2 (9 mL) was added to a suspension of DDQ (0.53 g, 
2.33 mmol) in CH2Cl2/H2O (9 mL, 10:1). The solution was stirred at rt for 2.5 h. The 
insoluble solid was removed by filtration and washed with CH2Cl2 (50 mL). The 
combined filtrate and washes were washed with NaHCO3 (40 mL), NaCl (40 mL), dried 
(Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by 
chromatography eluting with EtOAc/hexanes (1:5) to yield 1.039 mg (96%) of 3.24b as a 
clear liquid: 1H NMR (300 MHz) δ 5.08-5.00 (m, 1 H), 4.29 (dd, J = 11.9, 4.4 Hz, 1 H), 
4.18 (dd, J = 11.9, 5.7 Hz, 1 H), 3.68 (t, J = 5.5 Hz, 2 H), 3.58-3.53 (comp, 4 H), 2.33-
2.25 (comp, 5 H), 1.68-1.40 (comp, 8 H), 1.38-1.30 (comp, 12 H), 0.85 (s, 18 H), 0.01 (s, 
12 H); 13C NMR (75 MHz) δ 173.7, 173.3, 72.1, 63.2, 62.0, 61.4, 34.2, 34.0, 32.7, 30.0, 
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25.9, 25.6, 24.8, 18.3. –5.3; mass spectrum (CI) m/z 605.4273 [C31H65O7Si2 (M+1) 
requires 605.4267] (base), 589, 547, 473, 349, 331. 
NMR assignments. 1H NMR (300 MHz) δ 5.08-5.00 (m, 1 H, C2-H), 4.29 (dd, J 
= 11.9, 4.4 Hz, 1 H, C1-H), 4.18 (dd, J = 11.9, 5.7 Hz, 1 H, C1-H), 3.68 (t, J = 5.5 Hz, 2 
H, C3-H), 3.58-3.53 (comp, 4 H, C11-H & C11’-H), 2.33-2.25 (comp, 5 H, C5-H & C5’-
H & OH), 1.68-1.40 (comp, 8 H, C10-H & C10’-H & C6-H & C6’-H), 1.38-1.30 (comp, 
12 H, C7-H & C7’-H & C8-H & C8’-H& C9-H & C9’-H), 0.85 (s, 18 H, C13-H & C13’-
H), 0.01 (s, 12 H, C12-H & C12’-H); 13C NMR (75 MHz) δ 173.7 (C4’), 173.3(C4), 
72.1(C2), 63.2(C11 & C11’), 62.0(C1), 61.4(C3), 34.2(C5’), 34.0 (C5), 32.7 (C10 & 
C10’), 30.0 (C9 & C9’& C6 & C6’), 25.9 (C13 & C13’), 25.6 (C8 & C8’), 24.8(C7 & 










































dithiophospholane (3.25b). 2-Chloro-1,3,2-dithiophospholane (273 mg, 1.72 mmol) was 
added dropwise to a solution of 3.24b (1.039 mg, 1.72 mmol) and iPr2NEt (246 mg, 1.90 
mmol) in CH3CN (17 mL) at –38 °C (dry ice/1,2-dichloroethane). The solution was 
stirred at –38 °C for 2 h. The cold bath was removed, and the mixture was stirred for 1 h. 
A solution of sulfur (191 mg, 5.97 mmol) in CS2 (6.5 mL) was added in one portion, and 
the solution was stirred vigorously overnight. The mixture was concentrated under 
reduced pressure, and the residue was dissolved in acetone. The insoluble solid was 
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removed by filtration and washed with acetone. The combined filtrate and washing were 
concentrated under reduced pressure. The residue was purified by chromatography 
eluting with EtOAc/hexanes (1:7 then 1:4) to yield 1.037 g (80%) of 3.25b as a clear 
liquid: 1H NMR (300 MHz) δ 5.25-5.18 (m, 1 H), 4.30-4.09 (comp, 4 H), 3.68-3.52 
(comp, 8 H), 2.31-2.24 (comp, 4 H), 1.62-1.38 (comp, 8 H), 1.34-1.20 (comp, 12 H), 0.83 
(s, 18 H), -0.02 (s, 12 H); 13C NMR (75 MHz) δ 173.1, 172.6, 69.1 (d, J = 9.3 Hz), 65.3 
(d, J = 8.2 Hz), 63.0, 61.6, 41.4 (d, J = 7.2 Hz), 34.0, 33.9, 32.6, 28.9, 28.9, 25.9, 25.5, 
24.7, 18.2, -5.4; 31P NMR (121 MHz) δ 124.4; mass spectrum (CI) m/z 759.3395 
[C33H68O7Si2PS3 (M+1) requires 759.3403] (base), 743, 701, 587, 485.  
NMR assignments. 1H NMR (250 MHz) δ; 13C NMR (75 MHz) δ. 1H NMR 
(250 MHz) δ 5.25-5.18 (m, 1 H, C2-H), 4.30-4.09 (comp, 4 H, C1-H & C3-H), 3.68-3.52 
(comp, 8 H, C11-H & C11’-H & C15-H), 2.31-2.24 (comp, 4 H, C5-H & C5’-H), 1.62-
1.38 (comp, 8 H, C10-H & C10’-H & C6-H & C6’-H), 1.34-1.20 (comp, 12 H, C7-H & 
C7’-H & C8-H & C8’-H& C9-H & C9’-H), 0.83 (s, 18 H, C13-H & C13’-H), -0.02 (s, 12 
H, C12-H & C12’-H); 13C NMR (75 MHz) δ 173.1 (C4’), 172.6 (C4), 69.1 (d, J = 9.3 
Hz, C2), 65.3 (d, J = 8.2 Hz, C1), 63.0 (C11 & C11’), 61.6(C3), 41.4 (d, J = 7.2 Hz, 
C15), 34.0 (C5’), 33.9(C5), 32.6 (C10 & C10’), 28.9 (C9 & C9’& C6 & C6’), 25.9 (C13 
















































serine trimethylsilylethyl ester) phosphorodithioate (3.39b). By applying the same 
method to make 3.38aa, PS 3.38bb was prepared from 3.25b (500 mg, 0.66 mmol), 
trimethylsilylethyl N-Boc serine ester (201 mg, 0.66 mmol) and DBU (100 mg, 0.66 
mmol) in CH3CN (12 mL) as a clear liquid (77%, 587 mg); 31P NMR (121 MHz) δ 
116.8; mass spectrum (CI) m/z 1002.4880 [C44H89NO12PSi3S2 (M+1) requires 
1002.4872] 703, 398 (base). 
By applying the same method to make 3.39a, PS 3.39b was prepared from 3.38b 
(587 mg, 0.508 mmol) and 2.8 M HF (2.9 mL, 8.12 mmol) in CH3CN (17 mL) as a clear 
liquid (91%, 359 mg): 1H NMR (300 MHz, acetone-d6) δ 6.44 (d, J = 7.4 Hz, 1 H), 5.24-
5.17 (m, 1 H), 4.40 (dd, J = 12.0, 3.3 Hz, 1 H), 4.32-4.10 (comp, 6 H), 4.08-3.98 (comp, 
2 H), 3.56-3.42 (comp, 4 H), 2.35-2.27 (comp, 4 H), 1.66-1.22 (comp, 29 H), 1.08-1.00 
(m, 2 H), 0.06 (s, 9 H); 13C NMR (75 MHz, acetone-d6) δ 173.5, 173.2, 171.2, 156.2, 
79.2, 71.6 (d, J = 4.3 Hz), 65.2 (d, J = 6.5 Hz), 63.8, 63.7, 63.5, 62.4, 55.6, (d, J = 8.4 
Hz), 34.7, 34.5, 33.7, 29.7, 28.6, 26.5, 25.6, 17.9, -1.4; 31P NMR (121 MHz, acetone-d6) 
δ 119.6; mass spectrum (CI) m/z 774.3112 [C32H61NO12PSiS2 (M+1) requires 
774.3142], 411, 340 (base); 
NMR assignments. 1H NMR (300 MHz, acetone-d6) δ 6.44 (d, J = 7.4 Hz, 1 H, 
N-H), 5.24-5.17 (m, 1 H, C2-H), 4.40 (dd, J = 12.0, 3.3 Hz, 1 H, C1-H), 4.32-4.10 
(comp, 6 H, C1-H & C3-H & C12-H & C13-H), 4.08-3.98 (comp, 2 H, C18-H), 3.56-
3.42 (comp, 4 H, C11-H & C11’-H), 2.35-2.27 (comp, 4 H, C5-H & C5’-H), 1.66-1.22 
(comp, 29 H, C6-H & C6’-H & C7-H & C7’-H & C8-H & C8’-H & C9-H & C9’-H & 
C10-H & C10’-H & C15-H), 1.08-1.00 (m, 2 H, C19-H), 0.06 (s, 9 H, C20-H); 13C NMR 
(75 MHz, acetone-d6) δ 173.5(C4’), 173.2(C4), 171.2 (C17), 156.2 (C14), 79.2 (C16), 
71.6 (d, J = 4.3 Hz, C2), 65.2 (d, J = 6.5 Hz, C1), 63.8 (C12), 63.7 (C3), 63.5 (C18), 62.4 
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(C11 & C11’), 55.6 (d, J = 8.4 Hz, C13), 34.7 (C5’), 34.5 (C5), 33.7(C10 & C10’), 






































ate (3.5b).  
Method A: A mixture of protected PS 3.29a (50 mg, 0.047 mmol), ethanedithiol 
(80 µL, 95 mmol) in TFA (1.5 mL) and thioanisole (1.5 mL) was stirred at rt for 4.5 h. 
The solvent was removed under reduced pressure. The residue (product, thioanisole and 
ethanedithiol) was then separated by flash chronography, eluting first with 
acetone/CHCl3 (3:2) then with MeOH/CHCl3 (1:1). The resulting glass was dissolved in 
MeOH (2 mL), and stirred at rt for 2 d. The solvent was removed under reduced pressure, 
and the residue was purified by flash chromatography, eluting first with acetone/CHCl3 
(3:2) then with MeOH/CHCl3 (1:1). The resulting glass was then purified by reverse-
phase column chromatograph, eluting with CH3CN/H2O (9:1) to yield 9 mg (37%) of 
3.5b as a glass. 
Method B: By applying the same method to make 3.34a, PS 3.34b was prepared 
from 3.39b (26 mg, 0.034 mmol), 1 N TBAF in THF (98 µL, 0.098 mmol) in CH3CN 
(4.6 mL) as a glass (97%, 22 mg), contaminated with small amount of TBAF; 31P NMR 
(121 MHz, acetone-d6) δ 119.4; mass spectrum (CI-) m/z 674.2441 [C27H49NO12PS2 
(M-1) requires 674.2434], 580, 409 (base), 204. 
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By applying the same method to make 3.5a, PS 3.5b was prepared from 3.34b (12 
mg, 0.018 mmol), 1 N SnCl4 in heptane (103 µL, 0.103 mmol) in CH3CN (1.7 mL) as a 
glass (88%, 9 mg): 1H NMR (300 MHz, CD3OD) δ; 5.28-5.18 (m, 1 H), 4.50-4.00 
(comp, 7 H), 3.68-3.48 (comp, 4 H), 2.40-2.28 (comp, 4 H), 1.70-1.46 (comp, 8 H), 1.46-
1.26 (comp, 12 H); 13C NMR (75 MHz, CD3OD) δ 175.1, 174.8, 169.4, 71.8 (d, J = 9.2 
Hz), 64.9 (d, J = 5.2 Hz), 64.1 (d, J = 6.4 Hz), 63.7, 63.0, 54.5 (d, J = 8.8 Hz), 35.1, 34.9, 
33.6, 30.2, 30.1, 26.8, 25.9; 31P NMR (121 MHz, CD3OD) δ 118.0; mass spectrum 
(FAB-) m/z 574.1888 [C22H41NO10PS2 (M) requires 574.1910], 487, 275, 244 (base). 
NMR assignments. 1H NMR (300 MHz, CD3OD) δ 5.28-5.18 (m, 1 H, C2-H), 
4.50-4.00 (comp, 7 H, C1-H & C3-H & C12-H & C13-H), 3.68-3.48 (comp, 4 H, C11-H 
& C11’-H), 2.40-2.28 (comp, 4 H, C5-H & C5’-H), 1.70-1.46 (comp, 8 H, C6-H & C6’-
H & C10-H & C10’-H), 1.46-1.26 (comp, 12 H, C7-H & C7’-H & C8-H & C8’-H & C9-
H & C9’-H); 13C NMR (75 MHz, CD3OD) δ 175.1 (C4’), 174.8 (C4), 169.4 (C14), 71.8 
(d, J = 9.2 Hz, C2), 64.9 (d, J = 5.2 Hz, C1), 64.1 (d, J = 6.4 Hz, C12), 63.7 (C3), 63.0 
(C11 & C11’), 54.5 (d, J = 8.8 Hz, C13), 35.1(C5’), 34.9(C5), 33.6 (C10-H & C10’-H), 














6-Methoxymethoxyhexanoic acid (3.41). By applying the same basic hydrolysis 
procedure as to make 3.21a, acid 3.41 was prepared from the methyl ester (99%) as a 
clear liquid: 1H NMR (250 MHz) δ 4.58 (s, 2 H), 3.49 (t, J = 6.4 Hz, 2 H), 3.32 (s, 3 H), 
2.33 (t, J = 7.4 Hz, 2 H), 1.70-1.53 (comp, 4 H), 1.45-1.35 (comp, 2 H); 13C NMR (62 
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MHz) δ 179.6, 96.3, 67.5, 55.1, 33.9, 29.3, 25.7, 24.4; IR (neat) 3100 (br), 2940, 1709, 
1411 cm-1; mass spectrum (CI) m/z 177.1129 [C8H17O4 (M+1) requires 177.1127], 159, 
145, 115 (base).  
NMR assignments. 1H NMR (250 MHz) δ 4.58 (s, 2 H, C7-H), 3.49 (t, J = 6.4 
Hz, 2 H, C5-H), 3.32 (s, 3 H, C8-H), 2.33 (t, J = 7.4 Hz, 2 H, C2-H), 1.70-1.53 (comp, 4 
H, C3-H & C5-H), 1.45-1.35 (comp, 2 H, C4-H); 13C NMR (62 MHz) δ 179.6 (C1), 96.3 





























1,2-Di-(6’-methoxymethoxyhexanoyl)-sn-glycerylol (3.43). By applying the 
same DCC coupling procedure as to make 3.23a, diester 3.42 was prepared from 3.8 as a 
clear liquid. 1H NMR (300 MHz) δ 7.19 (d, J = 8.6 Hz, 2 H), 6.83 (d, J = 8.6 Hz, 2 H), 
5.17 (m, 1 H), 4.56 (s, 4 H), 4.45 (d, J = 11.7 Hz, 1 H), 4.39 (d, J = 11.7 Hz, 1 H), 4.29 
(dd, J = 11.9, 3.8 Hz, 1 H), 4.12 (dd, J = 11.9, 76.4 Hz, 1 H), 3.76 (s, 3 H), 3.52-3.44 
(comp, 6 H), 3.31 (s, 6 H), 2.33-2.22 (comp, 4 H), 1.67-1.50 (comp, 8 H), 1.42-1.31 
(comp, 4 H); 13C NMR (62 MHz) δ 175.0, 172.7, 159.2, 129.6, 129.1, 113.6, 72.8, 69.9, 
67.7, 67.3, 62.6, 55.1, 54.9, 34.0, 33.8, 29.2, 25.6, 25.5, 24.5, 24.4; IR (CHCl3) 2934, 
1739, 1612, 1513, 1464 cm-1; mass spectrum (CI) m/z 527.2857 [C27H43O10 (M-1) 
requires 527.2856], 383, 351(base). 
By applying the same DDQ cleavage procedure as to make 3.24a, alcohol 3.43 
was prepared from 3.42 (83% after two steps) as a clear liquid: 1H NMR (300 MHz) δ 
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5.05 (m, 1 H), 4.58 (s, 4 H), 4.29 (dd, J = 11.8, 7.2 Hz, 1 H), 4.17 (dd, J = 11.8, 6.1 Hz, 1 
H), 3.70-3.68 (comp, 2 H), 3.51-3.46 (comp, 4 H), 3.32 (s, 6 H), 2.37-2.15 (comp, 5 H), 
1.70-1.53 (comp, 8 H), 1.43-1.34 (comp, 4 H); 13C NMR (75 MHz) δ 173.8, 173.4, 96.6, 
72.4, 67.7(1), 67.6(9), 62.3, 61.7, 55.4, 34.4, 34.2, 29.6, 29.5, 26.0, 25.9, 24.9; IR 
(CHCl3) 3465, 2938, 1738 cm-1; mass spectrum (CI) m/z 409.2430 [C19H37O9 (M+1) 
requires 409.2438], 377, 345 (base), 333, 315, 231, 201.  
NMR assignments. 1H NMR (300 MHz) δ 5.05 (m, 1 H, C2-H), 4.58 (s, 4 H, 
C10-H & C10’-H), 4.29 (dd, J = 11.8, 7.2 Hz, 1 H, C1-H), 4.17 (dd, J = 11.8, 6.1 Hz, 1 
H, C1-H), 3.70-3.68 (comp, 2 H, C3-H), 3.51-3.46 (comp, 4 H, C9-H & C9’-H), 3.32 (s, 
6 H, C11-H), 2.37-2.15 (comp, 5 H, OH & C5-H & C5’-H), 1.70-1.53 (comp, 8 H, C6-H 
& C6’-H & C8-H & C8’-H), 1.43-1.34 (comp, 4 H, C7-H & C7’-H); 13C NMR (75 
MHz) δ 173.8 (C4’), 173.4 (C4), 96.6 (C10 & C10’), 72.4 (C2), 67.7 (C11 & C11’), 62.3 
(C1), 61.7 (C3), 55.4 (C9 & C9’), 34.4 (C5’), 34.2 (C5), 29.6(C8’), 29.5 (C8), 26.0 (C6’), 



































dithiophospholane (3.44). By applying the same method to make 3.25a, 
dithiophospholane 3.44 was prepared from 3.43 (65%) as a clear liquid: 1H NMR (300 
MHz) δ 5.27-5.20 (m, 1 H), 4.58 (s, 4 H), 4.32-4.13 (comp, 4 H), 3.69-3.54 (comp, 4 H), 
3.51-3.46 (comp, 4 H), 3.32 (s, 6 H), 2.36-2.29 (comp, 4 H), 1.69-1.53 (comp, 8 H), 1.43-
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1.34 (comp, 4 H); 13C NMR (75 MHz) δ 173.3, 172.9, 96.7, 69.5 (d, J = 8.8 Hz), 67.7, 
65.7 (d, J = 8.3 Hz), 62.0, 55.4, 41.8 (d, J = 5.5 Hz), 34.4, 34.2, 29.6, 26.0, 26.0, 24.9; 
31P NMR (121 MHz) δ 124.6; IR (neat) 2937, 1740, 1458 cm-1; mass spectrum (CI-) m/z 
561.1395 [C21H38O9PS3 (M-1) requires 527.2856], m/z 561, 534 (base), 216  
NMR assignments. 1H NMR (300 MHz) δ 5.27-5.20 (m, 1 H, C2-H), 4.58 (s, 4 H, 
C10-H & C10’-H), 4.32-4.13 (comp, 4 H, C1-H & C3-H), 3.69-3.34 (comp, 4 H, C12-H), 
3.51-3.46 (comp, 4 H, C9-H & C9’-H), 3.32 (s, 6 H, C11-H & C11’-H), 2.36-2.29 (comp, 
4 H, C5-H & C5’-H), 1.69-1.53 (comp, 8 H, C6-H & C6’-H & C8-H & C8’-H), 1.43-
1.34 (comp, 4 H, C7-H & C7’-H); 13C NMR (75 MHz) δ 173.3 (C4’), 172.9 (C4), 96.7 
(C10 & C10’), 69.5 (d, J = 8.8 Hz, C2), 67.7 (C11), 65.7 (d, J = 8.3 Hz, C1), 62.0 (C3), 
55.4 (C9), 41.8 (d, J = 5.5 Hz, C12), 34.4 (C4’), 34.2 (C4), 29.6 (C8 & C8’), 26.0 (C6 & 











































trimethylsilylethoxycarbonyl ethanolamine) phosphorodithioate (3.45b). DBU (15.6 
mg, 0.10 mmol) was added dropwise to a solution of 3.44 (55 mg, 0.098 mmol) and N-
Teoc ethanolamine (21 mg, 0.10 mmol) in dry CH3CN (2.5 mL) at rt. The solution was 
stirred at rt for 15 min, and the solvent was removed under reduced pressure. The residue 
was purified by flash chromatography eluting first with EtOAc then with EtOAc/MeOH 
(10:1) to yield 31 mg (45%) of 3.45b as a clear liquid: 1H NMR (250 MHz) δ 5.55-5.42 
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(br s, 1 H), 5.35-5.25 (m, 1 H), 4.59 (s, 4 H), 4.33 (dd, J = 12.3, 3.4 Hz, 1 H), 4.25-3.90 
(comp, 7 H), 3.52-3.35 (comp, 6 H), 3.32 (s, 6 H), 2.40-2.25 (comp, 4 H), 1.70-1.50 
(comp, 8 H), 1.46-1.20 (comp, 4 H), 1.20-0.88 (m, 2 H), 0.00 (s, 9 H); 13C NMR (75 
MHz, CD3OD) δ 173.9, 173.8, 158.1, 96.3, 70.5, 67.5, 66.0, 64.0, 63.6, 62.6, 55.1, 41.3, 
34.3, 34.0, 29.3, 25.7, 25.6, 24.5, 17.6, -1.5; mass spectrum (CI) m/z 706.2515 
[C27H53NO12PSiS2 (M-1) requires 706.2516], 240, 211 (base).  
NMR assignments. 1H NMR (250 MHz) δ 5.55-5.42 (br s, 1 H, N-H), 5.35-5.25 
(m, 1 H, C2-H), 4.59 (s, 4 H, C10-H & C10’-H), 4.33 (dd, J = 12.3, 3.4 Hz, 1 H, C1-H), 
4.25-3.90 (comp, 7 H, C1-H & C3-H & C12-H & C14-H), 3.52-3.35 (comp, 6 H, C9-H 
& C9’-H & C13-H), 3.32 (s, 6 H, C11-H & C11’-H), 2.40-2.25 (comp, 4 H, C5-H & C5’-
H), 1.70-1.50 (comp, 8 H, C6-H & C6’-H & C8-H & C8’-H), 1.46-1.20 (comp, 4 H, C7-
H & C7’-H), 1.20-0.88 (m, 2 H, C16-H), 0.00 (s, 9 H, C7-H); 13C NMR (75 MHz, 
CD3OD) δ 173.9 (C4’), 173.8 (C4), 158.1 (C14), 96.3 (C10 & C10’), 70.5, 67.5 (C9 & 
C9’), 66.0 (C1), 64.0 (C15), 63.6 (C12), 62.6 (C3), 55.1 (C11 & C11’), 41.3 (C13), 34.3 




































phosphorodithioate (3.46). A solution of 3.45b (13 mg, 0.018 mmol) in CH3CN (2.0 
mL) containing 1 N TBAF in THF (60 µL, 0.06 mmol) was stirred for 1 d. The solvent 
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was removed under reduced pressure and the residue was purified by flash 
chromatography eluting with acetone/CHCl3 (1:2 then 1:1) to yield 4 mg (39%) of 3.46 
as a pale yellow glass:1H NMR (300 MHz, CD3OD) δ 5.32-5.22 (m, 1 H), 4.59 (s, 4 H), 
4.44-4.08 (comp, 6 H), 3.51 (t, J = 6.5 Hz, 2 H), 3.50 (t, J = 6.5 Hz, 2 H), 3.48-3.40 (m, 2 
H), 3.34 (s, 6 H), 2.40-2.38 (comp, 4 H), 1.70-1.50 (comp, 8 H), 1.48-1.32 (comp, 4 H); 
13C NMR (75 MHz, CD3OD) δ 173.6, 173.3, 96.4, 70.2 (d, J = 8.7 Hz), 67.62, 67.57, 
64.2 (d, J = 5.9 Hz), 62.6, 62.2 (d, J= 5.2 Hz), 55.21, 55.18, 41.2, 34.2, 34.1, 29.7, 29.4, 
25.7, 25.73, 25.66, 24.7, 24.6; 31P NMR (121 MHz, CD3OD) δ 116.7; mass spectrum 
(CI) m/z 564.2076 [C21H43NO10PS2 (M+1) requires 564.2066]; mass spectrum (CI-) m/z 
562, 517, 443 (base).  
NMR assignments. 1H NMR (300 MHz, CD3OD) δ 5.32-5.22 (m, 1 H, C2-H), 
4.59 (s, 4 H, C10-H & C10’-H), 4.44-4.08 (comp, 6 H, C1-H & C3- H & C12-H), 3.51 (t, 
J = 6.5 Hz, 2 H, C9’-H), 3.50 (t, J = 6.5 Hz, 2 H, C9-H), 3.48-3.40 (m, 2 H, C13-H), 3.34 
(s, 6 H, C11-H & C11’-H), 2.40-2.38 (comp, 4 H, C5-H & C5’-H), 1.70-1.50 (comp, 8 H, 
C6-H & C6’-H & C8-H & C8’-H), 1.48-1.32 (comp, 4 H, C7-H & C7’-H); 13C NMR (75 
MHz, CD3OD) δ 173.6 (C4’), 173.3 (C4), 96.4 (C10 & C10’), 70.2 (d, J = 8.7 Hz, C2), 
67.62 (C9’), 67.57 (C9), 64.2 (d, J = 5.9 Hz, C1), 62.6 (C12), 62.2 (d, J = 5.2 Hz, C3), 
55.21 (C11’), 55.18 (C11), 41.2 (C13), 34.2 (C5’), 34.1 (C5), 29.7 (C8’), 29.4 (C8), 




























3-(S)-Bis(n-hexanoyloxy)butyl]phosphonic acid (1.58c). To a solution of the 
methyl phsphonate 3.51c (186 mg, 0.44 mmol) in dry CH2Cl2 (0.5 mL), was added 
bromotrimethylsilane (152 µL, 1.15 mmol) at rt over 30 min. The solution was stirred for 
6 h at rt. The solvent was removed under reduced pressure, and THF/H2O (1 mL, 1:9) 
was added. The mixture was refluxed for 1 h. Solvent was removed under reduced 
pressure and the residue oil was dissolved in CHCl3 (5 mL), dried (Na2SO4), filtered and 
evaporated to yield 160 mg of 1.58c as pale yellow liquid, which is sufficiently pure by 
NMR: 1H NMR (300 MHz) δ 11.00-9.40 (br, s, 2 H), 5.10-5.00 (br, s, 1 H), 4.28 (d, J = 
10.2 Hz, 1 H), 4.18-3.92 (br, s, 1 H), 2.38-2.24 (comp, 4 H), 2.00-1.70 (br, s, 3 H), 1.78-
1.52 (comp, 5 H), 1.40-1.20 (br, s, 8 H), 0.96-0.80 (m, 6 H); 13C NMR (75 MHz) δ 
173.9, 173.8, 71.3, 34.4 (d, J = 17.5 Hz), 31.4, 29.9, 24.7 (d, J = 7.1 Hz), 23.5 (d, J = 
77.6 Hz), 22.5, 14.1; 31P NMR (121 MHz) δ 35.0; IR (CHCl3) 3580, 2958, 1708, 1460, 
1414 cm-1; mass spectrum (CI) m/z 367.1882 [C18H37NO7P (M+1) requires 367.1886], 
233(base). 
NMR assignments. 1H NMR (300 MHz) δ 11.00-9.40 (br, s, 2 H, O-H), 5.10-
5.00 (br, s, 1 H, C2-H), 4.28 (d, J = 10.2 Hz, 1 H, C1-H), 4.18-3.92 (br, s, 1 H, C1-H), 
2.38-2.24 (comp, 4 H, C6-H & C12-H), 2.00-1.70 (br, s, 3 H, C13-H & C7-H), 1.78-1.52 
(comp, 5 H, C3-H & C4-H & C13-H), 1.40-1.20 (br, s, 8 H, C8-H & C9-H & C14-H & 
C15-H), 0.96-0.80 (m, 6 H, C10-H & C16-H); 13C NMR (75 MHz) δ 173.9 (C5), 173.8 
(C11), 71.3 (C2), 64.6 (C1), 34.5 (C6), 34.2 (C12), 31.4 (C7 & C13), 29.9 (C3), 24.7 


































phosphonate (3.52c). To a solution of phosphonic acid 1.58c (90 mg, 0.25 mmol) and N-
Boc- ethanolamine (183 mg, 1.14 mmol) in dry pyridine (6.6 mL) at 60 °C, was added 
trichloroacetonitrile (1.05 mL, 10.5 mmol). The reaction mixture was stirred at 62-75 °C 
(oil bath) for 46 h. The Pyridine was removed by distillation under vacuum. The dark 
orange residue was dissolved in CH2Cl2 (5 mL) and treated with activated carbon. The 
mixture was filtered through celite, concentrated, and the residue was purified by 
chromatography, eluting with CHCl3/MeOH (2:1), to yield 62 mg (49%) of 3.52c as a 
yellow oil: 1H NMR (300 MHz) δ 5.10-5.00 (br, m, 1 H), 4.22 (d, J = 10 Hz, 1 H), 3.90 
(dd, J = 11.7, 7.4 Hz, 1 H), 3.85-3.75 (br, s, 2 H), 3.30-3.05 (br, comp, 2 H), 2.25-2.17 
(comp, 4 H), 1.78-1.62 (br, s, 2 H), 1.60-1.42 (comp, 6 H), 1.36 (s, 9 H), 1.30-1.19 
(comp, 8 H), 0.86-0.78 (comp, 6 H); 13C NMR (75 MHz) δ 173.8, 156.8, 79.4, 72.1 (d, J 
= 15.3 Hz), 65.0, 63.9, 41.7, 34.5, 34.2, 31.5, 30.5, 28.6, 25.2, 24.9, 24.7, 22.6, 14.15, 
14.13; 31P NMR (121 MHz) δ 25.4; IR (CHCl3) 3580, 3018, 1734, 1216 cm-1; mass 
spectrum (CI) m/z 510.2828 [C23H45NO9P (M+1) requires 510.2832] (base), 480, 462, 
433, 419 (base). 
NMR assignments. 1H NMR (300 MHz) δ 5.10-5.00 (br, m, 1 H, C2-H), 4.22 (d, 
J = 10 Hz, 1 H, C1-H), 3.90 (dd, J = 11.7, 7.4 Hz, 1 H, C1-H), 3.85-3.75 (br, s, 2 H, C5-
H), 3.30-3.05 (br, comp, 2 H, C6-H), 2.25-2.17 (comp, 4 H, C8-H, C14-H), 1.78-1.62 (br, 
s, 2 H, C4-H), 1.60-1.42 (comp, 6 H, C9-H & C15-H & C3-H), 1.36 (s, 9 H, C21-H), 
1.30-1.18 (comp, 8 H, C10-H & C11-H & C16-H & C17-H), 0.86-0.78 (comp, 6 H, C12-
H & C-18 H); 13C NMR (75 MHz) δ 173.8 (C7 & C13), 156.8 (C19), 79.4 (C20), 72.1 
(d, J = 15.3 Hz, C2), 65.0 (C1), 63.9 (C5), 41.7 (C6), 34.5 (C8), 34.2(C14), 31.5 (C21), 
30.5 (C9 & C15), 28.6(C3), 25.2 (C3), 24.9 (C10), 24.7 (C16), 22.6(C11 & C17), 14.15 





























Ethanolamine 3-(S)-Bis(n-hexanoyloxy)butyl]phosphonate (3.53c). N-Boc 
protected PE 3.52c (26 mg, 0.051 mmol) was dissolved in dry CH2Cl2 (5 mL) containing 
TFA (0.5 mL), and the solution was stirred at rt for 35 min, cyclohexane (9 mL) was 
added to the pink solution, solvent was removed under reduced pressure and the residue 
was purified by chromatography eluting with CHCl3/MeOH (2:3) to yield 11 mg (55%) 
of 3.53c as a glass:1H NMR (300 MHz) δ 7.20-5.20 (br, s, 3 H), 5.11-5.00 (m, 1 H), 4.20 
(dd, J = 11.8, 2.8 Hz, 1 H), 4.06-3.90 (comp, 3 H), 2.98 (s, 2 H), 2.26-2.19 (comp, 4 H), 
1.77-1.69 (m, 2 H), 1.60-1.48 (comp, 6 H), 1.23 (comp, 8 H), 0.85-0.80 (m, 6 H); 13C 
NMR (75 MHz) δ 173.5, 173.4, 71.5 (d, J = 14.8 Hz), 64.6, 61.3, 40.5, 34.3, 34.0, 31.2, 
25.3, 24.6, 24.5, 22.4 (d, J = 138 Hz), 22.3, 13.9; 31P NMR (121 MHz) δ 27.2; mass 
spectrum (CI) m/z 410.2310 [C18H37NO7P (M+1) requires 410.2308] (base), 392, 294 
251, 170. 
NMR assignments. 1H NMR (300 MHz) δ 7.20-6.20 (br, s, 3 H, N-H), 5.11-5.00 
(m, 1 H, C2-H), 4.20 (dd, J = 11.8, 2.8 Hz, 1 H, C1-H), 4.06-3.90 (comp, 3 H, C1-H & 
C-5 H), 2.98 (s, 2 H, C6-H), 2.26-2.19 (comp, 4 H, C8-H, C14-H), 1.77-1.69 (m, 2 H, 
C4-H), 1.60-1.48 (comp, 6 H, C9-H & C15-H & C3-H), 1.23 (comp, 8 H, C10-H & C11-
H & C16-H & C17-H), 0.85-0.80 (m, 6 H, C12-H & C-18 H); 13C NMR (75 MHz) δ 
173.5 (C7), 173.4 (C13), 71.5 (d, J = 14.8 Hz, C2), 64.6 (C1), 61.3 (C5), 40.5 (C6), 34.3 
(C8), 34.0 (C14), 31.2 (C9 & C15), 25.3 (C3), 24.6(C10), 24.5 (C16), 22.4 (d, J = 138 






































3(S), 4-Dihexanoyloxybutyl (N-tert-butoxycarbonyl L-serine t-butyl ester) 1-
phosphonate (3.47). Trichloroacetonitrile (1.62 mL, 16.2 mmol) was added to a solution 
of phosphonic acid 1.68c (136 mg, 0.372 mmol) and N-Boc-Ser-O-tBu (292 mg, 1.16 
mmol) in dry pyridine (10 mL) at 60 °C, The reaction mixture was stirred at 60-70 °C 
(bath temperature) for 22 h. The pyridine was removed by distillation under vacuum. The 
dark orange residue was dissolved in CH2Cl2 (5 mL) and treated with activated carbon. 
The mixture was filtered through celite, concentrated, and the residue was purified by 
flash chromatography, eluting with CHCl3/MeOH (4:1) to yield 173 mg (76%) of 3.47as 
a yellow glass:1H NMR (250 MHz) δ 5.15-5.02 (br s, 1 H), 4.35-3.90 (comp, 6 H), 2.27-
2.20 (comp, 4 H), 1.85-1.68 (br s, 2 H), 1.68-1.45 (comp, 6 H), 1.45-1.18 (comp, 26 H), 
0.87-0.81 (comp, 6 H); 13C NMR (75 MHz) δ 173.4, 155.9, 82,4, 78.6, 71.9, 64.8, 56.4, 
55.1, 34.3, 34.0, 31.2, 28.4, 28.2, 28.0, 24.9, 24.6, 24.4, 22.3(d, J = 155.6 Hz), 13.9; 31P 
NMR (121 MHz) 25.8; mass spectrum (CI) m/z 610.3356 [C28H53NO11P (M+1) requires 
610.3356], 419, 262, 244 (base).  
NMR assignments. 1H NMR (250 MHz) δ 5.15-5.02 (br s, 1 H, C2-H), 4.35-3.90 
(comp, 6 H, C1-H & C11-H & C12-H & NH), 2.27-2.20 (comp, 4 H, C6-H & C6’-H), 
1.85-1.68 (br s, 2 H, C3-H), 1.68-1.45 (comp, 6 H, C4-H & C7-H & C7’-H), 1.45-1.18 
(comp, 26 H, C15-H & C18-H & C8-H & C8-H & C9-H & C9’-H), 0.87-0.81 (comp, 6 
H, C10-H & C10-H); 13C NMR (75 MHz) δ 173.4 (C5 & C5’), 155.9 (C13), 82.4 (C17), 
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78.6 (C14), 71.9 (C2), 64.8 (C1), 56.4 (C11), 55.1 (C12), 34.3 (C6’), 34.0 (C6), 31.2 
(C18), 28.4 (C7’), 28.2 (C7), 28.0 (C15), 24.9 (C3), 24.6 (C8 & C8’), 24.4 (C9 & C9’), 






























3(S), 4-Dihexanoyloxybutyl-1-phosphonyl L-serine (3.48). Protected PS 3.47 
(96 mg, 0.16 mmol) was dissolved in dry CH2Cl2 (4.0 mL) containing TFA (4.0 mL) at 0 
°C, and the solution was stirred at rt for 4.5 h. The solvent was removed under reduced 
pressure, and the residue was purified by chromatography eluting with CHCl3/MeOH 
(from 3:1 to 4:7) to yield 63 mg (88%) of 3.48 as a glass:1H NMR (300 MHz, 
CD3OD/TFA-d) δ 5.14-5.05 (m, 1 H), 4.40-4.32 (comp, 4 H), 4.03 (dd, J = 11.8, 6.4 Hz, 
1 H), 2.36-2.26 (comp, 4 H), 1.94-1.52 (comp, 8 H), 1.40-1.24 (comp, 8 H), 0.97-0.85 
(comp, 6 H); 13C NMR (75 MHz, CD3OD/TFA-d) δ 175.03, 174.97, 169.2, 72.9 (d, J = 
17.5 Hz), 65.5, 63.2 (d, J = 6.0 Hz), 54.6 (d, J = 4.9 Hz), 35.1, 34.9, 32.4, 25.7, 25.6, 25.5 
(d, J = 0.5 Hz), 23.4, 23.1 (d, J = 139.3), 14.3; 31P NMR (121 MHz) δ 35.1; mass 
spectrum (CI-) m/z 452.2039 [C19H35NO9P (M-1) requires 452.2049] (base), 365, 305.  
NMR assignments. 1H NMR (300 MHz, CD3OD/TFA-d) δ 5.14-5.05 (m, 1 H, 
C2-H), 4.40-4.32 (comp, 4 H, C1-H & C12-H & C11-H), 4.03 (dd, J = 11.8, 6.4 Hz, 1 H. 
C1-H), 2.36-2.26 (comp, 4 H, C6-H & C6’-H), 1.94-1.52 (comp, 8 H, C3-H & C4-H & 
C7-H & C7’-H), 1.40-1.24 (comp, 8 H, C8-H & C8’-H & C9-H & C9’-H), 0.97-0.85 
(comp, 6 H, C10-H & C10’-H); 13C NMR (75 MHz, CD3OD/TFA-d) δ 175.03 (C5’), 
174.97 (C5), 169.2 (C13), 72.9 (d, J = 17.5 Hz, C2), 65.5 (C1), 63.2 (d, J = 6.0 Hz, C11), 
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54.6 (d, J = 4.9 Hz, C12), 35.1 (C6’), 34.9 (C6), 32.4 (C7 & C7’), 25.7 (C8’), 25.6 (C8), 


























Diethyl 3(S),4-dibutyroyloxybutyl-1-phosphonate (3.51a). To a mixture of 
butyric acid (254 mg, 2.90 mmol), diol 3.50 (297 mg, 1.31 mmol) and DMAP (36 mg, 
0.29 mmol) in CH2Cl2 (5 mL) at 0 °C, was added DCC (619 mg, 3.0 mmol) in CH2Cl2 
(3.5 mL). The mixture was stirred at rt overnight. The insoluble solid was removed by 
filtration and washed with CH2Cl2. The combined filtrate and wash were concentrated 
under reduced pressure. The residue was redissolved in ether and filtered. The filtrate was 
concentrated under reduced pressure and the residue was purified by chromatography 
eluting with EtOAc/hexanes (from 1:1 to 4:1) to yield 267 mg (56%) of 3.50 as a clear 
liquid: 1H NMR (250 MHz) δ 4.98-4.89 (m, 1 H), 4.09 (dd, J =11.9, 3.8 Hz, 1 H), 4.01-
3.83 (comp, 5 H), 2.13 (t, J = 7.3 Hz, 2 H), 2.12 (t, J = 7.3 Hz, 2 H), 1.80-1.40 (comp, 8 
H), 1.16 (t, J = 7.1 Hz, 6 H), 0.78 (t, J = 7.4 Hz, 3 H), 0.77 (t, J = 7.4 Hz, 3 H); 13C NMR 
(62 MHz) δ 172.9, 172.7, 70.6 (d, J = 18.2 Hz), 64.0, 61.4 (d , J = 6.5 Hz), 35.9, 35.7, 
23.9 (d, J = 4.1 Hz), 21.4 (d, J = 143.6 Hz), 18.2, 18.1, 16.2, 16.1, 13.4; 31P NMR (121 
MHz) δ 31.9; IR (neat) 2967, 1758 cm-1; mass spectrum (CI) m/z 367.1876 
[C16H32NO7P (M+1) requires 367.1886] (base), 297, 279. 
NMR assignments. 1H NMR (250 MHz) δ 4.98-4.89 (m, 1 H, C2-H), 4.09 (dd, J 
= 11.9, 3.8 Hz, 1 H, C1-H), 4.01-3.83 (comp, 5 H, C1-H & C9-H), 2.13 (t, J = 7.3 Hz, 2 
H, C6’-H), 2.12 (t, J = 7.3 Hz, 2 H, C6-H), 1.80-1.40 (comp, 8 H, C3-H & C4-H & C7-H 
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& C7’-H), 1.16 (t, J = 7.1 Hz, 6 H, C10-H), 0.78 (t, J = 7.4 Hz, 3 H, C8’-H), 0.77 (t, J = 
7.4 Hz, 3 H, C8-H); 13C NMR (62 MHz) δ 172.9 (C5’), 172.7 (C5), 70.6 (d, J = 18.2 Hz, 
C2), 64.0 (C1), 61.4 (d, J = 6.5 Hz, C9), 35.9 (C6’), 35.7 (C6), 23.9 (d, J = 4.1 Hz, C3), 





























Diethyl 3(S),4-divaleroxyloxybutyl-1-phosphonate (3.51b). By applying the 
same method to make 3.51a, diester 3.51b was prepared (80%) as a pale yellow liquid: 
1H NMR (300 MHz) δ 5.09-5.01 (m, 1 H), 4.20 (dd, J = 11.8, 3.8 Hz, 1 H), 4.12-3.98 
(comp, 4 H), 3.99 (dd, J = 11.8, 5.9 Hz, 1 H), 2.29-2.23 (comp, 4 H), 1.92-1.63 (comp, 4 
H), 1.63-1.49 (comp, 4 H), 1.38-1.17 (comp, 10 H), 0.87 (t, J = 7.2 Hz, 3 H), 0.86 (t, J = 
7.2 Hz, 3 H); 13C NMR (75 MHz) δ 173.4, 173.2, 70.9 (d, J = 18 Hz), 64.3, 61.8 (d, J = 
6.6 Hz), 60.4, 34.1, 34.9, 27.1, 27.0, 24.2 (d, J = 4.4 Hz), 21.8 (d, J = 142.6 Hz), 22.3, 
16.6 (d, J = 6.0 Hz), 13.8; 31P NMR (121 MHz) δ 31.8.  
NMR assignments. 1H NMR (300 MHz) δ 5.09-5.01 (m, 1 H, C2-H), 4.20 (dd, J 
= 11.8, 3.8 Hz, 1 H, C1-H), 4.12-3.98 (comp, 4 H, C10-H), 3.99 (dd, J = 11.8, 5.9 Hz, 1 
H, C1-H), 2.29-2.23 (comp, 4 H, C6-H & C6’-H), 1.92-1.63 (comp, 4 H, C3-H & C4-H), 
1.63-1.49 (comp, 4 H, C7-H & C7’-H), 1.38-1.17 (comp, 10 H, C11-H & C8-H & C8’-
H), 0.87 (t, J = 7.2 Hz, 3 H, C9’-H), 0.86 (t, J = 7.2 Hz, 3 H, C9-H); 13C NMR (75 MHz) 
δ 173.4 (C5’), 173.2 (C5), 70.9 (d, J = 18 Hz, C2), 64.3 (C1), 61.8 (d, J = 6.6 Hz, C10), 
34.1 (C6’), 34.9 (C6), 27.1 (C7’), 27.0 (C7), 24.2 (d, J = 4.4 Hz, C3), 22.3 (C8 & C8’), 
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21.8 (d, J = 142.6 Hz, C4), 16.6 (d, J = 6.0 Hz, C11), 13.8 (C9 & C9’); 31P NMR (121 

































(3.52a). To a solution of 3.51a (208 mg, 0.57 mmol) in dry CH2Cl2 (1 mL), was added 
bromotrimethylsilane (195 µL, 1.48 mmol) at rt over 30 min. The solution was stirred for 
6 h at rt. The solvent was removed under reduced pressure, and THF/H2O (1 mL, 1:9) 
was added. The mixture was heated at reflux for 1 h. Solvent was removed under reduced 
pressure, and the residual oil was dissolved in CHCl3 (5 mL), dried (Na2SO4), filtered 
and evaporated to yield 160 mg of phosphonic acid as pale yellow liquid. 
 By applying the same method to make 3.52c, 3.52a was prepared from 
phosphonic acid (43%) as a yellow glass:1H NMR (300 MHz) δ 6.1-5.7 (br s, 1 H), 5.20-
5.00 (br, s, 1 H), 4.30 (d, J = 10.8 Hz, 1 H), 4.03-3.97 (m, 1 H), 3.86 (s, 2 H), 3.40-3.10 
(br s, 2 H), 2.32-2.22 (m, 4 H), 1.88-1.72 (br s, 2 H), 1.68-1.56 (comp, 6 H), 1.43 (s, 9 
H), 0.94 (t, J = 7.4 Hz, 3 H), 0.93 (t, J = 7.3 Hz, 3 H); 13C NMR (75 MHz) δ 173.6, 
156.8, 79.4, 72.1 (d, J = 15.8 Hz), 65.0, 63.9, 41.7, 36.5, 36.2, 28.7, 25.2, 22.4 (d, J= 
136.5 Hz), 18.6, 18.5, 13.9; 31P NMR (121 MHz) δ 25.1 (br); mass spectrum (CI) m/z 
454.2216 [C19H37NO9P (M+1) requires 454.2206] (base), 398, 354, 310, 282.  
NMR assignments. 1H NMR (300 MHz) δ 6.1-5.7 (br s, 1 H, NH), 5.20-5.00 (br, 
s, 1 H, C2-H), 4.30 (d, J = 10.8 Hz, 1 H, C1-H), 4.03-3.97 (m, 1 H, C1-H), 3.86 (s, 2 H, 
C9-H), 3.40-3.10 (br s, 2 H, C10-H), 2.32-2.22 (m, 4 H, C6-H & C6’-H), 1.88-1.72 (br s, 
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2 H, C3-H), 1.68-1.56 (comp, 6 H, C4-H & C7-H & C7’-H), 1.43 (s, 9 H, C13-H), 0.94 
(t, J = 7.4 Hz, 3 H, C8’-H), 0.93 (t, J = 7.3 Hz, 3 H, C8-H); 13C NMR (75 MHz) δ 173.6 
(C5 & C5’), 156.8 (C11), 79.4 (C12), 72.1 (d, J = 15.8 Hz, C2), 65.0 (C1), 63.9 (C9), 
41.7 (C10), 36.5 (C6’), 36.2 (C6), 28.7 (C13), 25.2 (C3), 22.4 (d, J= 136.5 Hz, C4), 18.6 



































phosphonylethanolamine (3.52b). By applying the same method to make 3.52c, 3.52b 
was prepared from 3.51b (19% after two steps) as a yellow glass:1H NMR (250 MHz) δ 
6.0-5.8 (br s, 1 H), 5.18-5.00 (m, 1 H), 4.30-4.16 (m, 1 H), 3.95 (dd, J = 11.8, 7.4 Hz, 1 
H), 3.85-3.7 (br s, 2 H), 3.4-3.1 (br s, 2 H), 2.28-2.20 (comp, 4 H), 1.85-1.65 (br, s, 2 H), 
1.65-1.45 (comp, 6 H), 1.38 (s, 9 H), 1.35-1.19 (comp, 4 H), 0.86 (t, J = 7.3 Hz, 3 H), 
0.85 (t, J = 7.2 Hz, 3 H); 13C NMR (62 MHz) δ 173.8, 156.8, 79.4, 72.1 (d, J = 15.2 Hz), 
65.0, 64.1, 41.7, 34.3, 34.0, 28.7, 27.2, 27.1, 25.2, 22.3 (d, J = 140.4 Hz), 22.4, 13.9; 31P 
NMR (121 MHz) δ 25.8; mass spectrum (CI) m/z 482.2524 [C21H41NO9P (M+1) 
requires 482.2519], 442, 351 (base), 324, 280.  
NMR assignments. 1H NMR (250 MHz) δ 6.0-5.8 (br s, 1 H, N-H), 5.18-5.00 
(m, 1 H, C2-H), 4.30-4.16 (m, 1 H, C1-H), 3.95 (dd, J = 11.8, 7.4 Hz, 1 H, C1-H), 3.85-
3.7 (br, s, 2 H, C10-H), 3.4-3.1 (br s, 2 H, C11-H), 2.28-2.20 (comp, 4 H, C6-H & C6’-
H), 1.85-1.65 (br, s, 2 H, C3-H), 1.65-1.45 (comp, 6 H, C4-H & C7-H & C7’-H), 1.38 (s, 
9 H, C14-H), 1.35-1.19 (comp, 4 H), 0.86 (t, J = 7.3 Hz, 3 H, C9’-H), 0.85 (t, J = 7.2 Hz, 
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3 H, C9-H); 13C NMR (62 MHz) δ 173.8 (C5 & C5’), 156.8 (C12), 79.4 (C13), 72.1 (d, J 
= 15.2 Hz, C2), 65.0 (C1), 64.1 (C10), 41.7 (C11), 34.3 (C6’), 34.0 (C6), 28.7 (C14), 



























3(S),4-Dibutyroyloxybutyl-1-phosphonylethanolamine (3.53a). N-Boc 
protected PE 3.52a (46 mg, 0.10 mmol) was dissolved in dry CH2Cl2 (4.5 mL) 
containing TFA (0.45 mL) at 0 °C, and the solution was stirred at rt for 45 min. The 
solvent was removed under reduced pressure, and the residue was purified by 
chromatography eluting with CHCl3/MeOH (from 3:1 to 2:3) to yield 28 mg (78%) of 
3.53a as a glass:1H NMR (300 MHz) δ 8.80-8.40 (br s, 3 H), 5.20-5.15 (m, 1 H), 4.28 
(dd, J = 11.8, 2.8 Hz, 1 H), 4.20-4.00 (br s, 2 H), 4.03 (dd, J = 11.8, 6.8 Hz, 1 H), 3.20-
3.06 (br s, 2 H), 2.33-2.26 (comp, 4 H), 1.90-1.72 (comp, 2 H), 1.72-1.54 (comp, 6 H), 
0.96 (t, J = 7.4 Hz, 3 H), 0.95 (t, J = 7.4 Hz, 3 H); 13C NMR (75 MHz) δ 173.6, 173.5, 
71.6 (d, J = 16.4 Hz), 64.8, 61.6, 40.7, 36.5, 36.2, 25.2, 22.3 (d, J = 137.1 Hz), 18.7, 18.5, 
13.9; 31P NMR (121 MHz) δ 27.4; mass spectrum (CI) m/z 354.1682 [C14H29NO7P 
(M+1) requires 354.1683] (base), 337, 367, 209.  
NMR assignments. 1H NMR (300 MHz) δ 8.80-8.40 (br s, 3 H, NH), 5.20-5.15 
(m, 1 H, C2-H), 4.28 (dd, J = 11.8, 2.8 Hz, 1 H, C1-H), 4.20-4.00 (br s, 2 H, C9-H), 4.03 
(dd, J = 11.8, 6.8 Hz, 1 H, C1-H), 3.20-3.06 (br s, 2 H, C10-H), 2.33-2.26 (comp, 4 H, 
C6-H & C6’-H), 1.90-1.72 (comp, 2 H, C3-H), 1.72-1.54 (comp, 6 H, C4-H & C7-H & 
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C7’-H), 0.96 (t, J = 7.4 Hz, 3 H, C8’-H), 0.95 (t, J = 7.4 Hz, 3 H, C8-H); 13C NMR (75 
MHz) δ 173.6 (C5’), 173.5 (C5), 71.6 (d, J = 16.4 Hz, C2), 64.8 (C1), 61.6 (C9), 40.7 
(C10), 36.5 (C6’), 36.2 (C6), 25.2 (C3), 22.3 (d, J = 137.1 Hz, C4), 18.7 (C7’), 18.5 (C7), 




























3(S),4-divaleroxyloxybutyl-1-phosphonylethanolamine (3.53b). By applying 
the same method to make 3.53a, PE 3.53b was prepared from 3.52b (74%) as glass:1H 
NMR (300 MHz) δ 8.90-8.50 (br s, 3 H), 5.20-5.12 (m, 1 H), 4.27 (dd, J = 11.8, 6.9 Hz, 1 
H), 4.14-3.94 (comp, 3 H), 3.18-3.04 (br s, 2 H), 2.32 (t, J = 7.5 Hz, 2 H), 2.30 (t, J = 7.4 
Hz, 2 H), 1.90-1.74 (comp, 2 H), 1.70-1.50 (comp, 6 H), 1.42-1.26 (comp, 4 H), 0.93 (t, J 
= 7.4 Hz), 0.92 (t, J =7.2 Hz); 13C NMR (75 MHz) δ 173.8, 173.7, 71.7 (d, J = 15.3 Hz), 
64.9, 61.3, 40.6, 34.3, 34.0, 27.3, 27.1, 25.4 (d, J = 3.8 Hz), 22.4, 22.4 (d, J = 136.6 Hz), 
14.0, 13.9; 31P NMR (121 MHz) δ 27.3; mass spectrum (CI) m/z 382.2002 
[C16H33NO7P (M+1) requires 382.1994] (base), 364.  
NMR assignments. 1H NMR (300 MHz) δ 8.90-8.50 (br s, 3 H, NH), 5.20-5.12 
(m, 1 H, C2-H), 4.27 (dd, J = 11.8, 6.9 Hz, 1 H, C1-H), 4.14-3.94 (comp, 3 H, C1-H & 
C10-H), 3.18-3.04 (br s, 2 H, C11-H), 2.32 (t, J = 7.5 Hz, 2 H, C6’-H), 2.30 (t, J = 7.4 
Hz, 2 H, C6-H), 1.90-1.74 (comp, 2 H, C3-H), 1.70-1.50 (comp, 6 H, C4-H & C7-H & 
C7’-H), 1.42-1.26 (comp, 4 H, C8-H & C8’-H), 0.93 (t, J = 7.4 Hz, C9’-H), 0.92 (t, J 
=7.2 Hz, C9-H); 13C NMR (75 MHz) δ 173.8 (C5’), 173.7 (C5), 71.7 (d, J = 15.3 Hz, 
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C2), 64.9 (C1), 61.3 (C10), 40.6 (C11), 34.3 (C6’), 34.0 (C6), 27.3 (C7’), 27.1 (C7), 25.4 






3-Chloro-5-(hydroxymethyl)phenol (4.27). (2-189). Methyl ester 4.26 (180 mg, 
0.97 mmol) was suspended in H2O/dioxane (5 mL, 4:1), and solid NaBH4 (280 mg, 7.4 
mmol) was added. The solution was stirred at rt overnight. The mixture was cooled to 0 
°C and 2 N HCl (7 mL) was added. The aqueous mixture was extracted with EtOAc (3 x 
15 mL). The combined organic phases were dried (Na2SO4), and concentrated under 
reduced pressure. The residue was purified by chromatography eluting with 
EtOAc/hexanes (1:1) to yield 125 mg (81%) of 4.27 as a clear liquid: 1H NMR δ (250 
MHz, acetone-d6) δ 9.00-8.50 (br s, 1 H), 6.87-6.83 (m, 1 H), 6.81-6.77 (m, 1 H), 6.75-
6.71 (m, 1 H), 4.56 (s, 3 H); 13C NMR δ (62 MHz, acetone-d6) δ 159.0, 146.5, 134.7, 
118.2, 114.6, 112.7, 63.8; mass spectrum (CI) m/z 159.0220 [C7H8O2Cl (M+1) requires 























chlorobenzene (4.28). (2-199). A solution of TBSCl (130 mg, 0.84 mmol) in CH2Cl2 (2 
mL) was added dropwise to a solution of phenol 4.27 (60 mg, 0.38 mmol) and DBU (139 
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mg, 0.91 mmol) in dry CH2Cl2 (3 mL) at 0 °C. The solution was stirred at rt for 90 min, 
and then poured into a mixture of cold H2O (10 mL) and CH2Cl2 (5 mL). The organic 
layer was separated and washed with 0.1 N HCl (10 mL), saturated NaHCO3 (10 mL), 
and dried (Na2SO4). The solvent was removed under reduced pressure to yield 129 mg 
(88%) of 4.28 as a clear liquid: 1H NMR (250 MHz) δ 6.85-6.82 (m, 1 H), 6.71-6.67 
(comp, 2 H), 4.64 (s, 2 H), 0.97 (s, 9 H), 0.94 (s, 9 H), 0.19 (s, 6 H), 0.09 (s, 6 H); 13C 
NMR (75 MHz) δ 156.2, 144.3, 134.1, 118.8 (2 C), 115.7, 64.0, 25.7, 25.5, 18.2, 18.0, -
4.6, -5.5; IR (neat) 2956, 2867, 1598, 1577, 1449 cm-1; mass spectrum (CI) m/z 
1387.1940 [C19H36O2SiCl (M+1) requires 387.1942], 371, 244 (base). 
NMR assignments. 1H NMR (250 MHz) δ 6.85-6.82 (m, 1 H, C4-H), 6.71-6.67 
(comp, 2 H, C2-H & C6-H), 4.64 (s, 2 H, C7-H), 0.97 (s, 9 H, C13-H), 0.94 (s, 9 H, C10-


















3-tert-Butyldimethylsilanyloxymethyl-5-chlorophenol (4.29). (2-263). A 
solution of 4.28 (1.11 g, 2.87 mmol) in THF (36 mL) containing 1 N TBAF in THF (2.87 
mL, 2.87 mmol) was stirred for 10 min at 0 °C. Saturated NH4Cl (30 mL) was added and 
the mixture extracted with Et2O (3 x 30 mL). The combined organic phases were dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with EtOAc/hexanes (1:5) to yield 711 mg (91%) of 4.29 as a 
clear oil: 1H NMR (250 MHz) δ 6.84-6.80 (m, 1 H), 6.70-6.64 (comp, 2 H), 5.07 (s, 1 H), 
4.63 (s, 2 H), 0.92 (s, 9 H), 0.09 (s, 6 H); 13C NMR (75 MHz) δ 156.2, 144.8, 134.7, 
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118.5, 114.3, 111.3, 64.1, 25.9, 18.4, -5.3; IR (neat) 3346 (br), 2951, 1695, 1583, 1461, 
1447 cm-1; mass spectrum (CI) m/z 273.1085 [C13H22O2SiCl (M+1) requires 273.1078] 
(base), 257, 215, 141. 
NMR assignments. 1H NMR (250 MHz) δ 6.84-6.80 (m, 1 H, C4-H), 6.70-6.64 
(comp, 2 H, C2-H & C6-H), 5.07 (s, 1 H, OH), 4.63 (s, 2 H, C7-H), 0.92 (s, 9 H, C10-H), 
0.09 (s, 6 H, C8-H); 13C NMR (75 MHz) δ 156.2 (C1), 144.8 (C5), 134.7 (C3), 118.5 


























chlorofuran-2-yl)-tetrahydro-2H-pyran (4.33). (2-240). n-BuLi in pentane (2.1 M, 1.26 
mL, 2.64 mmol) was added to a solution of i-Pr2NH (370 µL, 2.64 mmol) in THF (3 mL) 
at –10 °C (ice/MeOH bath). The solution was stirred at –10 °C for 25 min and cooled to -
78°C, whereupon 3-chlorofuran (246 mg, 2.40 mmol) was added. The solution was 
stirred at –78 °C for 3.5 h. A solution of glucolactone 4.31 (1.185 g, 2.20 mmol) in THF 
(6 mL) was added and stirring continued for 2.5 h at –78 °C and then 3 h at rt. The 
mixture was poured into H2O (10 mL). The resulting mixture was extracted with ether (2 
x 25 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated 
under reduced pressure. The crude material thus obtained was used in the next step 
without furthur purification: 1H NMR (300 MHz) δ 7.41-7.08 (comp, 21 H), 6.41 (d, J = 
1.8 Hz, 1 H), 4.98-4.85 (comp, 3 H), 4.76-4.48 (comp, 5 H), 4.26-3.54 (comp, 8 H); IR 
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(neat) 3002, 2864, 1726, 1495, 1452 cm-1; mass spectrum (CI) m/z 
641.2295[C38H38O7Cl (M+1) requires 625.2306], 623 (base), 533. 
The residue was dissolved in CH2Cl2 (40 mL) and cooled to –40 °C 
(dichloroethane/dry ice). Triethylsilane (1.15 mL, 7.20 mmol) and then TMSOTf (434 
µL, 2.40 mmol) were added slowly, and the mixture was stirred at –40 °C for 10 min. 
Saturated NaHCO3 (20 mL) was added and the mixture was extracted with ether (2 x 20 
mL). The combined organic layers were dried (Na2SO4) and filtered, and the filtrate was 
concentrated under reduced pressure. The residue was purified by chromatography 
eluting with EtOAc/hexanes (1:4) to yield 1.037 g (76% after two steps) of 4.33 as a light 
yellow solid: mp 68.5-72 °C; 1H NMR (300 MHz) δ 7.44-7.03 (comp, 21 H), 6.46 (d, J = 
1.8 Hz, 6.44 H), 4.98-4.84 (comp, 3 H), 4.68-4.46 (comp, 5 H), 4.10 (d, J = 10.2 Hz, 1 
H), 4.02-3.92 (m, 1 H), 3.86-3.68 (comp, 4 H), 3.66-3.56 (m, 1 H); 13C NMR (62 MHz) 
δ 146.2, 142.1, 138.6, 138.1, 138.0, 137.7, 128.4, 128.3, 128.1, 128.06, 127.97, 127.9, 
127.7, 127.62, 127.57, 127.5, 115.9, 112.4, 86.6, 80.2, 79.5, 77.9, 75.7, 75.1, 74.7, 73.5, 
71.9, 68.9; mass spectrum (CI) m/z 625.2339 [C38H38O6Cl (M+1) requires 625.2357], 
533, 433, 391 (base). 
NMR assignments. 1H NMR (300 MHz) δ 7.44-7.03 (comp, 21 H, aromatic H & 
C14-H), 6.46 (d, J = 1.8 Hz, 1 H, C13-H), 4.98-4.84 (comp, 3 H, benzylic H), 4.68-4.46 
(comp, 5 H, benzylic H), 4.10 (d, J = 10.5 Hz, 1 H, C1-H), 4.02-3.92 (m, 1 H, C2-H), 
























(3-chloro-5-trityloxybenzyloxy)(tert-butyl)dimethylsilane (4.41). (2-248, 2-
249, 2-251). Trityl bromide (729 mg, 2.26 mmol) in CH2Cl2 (5 mL) was added dropwise 
to a solution of 4.26 (383 mg, 2.05 mmol), Et3N (430 µL, 3.08 mmol) and DMAP (26 
mg, 0.21 mmol) in CH2Cl2 (5 mL) at 0 °C. The solution was stirred at 0 °C for 10 min 
and then at rt for 3 h. The mixture was poured into H2O (10 mL) and the resulting 
mixture was extracted with CH2Cl2 (2 x 20 mL). The solvent was removed under 
reduced pressure to yield 872 mg (99%) of 4.40 as a clear liquid.  
Methyl ester 4.40 (872 mg, 2.04 mmol) thus obtained in Et2O (10 mL) was added 
to a suspension of LiAlH4 (155 mg, 4.08 mmol) in Et2O (10 mL). The mixture was 
stirred at 0 °C for 5 min and then at rt for 1 h. The reaction was quenched by addition of 
EtOAc (1 mL), and the mixture was stirred for 20 min. Saturated NH4Cl (10 mL) was 
added. The solid was removed by vacuum filtration and washed with ether. The mixture 
was separated and the aqueous phase was extracted with Et2O (3 x 20 mL). The 
combined organic phases were dried (Na2SO4), filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography eluting with hexanes/EtOAc 
(3:1) to yield 660 mg (81%) of benzylic alcohol as a white foam: 1H NMR (250 MHz) δ 
7.50-7.41 (comp, 6 H), 7.31-7.17 (comp, 9 H), 6.79-6.76 (m, 1 H), 6.68-6.64 (m, 1 H), 
6.60-6.56 (m, 1 H), 4.31 (s, 2 H), 2.10-1.95 (br s, 1 H); 13C NMR (62 MHz) δ 157.0, 
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143.5, 142.5, 133.6, 128.7, 127.8, 127.3, 120.1, 119.7, 117.4, 91.0, 64.1; mass spectrum 
(CI) m/z 401.1305 [C26H22O2Cl (M+1) requires 401.1308], 383 (base). 
By applying the same method to make 4.28, 4.41 was prepared (94%) as a white 
solid from benzylic alcohol obtained above (634 mg, 1.59 mmol), DBU (320 mg, 2.10 
mmol) and TBSCl (288 mg, 1.91 mmol) in CH2Cl2 (10 mL): mp 69.5-71.5 °C: 1H NMR 
(250 MHz) δ 7.45-7.37 (comp, 6 H), 7.30-7.15 (comp, 9 H), 6.73-6.70 (m, 1 H), 6.60-
6.56 (m, 1 H), 6.53-6.48 (m, 1 H), 4.40 (s, 2 H), 0.84 (s, 9 H), -0.03 (s, 6 H); 13C NMR 
(62 MHz) δ 156.9, 143.7, 143.0, 133.4, 128.8, 127.8, 127.3, 119.7, 119.1, 116.7, 90.9, 
64.0, 25.9, 18.3, -5.4; IR (CHCl3) 1953, 2853, 1578, 1445 cm-1; mass spectrum (CI) m/z 
513.2013 [C32H334O2SiCl (M+1) requires 519.2017], 437, 383, 243 (base). 
NMR assignments. 1H NMR (250 MHz) δ 7.45-7.37 (comp, 6 H, C14-H), 7.30-
7.15 (comp, 9 H., C13-H & C15-H), 6.73-6.70 (m, 1 H, C4-H), 6.60-6.56 (m, 1 H, C2-































pyran-2-yl-4-chlorofuran-2-yl)(bromomethyl)dimethylsilane (4.42). (2-274). A 
solution of LDA in THF (0.48 M, 5.8 mL, 2.77 mmol) was added to 4.33 (1.019 g, 1.63 
mmol) in THF (12 mL) at –78 °C. The mixture was stirred at –78 °C for 2.5 h and then –
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38 °C for 4.5 h. The solution was cooled down to –78 °C and 
bromomethylchlorodimethylsilane (380 µL, 2.77 mmol) was then added dropwise, the 
mixture was then allowed to warm to rt and stirred overnight. The mixture was poured 
into NaHCO3 (1:1, 20 mL), and the resulting mixture was extracted with CH2Cl2 (3 x 20 
mL). The organic layers were combined, dried (Na2SO4)., filtered and concentrated 
under reduced pressure. The residue was purified by chromatography eluting with 
Et2O/hexanes (1:7) to yield 721 mg (56%, 71% brsm) of 4.42 as a clear liquid and 198 
mg of 4.33: 1H NMR (250 MHz) δ 7.34-7.12 (comp, 20 H), 6.71 (s, 1 H), 4.92-4.79 
(comp, 3 H), 4.65-4.40 (comp, 5 H), 4.03 (d, J = 10.4 Hz, 1 H), 4.04-3.92 (m, 1 H), 3.81-
3.68 (comp, 4 H), 3.62-3.50 (m, 1 H), 2.53 (s, 2 H), 0.37 (s, 3 H), 0.36 (s, 3 H); 13C NMR 
(62 MHz) δ 156.8, 150.9, 138.6, 138.2, 138.1, 137.8, 128.4, 128.3, 128.0, 127.82, 127.78, 
127.7, 127.62, 127.56, 123.3, 116.1, 86.6, 80.5, 79.6, 77.9, 75.7, 75.1, 74.8, 73.5, 72.2, 
68.8, 14.9, -4.37, -4.42; IR (neat) 3028, 2867, 1584, 1495, 1452 cm-1; mass spectrum 
(CI) m/z 774.1778 [C41H44O6SiClBr (M) requires 774.1779] 433, 391 (base). 
NMR assignments. 1H NMR (250 MHz) δ 7.34-7.12 (comp, 20 H, aromatic H), 
6.71 (s, 1 H, C13-H), 4.92-4.79 (comp, 3 H, benzylic H), 4.65-4.40 (comp, 5 H, benzylic 
H), 4.03 (d, J = 10.4 Hz, 1 H, C1-H), 4.04-3.92 (m, 1 H, C2-H), 3.81-3.68 (comp, 4 H, 
C3-H & C4-H & C6-H), 3.62-3.50 (m, 1 H, C5-H), 2.53 (s, 2 H, C16-H), 0.37 (s, 3 H, 






























pyran-2-yl-4-chlorofuran-2-yl)(iodomethyl)dimethylsilane (4.43). (2-275). A solution 
of 4.42 (279 mg, 0.36 mmol) and NaI (432 mg, 2.88 mmol) in acetone (12 mL) was 
heated under reflux overnight. The mixture was poured into H2O (20 mL), and the 
resulting mixture was extracted with Et2O (3 x 20 mL). The organic layers were 
combined, dried (Na2SO4). filtered and concentrated under reduced pressure. The residue 
was purified by chromatography eluting with Et2O/hexanes (1:7) to yield 284 mg (96%) 
of 4.43 as a clear liquid: 1H NMR (300 MHz) δ 7.44-7.04 (comp, 20 H), 6.78 (s, 1 H), 
5.02-4.84 (comp, 3 H), 4.78-4.52 (comp, 5 H), 4.13 (d, J = 10.5 Hz, 1 H), 4.10-4.04 (m, 1 
H), 3.90-3.76 (comp, 4 H), 3.74-3.60 (m, 1 H), 2.16 (s, 2 H), 0.46 (s, 3 H), 0.45 (s, 3 H); 
13C NMR (75 MHz) δ 157.3, 151.1, 138.9, 138.4, 138.1, 128.7, 128.6, 128.3, 128.14, 
128.06, 127.9, 123.4, 116.3, 86.9, 80.8, 79.9, 78.2, 76.0, 75.4, 75.1, 73.8, 72.5, 69.1, -3.0; 
IR (neat) 3026, 2863, 1495, 1452 cm-1; mass spectrum (CI) m/z 823.1731 
[C41H45O6SiClI (M+1) requires 823.1718] 733, 433, 391 (base). 
NMR assignments. 1H NMR (300 MHz) δ 7.44-7.04 (comp, 20 H, aromatic H), 
6.78 (s, 1 H, C13-H), 5.02-4.84 (comp, 3 H, benzylic H), 4.78-4.52 (comp, 5 H, benzylic 
H), 4.13 (d, J = 10.5 Hz, 1 H, C1-H), 4.10-4.04 (m, 1 H, C2-H), 3.90-3.76 (comp, 4 H, 
C3-H & C4-H & C6-H), 3.74-3.60 (m, 1 H, C5-H), 2.16 (s, 2 H, C16-H), 0.46 (s, C15-















(5-ethylfuran-2-yl)dimethylsilylmethanol (4.58). A 2.1 M solution of BuLi (3.8 
mL, 8.0 mmol) was added to 2-ethylfuran (700 mg, 7.29 mmol) in THF (17 mL) at –78 
°C. The mixture was stirred at –78 °C for 5 min and then at 0 °C for 1 h. The solution 
was cooled down to –78 °C and freshly distilled bromomethylchlorodimethylsilane (1 
mL, 7.3 mmol) was added dropwise, the mixture was then allowed to warm to rt and 
stirred for 3.5 h. The mixture was poured into NaHCO3 (1:1, 20 mL), and the resulting 
mixture was extracted with ether (3 x 25 mL). The organic layers were combined, dried 
(Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by 
chromatography eluting with hexanes to yield 1.335 g (74%) of bromide 4.57 as a clear 
liquid: 1H NMR (250 MHz) δ 6.62 (d, J = 3.1 Hz, 1 H), 5.98 (d, J = 3.1 Hz, 1 H), 2.66 (q, 
J = 7.5 Hz, 2 H), 2.60 (s, 2 H), 1.22 (t, J = 7.5 Hz, 3 H), 0.38 (s, 6 H); 13C NMR (62 
MHz) δ 163.1, 154.3, 122.3, 104.3, 21.5, 16.2, 12.1, -4.3. 
A solution of bromide 4.57 (500 mg, 2.02 mmol), KOAc (1.07 g, 11.0 mmol) and 
NaI (303 mg, 2.02 mmol) in DMF (10 mL) was heated at 70 °C for 4.5 h. The mixture 
was poured into H2O (30 mL), and the resulting mixture was extracted with ether (2 x 20 
mL). The combined organic layers was washed with brine (30 mL) and dried (Na2SO4), 
filtered and concentrated under reduced pressure. The residue was purified by 
chromatography eluting with Et2O/hexanes (1:6) to yield 407 mg (89%) of the acetate as 
a clear liquid: 1H NMR (250 MHz) δ 6.59 (d, J = 3.1 Hz, 1 H), 5.96 (d, J = 3.1 Hz, 1 H), 
3.91 (d, 3 H), 2.65 (q, J = 7.5 Hz, 2 H), 2.02 (s, 3 H), 1.21 (t, J = 7.5 Hz, 3 H), 0.30 (s, 6 
H); 13C NMR (62 MHz) δ 171.7, 163.0, 154.2, 122.1, 104.2, 56.3, 21.5, 20.7, 12.0, -4.7; 
IR (CHCl3) 2971, 1742 cm-1 
A solution of acetate (396 mg, 1.75 mmol) in ether (5 mL) was added to a slurry 
of LAH (210 mg, 5.27 mmol) in ether (20 mL) at 0 ºC. The mixture was stirred at 0 ºC 
for 10 min. EtOAc (2 mL) was added, stirring continued for another 5 min at 0 ºC, then a 
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solution of saturated NH4Cl added and stirring continued for another 5 min at rt. The 
mixture was filtered and the solids washed with ether and NH4Cl, The filtrated and the 
washes were separated and the aqueous layer was extracted with ether (3 x  25 mL). The 
organic layers were combined, dried (Na2SO4), filtered and concentrated under reduced 
pressure. The residue was purified by chromatography eluting with Et2O/hexanes (2:3) to 
yield 301 mg (95%) of 4.58 as a clear liquid: 1H NMR (300 MHz) δ 6.62 (d, J = 3.1 Hz, 
1 H), 5.98 (d, J = 3.1 Hz, 1 H), 3.53 (s, 2 H), 2.66 (q, J = 7.6 Hz, 2 H), 1.22 (t, J = 7.6 Hz, 
3 H), 1.30-1.10 (br s, 1 H), 0.30 (s, 6 H); 13C NMR (62 MHz) δ 163.3, 155.2, 122.5, 
104.5, 55.1, 21.8, 12.3, -4.9; mass spectrum (CI) m/z 185.0992 [C9H17O2Si (M+1) 
requires 185.0998], 151 (base). 
NMR assignments. 1H NMR (300 MHz) δ 6.62 (d, J = 3.1 Hz, 1 H, C5-H), 5.98 
(d, J = 3.1 Hz, 1 H, C4-H), 3.53 (s, 2 H, C8-H), 2.66 (q, J = 7.6 Hz, 2 H, C2-H), 1.22 (t, J 
= 7.6 Hz, 3 H, C1-H), 1.30-1.10 (br s, 1 H, O-H), 0.30 (s, 6 H, C7-H);13C NMR (62 



























silanyl)-5-ethylfuran (4.59). ADDP (100.3 mg, 0.398 mmol) was added to a solution of 
alcohol 4.58 (50 mg, 0.27 mmol), phenol 4.29 (75.5 mg, 0.277 mmol) and 
tributylphosphine (100 µL, 0.0405 mmol) in benzene (1 mL) at 0 °C. The mixture was 
stirred overnight and filtered through a short column, eluting with Et2O/hexane (1:10), 
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the fraction was collected, evaporated and repurified by chromatography eluting with 
Et2O/hexanes (1:100) to yield 87.2 mg (73%) of 4.59 as a clear liquid: 1H NMR (300 
MHz) δ 7.24 (m, 1 H), 6.85 (m, 1 H), 6.82 (m, 1 H), 6.64 (d, J = 2.8 Hz, 1 H), 5.98 (d, J 
= 3.3 Hz, 1 H), 4.64 (s, 2 H), 3.73 (s, 2 H), 2.67 (q, J = 7.4 Hz, 2 H), 1.22 (t, J = 7.4 Hz, 3 
H), 0.93 (s, 9 H), 0.37 (s, 6 H), 0.08 (s, 6 H); 13C NMR (62 MHz) δ 163.0, 162.1, 154.3, 
144.2, 134.5, 122.3, 118.0, 113.0, 110.3, 104.3, 64.4, 60.2, 25.9, 21.5, 18.4, 12.1, -4.8, -
5.3; mass spectrum (CI) m/z 438.1822 [C22H35O3Si2Cl (M) requires 438.1813] 343, 307 
(base), 211. 
NMR assignments. 1H NMR (300 MHz) δ 7.24 (m, 1 H), 6.85 (m, 1 H), 6.82 (m, 
1 H), 6.64 (d, J = 2.8 Hz, 1 H, C5-H), 5.98 (d, J = 3.3 Hz, 1 H, C4-H), 4.64 (s, 2 H, C15-
H), 3.73 (s, 2 H, C8-H), 2.67 (q, J = 7.4 Hz, 2 H, C2-H), 1.22 (t, J = 7.4 Hz, 3 H, C1-H), 
0.93 (s, 9 H, C18-H), 0.37 (s, 6 H, C7-H), 0.08 (s, 6 H, C16-H); 13C NMR (62 MHz) δ 
163.0 (C3), 162.1, 154.3 (C6), 144.2, 134.5, 122.3 (C5), 118.0, 113.0, 110.3, 104.3 (C4), 
























methyl 3-(5-ethylfuran-2-yl)dimethylsilylmethoxy-5-chlorobenzoate (4.60). 
(3-56). DIAD (22.2 mg, 1.1 mmol) was added to a solution of alcohol 4.58 (22 mg, 1.2 
mmol), phenol 4.26 (19 mg, 1.0 mmol) and triphenylphosphine (31.4 mg, 1.2 mmol) in 
toluene (0.5 mL). The mixture was stirred at rt for 2 h. the mixture was poured into H2O 
(5 mL) and extracted with ether (3 x 5 mL). The combined organic layers were dried 
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(Na2SO4), filtered, and concentrated under reduced pressure. The residue was purified by 
chromatography eluting first with Et2O/hexanes (1:100) then with Et2O/hexanes (1:20) to 
yield 26 mg (72%) of 4.60 as a clear liquid: 1H NMR (250 MHz) δ 7.55 (m, 1 H), 7.49 
(m, 1 H), 7.12 (app t. J = 2.0 Hz, 1 H), 6.64 (d, J = 3.1 Hz, 1 H), 5.98 (d, J = 3.1 Hz, 1 
H), 3.89 (s, 3 H), 3.78 (s, 2 H), 2.66 (q, J = 7.4 Hz, 2 H), 1.22 (t, J = 7.4 Hz, 3 H), 0.38 (s, 
6 H); 13C NMR (62 MHz) δ 165.9, 163.2, 162.0, 154.0, 134.9, 132.3, 122.4, 121.7, 
119.4, 113.5, 104.3, 60.7, 52.4, 21.5, 12.1, -4.9; mass spectrum (CI) m/z 352.0900 
[C17H21O4SiCl (M) requires 352.0898], 257 (base), 241. 
NMR assignments. 1H NMR (250 MHz) δ 7.55 (m, 1 H), 7.49 (m, 1 H), 7.12 
(app t. J = 2.0 Hz, 1 H), 6.64 (d, J = 3.1 Hz, 1 H, C5-H), 5.98 (d, J = 3.1 Hz, 1 H, C4-H), 
3.89 (s, 3 H, C16-H), 3.78 (s, 2 H, C8-H), 2.66 (q, J = 7.4 Hz, 2 H, C2-H), 1.22 (t, J = 7.4 
Hz, 3 H, C1-H), 0.38 (s, 6 H, C7-H); 13C NMR (62 MHz) δ 165.9 (C16), 163.2 (C3), 
162.0, 154.0 (C6), 134.9, 132.3, 122.4 (C5), 121.7, 119.4, 113.5, 104.3 (C4), 60.7 (C8), 



























pyran-2-yl-4-chlorofuran-2-yl)dimethylsilylmethanol (4.62). (3-63, 3-68) A solution 
of 4.42 (170 mg, 0.22 mmol), NaOAc (90 mg, 1.1 mmol) and NaI (66 mg, 0.44 mmol) in 
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DMF (6 mL) was heated at 70 °C for 4 h. The mixture was poured into H2O (10 mL), 
and the resulting mixture was extracted with ether (3 x 10 mL). The organic layers were 
combined, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue 
was purified by chromatography eluting with Et2O/hexanes (1:3) to yield 128 mg (78%) 
of 4.61 as a clear liquid: mass spectrum (CI) m/z 755.2746 [C43H48O8SiCl (M+1) 
requires 755.2807] (base), 739, 647. 
 A solution of acetate 4.61 (276 mg, 0.366 mmol) prepared as mentioned above 
in ether (5 mL) was added to a slurry of LAH (42 mg, 1.10 mmol) in ether at 0 ºC. The 
mixture was stirred at 0 ºC for 25 min. EtOAc (1.5 mL) was added, stirring continued for 
another 5 min at 0 ºC, then a solution of saturated NH4Cl added and stirring continued for 
another 5 min at rt. The mixture was filtered and the solids washed with ether and 
NH4Cl, The filtrated and the washes were separated and the aqueous layer was extracted 
with ether (3 x  25 mL). The organic layers were combined, dried (Na2SO4), filtered and 
concentrated under reduced pressure. The residue was purified by chromatography 
eluting with Et2O/hexanes (2:3) to yield 230 mg (88%) of 4.62 as a clear liquid: 1H NMR 
(500 MHz, benzene-d6) δ 1H NMR (500 MHz) δ 7.42-7.00 (comp, 20 H), 6.49 (s, 1 H), 
4.97-4.87 (comp, 3 H), 4.70 (d, J = 10 Hz, 1 H), 4.69-4.64 (comp, 2 H), 4.46 (d, J = 12.0, 
1 H), 4.34-4.29 (comp, 2 H), 4.25 (app t, J = 9.6, 9.2 Hz, 1 H), 3.92 (app t, J = 9.6, 9.2 
Hz, 1 H), 3.25 (t, J = 9.0 Hz, 1 H), 3.69 (dd, J = 11.2, 3.8 Hz, 1 H), 3.58 (dd, J = 11.2, 1.6 
Hz, 1 H), 3.44 (ddd, J = 9.6, 3.8, 1.6 Hz, 1 H), 3.19 (s, 2 H), 0.13 (s, 3 H), 0.12 (s, 3 H); 
13C NMR (75 MHz, benzene-d6) δ 158.3, 151.6, 139.5, 139.2, 138.9, 138.8, 128.4 (3), 
127.8 (2), 127.7, 127.5. 123.1, 116.1, 86.9, 80.9, 80.1, 78.2, 75.5, 74.9, 74.7, 73.5, 72.7, 
69.1, 53.6, -5.6 (2); mass spectrum (CI) m/z 711.2546 [C41H44O7SiCl (M-1) requires 
711.2544], 605 (base), 265. 
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NMR assignments. 1H NMR (500 MHz, benzene-d6) δ 7.42-7.00 (comp, 20 H, 
aromatic H), 6.49 (s, 1 H, C12-H), 4.97-4.87 (comp, 3 H, benzylic H), 4.70 (d, J = 10 Hz, 
1 H, C1-H), 4.69-4.64 (comp, 2 H, benzylic H), 4.46 (d, J = 12.0 Hz, 1 H, benzylic H), 
4.34-4.29 (comp, 2 H, benzylic H), 4.25 (app t, J = 9.6, 9.2 Hz, 1 H, C2-H), 3.92 (app t, J 
= 9.6, 9.2 Hz, 1 H, C4-H), 3.25 (t, J = 9.0 Hz, 1 H, C3-H), 3.69 (dd, J = 11.2, 3.8 Hz, 1 
H, C6-H), 3.58 (dd, J = 11.2, 1.6 Hz, 1 H, C6-H), 3.44 (ddd, J = 9.6, 3.8, 1.6 Hz, 1 H, 
C5-H), 3.19 (s, 2 H, C15-H), 0.13 (s, 3 H, C16-H), 0.12 (s, 3 H, C16-H),; 13C NMR (75 
MHz, benzene-d6) δ 158.3 (C11), 151.6 (C14), 139.5, 139.2, 138.9, 138.8, 128.4 (3), 
127.8 (2), 127.7, 127.5 (aromatic C), 123.1 (C12), 116.1 (C13), 86.9 (C3), 80.9 (C2), 
80.1 (C5), 78.2 (C4), 75.5, 74.9, 74.7, 73.5 (benzylic C), 72.7 (C1), 69.1 (C6), 53.6 





































chlorofuran-2-yl)-tetrahydropyran (4.63). (3-71a). DIAD (9.7 µL, 0.049 mmol) was 
added to a solution of alcohol 4.62 (38 mg, 0.053 mmol), phenol 4.29 (19 mg, 1.0 mmol) 
and triphenylphosphine (14 mg, 0.054 mmol) in benzene (0.2 mL). The mixture was 
stirred at rt for 4 h. and then filtered through a short column, eluting with Et2O/hexane 
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(1:3). The fraction was collected, evaporated and repurified by chromatography (Et3N 
deactivated silica) eluting with Et2O/hexanes (1:12) to yield 14.4 mg (31%) of 4.63 as 
clear liquid: 1H NMR (300 MHz, benzene-d6) δ 7.40-7.00 (comp, 21 H), 6.78 (comp, 2 
H), 6.48 (s, 1 H), 4.98-4.82 (comp, 3 H), 4.70 (d, J = 9.9 Hz, 1 H), 4.66-4.60 (comp, 2 
H), 4.43 (d, J = 12.6 Hz, 1 H), 4.41 (s, 2 H), 4.30-4.18 (comp, 3 H), 3.93 (app t, J = 9.3 
Hz, 1 H), 3.97-3.38 (comp, 4 H), 3.28 (d, J = 12.7 Hz, 1 H), 3.20 (d, J = 12.7 Hz, 1 H), 
0.93 (s, 9 H), 0.14 (s, 3 H), 0.13 (s, 3 H), 0.00 (s, 6 H); 13C NMR (75 MHz) δ 161.9, 
157.2, 151.1, 144.6, 138.9, 138.4, 138.3, 138.0, 134.9, 128.7, 128.6, 128.3, 128.1, 128.0, 
127.9 (2), 123.7, 118.6, 116.5, 113.1, 110.4, 86.9, 80.7, 79.8, 78.2, 76.0, 75.4, 75.1, 73.7, 
72.5, 69.1, 64.6, 59.6, 26.2, 18.7, -4.8; mass spectrum (CI) m/z 966.3498 
[C54H64O8SiCl2 (M+1) requires 966.3517], 827, 279 (base).  
NMR assignments. 1H NMR (300 MHz, benzene-d6) δ 7.40-7.00 (comp, 21 H, 
aromatic-H), 6.78 (comp, 2 H, aromatic-H), 6.48 (s, 1 H, C12-H), 4.98-4.82 (comp, 3 H, 
benzylic H), 4.70 (d, J = 9.9 Hz, 1 H, C1-H), 4.66-4.60 (comp, 2 H, benzylic H), 4.43 (d, 
J = ~12.6 Hz, 1 H, benzylic H), 4.41 (s, 2 H, C22-H), 4.30-4.18 (comp, 3 H, benzylic H 
& C1-H), 3.93 (app t, J = 9.3 Hz, 1 H, C4-H), 3.97-3.38 (comp, 4 H, C3-H & C6-H & 
C5-H), 3.28 (d, J = 12.7 Hz, 1 H, C15-H), 3.20 (d, J = 12.7 Hz, 1 H, C15-H), 0.93 (s, 9 
H, C24-H), 0.14 (s, 3 H, C26-H), 0.13 (s, 3 H, C26-H), 0.00 (s, 6 H, C23-H); 13C NMR 
(75 MHz) δ 161.9, 157.2 (C11), 151.1 (C14), 144.6, 138.9, 138.4, 138.3, 138.0, 134.9, 
128.7, 128.6, 128.3, 128.1, 128.0, 127.9 (2), 123.7 (CC12), 118.6, 116.5 (C13), 113.1, 
110.4, 86.9 (C3), 80.7(C2), 79.8 (C5), 78.2 (C4), 76.0, 75.4, 75.1, 73.7 (benzylic C), 72.5 




































benzoic acid methyl ester (4.64). (3-99). By applying similar method to make 4.59, 
ether 4.64 was prepared from alcohol 4.62 (41 mg, 0.058 mmol), phenol 4.26 (16.1 mg, 
0.086 mmol) and tributylphosphine (21.5 µL, 0.086 mmol) in CH2Cl2 (0.25 mL) as a 
clear liquid (29%, 14.5 mg): 1H NMR (300 MHz) δ 7.59 (m, 1 H), 7.45 (m, 1 H), 7.38-
7.27 (comp, 18 H), 7.05 (m, 1 H), 6.97-6.92 (comp, 2 H), 6.78 (s, 1 H), 4.96-4.84 (comp, 
3 H), 4.69-4.56 (comp, 3 H), 4.52 (d, J = 10.2 Hz, 1 H), 4.51 (d, J = 10.5 Hz, 1 H), 4.06 
(d, J = 10.8 Hz, 1 H), 4.10-4.00 (m, 1 H), 3.90 (s, 3 H), 3.83-3.70 (comp, 6 H), 3.68-3.58 
(m, 1 H), 0.41 (s, 6 H); 13C NMR (75 MHz) δ 166.1, 161.9, 156.9, 151.2, 138.8, 138.4, 
138.3, 137.9, 135.2, 132.6, 128.7, 128.6, 128.5, 128.3, 128.1, 128.0 (2), 127.9, 127.8, 
123.8, 122.2, 119.5, 116.5, 113.6, 86.9, 80.7, 79.8, 78.2, 75.9, 75.4, 75.0, 73.7, 72.4, 69.1, 
60.0, 52.7, -4.9, -5.0; mass spectrum (CI) m/z 880.2616 [C49H50O9SiCl (M) requires 
880.2601] 559, 433 (base). 
NMR assignments. 13C NMR (75 MHz) δ 166.1, 161.9, 156.9, 151.2 (C14), 
138.8, 138.4, 138.3, 137.9, 135.2, 132.6, 128.7, 128.6, 128.5, 128.3, 128.1, 128.0 (2), 
127.9, 127.8, 123.8 (C12), 122.2, 119.5, 116.5 (C13), 113.6, 86.9 (C3), 80.7 (C2), 79.8 
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(C5), 78.2 (C4), 75.9, 75.4, 75.0, 73.7 (benzylic-C), 72.4 (C1-H), 69.1 (C6), 60.0 (C23), 

















(5-Ethylfuran-2-yl)-dimethylvinylsilane (4.65). (3-151) By applying similar 
method to make 4.57, vinylsilane 4.65 was prepared from ethylfuran (1.27 g, 13.2 mmol), 
BuLi (2.5 M, 5.8 mL, 14.6 mmol) and chlorodimethylvinylsilane (1.82 mL, 13.2 mmol) 
in THF (25 mL) as a clear liquid (99%, 2.35 g): 1H NMR (250 MHz) δ 6.55 (d, J = 3.0 
Hz, 1 H), 6.24 (dd, J = 20.0, 14.6 Hz, 1 H), 6.02 (dd, J = 14.6, 4.0 Hz, 1 H), 5.97 (d, J = 
3.0 Hz, 1 H), 5.77 (dd, J = 20.0, 4.0 Hz, 1 H), 2.68 (q, J = 7.6 Hz, 2 H), 1.23 (t, J = 7.6 
Hz, 3 H), 0.32 (s, 6 H). 13C NMR (62 MHz) δ 162.7, 156.2, 136.9, 133.0, 121.4, 104.0, 
21.5, 12.1, -3.3; IR (neat) cm-1; IR (neat) 2966, 1588, 1495, 1402, 1248 cm-1; mass 
spectrum (CI) m/z 181.1045 [C10H17OSi (M+1) requires 181.1049] (base), 165. 
NMR assignments. 1H NMR (250 MHz) δ 6.55 (d, J = 3.0 Hz, 1 H, C2-H), 6.24 
(dd, J = 20.0, 14.6 Hz, 1 H, C7-H), 6.02 (dd, J = 14.6, 4.0 Hz, 1 H, C8-H), 5.97 (d, J = 
3.0 Hz, 1 H, C3-H), 5.77 (dd, J = 20.0, 4.0 Hz, 1 H, C9-H), 2.68 (q, J = 7.6 Hz, 2 H, C5-
H), 1.23 (t, J = 7.6 Hz, 3 H, C6-H), 0.32 (s, 6 H, C10-H). 13C NMR (62 MHz) δ 162.7 
















2-(5-Ethylfuran-2-yl)-dimethylsilanylethanol (4.66). (3-112) A solution of 
vinylsilane 4.65 (190 mg, 1.05 mmol) and 0.5 M 9-BBN in THF (2.3 mL, 1.15 mmol) 
was stirred overnight. A 30% NaOH solution (0.6 mL) was added at rt, then 30% H2O2 
(0.6 mL) was added immediately,. The mixture was stirred at rt for 1 h and then poured in 
to NaHCO3 (10 mL). The mixture was extracted with ether (3 x 10 mL). The organic 
layers were combined, dried (Na2SO4), filtered and concentrated under reduced pressure. 
The residue was purified by chromatography eluting with Et2O/hexanes (2:3) to yield 
167 mg (80%) of 4.66 as a clear liquid: 1H NMR (300 MHz) δ 6.53 (d, J = 3 Hz, 1 H), 
5.95 (d, J = 3 Hz, 1 H), 3.74 (t, J = 8.1 Hz, 2 H), 2.65 (q, J = 7.6 Hz, 2 H), 1.21 (t, J = 7.6 
Hz, 3 H), 1.15 (t, J = 8.1 Hz, 2 H), 0.25 (s, 6 H); 13C NMR (75 MHz) δ 162.8, 156.8, 
121.5, 104.4, 59.9, 21.8, 21.0, 12.4, -2.8; IR (CHCl3) 3346, 2969, 1588 cm-1; mass 
spectrum (CI) m/z 198.1072 [C10H18O2Si (M) requires 198.1076], 171, 149. 
NMR assignments. 1H NMR (300 MHz) δ 6.53 (d, J = 3 Hz, 1 H, C5-H), 5.95 
(d, J = 3 Hz, 1 H, C4-H), 3.74 (t, J = 8.1 Hz, 2 H, C8-H), 2.65 (q, J = 7.6 Hz, 2 H, C2-H), 
1.21 (t, J = 7.6 Hz, 3 H, C1-H), 1.15 (t, J = 8.1 Hz, 2 H, C7-H), 0.25 (s, 6 H, C9-H); 13C 
NMR (75 MHz) δ 162.8 (C3), 156.8 (C6), 121.5 (C5), 104.4 (C4), 59.9 (C8), 21.8 (C2), 


























chlorophenoxy]ethyl}dimethylsilanyl)-5-ethylfuran (4.67). (3-124) By applying 
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similar method to make 4.60, ether 4.67 was prepared from alcohol 4.66 (71 mg, 0.36 
mmol), phenol 4.29 (113 mg, 0.42 mmol) and triphenylphosphine (109 mg, 0.42 mmol) 
in CH2Cl2 (1.5 mL) as a clear liquid (49%, 80 mg): 1H NMR (300 MHz) δ 6.84 (m, 1 H), 
6.71 (m, 2 H), 6.56 (d, J = 3.0 Hz, 1 H), 5.96 (d, J = 3 Hz, 1 H), 4.64 (s, 2 H, C7-H), 4.06 
(t, J = 8.0 Hz, 2 H), 2.66 (q, J = 7.5 Hz, 2 H), 1.33 (t, J = 8.0 Hz, 2 H), 1.22 (t, J = 7.5 
Hz, 3 H), 0.92 (s, 9 H), 0.30 (s, 6 H), 0.08 (s, 6 H); 13C NMR (75 MHz) δ 162.9, 159.8, 
156.4, 144.7, 134.8, 121.6, 118.3, 113.5, 110.8, 104.4, 65.7, 64.5, 26.2, 21.8, 18.6, 16.8, 
12.4, -2.7, -5.0; IR (benzene) 29254, 2856, 1577, 1452 cm-1; mass spectrum (CI) m/z 
452.1963 [C23H37O3Si2Cl (M) requires 452.1970] (base), 321, 279. 
NMR assignments. 1H NMR (300 MHz) δ 6.84 (m, 1 H), 6.71 (m, 2 H), 6.56 (d, 
J = 3.0 Hz, 1 H, C3-H), 5.96 (d, J = 3 Hz, 1 H, C2-H), 4.64 (s, 2 H, C15-H), 4.06 (t, J = 
8.0 Hz, 2 H, C8-H), 2.66 (q, J = 7.5 Hz, 2 H, C5-H), 1.33 (t, J = 8.0 Hz, 2 H, C7-H), 1.22 
(t, J = 7.5 Hz, 3 H, C6-H), 0.92 (s, 9 H, C16-H), 0.30 (s, 6 H, C19-H), 0.08 (s, 6 H, C18-
H); 13C NMR (75 MHz) δ 162.9 (C1), 159.8, 156.4 (C4), 144.7, 134.8, 121.6 (C3), 
118.3, 113.5, 110.8, 104.4 (C2), 65.7 (C8), 64.5 (C15), 26.2 (C16), 21.8 (C6) 18.6 (C17), 
































furan-2-yl]-dimethylvinylsilane (4.68). (2-265). A 0.42 M solution of LDA in THF 
(1.38 mL, 0.576 mmol) was added to a solution of 4.33 (180 mg, 0.288 mmol) in THF 
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(2.5 mL) at –78 °C. The solution was stirred at –78 °C for 3 h and then at –40 °C for 3 h. 
The mixture was diluted with NaHCO3 (15 mL, 1:1), and the resulting mixture was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic layers was dried (Na2SO4), 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with Et2O/hexane (1:7) to yield 92 mg (45%, 61% brsm) of 4.68 
as a clear oil and 48 mg of 4.33: 1H NMR (300 MHz) δ 7.40-6.98 (comp, 20 H), 6.67 (s, 
1 H), 6.21 (dd, J = 19.6, 14.6 Hz, 1 H), 6.06 (dd, J = 14.6, 4.3 Hz, 1 H), 5.81 (d, J = 19.6, 
4.3 Hz, 1 H), 5.00-4.85 (comp, 3 H), 4.72-4.48 (comp, 5 H), 4.10 (d, J = 10.5 Hz, 1 H), 
4.12-4.00 (m, 1 H), 3.88-3.70 (comp, 4 H), 3.70-3.58 (m, 1 H) 0.35 (s, 6 H); 13C NMR 
(75 MHz) δ 158.8, 150.4, 138.6, 138.2, 138.1, 137.8, 135.4, 134.0, 128.3, 128.2, 127.91, 
127.85, 127.72, 127.67, 127.54, 127.46, 122.5, 115.9, 86.5, 80.4, 79.5, 77.9, 75.6, 75.0, 
74.7, 73.4, 72.2, 68.8, -3.6; mass spectrum (CI) m/z 707.2591 [C42H44O6SiCl (M+1) 
requires 707.2596], 601, 493, 391 (base), 265. 
NMR assignments. 1H NMR (300 MHz) δ 7.40-6.98 (comp, 20 H, aromatic H), 
6.67 (s, 1 H, C13-H), 6.21 (dd, J = 19.6, 14.6 Hz, 1 H, C16-H), 6.06 (dd, J = 14.6, 4.3 
Hz, 1 H, C17-H), 5.81 (d, J = 19.6, 4.3 Hz, 1 H, C18-H), 5.00-4.85 (comp, 3 H, benzylic 
H), 4.72-4.48 (comp, 5 H, benzylic H), 4.10 (d, J = 10.5 Hz, 1 H, C1-H), 4.12-4.00 (m, 1 
H, C2-H), 3.88-3.70 (comp, 4 H, C3-H & C4-H & C6-H), 3.70-3.58 (m, 1 H, C5-H) 0.35 































furan-2-yl]-dimethylsilanylethanol (4.69). By applying similar method to make 4.66, 
alcohol 4.69 was prepared from vinylsilane 4.68 (118 mg, 0.16 mmol), 9-BBN (0.36 mL, 
0.18 mL), 30% H2O2 (0.12 mL) and 3 N NaOH (0.12 mL) as a clear liquid (67%, 80 
mg): 1H NMR (300 MHz) δ 7.42-7.20 (comp, 18 H), 7.08-7.00 (comp, 2 H), 6.68 (s, 1 
H), 5.01-4.85 (comp, 3 H), 4.74-4.50 (comp, 5 H), 4.11 (d, J = 10.5 Hz, 1 H), 4.12-4.02 
(m, 1 H), 3.90-3.60 (comp, 5 H), 3.75 (t, J = 8.2 Hz, 2 H), 1.40-1.28 (br s), 1.18 (d, J = 
8.2 Hz, 2 H), 0.32 (s, 3 H), 0.31 (s, 3 H); mass spectrum (CI) m/z 727.2846 





































furan-2-yl]-tetrahydropyran (4.70). (3-146). DIAD (40.4 mg, 0.2 mmol) was added to 
a solution of alcohol 4.69 (96 mg, 0.13 mmol), phenol 4.29 (54 mg, 0.2 mmol) and 
triphenylphosphine (52 mg, 0.4 mmol) in benzene (1 mL). The mixture was stirred at rt 
for 15 min. Solvents evaporated under reduced pressure and the residue was purified by 
chromatography (Et3N deactivated silica) eluting with Et2O/hexanes (1:10) to yield 40 
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mg (31%) of 4.70 as a clear liquid: 1H NMR (300 MHz, benzene-d6) δ 7.36-6.96 (comp, 
21 H), 6.86 (m, 1 H), 6.80 (m, 1 H), 6.38 (s, 1 H), 4.96-4.82 (comp, 3 H), 4.69 (d, J = 9.3 
Hz, 1 H), 4.72-4.60 (comp, 2 H), 4.45 (d, J = 12.0 Hz, 1 H), 4.42 (s, 2 H), 4.32-4.24 
(comp, 2 H), 4.21 (app t, J = 9.9, 9.0 Hz, 1 H), 3.93 (t, J = 9.3 Hz , 1 H), 3.78-3.54 
(comp, 5 H), 3.48-3.36 (m, 1 H), 1.00 (t, J = 7.4 Hz, 2 H), 0.95 (s, 9 H), 0.07 (s, 6 H), 
0.00 (s, 6 H); 13C NMR (75 MHz, benzene-d6) δ 160.1, 159.2, 151.7, 146.7, 145.1, 
139.5, 139.3, 139.1, 138.8, 135.2, 122.7, 120.2, 118.7, 116.1, 113.2, 111.3, 87.0, 81.0, 
80.2, 78.3, 75.6, 75.0, 74.8, 73.6, 72.9, 69.2, 64.9, 64.3, 26.0, 18.5, 15.8, -3.3, -5.3; IR 
(benzene) 2927, 2856, 1577, 1453 cm-1; mass spectrum (CI) m/z 980.3650 
[C55H65O8Si2Cl2 (M) requires 980.3673], 849 (base), 431. 
NMR assignments. 1H NMR (300 MHz, benzene-d6) δ 7.36-6.96 (comp, 21 H, 
aromatic-H), 6.86 (m, 1 H, aromatic-H), 6.80 (m, 1 H, aromatic-H), 6.38 (s, 1 H, C12-H), 
4.96-4.82 (comp, 3 H, benzylic-H), 4.69 (d, J = 9.3 Hz, 1 H, C1-H), 4.72-4.60 (comp, 2 
H, benzylic-H), 4.45 (d, J = 12.0 Hz, 1 H, benzylic-H), 4.42 (s, 2 H, C23-H), 4.32-4.24 
(comp, 2 H, benzylic-H), 4.21 (app t, J = 9.9, 9.0 Hz, 1 H, C2-H), 3.93 (t, J = 9.3 Hz, 1 
H, C4-H), 3.78-3.54 (comp, 5 H, C3-H & C6-H & C16-H), 3.48-3.36 (m, 1 H, C5-H), 
1.00 (t, J = 7.4 Hz, 2 H, C15-H), 0.95 (s, 9 H, C25-H), 0.07 (s, 6 H, C27-H), 0.00 (s, 6 H, 
C24-H); 13C NMR (75 MHz, benzene-d6) δ 160.1, 159.2 (C11), 151.7 (C14), 146.7, 
145.1, 139.5, 139.3, 139.1, 138.8, 135.2, 122.7 (C12), 120.2, 118.7, 116.1 (C13), 113.2, 
111.3, 87.0 (C3), 81.0 (C2), 80.2 (C5), 78.3 (C4), 75.6, 75.0, 74.8, 73.6 (benzylic-C), 
72.9 (C1), 69.2 (C6), 64.9 (C23), 64.3 (C16), 26.0 (C25), 18.5 (C26), 15.8 (C15), -3.3 





















ylmethoxysilane (4.100). (3-256AB). A solution of sec-BuLi (1.16 M, 270 µL, 0.313 
mmol) in cyclohexane was added dropwise to a stirred solution of 4.39b (100 mg, 0.304 
mmol) in THF (2 mL) at –95 °C. The reaction was stirred for 25 min at –95 °C, and then 
furan (220 µL) was added dropwise. The reaction was allowed to warm up slowly to 0 °C 
whereupon saturated NH4Cl/H2O (3 mL, 5:1) was added. The mixture was extracted with 
EtOAc (3 x 6 mL). The combined organic layers were dried (Na2SO4), and concentrated 
under reduced pressure. The residue was purified by flash chromatography eluting with 
Et2O/Hexanes (1:7) to afford 72 mg (66%) of 4.100 as a clear oil: 1H NMR (400 MHz) δ 
7.03 (dd, J = 5.5, 1.7 Hz, 1 H), 6.98 (dd, J = 5.5, 1.7 Hz, 1 H), 6.87 (s, 1 H), 6.65 (s, 1 H), 
5.90 (s, 1 H), 5.65 (s, 1 H), 4.75 (s, 2 H), 3.80 (s, 3 H), 1.30-1.10 (comp, 21 H); 13C 
NMR (100 MHz) δ 152.1, 151.0, 142.6, 142.2, 140.9, 132.9, 111.0, 107.3, 82.5, 80.0, 
64.9, 55.8, 18.5, 12.5; mass spectrum (CI) m/z 361.2194 [C21H33O3Si (M+1) requires 
361.2199], 317, 187 (base). 
NMR assignments. 1H NMR (400 MHz) δ 7.03 (dd, J = 5.5, 1.7 Hz, 1 H), 6.98 
(dd, J = 5.5, 1.7 Hz, 1 H, C2-H), 6.87 (s, 1 H, C8-H), 6.65 (s, 1 H, C6-H), 5.90 (s, 1 H, 
C4-H), 5.65 (s, 1 H, C1-H), 4.75 (s, 2 H, C10-H), 3.80 (s, 3 H, C9-H), 1.30-1.10 (comp, 

























(methoxymethyl)-2H-pyran (4.113). (3-234). To a solution of the acetyl-2,3,4,6-tetra-
O-methyl-D-glucopyranose 4.112 (162 mg, 2.80 mmol) and furan (5.7 mL, 80 mmol) in 
CH2Cl2 (25 mL) was added BF3.Et2O (0.28 mL, 2.28 mmol) and the solution was stirred 
at rt overnight. The mixtures were poured into NaHCO3 (30 mL) and diluted with 
CH2Cl2 (30 mL), and the layers were separated. The organic layer was washed with 
NaHCO3 (30 mL), dried (Na2SO4), and concentrated under reduced pressure. The 
residue was purified by flash chromatography, eluting with EtOAc/hexanes (1:3) to yield 
475 mg (61%) 4.113 as a colorless oil: 1H NMR (400 MHz) δ 7.40 (dd, J = 1.0, 0.7 Hz, 1 
H), 6.39 (d, J = 3.1 Hz, 1 H), 6.35 (dd, J = 3.1, 1.8 Hz, 1 H), 4.15 (d, J = 9.9 Hz, 1 H), 
3.66 (s, 3 H), 3.63 (dd, J = 10.6, 2.1 Hz, 1 H), 3.60-3.54 (m, 1 H), 3.57 (s, 3 H), 3.48-3.36 
(comp, 2 H), 3.37 (s, 3 H), 3.27 (t, J = 8.5 Hz, 1 H), 3.22 (t, J = 9.0 Hz, 1 H), 3.17 (s, 3 
H); 13C NMR (75 MHz) δ 151.1, 142.4, 110.4, 109.8, 88.3, 82.4, 79.6, 79.0, 74.5, 71.5, 
60.8, 60.5, 59.9, 59.3; mass spectrum (CI) m/z 287.1497 [C14H23O6 (M+1) requires 
287.1495] 255, 223, 163 (base), 145. 
NMR assignments. 1H NMR (400 MHz) δ 7.40 (dd, J = 1.0, 0.7 Hz, 1 H, C10-
H), 6.39 (d, J = 3.1 Hz, 1 H, C9-H), 6.35 (dd, J = 3.1, 1.8 Hz, 1 H, C8-H), 4.15 (d, J = 9.9 
Hz, 1 H, C1-H), 3.66 (s, 3 H, Sugar-OCH3), 3.63 (dd, J = 10.6, 2.1 Hz, 1 H, C6-H), 3.60-
3.54 (m, 1 H, C6-H), 3.57 (s, 3 H, Sugar-OCH3), 3.48-3.36 (comp, 2 H, C5-H & C3-H), 
3.37 (s, 3 H, Sugar-OCH3), 3.27 (t, J = 8.5 Hz, 1 H), 3.22 (t, J = 9.0 Hz, 1 H), 3.17 (s, 3 
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H); 13C NMR (75 MHz) δ 151.1 (C7), 142.4 (C10), 110.4 (C9), 109.8 (C8), 88.3 (C2), 
82.4 (C1), 79.6 , 79.0, 74.5 (C6), 71.5 (C5), 60.8 (C13), 60.5 (C11), 59.9 (C14), 59.3 
(C12). 
 
General procedure for glucosyl furan Diels-Alder reactions. sec-Butyllithium 
(0.25 mL, 0.29 mmol, 1.16 M in cyclohexanes) was added dropwise to a solution of 2-
chloro-1,4-dimethoxybenzene (4.103, 50 mg, 0.29 mmol), in THF (1.5 mL) at -95 °C. 
The mixture was stirred for 15~25 min and a solution of glycosyl furan (0.088 mmol) in 
THF (0.6 mL) was added at -95 °C. The reaction was warmed -95 °C without removing 
cooling bath whereupon, NH4Cl (3 mL) and H2O (0.5 mL) were added and poured onto 
H2O (20 mL), and the resulting mixture was extracted with EtOAc (2 x 15 mL). The 
mixture was extracted with EtOAc (3 x 5 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated, and the residue was purified by flash 
chromatography, eluting with Et2O/hexanes or EtOAc/hexanes. (Note: Those 
cycloadduct, often isolated as a mixture of diastereomers were typically not fully 
































Cycloadduct (4.95a). Cycloadduct 4.95a was prepared in 25% yield (single 
diastereomer) as a pale clear oil according to the general procedure described above: 1H 
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NMR (400 MHz) δ 7.42-6.98 (comp, 23 H), 6.36 (s, 1 H), 5.04-4.82 (comp, 3 H), 4.80-
4.28 (comp, 6 H), 4.60 (s, 2 H), 4.04-3.96 (m, 1 H), 3.88-3.62 (comp, 3 H), 3.58-3.48 (m, 
1 H), 3.39 (s, 3 H), 3.44-3.22 (m, 1 H), 1.06 (s, 9 H), 0.11 (s, 3 H); mass spectrum (CI) 
m/z 875.3734 [C52H60O8SiCl (M+1) requires 875.3746], 840, 767, 659 (base).  
NMR assignments. 1H NMR (400 MHz) δ 7.42-6.98 (comp, 23 H, aromatic-H & 
C3-H &C6-H &C8-H), 6.36 (s, 1 H, C4-H), 5.04-4.82 (comp, 3 H, benzylic-H), 4.80-
4.28 (comp, 6 H, C1-H & benzylic-H), 4.60 (s, 2 H, C12-H), 4.04-3.96 (m, 1 H, C16-H), 
3.88-3.62 (comp, 3 H, C17-H & C20-H), 3.58-3.48 (m, 1 H, C19-H), 3.39 (s, 3 H, OMe-






























Cycloadduct (4.114). (3-288) Cycloadduct 4.114 was prepared in 76% yield (8:1 
mixture of diastereomers) as pale yellow oil according to the general procedure described 
above: 1H NMR (400 MHz) δ 7.42-7.14 (comp, 20 H), 6.69 (d, J = 1.7 Hz, 0.89 H, major 
isomer), 6.65 (d, J = 1.7 Hz, 0.11 H, minor isomer), 6.63 (d, J = 8.9 Hz, 0.89 H, major 
isomer), 6.58 (s, 0.22 H, minor isomer), 6.52 (d, J = 8.9 Hz, 0.89 H, major isomer), 6.95 
(d, J =1.7 Hz, 0.89 H, major isomer), 6.01 (d, J = 1.7 Hz, 0.11 H, minor isomer), 5.06-
4.78 (comp, 5 H), 4.65 (d, J = 10.6 Hz, 1 H), 4.53-4.40 (comp, 3 H), 4.00-3.60 (comp, 6 
H), 3.82 (s, 3 H), 3.64 (s, 3 H). 13C NMR (100 MHz) δ 149.8, 148.9, 147.5, 138.6, 138.4, 
138.3, 138.2, 137.7, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 125.5, 127.4, 
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127.3, 127.2, 112.1, 114.5, 94.4, 87.5, 80.1, 79.8, 79.1, 78.9, 75.7, 75.1, 74.9, 72.9, 69.1, 
56.3, 55.9. 
NMR assignments. 1H NMR (400 MHz) δ 7.42-7.14 (comp, 20 H, aromatic-H), 
6.69 (d, J = 1.7 Hz, 0.89 H, major isomer, C3-H), 6.65 (d, J = 1.7 Hz, 0.11 H, minor 
isomer, C3-H), 6.63 (d, J = 8.9 Hz, 0.89 H, major isomer, C6-H), 6.58 (s, 0.22 H, minor 
isomer, C6-H & C7-H), 6.52 (d, J = 8.9 Hz, 0.89 H, major isomer, C7-H), 6.95 (d, J =1.7 
Hz, 0.89 H, major isomer, C4-H), 6.01 (d, J = 1.7 Hz, 0.11 H, minor isomer, C4-H), 5.06-
4.78 (comp, 5 H, benzylic-H & C1-H), 4.65 (d, J = 10.6 Hz, 1 H, benzylic-H), 4.53-4.40 
(comp, 3 H, benzylic-H), 4.00-3.60 (comp, 6 H, C14-H & C15-H & C16-H & C17-H & 













Cycloadduct (4.143). (4-227). According to the general procedure described 
above, cycloadduct 4.143 was obtained in 55% yield as a thick oil from the cycloaddition 
of chloronaphthalene 4.142 (23 mg, 0.030 mmol) and furan (25 µL, 0.30 mmol) after 
purification by flash chromatography eluting with Et2O/Hexanes (1:2): 1H NMR (400 
MHz) δ 7.38-7.16 (comp, H), 7.08-6.72 (comp, 22 H), 6.2 (app d. J = 6.8 Hz, 1 H), 6.40 
(d, J = 9.6 Hz, 1 H), 6.37 (d, J = 7.2 Hz, 1 H), 6.28-6.23 (m, 1 H), 6.01 (br s, 1 H), 5.02-
4.80 (comp, 3 H), 4.68-4.44 (comp, 3 H), 4.29 (d, J = 10.6 Hz, 0.5 H), 4.09 (d, J = 9.9 
Hz, 0.5 H), 4.00-3.58 (comp, 6 H), 3.27 (d, J = 10.3 Hz, 0.5 H), 3.13 (t, J = 9.2 Hz, 0.5 
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H); IR (CH2Cl2) 3029, 2864, 1668, 1565, 1453, 1094 cm-1; MS (CI) m/z 807.3536 


































yl)-naphthalen-1-ol (4.133). (4-243, 4-244). According to the general procedure 
described above, crude cycloadduct 4.132 (2.57 g) was obtained as a thick oil along with 
recovered 4.104 (386 mg) from glucosylfuran 4.104 (1.97 g, 3.34 mmol) and 2-chloro-
1,4-dimethoxy-benzne (1.72 g, 10.0 mmol) after purification by flash chromatography 
eluting with Et2O/hexanes (1:2).  
BF3·Et2O (960 µL, 7.58 mmol) was added to a solution of the crude cycloadduct 
(2.57 g, 3.54 mmol) obtained above dissolved in CH2Cl2 (75 mL) containing 2,6-lutidine 
(600 µL, 5.15 mmol) at -5°C. The mixture was stirred at -5°C overnight, and more 
BF3·Et2O (220 µL, 1.58 mmol) was added. The reaction was stirred for another 6 h, 
whereupon saturated NaHCO3 (50 mL) was added. The layers were separated and the 
aqueous layer was extracted with EtOAc (2 x 40 mL). The combined organic layers were 
dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by 
flash chromatography eluting with Et2O/hexanes (1:2) to afford 1.477 g (61%, 76% brsm 
over two steps) of 4.133 as a thick oil: 1H NMR (400 MHz) δ 10.03 (s, 1 H), 7.86 (d, J = 
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8.2 Hz, 1 H), 7.48-7.28 (comp, 15 H), 7.16 (tt, J = 7.2, 1.4 Hz, 1 H), 7.08 (app t, J = 7.2 
Hz, 2 H), 7.04 (d, J = 8.2 Hz, 1 H), 6.74 (s, 2 H), 6.64 (d, J = 8.2 Hz, 2 H), 6.24 (d, J = 
9.2 Hz, 1 H), 5.05 (d, J = 10.9 Hz, 1 H), 4.99 (d, J = 10.6 Hz, 1 H), 4.97 (d, J = 10.9 Hz, 
1 H), 4.76 (d, J = 12.3 Hz, 1 H), 4.74 (d, J = 10.6 Hz, 1 H), 4.65 (d, J = 12.3 Hz, 1 H), 
4.35 (d, J = 10.3 Hz, 1 H), 4.03 (s, 3 H), 4.00-3.76 (comp, 5 H), 3.83 (s, 3 H), 3.72 (d, J = 
10.3 Hz, 1 H), 3.63 (t, J = 8.9 Hz, 1 H); 13C NMR (100 MHz) δ 154.6, 152.6, 150.4, 
138.8, 138.4, 138.3, 138.0, 128.32, 128.26, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 
127.5, 127.4, 127.3, 127.1, 127.01, 127.00, 116.2, 111.4, 106.4, 103.6, 87.1, 86.0, 79.4, 
78.8, 75.4, 75.0, 74.4, 73.3, 69.3, 56.4, 56.1; IR (CH2Cl2) 3354, 3029, 2883, 1619, 1526, 
1453, 1060 cm-1; MS (CI) m/z 726.3193 [C46H46O8 (M) requires 726.3193], 619, 511 
(base). 
NMR assignments. 1H NMR (400 MHz) δ 10.03 (s, 1 H, OH), 7.86 (d, J = 8.2 
Hz, 1 H, C3-H), 7.48-7.28 (comp, 15 H), 7.16 (tt, J = 7.2, 1.4 Hz, 1 H, C23-H), 7.08 (app 
t, J = 7.2 Hz, 2 H, C22-H), 7.04 (d, J = 8.2 Hz, 1 H, C2-H), 6.74 (s, 2 H, C6-H & C7-H), 
6.64 (d, J = 8.2 Hz, 2 H, C21-H), 6.24 (d, J = 9.2 Hz, 1 H. C11-H), 5.05 (d, J = 10.9 Hz, 
1 H, C18-H), 4.99 (d, J = 10.6 Hz, 1 H, C19-H), 4.97 (d, J = 10.9 Hz, 1 H, C18-H), 4.76 
(d, J = 12.3 Hz, 1 H, C20-H), 4.74 (d, J = 10.6 Hz, 1 H, C19-H), 4.65 (d, J = 12.3 Hz, 1 
H, C20-H), 4.35 (d, J = 10.3 Hz, 1 H, C17-H), 4.03 (s, 3 H, C24-H), 4.00-3.76 (comp, 5 
H, C13-H & C14-H &C15-H & C16-H), 3.83 (s, 3 H, C25-H), 3.72 (d, J = 10.3 Hz, 1 H, 
C17-H), 3.63 (t, J = 8.9 Hz, 1 H, C12-H); 13C NMR (100 MHz) δ 154.6, 152.6, 150.4, 
138.8, 138.4, 138.3, 138.0, 128.32, 128.26, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 
127.5, 127.4, 127.3, 127.1, 127.01, 127.00, 116.2, 111.4, 106.4, 103.6, 87.1 (C13), 86.0 
(C12), 79.4 (C14), 78.8 (C15), 75.4 (C18), 75.0 (C19), 74.4 (C17), 73.3 (C20), 69.3 



































tetrahydropyran-2-yl)-naphthalen-1-ol (4.141). (4-196). A solution of naphthol 4.133 
(51 mg, 0.070 mmol) and NCS (10.3 mg, 0.077 mmol) in AcOH (1.5 mL) was stirred at 
rt for 2 d. The solvent was evaporated under reduced pressure. The residue was purified 
by flash chromatography eluting with Et2O/hexanes (1:3 then 1:2) to afford 20 mg (37%) 
of 4.141 as a light green oil: 1H NMR (400 MHz) δ 10.55 (s, 1 H), 7.82 (s, 1 H), 7.40-
7.18 (comp, 18 H), 7.09 (app t, J = 7.3, 1 H), 7.00 (app t, J = 7.5 Hz, 2 H), 6.75 (d, J = 
8.5 Hz, 1 H), 6.67 (d, J = 8.9 Hz, 1 H), 6.53 (d, J = 8.2 Hz, 2 H), 6.09 (d, J = 9.2 Hz, 1 
H), 4.96 (d, J = 10.9 Hz, 1 H), 4.93–4.85 (comp, 2 H), 4.68 (d, J = 12.3 Hz, 1 H), 4.64 (d, 
J = 10.6 Hz, 1 H), 4.60 (d, J = 12.3 Hz, 1 H), 4.33 (d, J = 10.4 Hz, 1 H), 4.05 (s, 3 H), 
3.90-3.66 (comp, 5 H), 3.76 (s, 3 H), 3.69 (d, J = 10.4 Hz, 1 H), 3.50-3.44 (m, 1 H); 13C 
NMR (100 MHz) δ 152.8, 149.8, 149.6, 138.8, 138.4, 138.2, 137.9, 128.6, 128.42, 
128.36, 128.2, 128.1, 127.9, 127.73, 127.70, 127.6, 127.50, 127.47, 127.2, 125.6, 116.9, 
116.3, 109.7, 106.6, 105.1, 87.1, 86.0, 79.4, 78.9, 76.7, 75.4, 75.1, 74.7, 73.3, 69.3, 57.0, 
56.1; IR (CH2Cl2) 3301, 2861, 1618, 1250, 1057, 738, 697 cm-1. 
NMR assignments. 1H NMR (400 MHz) δ 10.55 (s, 1 H, OH), 7.82 (s, 1 H, C3-
H), 7.40-7.18 (comp, 18 H, benzyl aromatics), 7.09 (app t, J = 7.3, 1 H, C23-H), 7.00 
 298
(app t, J = 7.5 Hz, 2 H, C22-H), 6.75 (d, J = 8.5 Hz, 1 H, C7-H), 6.67 (d, J = 8.9 Hz, 1 H, 
C6-H), 6.53 (d, J = 8.2 Hz, 2 H, C21-H), 6.09 (d, J = 9.2 Hz, 1 H, C11-H), 4.96 (d, J = 
10.9 Hz, 1 H, C18-H), 4.93–4.85 (comp, 2 H, C18-H & C19-H), 4.68 (d, J = 12.3 Hz, 1 
H, C20-H), 4.64 (d, J = 10.6 Hz, 1 H, C19-H), 4.60 (d, J = 12.3 Hz, 1 H, C20-H), 4.33 (d, 
J = 10.4 Hz, 1 H, C17-H), 4.05 (s, 3 H, C24-H), 3.90-3.66 (comp, 5 H, C13-H & C14-H 
& C15-H & C16-H), 3.76 (s, 3 H, C25-H), 3.69 (d, J = 10.4 Hz, 1 H, C17-H), 3.50-3.44 
(m, 1 H, C12-H); 13C NMR (100 MHz) δ 152.8, 149.8, 149.6, 138.8, 138.4, 138.2, 137.9, 
128.6, 128.42, 128.36, 128.2, 128.1, 127.9, 127.73, 127.70, 127.6, 127.50, 127.47, 127.2, 
125.6, 116.9, 116.3, 109.7, 106.6, 105.1, 87.1 (C13), 86.0 (C12), 79.4 (C14), 78.9 (C15), 


































benzyloxymethyltetrahydropyran-2-yl)naphthalen-1-ol (4.138). (4-274). A solution of 
Br2 (0.15 mL, 2.92 mmol) in CCl4 (2 mL) was added to naphthol 4.133 (1.86 g, 2.56 
mmol) at 0 °C in CCl4 (24 mL). The mixture was stirred at 0 °C for 3 min. The reaction 
was quenched by addition of saturated NaHCO3 (40 mL). The layers were separated, and 
the aqueous layer was extracted with CHCl3 (2 x 30 mL). The combined organic layers 
were dried (Na2SO4), and concentrated under reduced pressure. The residue was purified 
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by flash chromatography eluting with Et2O/hexanes (1:2) to afford 1.42 g (69%) of 4.138 
as a thick oil: 1H NMR (500 MHz) δ 10.67 (s, 1 H), 7.95 (s, 1 H), 7.39-7.19 (comp, 15 
H), 7.08 (tt, J = 7.4, 1.3 Hz, 1 H), 7.00 (app t, J = 7.3 Hz, 2 H), 6.74 (d, J = 8.7 Hz, 1 H), 
6.67 (d, J = 8.7 Hz, 1 H), 6.53 (app d, J = 6.9 Hz, 2 H), 6.07 (d, J = 9.3 Hz, 1 H), 4.96 (d, 
J = 11.3 Hz, 1 H), 4.89 (d, J = 11.3 Hz, 1 H), 4.88 (d, J = 10.7 Hz, 1 H), 4.70-4.62 (comp, 
2 H), 4.60 (d, J = 12.3 Hz, 1 H), 4.33 (d, J = 10.6 Hz, 1 H), 4.02 (s, 3 H), 3.90-3.67 
(comp, 5 H), 3.75 (s, 3 H), 3.70 (d, J = 10.6 Hz, 1 H), 3.47 (app t, J = 9.0 Hz, 1 H); 13C 
NMR (125 MHz) δ 152.9, 150.6, 149.6, 138.9, 138.4, 138.3, 137.9, 131.2, 128.5, 128.4, 
128.35, 128.32, 128.0, 127.9, 127.71, 127.66, 127.56, 127.5, 127.4, 127.1, 126.1, 116.8, 
106.8, 105.7, 105.2, 87.2, 86.0, 79.5, 78.9, 76.7, 75.3, 75.1, 74.7, 73.3, 69.3, 57.0, 56.2; 
IR (CH2Cl2) 3299, 2861, 1616, 1452, 1249, 1097, 1058 cm-1; MS (CI) m/z 804.2289 
[C46H45O8Br (M) requires 804.2298]; (CI-) 806 (base), 804, 762, 671. 
NMR assignments. 1H NMR (500 MHz) δ 10.67 (s, 1 H, OH), 7.95 (s, 1 H, C3-
H), 7.39-7.19 (comp, 15 H, benzyl aromatics), 7.08 (tt, J = 7.4, 1.3 Hz, 1 H, C23-H), 7.00 
(app t, J = 7.3 Hz, 2 H, C22-H), 6.74 (d, J = 8.7 Hz, 1 H, C7-H), 6.67 (d, J = 8.7 Hz, 1 H, 
C6-H), 6.53 (d, J = 6.9 Hz, 2 H, C21-H), 6.07 (d, J = 9.3 Hz, 1 H, C11-H), 4.96 (d, J = 
11.3 Hz, 1 H, C18-H), 4.89 (d, J = 11.3 Hz, 1 H, C18-H), 4.88 (d, J = 10.7 Hz, 1 H, C19-
H), 4.70-4.62 (comp, 2 H, C19-H & C20-H), 4.60 (d, J = 12.3 Hz, 1 H, C20-H), 4.33 (d, 
J = 10.6 Hz, 1 H, C17-H), 4.02 (s, 3 H, C24-H), 3.90-3.67 (comp, 5 H, C13-H & C14-H 
& C15-H & C16-H), 3.75 (s, 3 H, C25-H), 3.70 (d, J = 10.6 Hz, 1 H, C17-H), 3.47 (app t, 
J = 9.0 Hz, 1 H, C12-H); 13C NMR (125 MHz) δ 152.9, 150.6, 149.6, 138.9, 138.4, 
138.3, 137.9, 131.2 (C3), 128.5, 128.4, 128.35, 128.32, 128.0, 127.9, 127.71, 127.66, 
127.56, 127.5, 127.4, 127.1, 126.1(C23), 116.8, 106.8 (C6), 105.7, 105.2 (C7), 87.2 
(C13), 86.0 (C12), 79.5 (C14), 78.9 (C15), 76.7 (C11), 75.3 (C18), 75.1 (C19), 
74.7(C17), 73.3 (C20), 69.3 (C16), 57.0 (C24), 56.2 (C25). Note: 1H-13C HSQC revealed 
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methoxymethoxynaphthalen-1-yl)-tetrahydropyran (4.139). (4-195). To a solution of 
bromonaphthol 4.138 (85 mg, 0.105 mmol) in DMF (4.5 mL) at 0 °C, was added NaH 
(6.6 mg, 0.17 mmol, 60% suspension in mineral oil) and then MOMCl (13 µL, 0.17 
mmol). The mixture was stirred at rt overnight. Saturated NaHCO3 (15 mL) was added, 
and the mixture was extracted with EtOAc (3 x 15 mL). The combined organic layers 
were washed with NaCl (15 mL), dried (Na2SO4), and concentrated under reduced 
pressure. The residue was purified by flash chromatography eluting with Et2O/hexanes 
(1:2 then 2:3) to afford 85 mg (95%) of 4.139 as a thick oil: 1H NMR (500 MHz) δ 8.01 
(s, 1 H), 7.40-7.18 (comp, 15 H), 7.07 (tt, J = 7.4, 1.3 Hz, 1 H), 6.98 (app t, J = 7.5 Hz, 2 
H), 6.81 (d, J = 8.7 Hz, 1 H), 6.72 (d, J = 8.7 Hz, 1 H), 6.47 (d, J = 8.2 Hz, 12 H), 6.14 
(d, J = 9.2 Hz, 1 H), 5.10 (d, J = 5.4 Hz, 1 H), 5.04 (d, J = 5.4 Hz, 1 H), 4.97 (d, J = 11.2 
Hz, 1 H), 4.90 (d, J = 11.2 Hz, 1 H), 4.88 (d, J = 10.8 Hz, 1 H), 4.67 (d, J = 12.4 Hz, 1 
H), 4.65 (d, J = 10.8 Hz, 1 H), 4.60 (d, J = 12.4 Hz, 1 H), 4.32 (d, J = 10.4 Hz, 1 H), 3.90 
(s, 3 H), 3.88-3.70 (comp, 5 H), 3.75 (s, 3 H), 3.71 (s, 3 H), 3.62 (d, J = 10.4 Hz, 1 H), 
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3.47 (app t , J = 9.0 Hz, 1 H); ); 13C NMR (100 MHz) δ 152.3, 149.4, 149.1, 138.7, 
138.3, 138.1, 137.6, 134.1, 130.2, 128.4, 128.3, 128.0, 127.9, 127.7, 127.6, 127.5, 127.4, 
127.2, 126.9, 122.5, 116.0, 107.7, 100.8, 87.1, 85.9, 79.5, 78.7, 75.3, 75.1, 74.7, 73.3, 
69.1, 58.3, 57.0, 56.2; IR (CH2Cl2) 2901, 1608, 1570, 1453, 1258, 1059 cm-1; MS (CI) 
m/z 848.2556 [C48H49O9Br (M) requires 848.2460], 849 (base), 817, 741, 645. 
NMR assignments. 1H NMR (500 MHz) δ 8.01 (s, 1 H, C3-H), 7.40-7.18 (comp, 
15 H, benzyl aromatics), 7.07 (tt, J = 7.4, 1.3 Hz, 1 H, C23-H), 6.98 (app t, J = 7.5 Hz, 2 
H, C22-H), 6.81 (d, J = 8.7 Hz, 1 H, C7-H), 6.72 (d, J = 8.7 Hz, 1 H, C6-H), 6.47 (d, J = 
8.2 Hz, 2 H, C21-H), 6.14 (d, J = 9.2 Hz, 1 H, C11-H), 5.10 (d, J = 5.4 Hz, 1 H, C26-H), 
5.04 (d, J = 5.4 Hz, 1 H, C26-H), 4.97 (d, J = 11.2 Hz, 1 H, C18-H), 4.90 (d, J = 11.2 Hz, 
1 H, C18-H), 4.88 (d, J = 10.8 Hz, 1 H, C19-H), 4.67 (d, J = 12.4 Hz, 1 H, C20-H), 4.65 
(d, J = 10.8 Hz, 1 H, C19-H), 4.60 (d, J = 12.4 Hz, 1 H, C20-H), 4.32 (d, J = 10.4 Hz, 1 
H, C17-H), 3.90 (s, 3 H, C24-H), 3.88-3.70 (comp, 5 H, C13-H & C14-H & C15-H & 
C16-H), 3.75 (s, 3 H, C25-H), 3.71 (s, 3 H. C27-H), 3.62 (d, J = 10.4 Hz, 1 H, C17-H), 
3.47 (app t , J = 9.0 Hz, 1 H, C12-H); 13C NMR (100 MHz) δ 152.3, 149.4, 149.1, 138.7, 
138.3, 138.1, 137.6, 134.1, 130.2, 128.4, 128.3, 128.0, 127.9, 127.7, 127.6, 127.5, 127.4, 
127.2, 126.9, 122.5, 116.0, 107.7, 100.8 (C26), 87.1 (C13), 85.9 (C12), 79.5 (C14), 
78.7(C15), 75.3 (C18), 75.1 (C19), 74.7 (C17), 73.3 (C20), 69.1 (C16), 58.3 (C27), 57.0 




































trimethoxynaphthalen-1-yl)tetrahydropyran (4.140). (4-254). To a solution of 
bromonaphthol 4.138 (802 mg, 0.998 mmol) in DMF (24 mL) at 0 °C, was added NaH 
(80 mg, 2.00 mmol, 60% suspension in mineral oil) and then MeI (125 µL, 2.00 mmol). 
The mixture was stirred at rt overnight. Saturated NaHCO3 (25 mL) and H2O (10 mL) 
were added, and the mixture was extracted with EtOAc (2 x 50 mL). The combined 
organic layers were washed with H2O (3 x 60 mL), dried (Na2SO4), and concentrated 
under reduced pressure. The residue was purified by flash chromatography eluting with 
Et2O/Hexanes (1:2) to afford 780 mg (96%) of 4.140 as a thick oil: 1H NMR (400 MHz) 
δ 8.00 (s, 1 H), 7.41-7.18 (comp, 15 H), 7.08 (app t, J = 7.4 Hz, 1 H), 6.99 (t, J = 7.5 Hz, 
2 H), 6.84 (d, J = 8.7 Hz, 1 H), 6.75 (d, J = 8.7 Hz, 1 H), 6.48 (d, J = 7.2 Hz, 1 H), 6.16 
(d, J = 9.2 Hz, 1 H), 4.97 (d, J = 11.1 Hz, 1 H), 4.90 (d, J = 11.1 Hz, 1 H), 4.89 (d, J = 
10.6 Hz, 1 H), 4.68 (d, J = 12.3 Hz, 1 H), 4.64 (d, J = 10.6 Hz, 1 H), 4.60 (d, J = 12.3 Hz, 
1 H), 4.33 (d, J = 10.6 Hz, 1 H), 3.94 (s, 3 H), 3.90-3.70 (comp, 5 H), 3.86 (s, 3 H), 3.76 
(s, 3 H), 3.65 (d, J = 10.6 Hz, 1 H), 3.49 (app t , J = 9.0 Hz, 1 H); 13C NMR (100 MHz) δ 
152.8, 152.3, 149.9, 138.8, 138.4, 138.2, 137.7, 134.0, 130.3, 128.4, 128.1, 128.0, 127.8, 
127.7, 127.6, 127.50, 127.48, 127.2, 126.9, 123.0, 115.9, 108.1, 107.9, 87.1, 85.9, 79.5, 
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78.8, 75.4, 75.1, 74.8, 73.3, 69.2, 61.8, 57.5, 56.3; IR (CH2Cl2) 2930, 1608, 1569, 1496, 
1259, 1099, 1056 cm-1; MS (CI) m/z 818.2456 [C47H47O8Br (M) requires 818.2454], 
605, 519, 445, 433 (base). 
NMR assignments. 1H NMR (400 MHz) δ 8.00 (s, 1 H, C3-H), 7.41-7.18 (comp, 
15 H, benzylic aromatics), 7.08 (app t, J = 7.4 Hz, 1 H, C23-H), 6.99 (t, J = 7.5 Hz, 2 H, 
C22-H), 6.84 (d, J = 8.7 Hz, 1 H, C7-H), 6.75 (d, J = 8.7 Hz, 1 H, C6-H), 6.48 (d, J = 7.2 
Hz, 2 H, C21-H), 6.16 (d, J = 9.2 Hz, 1 H, C11-H), 4.97 (d, J = 11.1 Hz, 1 H, C18-H), 
4.90 (d, J = 11.1 Hz, 1 H, C18-H), 4.89 (d, J = 10.6 Hz, 1 H, C19-H), 4.68 (d, J = 12.3 
Hz, 1 H, C20-H), 4.64 (d, J = 10.6 Hz, 1 H, C19-H), 4.60 (d, J = 12.3 Hz, 1 H, C20-H), 
4.33 (d, J = 10.6 Hz, 1 H, C17-H), 3.94 (s, 3 H, C24-H), 3.90-3.70 (comp, 5 H, C13-H & 
C14-H & C15-H & C16-H), 3.86 (s, 3 H, C25-H), 3.76 (s, 3 H, C26-H), 3.65 (d, J = 10.6 
Hz, 1 H, C17-H), 3.49 (app t , J = 9.0 Hz, 1 H, C12-H); 13C NMR (100 MHz) δ 152.8, 
152.3, 149.9, 138.8, 138.4, 138.2, 137.7, 134.0, 130.3, 128.4, 128.1, 128.0, 127.8, 127.7, 
127.6, 127.50, 127.48, 127.2, 126.9, 123.0, 115.9, 108.1, 107.9, 87.1 (C13), 85.9 (C12), 
79.5 (C14), 78.8 (C15), 75.4 (C18), 75.1 (C19), 74.8 (C17), 73.3 (C20), 69.2 (C16), 61.8 




































trimethoxynaphthalen-1-yl)tetrahydropyran (4.142). (4-215). A solution of n-BuLi in 
hexane (90 µL, 2.2 M, 0.198 mmol) was added to bromonaphthalene 4.140 (128 mg, 
0.168 mmol) in THF (1.2 mL) at –78°C. The mixture was stirred at -78 °C for 50 min, 
whereupon a solution of C2Cl6 (56 mg, 0236 mmol) in THF (0.2 mL) was added. The 
mixture was stirred at –78 °C for 3 h and then warmed to rt. The solvent was evaporated 
under reduced pressure, and the residue was purified by flash chromatography eluting 
with Et2O/Hexanes (1:2) to afford 72 mg (79%) of 4.142 as a thick oil: 1H NMR (400 
MHz) δ 7.91 (s, 1 H), 7.40-7.22 (comp, 15 H), 7.12 (app t. J = 7.4 Hz, 1 H), 7.03 (app t, J 
= 7.5 Hz, 2 H), 6.86 (d, J = 8.5 Hz, 1 H), 6.77 (d, J = 8.5 Hz, 1 H), 6.52 (d, J = 7.2 Hz, 2 
H), 6.22 (d, J = 9.6 Hz, 1 H), 5.02 (d, J = 10.7 Hz, 1 H), 4.95 (d, J = 11.3 Hz, 1 H), 4.94 
(d, J = 10.7 Hz, 1 H), 4.72 (d, J = 12.5 Hz, 1 H), 4.69 (d, J = 11.3 Hz, 1 H), 4.64 (d, J = 
12.5 Hz, 1 H), 4.37 (d, J = 10.3 Hz, 1 H), 3.98 (s, 3 H), 3.96-3.72 (comp, 5 H), 3.92 (s, 3 
H), 3.79 (s, 3 H), 3.69 (d, J = 10.3 Hz, 1 H), 3.53 (app t, J = 9.1 Hz, 1 H); 13C NMR (100 
MHz) δ 152.2, 151.6, 150.0, 138.7, 138.3, 138.2, 137.7, 133.7, 128.4, 128.3, 128.0, 
127.9, 127.71, 127.65, 127.56, 127.48, 127.46, 127.2, 126.3, 125.8, 123.0, 108.1, 107.7, 
87.1, 85.9, 79.5, 78.7, 75.4, 75.1, 74.7, 73.3, 69.2, 61.7, 57.5, 56.3; IR (CH2Cl2) 2931, 
2864, 1608, 1576, 1453, 1259, 1057 cm-1; MS (CI) m/z 774.2960 [C47H47O8Cl (M) 
requires 774.2959], 775 (base), 559, 423. 
NMR assignments. δ 7.91 (s, 1 H, C3-H), 7.40-7.22 (comp, 15 H, benzyl 
aromatics), 7.12 (app t. J = 7.4 Hz, 1 H, C23-H), 7.03 (app t, J = 7.5 Hz, 2 H, C22-H), 
6.86 (d, J = 8.5 Hz, 1 H, C7-H), 6.77 (d, J = 8.5 Hz, 1 H, C6-H), 6.52 (d, J = 7.2 Hz, 2 H, 
C21-H), 6.22 (d, J = 9.6 Hz, 1 H, C11-H), 5.02 (d, J = 10.7 Hz, 1 H, C18 H), 4.95 (d, J = 
11.3 Hz, 1 H, C19-H), 4.94 (d, J = 10.7 Hz, 1 H, C18-H), 4.72 (d, J = 12.5 Hz, 1 H, C20-
H), 4.69 (d, J = 11.3 Hz, 1 H, C19-H), 4.64 (d, J = 12.5 Hz, 1 H, C20-H), 4.37 (d, J = 
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10.3 Hz, 1 H, C17-H), 3.98 (s, 3 H), 3.96-3.72 (comp, 5 H, C13-H & C14-H & C15-H & 
C16-H), 3.92 (s, 3 H, C25-H), 3.79 (s, 3 H, C27-H), 3.69 (d, J = 10.3 Hz, 1 H, C17-H), 
3.53 (app t, J = 9.1 Hz, 1 H, C12-H); 13C NMR (100 MHz) δ 152.2, 151.6, 150.0, 138.7, 
138.3, 138.2, 137.7, 133.7, 128.4, 128.3, 128.0, 127.9, 127.71, 127.65, 127.56, 127.48, 
127.46, 127.2, 126.3, 125.8, 123.0, 108.1, 107.7, 87.1 (C13), 85.9 (C12), 79.5 (C14), 78.7 
(C15), 75.4 (C18), 75.1 (C19), 74.7 (C17), 73.3 (C20), 69.2 (C16), 61.7 (C26), 57.5 





















(2S, 3S, 4S)-3,4-Bis(benzyloxy)-3,4-dihydro-2-methyl-6-phenyl-2H-pyran 
(4.156b). (5-86). A solution of sec-BuLi (3.1 mL, 1.3 M, 4.0 mmol) in cyclohexane was 
added dropwise to a stirred solution of 2-chloro-1,4-dimethoxybenzne (690 mg, 4.0 
mmol) in THF (9 mL) at -95 ºC. The mixture was stirred for 15 min at -95 ºC, whereupon 
2-triisopropylsilyloxyfuran (500 mg, 2.08 mmol) was added dropwise. The reaction was 
allowed to warm up rapidly to 0 ºC, whereupon saturated NaHCO3 (10 mL) was added. 
The layers were separated, and the aqueous layer was extracted with Et2O (3 x 15 mL). 
The combined organic layers were dried (Na2SO4), and concentrated under reduced 
pressure. The residue was dissolved in CH3CN (20 mL) and extracted with hexanes (2 x 
15 mL), the combined organic layers were dried to afford 704 mg (90%) of 4.156b as a 
pale yellow solid. 1H NMR (400 MHz) δ 6.99 (dd, J = 5.5, 2.3 Hz, 1 H), 6.83 (d, J = 5.5 
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Hz, 1 H), 6.53 (d, J = 8.9 Hz, 1 H), 6.49 (d, J = 8.9 Hz, 1 H), 5.64 (d, J = 2.3 Hz, 1 H), 
3.74 (s, 3 H), 3.73 (s, 3 H), 1.26-1.12 (comp, 3 H), 1.12-1.00 (comp, 18 H); 13C NMR 
(100 MHz) δ 148.7, 147.1, 144.6, 144.4, 139.3, 112.7, 112.4, 111.4, 75.0, 56.7, 56.2, 
17.87, 17.86, 12.8; IR (CHCl3) 2943, 1496, 1318, 1256, 1066 cm-1.  
NMR assignments. 1H NMR (400 MHz) δ 6.99 (dd, J = 5.5, 2.3 Hz, 1 H., C2-H), 
6.83 (d, J = 5.5 Hz, 1 H, C3-H), 6.53 (d, J = 8.9 Hz, 1 H, C6-H or C7-H), 6.49 (d, J = 8.9 
Hz, 1 H, C6-H or C7-H), 5.64 (d, J = 2.3 Hz, 1 H, C1-H), 3.74 (s, 3 H, C9-H or C10-H), 
3.73 (s, 3 H, C9-H or C10-H), 1.26-1.12 (comp, 3 H, C11-H), 1.12-1.00 (comp, 18 H, 
C12-H); 13C NMR (100 MHz) δ 148.7, 147.1, 144.6, 144.4, 139.3, 112.7, 112.4, 111.4, 
























4-tert-Butyldimethylsilyloxy-5,8-dimethoxynaphthalen-1-ol (4.157b). (5-62). 
A solution of sec-BuLi (2.3 mL, 1.3 M, 3.0 mmol) in cyclohexane was added dropwise to 
a stirred solution of 2-chloro-1,4-dimethoxybenzne (518 mg, 3.0 mmol) in THF (7 mL) at 
–95 ºC. The mixture was stirred for 15 min at -95 ºC, whereupon 2-tert-
butyldimethylsilylloxyfuran (200 mg, 1.0 mmol) was added dropwise. The reaction was 
allowed to warm up rapidly to 0 ºC, whereupon saturated NaHCO3 (15 mL) was added. 
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The layers were separated, and the aqueous layer was extracted with Et2O (3 x 15 mL). 
The combined organic layers were dried (Na2SO4), and concentrated under reduced 
pressure. The residue was purified by flash chromatography on basic alumina eluting 
with Et2O/hexanes (1:20) to afford 342 mg (90%) of 4.157b as a white solid. 1H NMR 
(250 MHz) δ 9.42 (d, 1 H), 6.80 (d, J = 8.4 Hz, 1 H), 6.74 (d, J = 8.4 Hz, 1 H), 6.64 (d, J 
= 8.6 Hz, 1 H), 6.58 (d, J = 8.6 Hz, 1 H), 3.95 (s, 3 H), 3.81 (s, 3 H), 1.01 (comp, 9 H), 
0.14 (s, 6 H); 13C NMR (63 MHz) δ 151.8, 149.9, 148.6, 121.3, 118.4, 117.1, 111.1, 









Methyl 3-bromo-4-chloro-5-hydroxybenzoate (4.168). (4-207, 4-218, 4-220). A 
cold solution of NaNO2 (1.15 g, 16.7 mmol) in H2O (5 mL) was added to a suspension of 
amine 4.165 (3.0 g, 13.9 mmol) in HBr (48% aqueous, 20 mL) at 0 °C. The mixture was 
stirred at 0°C for 40 min and it was then added slowly to a solution of CuBr (1.32 g, 9.17 
mmol) in HBr (48% aquaous, 4 mL) at 100 °C. The mixture was hearted at 100 °C for 15 
min and cooled to rt. The solid/liquid mixture was extracted with CH2Cl2 (2 x 50 mL) 
and ether (50 mL). The combined organic layers were washed with H2O (50 mL) and 
NaHCO3 (50 mL). The organic layers was dried (Na2SO4), and concentrated under 
reduced pressure. The residue was purified by flash chromatography eluting with 
Et2O/hexanes (1:10 then 1:7) to afford 3.05 g (79 %) of 4.166 as a white solid. 
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A solution of BBr3 (4.38 g, 17.5 mmol) and 4.166 (2.87 g, 10.3 mmol) was stirred 
at rt overnight, whereupon MeOH was slowly added and the mixture was concentrated 
under reduced pressure to dryness. The residue was dissolved in MeOH (100 mL) 
containing conc. H2SO4 (10 d) and heated at reflux for 6 h. The mixture was cooled to rt 
and concentrated under reduced pressure. The residue was dissolved in EtOAc (50 mL) 
and washed with NaHCO3 (50 mL) and NaCl (50 mL). The organic layer was 
concentrated and purified by crystallization from hexanes/CHCl3 to afford 2.45 g (91 %) 
of 4.168 as a pink solid: 1H NMR (400 MHz, acetone-d6) δ 7.73 (br s, 1 H), 7.60 (br s , 1 
H), 3.87 (s, 3 H); 13C NMR (100 MHz, acetone-d6) δ 165.3, 155.3, 131.2, 126.9, 125.5, 









Methyl 3-iodo-4-chloro-5-hydroxybenzoate (4.169). (4-206, 4-211, 4-216). A 
cold solution of NaNO2 (1.15 g, 16.7 mmol) in H2O (20 mL) was added to a suspension 
of amine 4.165 (3.0 g, 13.9 mmol) in HCl (6 M, 60 mL) at 0 °C. The mixture was stirred 
at 0°C for 45 min, whereupon a solution of KI (3.46 g, 20.9 mmol) in H2O (30 mL) was 
added slowly. The mixture was slowed to warm to rt and stirred for 20 min. The mixture 
was extracted with Et2O (100 mL). The organic layers were washed with H2O (50 mL) 
NaHCO3 (50 mL), Na2S2O3 (50 mL) and NaCl (50 mL). The organic layers was dried 
(Na2SO4), and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with Et2O/hexanes (1:7) to afford 3.3 g (73 %) of 4.167 as a 
white solid. 
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By applying similar method to make 4.168, alcohol 4.169 was prepared from 
methyl ether 4.167 (168 mg, 0.515 mmol), BBr3 (53 µL, 0.567 mmol) as a light brown 
solid (80%, 128 mg): 1H NMR (400 MHz, acetone-d6) δ 7.97 (d, J = 1.9 Hz, 1 H), 7.60 
(d, J = 1.9 Hz, 1 H), 387 (s, 3 H); 13C NMR (100 MHz, acetone-d6) δ 165.2, 154.1, 













bromofuran-2-yl)-tetrahydro-2H-pyran (4.180). (5-282). A solution of Br2 (96 µL, 
1.87 mmol) in CCl4 (1 mL) was added to glycsyl furan 4.104 (1.00 g, 1.70 mmol) in 
CCl4 (20 mL). The mixture was stirred at rt for 5 min. The reaction was quenched by 
addition of saturated NaHCO3 (40 mL). The layers were separated, and the organic layer 
was washed with NaHCO3 (25 mL) and brine (25 mL). The organic layers was dried 
(Na2SO4), and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with Et2O/hexanes (1:3) to afford 1.023 g (90 %) of 4.180 as a 
light yellow solid: 1H NMR (400 MHz) δ 7.38-7.20 (comp, 16 H), 7.17-7.12 (comp, 2 
H), 7.06-7.01 (comp, 2 H), 6.41 (d, J = 3.5 Hz, 1 H), 6.32 (d, J = 3.5 Hz, 1 H), 4.95 (d, J 
= 11.0 Hz, 1 H), 4.89 (d, J = 11.3 Hz, 1 H), 4.83 (d, J = 10.6 Hz, 1 H), 4.62-4.51 (comp, 
4 H), 4.26 (d, J = 9.9 Hz, 1 H), 4.17 (d, J = 10.6 Hz, 1 H), 3.87 (appt, J = 9.2 Hz, 1 H), 
3.78-3.65 (comp, 4 H), 3.59-3.52 (m, 1 H); 13C NMR (100 MHz) δ 153.3, 138.5, 138.0, 
137.9, 137.6, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 121.9, 112.7, 112.2, 
86.5, 80.6, 79.3, 77.9, 75.5, 75.1, 74.8, 74.6, 73.4, 68.9; IR (CHCl3) 3030, 2864, 1496, 
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1453, 1360, 1069 cm-1; MS (CI) m/z 669.1824 [C38H38O6Br (M+1) requires 669.1852] 














2H-pyran-2-yl)furan-2-yl)(bromomethyl)dimethylsilane (4.181). (6-29). n-BuLi in 
hexanes (2.6 M, 1.60 mL, 4.16 mmol) was added to to 4.180 (2.428 g, 3.63 mmol) in 
THF (50 mL) at –78 °C. The mixture was stirred at –78 °C for 40 min whereupon 
bromomethylchlorodimethylsilane (570 µL, 4.18 mmol) was then added dropwise, the 
mixture was then allowed to warm to rt and stirred for 4 h at rt. The reaction was 
quenched by addition of saturated NaHCO3 (50 mL). The layers were separated, and the 
aqueous layer was extracted with Et2O (2 x 50 mL). The combined organic layers were 
dried (Na2SO4), and concentrated under reduced pressure. The residue was purified by 
flash chromatography eluting with Et2O/hexanes (1:3) to afford 2.606 g (97%) of 4.181 
as a thick oil: 1H NMR (400 MHz) δ 7.40-7.16 (comp, 20 H), 7.02-6.97 (comp, 2 H), 
6.79 (d, J = 3.4 Hz, 1H), 6.51 (d, J = 3.4 Hz, 1 H), 4.97 (d, J = 10.9 Hz, 1 H), 4.95-4.84 
(comp, 2 H), 4.67 (d, J = 12.3 Hz, 1 H), 4.63 (d, J = 10.9 Hz, 1 H), 4.60 (d, J = 12.3 Hz, 1 
H), 4.54 (d, J = 10.9 Hz, 1 H), 4.41 (d, J = 9.6 Hz, 1 H), 4.04 (d, J = 10.3 Hz, 1 H), 3.97-
3.92 (m, 1 H), 3.83-3.72 (comp, 4 H), 3.64-3.57 (m, 1 H), 2.61 (s, 2 H), 0.44 (s 3 H), 0.43 
(s, 3 H); 13C NMR (100 MHz) δ 156.4, 56.3, 138.6, 138.1, 138.0, 137.8, 128.4, 128.3, 
128.2, 128.0, 127.9, 127.82, 127.76, 127.7, 127.6, 127.56, 127.46, 122.5, 110.2, 86.5, 
81.6, 79.4, 78.0, 75.6, 75.1, 74.8, 74.7, 73.4, 68.9, 15.6, -4.21, -4.24; mass spectrum (CI) 













2H-pyran-2-yl)furan-2-yl)dimethylvinylsilane (4.184). (5-289). n-BuLi in hexanes 
(2.45 M, 0.73 mL, 1.79 mmol) was added to to 4.180 (1.00 g, 1.49 mmol) in THF (20 
mL) at –78 °C. The mixture was stirred at –78 °C for 60 min whereupon 
chlorodimethylvinylsilane (250 µL, 1.81 mmol) was then added dropwise, the mixture 
was then allowed to warm to rt and stirred overnight at rt. The reaction was quenched by 
addition of saturated NaHCO3 (40 mL). The layers were separated, and the aqueous layer 
was extracted with Et2O (2 x 30 mL). The combined organic layers were dried (Na2SO4), 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with Et2O/hexanes (1:3) to afford 0.877 g (87%) of 4.184 as a 
thick oil: 1H NMR (300 MHz) δ 7.36-7.12 (comp, 18 H), 7.00-6.94 (comp, 2 H), 6.67 (d, 
J = 3.1 Hz, 1 H), 6.46 (d, J = 3.1 Hz, 1 H), 6.22 (dd, J = 20.1, 14.7 Hz, 1 H), 6.01 (dd, J = 
14.7, 3.8 Hz, 1 H), 5.78 (dd, J = 20.1, 3.8 Hz, 1 H), 4.94 (d, J = 10.9 Hz, 1 H), 4.88 (d, J 
= 10.9 Hz, 1 H), 4.86 (d, J = 10.6 Hz, 1 H), 4.63 (d, J = 12.0 Hz, 1 H), 4.60 (d, J = 10.6 
Hz, 1 H), 4.55 (d, J = 12.0 Hz, 1 H), 4.37 (d, J = 9.5 Hz, 1 H), 4.01 (d, J = 10.6 Hz, 1 H), 
3.96-3.90 (m, 1 H), 3.80-3.70 (comp, 4 H), 3.60-3.54 (m, 1 H), 0.33 (s, 6 H); mass 















tetrahydro-2H-pyran-2-yl)furan-2-yl)dimethylsilyl)ethanol (4.185). (5-296). A 
solution of vinylsilane 4.184 (100 mg, 0.148 mmol) and 9-BBN (45 mg, 0.37 mmol) in 
THF (1 mL) was stirred overnight. A NaOH solution (3 N, 0.4 mL) was added at rt, then 
30% H2O2 (0.2 mL) was added after 15 sec. The mixture was stirred for 30 min. The 
mixture was extracted with ether (2 x 7 mL) and then EtOAc (7 mL). The organic layers 
were combined, dried (Na2SO4), filtered and concentrated under reduced pressure. The 
residue was purified by chromatography eluting with Et2O/hexanes (1:1) to yield 84 mg 
(82%) of 4.185 as a clear liquid: 1H NMR (400 MHz) δ 7.40-7.20 (comp, 18 H), 7.04-
7.00 (comp, 2 H), 6.71 (d, J = 3.2 Hz, 1 H), 6.51 (d, J = 3.2 Hz, 1 H)), 5.01-4.80 (comp, 3 
H), 4. 66 (d, J = 12.3 Hz, 1 H), 4.65 (d, J = 10.6 Hz, 1 H), 4.61-4.53 (comp, 2 H), 4.42 (d, 
J = 10.0 Hz, 1 H), 4.06 (d, J = 10.6 Hz, 1 H), 4.00-3.92 (m, 1 H), 3.84-3.72 (comp, 4 H), 
3.75 (t, J = 7.5 Hz, 2 H), 3.66-3.58 (m, 1 H), 1.19 (app t, J = 7.5 Hz, 2 H), 0.32 (s, 3 H), 
0.31 (s, 3 H); 13C NMR (100 MHz) δ 158.8, 155.8, 138.6, 138.1, 138.0, 137.9, 128.4, 
128.3, 128.2, 128.0, 127.9, 127.8, 127.72, 127.68, 127.6, 127.5, 121.3, 1100, 86.5, 81.6, 
79.3, 78.0, 75.6, 75.1, 74.7, 74.6, 73.4, 68.9, 59.5, 20.4, -3.0, -3.1; mass spectrum (CI) 


















chlorobenzoate (4.182). (6-23). A mixture of tetrabutylammonium iodide (TBAI) (10.2 
mg, 0.0276 mmol), Na2CO3 (12.3 mg, 0.115 mmol), bromomethylsilane 4.181 (17 mg, 
0.023 mmol), and phenol 4.168 (6.7 mg, 0.025 mmol) in DMF (0.3 mL) was heated at 70 
°C for 7 h. The mixture was alloed to cool to rt and was directly poured on top of a 
column and purified by flash chromatography eluting with Et2O/hexanes (1:4 then 1:2) to 
give 20 mg (94%) of 4.182 as a colorless oil: 1H NMR (400 MHz) δ 7.85 (dd, J = 1.7, 0.7 
Hz, 1 H), 7.53 (d, J = 1.7 Hz, 1 H), 7.38-7.24 (comp, 13 H), 7.18-7.12 (comp, 5 H), 6.92-
6.86 (comp, 2 H), 6.82 (d, J = 3.0 Hz, 1 H), 6.49 (d, J = 3.0 Hz, 1 H), 4.92 (d, J = 11.1 
Hz, 1 H), 4.86 (d, J = 11.1 Hz, 1 H), 4.85 (d, J = 10.8 Hz, 1 H), 4.61 (d, J = 11.7 Hz, 1 
H), 4.59 (d, J = 10.8 Hz, 1 H), 4.53 (d, J = 11.7 Hz, 1 H), 4.46 (d, J = 10.3 Hz, 1 H), 4.38 
(d, J = 9.6 Hz, 1 H), 3.99 (d, J = 10.6 Hz, 1 H), 3.94-3.88 (m, 1 H), 3.89 (s, 3 H), 3.82 (s, 
2 H), 3.77-3.72 (comp, 4 H), 3.60-3.54 (m, 1 H), 0.46 (s, 3 H), 0.45 (s, 3 H); 13C NMR 
(100 MHz) δ 165.3, 157.6, 156.4, 156.0, 138.6 138.1, 138.0, 137.8, 129.6, 128.6, 128.4, 
128.3, 128.2, 128.0, 127.83, 127.76, 127.7, 127.6, 127.5, 126.1, 123.5, 122.8, 111.4, 

















(4.183). (6-35). A mixture of tetrabutylammonium iodide (TBAI) (306 mg, 0.83 mmol), 
Na2CO3 (370 mg, 3.49 mmol), bromomethylsilane 4.181 (510 mg, 0.69 mmol), and 
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phenol 4.169 (240 mg, 0.77 mmol) in DMF (9 mL) was heated at 70 °C for 8 h. The 
mixture was alloed to cool to rt and H2O (15 mL) was added, and the aqueous mixture 
was extracted with Et2O (20 mL) and then EtOAc (2 x 15 mL). The combined organic 
layers were washed with H2O (20 mL), 1 N NaOH (20 mL), brine (20 mL), dried 
(Na2SO4), and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with Et2O/hexanes (1:3 then 1:2) to give 478 mg (70%) of 4.183 
as a colorless oil: 1H NMR (400 MHz) δ 8.07 (d, J = 1.6 Hz, 1 H), 7.55 (d, J = 1.6 Hz, 1 
H), 7.38-7.24 (comp, 13 H), 7.20-7.12 (comp, 5 H), 6.92-6.87 (comp, 2 H), 6.83 (d, J = 
3.1 Hz, 1 H), 6.50 (d, J = 3.1 Hz, 1 H), 4.92 (d, J = 10.9 Hz, 1 H), 4.87 (d, J = 10.9 Hz, 1 
H), 4.86 (d, J = 10.6 Hz, 1 H), 4.61 (d, J = 12.2 Hz, 1 H), 4.59 (d, J = 10.6 Hz, 1 H), 4.55 
(d, J = 12.2 Hz, 1 H), 4.46 (d, J = 10.4 Hz, 1 H), 4.39 (d, J = 9.9 Hz, 1 H), 3.99 (d, J = 
10.4 Hz, 1 H), 3.95-3.90 (m, 1 H), 3.89 (s, 3 H), 3.85-3.78 (comp, 2 H), 3.77-3.72 (comp, 
4 H), 3.62-3.55 (m, 1 H), 0.46 (s, 3 H), 0.45 (s, 3 H); 13C NMR (100 MHz) δ 165.0, 
156.6, 156.3, 156.0, 138.5 138.0, 137.9, 137.7, 132.33, 132.27, 130.0, 128.3, 128.2, 
128.1, 127.9, 127.8, 127.7, 127.59, 127.56, 127.5, 122.7, 112.2, 110.3, 99.1, 86.4, 81.5, 

















chlorobenzoate (4.186). (6-150). Alcohol 4.185 (25 mg, 0.036 mmol), phenol 4.168 
(19.1 mg, 0.072 mmol) and PPh3 (12.3 mg, 0.047 mmol) were dissolved in toluene (0.35 
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mL) and DIAD (7.5 µL, 0.038 mmol) was added dropwise at 0 °C. The solution was then 
heated at 80 °C for 2 h and then cooled. The mixture was purified without concentration 
by chromatography on silica gel eluting with Et2O/hexanes (1:6 then 2:5) to afford 17 mg 
(50%) of aryl ether 4.186 as a clear oil. 1H NMR (400 MHz) δ 7.87 (d, J = 1.6 Hz, 1 H), 
7.41 (d, J = 1.6 Hz, 1 H), 7.38-7.22 (comp, 13 H), 7.22-7.12 (comp, 5 H), 6.96-6.88 
(comp, 2 H), 6.72 (d, J = 3.1 Hz, 1 H), 6.47 (d, J = 3.1 Hz, 1 H), 4.92 (d, J = 11.1 Hz, 1 
H), 4.87 (d, J = 11.1 Hz, 1 H), 4.85 (d, J = 10.6 Hz, 1 H), 4.61 (d, J = 12.0 Hz, 1 H), 4.60 
(d, J = 10.6 Hz, 1 H), 4.54 (d, J = 12.0 Hz, 1 H), 4.48 (d, J = 10.3 Hz, 1 H), 4.37 (d, J = 
9.9 Hz, 1 H), 4.22-4.02 (comp, 2 H), 3.99 (d, J = 10.3 Hz, 1 H), 3.92-3.82 (m, 1 H), 3.89 
















phenoxy)ethyl)dimethylsilane (4.188). (6-168). Alcohol 4.185 (23 mg, 0.033 mmol), 
phenol 4.187 (18.7 mg, 0.0662 mmol) and PPh3 (11.3 mg, 0.043 mmol) were dissolved in 
benzene (0.4 mL) and DIAD (8.5 µL, 0.043 mmol) was added dropwise at rt. The 
solution was then heated at 75 °C for 3 h and then cooled. The mixture was purified 
without concentration by chromatography on silica gel eluting with Et2O/hexanes (1:6 
then 1:2 then 2:3) to afford 26 mg (82%) of aryl ether 4.188 as a clear oil. 1H NMR (400 
MHz) δ 7.40-7.16 (comp, 19 H), 7.00-6.94 (comp, 2 H), 6.77 (d, J = 1.7 Hz, 1 H), 6.74 
(d, J = 3.3 Hz, 1 H), 6.50 (d, J = 3.3 Hz, 1 H), 4.96 (d, J = 11.1 Hz, 1 H), 4.90 (d, J = 
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11.1 Hz, 1 H), 4.89 (d, J = 10.6 Hz, 1 H), 4.69 (s, 2 H), 4.66-4.60 (comp, 2 H), 4.56 (d, J 
= 10.1 Hz, 1 H), 4.51 (d, J = 10.3 Hz, 1 H), 4.48 (s, 3 H), 4.40 (d, J = 9.6 Hz, 1 H), 4.20-
4.12 (comp, 2 H), 4.02 (d, J = 10.6 Hz, 1 H), 3.92 (appt, J = 9.4 Hz, 1 H), 3.82-3.70 
(comp, 4 H), 3.64-3.56 (m, 1 H), 3.41 (s, 3 H), 1.46 (t, J = 7.9 Hz, 1 H), 0.39 (s, 3 H); 
13C NMR (100 MHz) δ 158.3, 156.1, 155.4, 138.6, 138.3, 138.1, 138.0, 137.8, 128.4, 
128.3, 128.2, 128.0, 127.9, 127.8, 127.74, 127.70, 127.6, 127.5, 124.0, 123.6, 122.5, 
121.6, 110.7, 110.1, 95.7, 86.5, 81.7, 79.4, 78.0, 75.6, 75.1, 74.73, 74.68, 73.4, 68.9, 67.9, 


















tetrahydropyran (4.196). (6-175, 6-177). A solution of ester 4.186 (132 mg, 0.140 
mmol) in CH2Cl2 (10 mL) containg DIBAL-H (1 M, 32 µL, 0.32 mmol) was stirred at 0° 
for 15 min, whereupon saturated Rochelle's salt (15 mL) was added. The mixture was 
stirred overnight and the layers were separated. The aqueous layer was extracted with 
Et2O (2 x 16 mL). The combined organic layers were dried (Na2SO4), concentrated 
under reduced pressure. The residue was purified by flashing chromatography, eluting 
with Et2O/hexanes (2:3 to 3:2) to yield 98 mg of benzylic alcohol as clear liquid.  
A solution of benzylic alcohol (98 mg, 0.107 mmol) obtained above, 2,6-lutidine 
(50 µL, 0.92 mmol), TIPSOTf (58 µL, 0.214 mmol) was stirred in CH2Cl2 (5 mL) at rt 
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for 3 h. The reaction was quenched by addition of NaHCO3 (10 mL) and the layers were 
separated. The aqueous layer was extracted with Et2O (2 x 10 mL). The combined 
organic layers were dried (Na2SO4), concentrated under reduced pressure. The residue 
was purified by flashing chromatography, eluting with Et2O/hexanes (1:5 to 1:4) to yield 
116 mg (78% over two steps) of 4.196 as clear liquid: 1H NMR (400 MHz) δ 7.36-7.24 
(comp, 13 H), 7.20-7.12 (comp, 6 H), 6.96-6.90 (comp, 2 H), 6.84 (d, J = 1.0 Hz, 1 H), 
6.69 (d, J = 3.4 Hz, 1 H), 6.46 (d, J = 3.4 Hz, 1 H), 4.92 (d, J = 11.1 Hz, 1 H), 4.87 (d, J 
= 11.1 Hz, 1 H), 4.85 (d, J = 10.6 Hz, 1 H), 4.71 (s, 2 H), 4.60 (d, J = 12.0 Hz, 1 H), 4.59 
(d, J = 10.6 Hz, 1 H), 4.53 (d, J = 12.0 Hz, 1 H), 4.48 (d, J = 10.6 Hz, 1 H), 4.36 (d, J = 
9.6 Hz, 1 H), 4.16-4.08 (comp, 2 H), 3.99 (d, J = 10.4 Hz, 1 H), 3.89 (t, J = 9.2 Hz, 1 H), 
3.78-3.70 (comp, 4 H), 3.60-3.54 (m, 1 H), 1.43 (t, J = 7.9 Hz, 1 H), 1.20-1.12 (comp 21 
H), 0.34 (s, 6 H); 13C NMR (100 MHz) δ 158.3, 156.1, 155.4, 142.1, 138.6, 138.1, 138.0, 
137.8, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 123.3, 121.9, 121.6, 121.3, 
110.1, 109.0, 86.5, 81.7, 79.4, 78.1, 75.6, 75.1, 74.8, 73.4, 71.8, 68.9, 66.5, 63.8, 59.1, 


















tetrahydropyran. (4.195). (6-48, 6-51). By applying the same method to make 4.196, 
ether 4.195 was prepared from ester 4.183 (462 mg, 0.467 mmol) in 76% yield as a clear 
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liquid after purification by flash chromatography eluting with EtOAc/hexanes (1:10): 1H 
NMR (400 MHz) δ 7.40-7.39 (m, 1 H), 7.36-7.224 (comp, 13 H), 7.18-7.14 (comp, 5 H), 
6.94-6.88 (comp, 3 H), 6.82 (d, J = 3.2 Hz, 1 H), 6.49 (d, J = 3.2 Hz, 1 H), 4.92 (d, J = 
11.1 Hz, 1 H), 4.87 (d, J = 11.1 Hz, 1 H), 4.85 (d, J = 10.8 Hz, 1 H), 4.68 (s, 2 H), 4.61 
(d, J = 12.3 Hz, 1 H), 4.59 (d, J = 10.8 Hz, 1 H), 4.54 (d, J = 12.3 Hz, 1 H), 4.46 (d, J = 
10.3 Hz, 1 H), 4.37 (d, J = 9.9 Hz, 1 H), 3.99 (d, J = 10.6 Hz, 1 H), 3.94-3.88 (m, 1 H), 
3.80-3.70 (comp, 6 H), 3.60-3.54 (m, 1 H), 1.20-1.14 (comp, 21 H), 0.43 (s, 6 H); 13C 
NMR (100 MHz) δ 156.6, 156.22, 156.18, 142.4, 138.5, 138.0, 137.9, 137.7, 128.24, 
128.16, 128.07, 127.9, 127.74, 127.71, 127.60, 127.55, 127.5, 127.4, 125.2, 122.5, 110.2, 





























deoxy-D-arabino-hexopyranosil)-4-naphthol (4.212). (3-280) Cycloadduct 4.212 was 
prepared in 89% yield (1:1 mixture of diastereomers) as pale yellow oil according to the 
general procedure described above. 1H NMR (400 MHz) δ 7.24 (d, J = 5.5 Hz, 0.5 H, 
isomer A), 7.10 (dd, J = 5.5, 1.7 Hz, 0.5 H, isomer B), 7.06 (d, J = 5.5 Hz, 0.5 H, isomer 
B), 7.03 (dd, J = 5.5, 1.7 Hz, 0.5 H isomer A), 6.57 (d, J = 8.9 Hz, 0.5 H, isomer A), 6.56 
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(d, J = 8.9 Hz, 0.5 H, isomer B), 6.53 (d, J = 8.9 Hz, 0.5 H, isomer A), 6.52 (d, J = 8.9 
Hz, 0.5 H, isomer B), 5.94 (d, J = 1.7 Hz, 0.5 H, isomer B), 5.92 (d, J = 1.7 Hz, 0.5 H, 
isomer A), 5.35 (dd, J = 5.1, 1.4 Hz, 0.5 H, isomer B), 5.17 (dd, J = 5.1, 1.4 Hz, 0.5 H, 
isomer A), 4.48-4.30 (comp, 3 H), 4.27-4.23 (m, 0.5 H, isomer B), 4.23-4.18 (m, 0.5 H, 
isomer A), 4.02-3.86 (m, 0.5 H, isomer A), 3.9-3.84 (m, 0.5 H, isomer B), 3.80 (s, 1.5 H, 
isomer A), 3.79 (s, 1.5 H, isomer B), 3.70 (s, 1.5 H, isomer A), 3.67 (s, 1.5 H, isomer B), 
1.20-0.90 (comp, 63 H); mass spectrum (CI) m/z 817.5277 [C45H81O7Si3 (M+1) requires 
817.5290], 774, 644 (base), 599, 386. 
NMR assignments. 1H NMR (400 MHz) δ 7.24 (d, J = 5.5 Hz, 0.5 H, isomer A, 
C2-H), 7.10 (dd, J = 5.5, 1.7 Hz, 0.5 H, isomer B, C3-H), 7.06 (d, J = 5.5 Hz, 0.5 H, 
isomer B, C2-H), 7.03 (dd, J = 5.5, 1.7 Hz, 0.5 H, isomer A, C3-H), 6.57 (d, J = 8.9 Hz, 
0.5 H, isomer A, C6-H), 6.56 (d, J = 8.9 Hz, 0.5 H, isomer B, C6-H), 6.53 (d, J = 8.9 Hz, 
0.5 H, isomer A, C7-H), 6.52 (d, J = 8.9 Hz, 0.5 H, isomer B, C7-H), 5.94 (d, J = 1.7 Hz, 
0.5 H, isomer B, C4-H), 5.92 (d, J = 1.7 Hz, 0.5 H, isomer A, C4-H), 5.35 (dd, J = 5.1, 
1.4 Hz, 0.5 H, isomer B, C14-H), 5.17 (dd, J = 5.1, 1.4 Hz, 0.5 H, isomer A, C14-H), 
4.48-4.30 (comp, 3 H, C15-H & C18-H), 4.27-4.23 (m, 0.5 H, isomer B, C17-H), 4.23-
4.18 (m, 0.5 H, isomer A, C17-H), 4.02-3.86 (m, 0.5 H, isomer A, C16-H), 3.9-3.84 (m, 
0.5 H, isomer B, C16-H), 3.80 (s, 1.5 H, isomer A, C12-H), 3.79 (s, 1.5 H, isomer B, 
C12-H), 3.70 (s, 1.5 H, isomer A, C11-H), 3.67 (s, 1.5 H, isomer B, C11-H), 1.20-0.90 





























hex-1-enit-1-yl)-4-naphthol (4.213). (4-22). To a solution of cycloadduct 4.212 (283 
mg, 0.35 mmol) at –40 °C in CH2Cl2 (10 mL), was added BF3⋅Et2O (25 µL) dropwise. 
The solution quickly darkened, and the mixture was stirred at –40 °C for 15 min. The 
reaction was quenched by addition of saturated NaHCO3 at –40 °C through syringe. The 
mixture was diluted with EtOAc (5 mL) and the layers were separated. The aqueous layer 
was extracted with EtOAc (3 x 15 mL). The combined organic layers were dried 
(Na2SO4), concentrated under reduced pressure. The residue was purified by flashing 
chromatography, eluting with EtOAc/hexanes (1:19) to yield 213 mg (75%) phenol 4.213 
as clear liquid: 1H NMR (400 MHz) δ 9.86 (s, 1 H), 7.32 (d, J = 8.2 Hz, 1 H), 6.85 (d, J = 
8.2 Hz, 1 H), 6.74 (d, J = 8.6 Hz, 1 H), 6.71 (d, J = 8.6 Hz, 1 H), 4.81 (d, J = 4.4 Hz, 1 
H), 4.42-4.24 (comp, 4 H), 4.03 (s, 3 H), 4.04-3.97 (m, 1 H), 3.83 (s, 3 H), 1.20-1.00 
(comp, 63 H); 13C NMR (100 MHz) δ 156.2, 155.2, 151.4, 150.1, 132.6, 126.3, 124.4, 
116.1, 110.6, 105.2, 104.2, 96.5, 80.9, 68.8, 67.4, 61.9, 56.7, 56.6, 55.8, 18.3, 18.2, 18.1, 
18.0, 12.6, 12.5, 12.0; mass spectrum (CI) m/z 817.5285 [C45H81O7Si3 (M+1) requires 
817.5290] (base), 773, 643.  
NMR assignments. 1H NMR (400 MHz) δ 9.86 (s, 1 H, C4-OH), 7.32 (d, J = 8.2 
Hz, 1 H, C2-H), 6.85 (d, J = 8.2 Hz, 1 H, C3-H), 6.74 (d, J = 8.6 Hz, 1 H, C7-H), 6.71 (d, 
 321
J = 8.6 Hz, 1 H, C6-H), 4.81 (d, J = 4.4 Hz, 1 H, C14-H), 4.42-4.24 (comp, 4 H, C15-H 
& C16-H & C17-H & C-18 H), 4.03 (s, 3 H, C12-H), 4.04-4.37 (m, 1 H, C18-H), 3.83 (s, 
3 H, C11-H), 1.20-1.00 (comp, 63 H, sugar-OTIPS-H); 13C NMR (100 MHz) δ 156.2 
(C13), 155.2 (C4), 151.4 (C8), 150.1 (C5), 132.6 (C1), 126.3 (C2), 124.4 (C9), 116.1 
(C10), 110.6 (C3), 105.2 (C7), 104.2 (C6), 96.5 (C14), 80.9 (C17), 68.8 (C16), 67.4 
(C15), 61.9 (C18), 56.6 (C12), 55.8 (C11), 18.3 (C19), 18.2 (C19), 18.0 (C19), 12.6 




































hex-1-enit-1-yl)-4-methoxymethoxynaphthalene (4.216). (4-22) Phenol 4.213 (319 mg, 
0.390 mmol) in THF (3 mL) was added to a suspension of NaH (24 mg, 60% suspension 
in mineral oil, 0.6 mmol) in THF (2 mL) at 0 °C. The mixture was stirred at rt for 30 min. 
The solution was cooled back down to 0 °C and MOMCl (48.3 mg, 0.60 mmol) was 
added. The mixture was stirred at rt for 1 h and iPr2NEt (26 mg, 0.2 mmol) was added. 
The mixture was stirred overnight and NaHCO3 (10 mL) was added. The mixture was 
extracted with EtOAc (3 x 100 mL), and the combined organic layers were dried 
(Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by 
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column chromatography, eluting with EtOAc/hexanes (100:3) to yield 281 mg (84%) of 
4.216 as a clear liquid: 1H NMR (400 MHz) δ 7.32 (d, J = 8.0 Hz, 1 H), 7.03 (d, J = 8.0 
Hz, 1 H), 6.83 (d, J = 8.6 Hz, 1 H), 6.76 (d, J = 8.6 Hz, 1 H), 5.27 (s, 2 H), 4.81 (d, J = 
5.1 Hz, 1 H), 4.60-4.20 (comp, 4 H), 4.04-3.92 (m, 1 H), 3.87 (s, 3 H), 3.81 (s, 3 H), 3.58 
(s, 3 H), 1.18-0.98 comp, 63 H); 13C NMR (100 MHz) δ 156.3, 154.2, 150.1, 150.7, 
131.1, 127.9, 126.8, 120.3, 113.3, 108.5, 106.3, 96.8, 96.1, 80.9, 68.7, 67.1, 61.9, 57.9, 
56.3, 55.9, 18.3, 18.2, 18.0, 17.2, 12.6, 12.0, 11.7; mass spectrum (CI) m/z 861.5527 
[C47H85O8Si3 (M+1) requires 861.5552] (base), 687. 
NMR assignments. 1H NMR (400 MHz) δ 7.32 (d, J = 8.0 Hz, 1 H, C2-H), 7.03 
(d, J = 8.0 Hz, 1 H, C3-H), 6.83 (d, J = 8.6 Hz, 1 H, C7-H), 6.76 (d, J = 8.6 Hz, 1 H, C6-
H), 5.27 (s, 2 H, C13-H), 4.81 (d, J = 5.1 Hz, 1 H, C16-H), 4.60-4.20 (comp, 4 H, C17-H 
& C18-H & C19-H & C20-H), 4.04-3.92 (m, 1 H, C20-H), 3.87 (s, 3 H, C12-H), 3.81 (s, 
3 H, C11-H), 3.58 (s, 3 H, C14-H); 13C NMR (100 MHz) δ 156.3 (C15), 154.2 (C4), 
150.1 (C8), 150.7 (C5), 131.1 (C1), 127.9 (C2), 126.8 (C9), 120.3 (C10), 113.3 (C3), 
108.5 (C7), 106.3 (C6), 96.8 (C16), 96.1 (C13), 80.9 (C19), 68.7 (C18), 67.1 (C17), 61.9 
(C20), 57.9 (C14), 56.3 (C12), 55.9 (C11), 18.3 (C21), 18.2 (C21), 18.0 (C21), 17.2 






























dimethoxy-11-oxa-tricyclo[6.2.1.02,7]undeca-2(7),3,5,9-tetraene. (4-223). Crude 4.223 
was obtained in 95% yield as a thick oil from cycloaddition of glucosylfuran 4.222 (1.86 
g, 3.86 mmol) and 2-chloro-1,4-dimethoxybenzne (2.0 g, 11.6 mmol) after purification 
by flash chromatography eluting with Et2O/hexanes (from 1:2 to 2:3): 1H NMR (400 
MHz) δ 7.44-7.20 (comp, 15 H), 7.18-7.06 (comp, 2 H), 6.57 (app d, J = 8.4 Hz, 1 H), 
6.53 (d, J = 8.6 Hz, 0.5 H), 6.53 (d, J = 8.6 Hz, 0.5 H), 6.96 (s, 1 H), 5.45 (d, J = 2.8 Hz, 
0.5 H), 5.36 (d, J = 2.0 Hz, 0.5 H), 4.95 (d, J = 10.9 Hz, 0.5 H), 4.91 (d, J = 11.3 Hz, 0.5 
H), 4.78 (d, J = 11.3 Hz, 0.5 H), 4.73 (d, J = 11.6 Hz, 0.5 H), 4.71 (d, J = 11.6 Hz, 0.5 H), 
4.72-4.66 (m, 0.5 H), 4.63 (d, J = 11.6 Hz, 0.5 H), 4.65-4.58 (comp, 2 H), 4.54 (d, J = 
12.0 Hz, 0.5 H), 4.48-4.42 (comp,1 H), 4.33-4.27 (m, 0.5 H), 4.26-4.20 (m , 0.5 H), 4.12 
(dd, J = 9.8, 6.8 Hz, 0.5 H), 4.06 (dd, J = 8.9 Hz, 6.5 Hz, 0.5 H), 4.00-3.57 (comp, 2 H), 
3.80 (s, 3 H), 3.63 (s, 3 H); IR (CH2Cl2) 2936, 1495, 1256 cm-1; MS (CI) m/z 619.2705 































naphthalen-1-yl)-3,4-dihydro-2H-pyran (4.219). (4-155, 4-157). A mixture of TIPS 
protected glucal 4.216 (893 mg, 1.04 mmol) and TBAF in THF (3.64 mL, 1 M, 3.64 
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mmol) in THF (20 mL) was stirred at rt for 3 h. The mixture was concentrated under 
reduced pressure and the residue was purified by flash chromatography eluting first with 
EtOAc then with EtOAc/MeOH (5:1) to afford 360 mg of crude 4.218 as a white solid. 
NaH (181 mg, 4.54 mmol, 60% suspension in mineral oil) was added to a solution 
of triol 4.218 obtained above (360 mg, 0.918 mmol) and BnBr (0.50 mL, 4.14 mmol) in 
DMF (7 mL). The mixture was stirred at rt overnight. Saturated NaHCO3 (40 mL) was 
added, and the mixture was extracted with EtOAc (3 x 30 mL). The combined organic 
layers were washed with H2O (2 x 60 mL), dried (Na2SO4), and concentrated under 
reduced pressure. The residue was purified by flash chromatography eluting with 
Et2O/hexanes (1:1) to afford 527 mg (77% after two steps) of 4.219 as a thick oil: 1H 
NMR (400 MHz) δ 7.50-7.26 (comp, 16 H), 7.10 (d, J = 7.9 Hz, 1 H), 6.89 (d, J = 8.5 
Hz, 1 H), 6.84 (d, J = 8.5 Hz, 1 H), 5.31 (s, 2 H), 5.12-5.00 (br s, 1 H), 5.03 (d, J = 10.9 
Hz, 1 H), 4.84-4.76 (comp, 2 H), 4.72 (d, J = 11.6 Hz, 1 H), 4.68-4.58 (m, 1 H), 4.62 (d, 
J = 12.0 Hz, 1 H), 4.54 (d, J = 12.0 Hz, 1 H), 4.40-4.30 (br d, 1 H), 4.15 (dd, J = 9.9, 6.9 
Hz, 1 H), 3.94 (s, 3 H), 3.98-3.92 (comp, 2 H), 3.86 (s, 3 H), 3.64 (s, 3 H); 13C NMR (75 
MHz) δ 158.9, 154.6, 150.9, 150.5, 138.7, 138.4, 130.4, 128.3, 128.1, 127.9, 127.7, 
127.6, 127.5, 127.4, 127.3, 127.0, 126.8, 120.2, 112.7, 108.2, 107.1, 96.6, 78.5, 78.0, 
75.0, 74.0, 73.3, 70.1, 68.9, 57.6, 56.8, 56.3; IR (CH2Cl2) 2931, 1668, 1588, 1268, 1044 


































naphthalen-1-yl)tetrahydropyran-3-ol (4.220). (4-109). A solution of glucal 4.219 (54 
mg, 0.0816 mmol) and BH3·DMS (25 µL, 10 M, 0.25 mmol) was stirred at rt for 20 h. A 
solution of NaOH (90 µL, 5 M, 0.45 mmol) and then H2O2 (90 µL, 30%) were added and 
the mixture was stirred at rt for 20 h. Saturated NaHCO3 (10 mL) was added and the 
mixture was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried 
(Na2SO4), and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with Et2O/Hexanes (1:1) to afford 31 mg (56%) of 4.220 as a 
white solid: 1H NMR (400 MHz) δ 7.75 (d, J = 8.2 Hz, 1 H), 7.41 (d, J = 6.8 Hz, 2 H), 
7.36-7.22 (comp, 13 H), 7.18 (d, J = 8.5 Hz, 1 H), 6.83 (d, J = 8.5 Hz, 1 H), 6.80 (d, J = 
8.5 Hz, 1 H), 5.81 (d, J = 8.9 Hz, 1 H), 5.24 (s, 2 H), 5.03 (d, J = 11.3 Hz, 1 H), 4.93 (d, J 
= 11.3 Hz, 1 H), 4.92 (d, J = 10.6 Hz, 1 H), 4.68-4.60 (comp, 2 H), 4.54 (d, J = 12.0 Hz, 
1 H), 3.91 (s, 3 H), 3.89 (s, 3 H), 3.85-3.68 (comp, 6 H), 3.59 (s, 3 H), 2.65 (d, J = 5.1 
Hz, 1 H); 13C NMR (75 MHz) δ 153.8, 151.7, 150.5, 138.9, 138.3, 138.2, 129.2, 128.4, 
128.3, 128.2, 128.0, 127.7, 127.6, 127.5, 126.5, 120.6, 114.4, 107.3, 107.2, 96.9, 87.7, 
79.7, 78.4, 77.5, 77.2, 75.1, 73.4, 69.4, 57.6, 56.4, 55.9; IR (CH2Cl2) 3352, 2918, 1618, 
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1280, 1099, 1047 cm-1; MS (CI) m/z 680.2993 [C41H44O9 (M) requires 680.2985], 681 
(base), 555. 
NMR assignments. 1H NMR (400 MHz) δ 7.75 (d, J = 8.2 Hz, 1 H, C3-H), 7.41 
(d, J = 6.8 Hz, 2 H, benzyl aromatics), 7.36-7.22 (comp, 13 H, benzyl aromatics), 7.18 (d, 
J = 8.5 Hz, 1 H, C2-H), 6.83 (d, J = 8.5 Hz, 1 H, C7-H), 6.80 (d, J = 8.5 Hz, 1 H, C6-H), 
5.81 (d, J = 8.9 Hz, 1 H, C4-H), 5.24 (s, 2 H, C26-H), 5.03 (d, J = 11.3 Hz, 1 H, C18-H), 
4.93 (d, J = 11.3 Hz, 1 H, C18-H), 4.92 (d, J = 10.6 Hz, 1 H, C19-H), 4.68-4.60 (comp, 2 
H, C19-H & C20-H), 4.54 (d, J = 12.0 Hz, 1 H, C20-H), 3.91 (s, 3 H), 3.89 (s, 3 H), 3.85-
3.68 (comp, 6 H), 3.59 (s, 3 H), 2.65 (d, J = 5.1 Hz, 1 H, OH); 13C NMR (75 MHz) δ 
153.8, 151.7, 150.5, 138.9, 138.3, 138.2, 129.2, 128.4, 128.3, 128.2, 128.0, 127.7, 127.6, 
127.5, 126.5, 120.6, 114.4, 107.3, 107.2, 96.9, 87.7, 79.7, 78.4, 77.5, 77.2, 75.1, 73.4, 
69.4, 57.6, 56.4, 55.9. 
 
General procedure for Converting 2-deoxyglucolactone to 1-furylglycal. To a 
solution of 2-deoxyglucolactone (0.175 mmol) in THF (1 mL) at –78 °C, was added 2-
lithiofuran (640 µL, 0.296 M, 0.19 mmol), which was generated by adding t-BuLi (540 
µL, 1.56 M, 0.84 mmol) to furan (56 µL, 77 mmol) in THF (2 mL) at –78 °C followed by 
stirring at –5 °C for 45 min. The mixture was stirred at –78 °C for 4.5 h, whereupon 
pyridine (43 µL, 0.53 mmol), DMAP (24 mg, 0.20 mmol) in THF (0.3 mL) and TFAA 
(58 µL, 0.44 mmol) was added sequentially. The cold bath was then packed with dry ice, 
stirred and warmed up overnight. Saturated NaHCO3 (5 mL) was added and the mixture 
was extracted with EtOAc (3 x 5 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated, and the residue was purified by flash 


























(4.222). Method A (4-163, 4-167): A mixture of TIPS protected glucal 4.211 (2.754 g, 
4.05 mmol) and TBAF in THF (13.7 mL, 1 M, 13.7 mmol) in THF (45 mL) was stirred at 
rt for 4 h. The mixture was concentrated under reduced pressure, and the residue was 
purified by flash chromatography eluting with EtOAc to afford 920 mg of crude 4.221 as 
yellow powder. 
NaH (920 mg, 23.0 mmol, 60% suspension in mineral oil) was added to a solution 
of triol 4.221 obtained above (920 mg) and BnBr (2.32 mL, 19.4 mmol) in DMF (25 
mL). The mixture was stirred at rt overnight. Saturated NaHCO3 (60 mL) was added, and 
the mixture was extracted with EtOAc (3 x 60 mL). The combined organic layers were 
washed with NaCl (3 x 80 mL), dried (Na2SO4), and concentrated under reduced 
pressure. The residue was purified by flash chromatography eluting with Et2O/hexanes 
(1:6) to afford 1.865 (96% after two steps) of 4.222 as a white solid. 
Method B (4-267-2): Glucal 4.222 was prepared in 75% yield from 2-
deoxyglucolactone 4.224 (75 mg, 0.175 mmol) as thick oil according to the general 
procedure: 1H NMR (400 MHz) δ 7.42-7.25 (comp, 16 H), 6.55 (d, J = 3.4 Hz, 1 H), 6.42 
(dd, J = 3.4, 1.7 Hz, 1 H), 5.53 (d, J = 3.4 Hz, 1 H), 4.87 (d, J = 11.6 Hz, 1 H), 4.72 (d, J 
= 11.6 Hz, 1 H), 4.71 (d, J = 11.3 Hz, 1 H), 4.65-4.58 (comp, 3 H), 4.37 (dd, J = 5.8, 3.1 
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Hz, 1 H), 4.26 (ddd, J = 7.8, 4.8, 3.1 Hz, 1 H), 3.98 (dd, J = 8.2, 5.8 Hz, 1 H), 3.92 (dd, J 
= 10.9, 4.9 Hz, 1 H), 3.86 (dd, J = 10.9, 2.9 Hz, 1 H); 13C NMR (100 MHz) δ 148.9, 
145.3, 142.5, 138.3, 138.2, 138.1, 128.4, 128.3, 127.9, 127.7,2, 127.70, 127.62, 127.59, 
127.54, 111.1, 107.6, 94.8, 75.6, 7.2, 73.5, 73.4, 70.2, 68.3; IR (CH2Cl2) 3029, 2864, 
1668, 1565, 1453, 1094 cm-1; MS (CI) m/z 483.2165 [C31H31O5 (M+1) requires 






















2H-pyran (4.230). (5-58). Glucal 4.230 was obtained as a clear oil in 60% yield from 
4.224 (75 mg, 0.175 mmol) and phenyllithium (0.24 mmol) after purification by 
chromatography eluting with Et2O/hexanes (1:7): 1H NMR (400 MHz) δ 7.68-7.60 
(comp, 2 H), 7.44-7.24 (comp, 18 H), 5.46 (d, J = 3.1 Hz, 1 H), 4.89 (d, J = 11.3 Hz, 1 
H), 4.80-4.60 (comp, 5 H), 4.41 (dd, J = 5.8, 3.1 Hz, 1 H), 4.34-4.24 (m, 1 H), 4.06-3.88 
(comp, 3 H); 13C NMR (100 MHz) δ 152.7, 138.5, 138.2,134.5, 128.7, 128.4, 128.38, 
128.3, 128.1, 127.9, 127.7, 127.6, 127.5, 125.2, 96.0, 76.6, 74.3, 73.5, 73.4, 70.4, 68.6; 
























pyran (4.247). (4-300). 6-Deoxyglucal 4.247 was obtained as a pale yellow wax in 92% 
yield from 4.246 (31 mg, 0.095 mmol) and 2-lithiofuran (0.10 mmol) after purification by 
flash chromatography eluting with Et2O/hexanes (1:6): 1H NMR (400 MHz) δ 7.43-7.27 
(comp, 11 H), 6.50 (d, J = 3.4 Hz, 1 H), 6.40 (dd, J = 3.1, 1.7 Hz, 1 H), 5.51 (d, J = 3.1 
Hz, 1 H), 4.92 (d, J = 11.3 Hz, 1 H), 4.76 (d, J = 11.3 Hz, 1 H), 4.74 (d, J = 11.3 Hz, 1 
H), 4.63 (d, J = 11.6 Hz, 1 H), 4.39 (dd, J = 6.5, 3.0 Hz, 1 H), 4.12 (dq, J = 8.9, 6.2 Hz, 1 
H), 3.59 (dd, J = 8.9, 6.5 Hz, 1 H), 1.48 (d, J = 6.5 Hz, 3 H); 13C NMR (100 MHz) δ 
150.0, 145.6, 142.5, 138.4, 138.2, 128.4, 128.0, 127.8, 127.7, 127.6, 111.1, 107.4, 95.1, 
79.4, 76.7, 74.4, 73.9, 70.3, 17.5; IR (CDCl3) 2867, 1667, 1491, 1110 cm-1; MS (CI) m/z 
377.1741 [C24H25O4 (M+1) requires 377.1753], 269 (base).  
NMR assignments. 1H NMR (400 MHz) δ 7.43-7.27 (comp, 11 H, aromatic H), 
6.50 (d, J = 3.4 Hz, 1 H), 6.40 (dd, J = 3.1, 1.7 Hz, 1 H), 5.51 (d, J = 3.1 Hz, 1 H, C2-H), 
4.92 (d, J = 11.3 Hz, 1 H, C7-H), 4.76 (d, J = 11.3 Hz, 1 H, C7-H), 4.74 (d, J = 11.3 Hz, 
1 H, C7-H), 4.63 (d, J = 11.6 Hz, 1 H, C7-H), 4.39 (dd, J = 6.5, 3.0 Hz, 1 H, C3-H), 4.12 
(dq, J = 8.9, 6.2 Hz, 1 H, C5-H), 3.59 (dd, J = 8.9, 6.5 Hz, 1 H, C4-H), 1.48 (d, J = 6.5 
Hz, 3 H, C6-H); 13C NMR (100 MHz) δ 150.0 (C1), 145.6, 142.5, 138.4, 138.2, 128.4, 
128.0, 127.8, 127.7, 127.6, 111.1, 107.4, 95.1 (C2), 79.4 (C4), 76.7 (C3), 74.4, 73.9, 70.3 





















(2S, 3S, 4S)-3,4-Bis(benzyloxy)-3,4-dihydro-2-methyl-6-phenyl-2H-pyran 
(4.248). (5-45). 6-Deoxyglucal 4.248 was obtained as a white wax in 91% yield from 
4.246 (51 mg, 0.174 mmol) and phenyllithium (0.225 mmol) after purification by flash 
chromatography eluting with Et2O/hexanes (1:7): 1H NMR (400 MHz) δ 7.63-7.57 
(comp, 2 H), 7.44-7.28 (comp, 13 H), 5.44 (d, J = 2.9 Hz, 1 H), 4.94 (d, J = 11.6 Hz, 1 
H), 4.76 (d, J = 11.3 Hz, 1 H), 4.75 (d, J = 11.3 Hz, 1 H), 4.68 (d, J = 11.6 Hz, 1 H), 4.42 
(dd, J = 6.5, 2.9 Hz, 1 H), 4.15 (dq, J = 8.9, 6.3 Hz, 1 H), 3.61 (dd, J = 8.9, 6.5 Hz, 1 H), 
1.52 (d, J = 6.3 Hz, 3 H); 13C NMR (100 MHz) δ 152.9, 138.5, 138.3, 134.5, 128.6, 
128.41, 128.39, 128.1, 128.0, 127.7, 127.6, 125.1, 96.2, 79.5, 77.5, 74.4, 73.9, 70.5, 17.6; 
IR (CHCl3) 2870, 1650, 1495, 1451, 1112, 912 cm-1; MS (CI) m/z 387.1964 [C26H27O3 
(M+1) requires 387.1960], 297, 279 (base).  
NMR assignments. 1H NMR (400 MHz) δ 7.63-7.57 (comp, 2 H, aromatic H), 
7.44-7.28 (comp, 13 H, aromatic H), 5.44 (d, J = 2.9 Hz, 1 H, C2-H), 4.94 (d, J = 11.6 
Hz, 1 H, C7-H), 4.76 (d, J = 11.3 Hz, 1 H, C7-H), 4.75 (d, J = 11.3 Hz, 1 H, C7-H), 4.68 
(d, J = 11.6 Hz, 1 H, C7-H), 4.42 (dd, J = 6.5, 2.9 Hz, 1 H, C3-H), 4.15 (dq, J = 8.9, 6.3 
Hz, 1 H, C5-H), 3.61 (dd, J = 8.9, 6.5 Hz, 1 H, C4-H), 1.52 (d, J = 6.3 Hz, 3 H, C6-H); 
13C NMR (100 MHz) δ 152.9 (C1), 138.5, 138.3, 134.5, 128.6, 128.41, 128.39, 128.1, 
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2H-pyran (4.249). (5-68). 6-Deoxyglucal 4.249 was obtained as a pale yellow wax in 
80% yield from 4.246 (57 mg, 0.174 mmol) and 4-methoxyphenyllithium (0.21 mmol) 
after purification by flash chromatography eluting with Et2O/hexanes (1:7): 1H NMR 
(400 MHz) δ 7.54 (d, J = 8.9 Hz, 2 H), 7.44-7.26 (comp, 10 H), 6.88 (d, J = 8.9 Hz, 2 H), 
5.32 (d, J = 2.7 Hz, 1 H), 4.94 (d, J = 11.6 Hz, 1 H), 4.77 (d, J = 11.6 Hz, 1 H), 4.75 (d, J 
= 11.6 Hz, 1 H), 4.68 (d, J = 11.6 Hz, 1 H), 4.42 (dd, J = 6.5, 2.7 Hz, 1 H), 4.13 (dq, J = 
8.9, 6.5 Hz, 1 H), 3.82 (s, 3 H), 3.60 (dd, J = 8.9, 6.5 Hz, 1 H), 1.51 (d, J = 6.5 Hz, 3 H); 
13C NMR (100 MHz) δ 160.0, 152.7, 138.6, 138.3, 128.4, 0, 128.38, 128.0, 127.7, 127.7, 
127.6, 127.2, 126.5, 113.4, 94.6, 79.6, 77.6, 74.2, 73.9, 70.4, 55.2, 17.6; IR (CHCl3) 
2894, 1650, 1511, 1545, 1250, 1109 cm-1; MS (CI) m/z 417.2059 [C27H29O4 (M+1) 
requires 417.2066], 309, 107 (base). 
NMR assignments. 1H NMR (400 MHz) δ 7.54 (d, J = 8.9 Hz, 2 H, C13-H), 
7.44-7.26 (comp, 10 H, aromatic H), 6.88 (d, J = 8.9 Hz, 2 H, C14-H), 5.32 (d, J = 2.7 
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Hz, 1 H, C2-H), 4.94 (d, J = 11.6 Hz, 1 H, C7-H), 4.77 (d, J = 11.6 Hz, 1 H, C7-H), 4.75 
(d, J = 11.6 Hz, 1 H, C7-H), 4.68 (d, J = 11.6 Hz, 1 H, C7-H), 4.42 (dd, J = 6.5, 2.7 Hz, 1 
H, C3-H), 4.13 (dq, J = 8.9, 6.5 Hz, 1 H, C5-H), 3.82 (s, 3 H, C16-H), 3.60 (dd, J = 8.9, 
6.5 Hz, 1 H, C4-H), 1.51 (d, J = 6.5 Hz, 3 H, C6-H); 13C NMR (100 MHz) δ 160.0 (C1), 
152.7 (C15), 138.6, 138.3, 128.4, 128.38, 128.0, 127.7, 127.7, 127.6, 127.2, 126.5, 113.4, 



















pyran (4.250). (5-69): 6-Deoxyglucal 4.250 was obtained as a pale yellow wax in 90% 
yield from 4.246 (57 mg, 0.174 mmol) and 1-naphthyllithium (0.121 mmol) after 
purification by chromatography eluting with Et2O/hexanes (0:100 to 1:20 to 1:10): 1H 
NMR (400 MHz) δ 8.18 (d, J = 1.7 Hz, 1 H), 7.88-7.80 (comp, 2 H), 7.60-7.28 (comp, 14 
H), 5.25 (d, J = 2.7 Hz, 1 H), 5.00 (d, J = 11.3 Hz, 1 H), 4.83 (d, J = 11.3 Hz, 1 H), 4.77 
(d, J = 11.6 Hz, 1 H), 4.68 (d, J = 11.6 Hz, 1 H), 4.49 (dd, J = 6.5, 2.7 Hz, 1 H), 4.34 (dq, 
J = 8.9, 6.5 Hz, 1 H), 3.76 (dd, J = 9.2, 6.5 Hz, 1 H), 1.55 (d, J = 6.5 Hz, 3 H); 13C NMR 
(100 MHz) δ 154.4, 138.45, 138.40, 133.7, 131.2, 129.3, 128.48, 128.46, 128.3, 128.0, 
127.9, 127.8, 127.7, 126.8, 126.3, 125.9, 125.7, 125.1, 101.1, 79.7, 77.5, 74.8, 74.0, 70.7, 
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17.8; IR (CHCl3) 2868, 1660, 1453, 1100 cm-1; MS (CI) m/z 437.2119 [C30H29O3 
(M+1) requires 437.2114], 329 (base), 172.  
NMR assignments. 1H NMR (400 MHz) δ 8.18 (d, J = 1.7 Hz, 1 H, aromatic H), 
7.88-7.80 (comp, 2 H, aromatic H), 7.60-7.28 (comp, 14 H, aromatic H), 5.25 (d, J = 2.7 
Hz, 1 H, C2-H), 5.00 (d, J = 11.3 Hz, 1 H, C7-H), 4.83 (d, J = 11.3 Hz, 1 H, C7-H), 4.77 
(d, J = 11.6 Hz, 1 H, C7-H), 4.68 (d, J = 11.6 Hz, 1 H, C7-H), 4.49 (dd, J = 6.5, 2.7 Hz, 1 
H, C3-H), 4.34 (dq, J = 8.9, 6.5 Hz, 1 H, C5-H), 3.76 (dd, J = 9.2, 6.5 Hz, 1 H, C4-H), 
1.55 (d, J = 6.5 Hz, 3 H, C6-H); 13C NMR (100 MHz) δ 154.4 (C1), 138.45, 138.40, 
133.7, 131.2, 129.3, 128.48, 128.46, 128.3, 128.0, 127.9, 127.8, 127.7, 126.8, 126.3, 























dihydro-2H-pyran (4.252). (4-301). Galactal 4.251 was obtained as a clear oil in 31% 
yield from 4.243 (75 mg, 0.175 mmol) and 2-lithiofuran (0.19 mmol) after purification by 
chromatography eluting with Et2O/hexanes (1:6): 1H NMR (400 MHz) δ 7.40-7.25 
(comp, 16 H), 6.51 (d, J = 3.4 Hz, 1 H), 6.38 (dd, J = 3.4, 1.7 Hz, 1 H), 5.49 (d, J = 3.4 
Hz, 1 H), 4.89 (d, J = 12.0 Hz, 1 H), 4.73 (d, J = 12.0 Hz, 1 H), 4.68 (d, J = 12.0 Hz, 1 
H), 4.67 (d, J = 12.3 Hz, 1 H), 4.52 (d, J = 1.20 Hz, 1 H), 4.47 (d, J = 12.0 Hz, 1 H), 
4.40-4.34 (m, 1 H), 4.34-4.30 (m, 1 H), 4.05-4.01 (m, 1 H), 3.88 (dd, J = 10.3, 6.8 Hz, 1 
H), 3.81 (dd, J = 10.3, 5.1 Hz, 1 H); 13C NMR (100 MHz) δ 149.2, 144.9, 142.6, 138.8, 
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1386, 138.4, 128.6, 128.5, 128.4, 128.0, 127.92, 127.89, 127.8, 127.7, 111.4, 107.6, 95.2, 
76.5, 73.6, 73.4, 71.5, 71.1, 71.0, 68.4; IR (CDCl3) 2865, 1665, 1493, 1094 cm-1; MS 
(CI) m/z 483.2164 [C31H31O5 (M+1) requires 483.2171], 375 (base), 107.  
NMR assignments. 1H NMR (400 MHz) δ 7.40-7.25 (comp, 16 H, aromatic H), 
6.51 (d, J = 3.4 Hz, 1 H), 6.38 (dd, J = 3.4, 1.7 Hz, 1 H), 5.49 (d, J = 3.4 Hz, 1 H, C2-H), 
4.89 (d, J = 12.0 Hz, 1 H, C7-H), 4.73 (d, J = 12.0 Hz, 1 H, C7-H), 4.68 (d, J = 12.0 Hz, 
1 H, C7-H), 4.67 (d, J = 12.3 Hz, 1 H, C7-H), 4.52 (d, J = 1.20 Hz, 1 H, C7-H), 4.47 (d, J 
= 12.0 Hz, 1 H, C7-H), 4.40-4.34 (m, 1 H, C5-H), 4.34-4.30 (m, 1 H), 4.05-4.01 (m, 1 H), 
3.88 (dd, J = 10.3, 6.8 Hz, 1 H, C6-H), 3.81 (dd, J = 10.3, 5.1 Hz, 1 H, C6-H); 13C NMR 
(100 MHz) δ 149.2, 144.9, 142.6, 138.8, 1386, 138.4, 128.6, 128.5, 128.4, 128.0, 127.92, 





















(4-291-1): Glucal 4.252 was prepared in 64% yield from 2-deoxyglucolactone 4.236 (61 
mg, 0.3 mmol) as thick oil according to the general procedure: 1H NMR (250 MHz) δ 
7.33 (dd, J = 1.6, 0.7 Hz, 1 H), 6.50 (d, J = 2.0 Hz, 1 H), 6.35 (dd, J = 3.4, 1.9 Hz, 1 H), 
5.41 (d, J =3.4 Hz, 1 H), 4.14-4.05 (m, 1 H), 4.00 (dd, J = 5.7, 3.54 Hz, 1 H), 3.73-3.68 
(comp, 2 H), 3.58-3.50 (m, 1 H), 3.53 (s, 3 H), 3.43 (s, 3 H), 3.41 (s, 3 H); 13C NMR (75 
MHz) δ 148.8, 145.3, 142.5, 111.1, 107.6, 94.5, 76.9, 75.7, 70.6, 59.3, 59.1, 55.7; IR 
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(CH2Cl2) 2930, 2823, 1668, 1566, 1106 cm-1; MS (CI) m/z 255.1223 [C13H19O5 (M+1) 


















(2S, 3S, 4S)-3,4-Bis(benzyloxy)-6-ethyl-3,4-dihydro-2-methyl-2H-pyran 
(4.253). (5-24). 6-Deoxyglucal 4.253 was obtained as a clear oil in 19% yield from 4.246 
(57 mg, 0.174 mmol) and EtMgCl (0.36 mmol, 2 M) after purification by 
chromatography eluting with Et2O/hexanes (1:8): 1H NMR (500 MHz) δ 7.37-7.25 
(comp, 10 H), 4.87 (d, J = 11.4 Hz, 1 H), 4.70 (d, J = 11.4 Hz, 1 H), 4.65 (d, J = 11.7 Hz, 
1 H), 4.57 (d, J = 11.7 Hz, 1 H), 4.67-4.64 (dt, J = 2.4, 1.0 Hz, 1 H), 4.21-4.18 (m, 1 H), 
3.94 (dq, J = 8.8, 6.5 Hz, 1 H), 3.45 (dd, J = 6.4, 8.8 Hz, 1 H), 2.05 (qt, J = 7.4, 1.0 Hz,1 
H), 1.37 (d, J = 6.5 Hz, 3 H), 1.04 (t, J = 7.5 Hz, 3 H); 13C NMR (100 MHz) δ 157.7, 
138.6, 138.4, 128.4, 128.0, 127.8, 127.7, 127.6, 94.4, 79.7, 77.1, 73.8, 73.7, 70.4, 26.5, 
17.6, 11.2.  
NMR assignments. 1H NMR (500 MHz) δ 7.37-7.25 (comp, 10 H, aromatic H), 
4.87 (d, J = 11.4 Hz, 1 H, C8-H), 4.70 (d, J = 11.4 Hz, 1 H, C8-H), 4.65 (d, J = 11.7 Hz, 
1 H, C7-H), 4.57 (d, J = 11.7 Hz, 1 H, C7-H), 4.67-4.64 (dt, J = 2.4, 1.0 Hz, 1 H, C2-H), 
4.21-4.18 (m, 1 H, C3-H), 3.94 (dq, J = 8.8, 6.5 Hz, 1 H, C5-H), 3.45 (dd, J = 6.4, 8.8 
Hz, 1 H, C4-H), 2.05 (qt, J = 7.4, 1.0 Hz, 1 H, C9-H), 1.37 (d, J = 6.5 Hz, 3 H, C6-H), 
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1.04 (t, J = 7.5 Hz, 3 H, C10-H); 13C NMR (100 MHz) δ 157.7 (C1), 138.6, 138.4, 128.4, 
128.0, 127.8, 127.7, 127.6, 94.4 (C2), 79.7 (C4), 77.1 (C3), 73.8 (C8 or C5), 73.7 (C8 or 




















(2S, 3S, 4S)-3,4-Bis(benzyloxy)-6-butyl-3,4-dihydro-2-methyl-2H-pyran 
(4.254). (5-33). 6-Deoxyglucal 4.254 was obtained as a clear oil in 36% yield from 4.246 
(47 mg, 0.144 mmol) and n-BuLi (0.173 mmol) after purification by chromatography 
eluting with Et2O/hexanes (1:7): 1H NMR (400 MHz) δ 7.39-7.26 (comp, 10 H), 4.88 (d, 
J = 11.6 Hz, 1 H), 4.70 (d, J = 11.3 Hz, 1 H), 4.66 (d, J = 11.6 Hz, 1 H), 4.60 (d, J = 2.4 
Hz, 1 H), 4.57 (d, J = 11.9 Hz, 1 H), 4.23-4.17 (m, 1 H), 3.94 (dq, J = 8.7, 6.3 Hz, 1 H), 
3.45 (dd, J = 8.7, 6.2 Hz, 1 H), 2.03 (t, J = 7.5 Hz, 2 H), 1.50-1.19 (comp, 4 H), 1.38 (d, J 
= 6.3 Hz, 3 H), 0.90 (t, J = 7.3 Hz, 3 H); 13C NMR (100 MHz) δ 156.6, 138.6, 138.4, 
128.4, 127.9, 127.7, 127.6, 127.5, 95.0, 79.6, 77.1, 73.8, 73.7, 70.3, 33.2, 28.9, 22.3, 17.5, 
13.9; IR (CHCl3) 2956, 1673, 1453, 1103 cm-1; MS (CI) m/z 367 (base), 259.  
NMR assignments. 1H NMR (400 MHz) δ 7.39-7.26 (comp, 10 H, aromatic H), 
4.88 (d, J = 11.6 Hz, 1 H, C7-H), 4.70 (d, J = 11.3 Hz, 1 H, C7-H), 4.66 (d, J = 11.6 Hz, 
1 H, C7-H), 4.60 (d, J = 2.4 Hz, 1 H, C2-H), 4.57 (d, J = 11.9 Hz, 1 H, C7-H), 4.23-4.17 
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(m, 1 H, C3-H), 3.94 (dq, J = 8.7, 6.3 Hz, 1 H, C5-H), 3.45 (dd, J = 8.7, 6.2 Hz, 1 H, C4-
H), 2.03 (t, J = 7.5 Hz, 2 H, C12-H), 1.50-1.19 (comp, 4 H, C13-H & C14-H), 1.38 (d, J 
= 6.3 Hz, 3 H, C6-H), 0.90 (t, J = 7.3 Hz, 3 H, C15-H); 13C NMR (100 MHz) δ 156.6 
(C1), 138.6, 138.4, 128.4, 127.9, 127.7, 127.6, 127.5, 95.0 (C2), 79.6 (C4), 77.1 (C3), 




























3-yl)-2,2,2-trifluoro-ethanone (4.235). (4-269). Trifluoroketone 4.235 was prepared in 
63% yield from furylglucal 4.222 (13.3 mg, 0.0276 mmol), pyridine (21 µL, 0.266 
mmol), DMAP (12 mg, 0.098 mmol) and TFAA (74 mg, 0.35 mmol) in THF (1.3 mL) as 
clear oil according to a slightly modified general procedure B: 1H NMR (400 MHz) δ 
7.51 (d, J = 1.0 Hz, 1 H), 7.40-7.24 (comp, 13 H), 7.19-7.14 (comp, 2 H), 6.85 (d, J = 3.4 
Hz, 1 H), 6.51 (dd, J = 3.4, 1.7 Hz, 1 H), 4.80 (dq, J = 9.5, 2.1 Hz, 1 H), 4.62 (d, J = 12.0 
Hz, 1 H), 4.59 (d, J = 12.0 Hz, 1 H), 4.58 (m, 1 H), 4.50 (s, 1 H), 4.48 (d, J = 11.3 Hz, 1 
H), 4.42 (d, J = 11.3 Hz, 1 H), 3.96 (app t, J = 2.2 Hz, 1 H), 3.87 (dd, J = 10.5, 7.2 Hz, 1 
H), 3.71 (dd, J = 10.5, 5.1 Hz, 1 H); 13C NMR (100 MHz) δ 186.7, 186.5, 151.4, 147.3, 
145.3, 137.7, 137.4, 137.2, 128.6, 128.4, 128.3, 128.1, 127.9, 127.84, 127.82, 127.7, 
127.5, 117.3, 113.8, 112.3, 106.0, 77.4, 77.3, 77.0, 76.7, 73.3, 72.3, 71.9, 71.5, 66.7; IR 
(CHCl3) 2865, 1696, 1630, 1144 cm-1. 
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